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ABSTRACT 
 
BRANDON S. MOYER: CATALYTIC STEREOSELECTIVE INSTALLATION OF 
BORON VIA C–C BOND FORMATION 
(Under the guidance of Simon J. Meek) 
 
Enantiomerically pure chiral boron-containing molecules provide enabling platforms 
for chemical synthesis in that they are configurationally stable, they function as useful 
synthons for various functional groups, and their transformations into those diverse 
functionalities are stereospecific. With consensus that chiral alkyl sp3 C–B bond-containing 
compounds are desirable building blocks, and given that most enantioselective preparations 
to date focus on installing a stereodefined C–B bond, our group sought to develop catalytic 
methods to generate and use chiral α-boron-containing nucleophiles that would enable the 
direct formation of a new C–C bond. To this extent, we exploited the utility of alkyl 1,1-
diboron reagents, which have been shown to readily undergo facile activation and 
transmetalation in the presence of alkoxide bases to form chiral a-boryl nucleophiles. 
The result of these investigations was the development of the first catalytic enantio- 
and diastereoselective synthesis of syn-1,2-hydroxyboronates via addition to aldehydes (Ch. 
1). The reactions are promoted by a readily available chiral monodentate phosphoramidite–
Cu(I) complex in the presence of an alkyl 1,1-diboron reagent. The products contain two 
contiguous stereogenic centers and are obtained in up to 91% yield, >98:2 d.r., and 98:2 e.r. 
The reaction is tolerant of aryl and vinyl aldehydes, and the 1,2-hydroxyboronate products 
can be transformed into versatile derivatives. Mechanistic experiments indicate that control 
of absolute stereochemistry resides at the α-boryl component.
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Further investigations resulted in the development of a substantially more reactive 
Ag(I) catalytic protocol for the diastereoselective synthesis of complementary anti-1,2-
hydroxyboronates with up to 99:1 d.r. (Ch. 2). We found that the increased reactivity of 
Ag(I), in conjunction with stoichiometric KOtBu, allowed for a substantial broadening of 
substituted 1,1-diboronates that participate in the reaction. In addition, alkyl aldehydes were 
found to be suitable electrophiles with n-BuLi as an activator. 
BRANDON S. MOYER: STEREOSELECTIVE SYNTHESIS OF N-HETEROCYCLIC 
SCAFFOLDS VIA MAIN GROUP LEWIS ACID CATALYSIS 
(Under the guidance of Michel R. Gagné) 
 
 Silylium ions (formally [R3Si]+) have long been the subject of investigations and 
significant debate in both theoretical and experimental chemistry, but few catalytic, synthetic 
applications have been reported due to the exceptionally high reactivity and Lewis acidity of 
these elusive species. Chapter 3 discusses the application of easily accessible silylium ion 
catalysts to the stereoselective synthesis of various N-heterocyclic pyrrolidine and piperidine 
scaffolds. The tested substrates are derived from the chiral pool and can be obtained in three 
high-yielding steps from amino alcohols; subsequent stereoselective silylium ion-catalyzed 
Prins-cyclization and trapping with R3Si–Nu nucleophiles (e.g. Nu = H, allyl, azide, and enol 
ethers) results in novel nitrogen-containing polycyclic scaffolds with potential medicinal 
chemistry applications. An appendix to this chapter (A) discusses the substrate scope of the 
unpublished discovery that the Lewis acid B(C6F5)3 catalyzes a stereospecific Prins 
cyclization followed by an elimination (formally a carbonyl-ene reaction) to form trans-
tetrahydropyridine products in exceptionally high yield and diastereoselectivity.
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LIST OF ABBREVIATIONS 
 
°C     degrees Celsius  
Å     angstrom  
Ac     acetyl  
aq.    aqueous  
BCF    tris[pentafluorophenyl]borane; B(C6F5)3 
Bn     benzyl  
Bz     benzoyl 
Cbz    carboxybenzyl 
δ     delta – chemical shift (NMR)  
d     doublet (NMR)  
D     dextrorotary (stereochemistry, relative to glyceraldehyde) 
DCM    dichloromethane  
DMAP    4-dimethylaminopyridine 
DMF    dimethylformamide 
DMP    Dess-Martin periodinane 
DMSO    dimethylsulfoxide 
eq.     equivalent 
ESI     electrospray ionization  
Et     ethyl  
g     gram  
µg     microgram 
GCMS     gas chromatography – mass spectroscopy  
 xxi 
h     hour  
HR-MS    high resolution – mass spectrometry  
Hz     hertz (NMR coupling constants)  
i-Pr    isopropyl 
L     liter  
L     Levorotary (stereochemistry, relative to glyceraldehyde) 
mg    milligram  
mL     milliliter  
µL    microliter  
λ     lambda - wavelength  
M     molar – 1 mol / liter (concentration)  
Me     methyl  
MeOH    methanol  
mg     milligram  
MgSO4    magnesium sulfate  
MHz     megahertz  
µL     microliter  
min     minutes  
mM     millimolar – 10-3 mol / liter (concentration)  
mmol     millimole  
mol %     mole percent (catalyst loading)  
MS     molecular sieves  
m/z     mass-to-charge ratio (mass spectrometry)  
 xxii 
NMR     nuclear magnetic resonance  
PG     any unspecified protecting group  
PPTS    pyridinium p-toluenesulfonate (an acidic a resin) 
Ph     phenyl  
p    pi – electrons involved in multiple bonds 
PPh3     triphenylphosphine  
ppm     parts per million (NMR relative difference)  
iPr     iso-propyl  
q     quartet (NMR)  
R-     any unspecified carbon-containing group  
RT     room temperature  
σ     sigma – electrons involved in C-C single bonds  
σ*     antibonding orbital in C-C single bonds  
s     singlet (NMR))  
t     triplet (NMR)  
t-Bu    tert-butyl 
TES    triethylsilyl 
THF     tetrahydrofuran  
TMS     trimethylsilyl 
trityl BArF20   trityl tetrakis[pentafluorophenyl]borate; [Ph3C][B(C6F5)4] 
WCA    weakly coordinating anion 
wt  %    weight percent
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1 Chapter 1: Enantio- and Diastereoselective Synthesis of 1,2-Hydroxyboronates through 
Cu-Catalyzed Additions of Alkylboronates to Aldehydes 
This chapter is adapted and reprinted with permission from Joannou, M. V.; Moyer, 
B. S.; Meek, S. J. J. Am. Chem. Soc. 2015, 137, 6176-6179. Copyright © 2015 American 
Chemical Society. This chapter resulted from a collaboration with Dr. Matthew V. Joannou.
1.1 Introduction 
1.1.1 Background 
Enantiomerically pure chiral boron-containing molecules provide enabling platforms 
for chemical synthesis.1 Chiral organoborons are among the most configurationally stable 
classes of organometallic reagents (e.g. organolithiums < organomagnesiums < organozincs 
< organocuprates < organosilanes < organostannanes < organoboranes), and are considered 
to be non-toxic.2 In addition, boronic esters function as useful synthons for numerous 
functional groups (Scheme 1.1). Their transformations are almost universally highly 
stereospecific and often proceed with retention of stereochemistry. In combination, these 
properties establish boronic esters as excellent chiral intermediates / versatile building blocks 
in organic synthesis. A selection of transformations are shown below in Scheme 1.1, 
including amination,3 homologation,4 Suzuki-Miyaura cross-coupling (1° and 2° alkyl 
boronic esters),5 heteroarylation,6 and oxidation.7 
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Scheme 1.1. Stereospecific transformations of chiral boronic esters. 
Direct catalytic enantioselective preparation of chiral alkyl sp3 carbon–boron-
containing compounds can be achieved by a number of reported methods, for example, 
hydroboration,8,9 diboration (Scheme 1.2a),10 allylic substitution,9,11 conjugate boron addition 
(Scheme 1.2b),12 and arylborylation.13 These methods directly generate stereodefined C–B 
bonds. 
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Scheme 1.2. Select examples of enantioselective diboration10e and conjugate boration12g. 
An alternative approach is through the use of chiral α-boron-containing nucleophiles; 
such reagents do not involve the direct formation of a new C–B bond but rather a C–C bond. 
α-Boron–carbon nucleophiles can be generated in a number of ways: (1) Through the 
formation of stoichiometric copper reagents, (2) deprotonation of alkyl boronates, and (3) the 
activation of 1,1-diboronates. α-Boron substituted alkyl cuprates, developed by Knochel and 
further investigated by Miyaura and coworkers, readily undergo C–C bond formation with a 
variety of electrophiles (particularly aldehydes), providing an effective stoichiometric 
method for the installation of alkyl α-boron units (Scheme 1.3a and b).14 In addition, 
alkylation methods that employ boron-stabilized carbanions generated through deprotonation 
of alkyl boronate esters and boranes are limited due to the requirement of strong alkyl or 
amide lithium bases (Scheme 1.3c).15 Alternatively, reactive α-boryl species can be 
conveniently accessed through deborylation by treatment of 1,1-diboronates with an alkoxide 
base (d).10i,16  
b) Hoveyda (2010): NHC-Cu-catalyzed conjugate boron addition
a) Morken (2013): Diboration of monosubstituted alkenes:
1 mol % Pt(dba)3,
1.2 mol % chiral phosphonite
THF, 60 °C;
then NaOH, H2O2
R
R = aryl, alkyl
R
OH
OH
Up to 92:8 e.r.
B B
O
OO
O
B2pin2 (1.05 eq.)
+
5 mol % chiral NHC-Cu complex
13 mol % NaOt-Bu, MeOH (1.2 eq.),
THF, —50 °C
B B
O
OO
O
B2pin2 (1.10 eq.)
+ G
O
R
R B(pin)
G
O
R2
R1
R = aryl, alkyl
G = alkyl, alkoxy,
alkylthio
Up to >98:2 e.r.
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Scheme 1.3. Methods (1-3) to generate a-boryl nucleophiles. 
The emerging utility of alkyl 1,1-diboron reagents for chemical synthesis has recently 
been demonstrated in chemoselective Suzuki cross-coupling reactions by Shibata and co-
workers.17 Using the reported methodology, 1,1-diboronates undergo facile transmetalation at 
room temperature, allowing for chemoselectivity even in the presence of primary alkyl 
boronates (Scheme 1.4). The observed absence of b-hydride elimination and protodeboration 
in these reactions is attributed to the stabilizing effect of the a-boryl-palladium intermediate 
on the s-alkyl-palladium bond. DFT calculations (B3LYP/6-31G**) performed by the group 
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Me
1) CuCN.2LiCl
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I
b) Miyaura: Expanded application/investigation of alkyl 1,1-Cu-B-heterobimetallics
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THF, 25 °C, 20 min.
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    0 °C, 5 min.
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a) Knochel: Precedent for preparation of an sp3-hybridized α-boryl organometallic nucleophile:
[Cu] = Cu(CN)ZnI
c) Pelter: Deprotonation–alkylation (alkyl dimesitylboron-stabilized carbanions)
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suggest that the reason for such facile activation and transmetallation of the 1,1-diboronates 
is due to the presence of a large, delocalized LUMO distributed between the adjacent boron 
atoms. 
 
Scheme 1.4. Chemoselective Suzuki coupling of 1,1-diboronates. 
More recently, Morken and co-workers (and shortly thereafter Hall and co-workers) 
reported efficient enantioselective Pd-catalyzed Suzuki couplings of alkyl 1,1-diboronates 
with aryl (Scheme 1.5a) and vinyl halides.18 The catalysis proceeds via a stereochemistry-
determining transmetalation step to form a stereodefined a-boryl Pd(II)-alkyl complex 
ligated by a chiral, monodentate phosphoramidite ligand. Mechanistic experiments with 
chiral 10B-enriched 1,1-diboronates suggest that the reaction occurs by a stereospecific 
transmetalation that occurs with inversion of configuration at carbon (Scheme 1.5b). Such a 
transmetalation step must occur via either a desymmetrization of equivalent 1,1-diboronates 
or a dynamic kinetic resolution (DKR) of racemic monoborate species. This seminal work 
was proof-of-concept to us that chiral a-boryl organometallics could be generated in catalytic 
quantities and used to form stereodefined C–C bonds in useful organic transformations.  
5 mol % Pd[P(t-Bu)3]2
4.5 eq. KOH
H2O/dioxane, 25 °C
+ Br B(pin)
B(pin)
3 B(pin)
85% conv. (NMR)
B(pin)
B(pin)Ph 3 Ph
PdL
Ar
R
B(OR)n
via:
α-B,Pd intermediate
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Scheme 1.5. Catalytic, enantioconvergent Suzuki reaction with aryl electrophiles. 
As an addendum, since the publication of the manuscript on which this dissertation 
chapter is based, numerous other examples of 1,1-organodiboronate esters being developed 
as a-boryl carbanions for use in stereoselective deborylative C–C bond forming reactions 
have emerged.19 This includes an elaboration of the methodology described here in Chapter 1 
with application to enantio- and diastereoselective 1,2-additions to α-ketoesters with 
substituted 1,1-diboron reagents.19a In general, however, the development of catalytic, 
enantioselective protocols which employ substituted 1,1-diborylalkanes is still a challenge. 
One very recently published, clever workaround to this problem involves a multicomponent 
enantioselective borylcupration of vinyl boronates to produce a stereodefined a,b-bisboryl-
alkyl-Cu, followed by a diastereoselective 1,2-addition to aldehydes. This protocol enables 
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 7 
the production of hydroxy bis(boronates) containing a new C–C and C–B bond and up to 
three contiguous stereocenters.20 
1.1.2 Research objectives 
Our laboratory’s research objective (highlighted in Scheme 1.6) was to develop 
robust methodology for the catalytic, enantio-, and diastereoselective 1,2-additions of chiral 
a-boryl organometallics to sp2-hybridized (carbonyl-derived) electrophiles, namely 
aldehydes. While Chapters 1 and 2 in this dissertation (and the publications on which they 
are based) describe methodology for 1,2-additions to aldehyde substrates, much as yet 
unpublished work has been conducted on catalytic 1,2-additions to aryl phosphinoyl-
protected imines and aryl CF3-ketones. The foundation of all of our methodology has been 
the screening and development of catalytic systems that allow for stereoselective 
transmetalation to produce stable, a-boryl organometallic species. To this extent, we built off 
of the precedent and insights set by Morken and co-workers (Scheme 1.5) with Pd(II) and the 
stoichiometric work by Knochel and Miyaura with Cu(I) (Scheme 1.3). Chapter 1 discusses 
our success in developing a catalytic, stereoselective protocol based on the latter Cu(I) 
manifold.  
 
Scheme 1.6. Strategy for the 1,2-addition of a-borylated organometallics to electrophiles. 
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1.2 Strategy for the synthesis of syn-1,2-hydroxyboronates 
In this chapter, we discuss our published protocol for the enantio- and 
diastereoselective generation of 1,2-hydroxyboronates through the Cu-catalyzed addition of 
sp3 1,1-diboron reagents to aryl and vinyl aldehydes (Scheme 1.7). Reactions are promoted 
by 7.5-10 mol % of a readily available Cu(I) salt and chiral monodentate phosphine in 
conjunction with an alkoxide base; products are delivered in up to 91% yield, 98:2 e.r., and 
>98:2 d.r., and the chiral 1,2-hydroxyboronate building blocks can be further elaborated to 
directly access functionalized small molecules. 
 
Scheme 1.7. Strategy for the synthesis of 1,2-hydroxyboronates. 
1.3 Optimization of the catalytic reaction 
Initial studies of catalytic reaction conditions identified Cu salts in conjunction with 
monodentate phosphines as effective promoters for the addition of 1,1-diboryl reagents to 
aldehydes.i The data illustrated in Table 1.1 summarize the optimization of Cu-phosphine 
conditions. As entry 1 shows, there is no background addition of 1.1 to benzaldehyde with 
LiOt-Bu at 45 °C. Conversely, use of sodium or potassium alkoxides lead to a significant 
nonselective background reaction. Of note, catalytic quantities of LiOt-Bu were found not to 
be effective in promoting the reaction, while increasing the amount of base (>1.3 eq.) leads to 
>98% consumption of aldehyde but low conversion to product. We found bidentate 
                                                
iReactions of more substituted 1,1-diboron reagents result in low conversions to product; the result of these 
studies are reported in Joannou, M. V.; Moyer, B. S.; Goldfogel, M. J. Angew. Chem. Int. Ed. 2015, 54, 
14141-14145 and form the basis for Chapter 2 of this dissertation. 
R H
O
Me(pin)B
B(pin)
R
OH
Me
B(pin)
1.1
achiral
1,1-diboronate
Ln*Cu—OR MeLn*Cu
B(pin)
chiral
Cu-alkyl
l new C—C bond
l two new (syn) stereocenters
l functionalizable sp3 C—B bond
(chiral Cu
catalyst)
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phosphine–Cu complexes to be ineffective (for example, (R)-binap, (R)-DTBM-segphos, and 
L1, entries 2-4, Table 1.1), but discovered that a monodentate phosphine–Cu complex can 
deliver the desired 1,2-hydroxyboronate 1.2. Treatment of benzaldehyde and 1.1 with  
10 mol % of the Cu–phosphine complex derived from Cu(OTf)2 and ligand L2 with LiOt-Bu 
at 45 ° C affords 1.2 (65% conv.) in favor of the syn-diastereoisomer (91:9 d.r. and 88:12 
e.r.). Steric modification of the lithium alkoxide base revealed that LiOt-Am (entry 6) is an 
equally efficient (64% conv.) but more stereoselective activator (91:9 d.r. and 94:6 e.r.) for 
the formation of 1.2.ii Catalytic 1,2-additions in the presence of various Cu(I) and Cu(II) salts 
(entries 7− 9) revealed Cu(NCMe)4PF6 to be the most effective promoter, delivering 1.2 in 
66% conversion, 92:8 d.r., and 94:6 e.r (entry 9).iii The reaction efficiency was found to 
further improve upon conducting the reaction at 22 °C for 48 h (entry 10); 1.2 is generated in 
92% conversion, 92:8 d.r., and 94:6 e.r. Further efforts to increase reaction selectivity 
through modification of the phosphoramidite N-(alkyl)2 moiety (L3-5) result in a decrease in 
reaction efficiency and stereoselectivity (entries 11-13).iv 
                                                
iiApplication of lithium alkoxide bases containing smaller alkyl groups than t-Bu (e.g. methyl) leads to 
<5% conversion. 
 
iiiCu(OMe)2 results in inconsistent conversion. 
 
ivReactions performed with 10 mol % Cu(NCMe)4PF6 and 10 mol % L2 result in decreased conversion to 
product. 
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Table 1.1. Cu catalyst optimization. 
 
 
1.4 Cu(I)-catalyzed 1,2-additions of diboryl ethane to aryl aldehydes 
The monodentate phosphine-Cu-catalyzed 1,2-addition can be used for the enantio- 
and diastereoselective preparation of synthetically valuable sp3 organoboron molecules in 
good yield; representative examples are illustrated in Table 1.2. Transformations proceed in 
the presence of 10 mol % Cu catalyst at 22 °C within 48 h. The resulting 1,2-
hydroxyboronate products (1.3) demonstrate variable stability toward elimination during 
column chromatography. For ease of isolation and enantiomeric ratio determination, the 
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Me
L5
1
2
3
4
5
6
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Cu(OTf)2
Cu(OTf)2
Cu(OTf)2
Cu(OTf)2
Cu(OTf)2
LiOt-Bu; 130
LiOt-Bu; 130
LiOt-Bu; 130
LiOt-Bu; 130
LiOt-Bu; 130
LiOt-Am; 90
45
45
45
45
45
45
<2
<2
<2
<2
65
64
–
–
–
–
91:9
91:9
–
–
–
–
88:12
94:6
Entry Cu salt Li alkoxide; mol % temp (°C) NMR conv (%)b d.r.b e.r.c
7
8
9
10d
11d
12d
Cu(OMe)2
CuCl
Cu(NCMe)4PF6
Cu(NCMe)4PF6
Cu(NCMe)4PF6
Cu(NCMe)4PF6
LiOt-Am; 90
LiOt-Am; 90
LiOt-Am; 90
LiOt-Am; 90
LiOt-Am; 90
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45
45
45
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22
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66
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57
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92:8
85:15
92:8
92:8
88:12
87:13
96:4
81:19
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94:6
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91:9
13d Cu(NCMe)4PF6 LiOt-Am; 90 22 30 92:8 67:33
aReactions performed under a N2 atmosphere. bConversion to 1.2, values determined by analysis of 400 or 600 MHz 1H NMR spectra of 
unpurified mixtures with HMDS as internal standard. cDetermined by NaBO3 oxidation to diol and HPLC analysis; see Experimental 
Section (below) for details. d48 h reaction.
–
(R)-binap; 10
(R)-segphos; 10
L1; 10
L2; 20
L2; 20
ligand; mol %
L2; 20
L2; 20
L2; 20
L2; 20
L3; 20
L4; 20
L5; 20
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products were oxidized to the corresponding diols. For utilization and functionalization of 
1,2-hydroxyboronate products, see section 1.7. Benzaldehyde derived syn-diol 1.4 is isolated 
in 67% yield (92:8 d.r.) and in 94:6 e.r. after oxidation (NaBO3–4H2O). Aryl aldehydes 
incorporating halogens may be used; 10 mol % Cu complex delivers 1.5 (77% yield, 94:6 
e.r.) and 1.6 (91% yield, 95:5 e.r.) in 48 h at 22 °C after oxidation. Cu-catalyzed 1,2-
additions to aryl aldehydes containing an electron-donating p-MeO group work effectively, 
generating 1.7 in 69% yield (97:3 d.r. and 93:7 e.r.). Conversely, the presence of electron-
withdrawing p-NO2 or m-NO2 substituents delivers 1.8 and 1.9 in lower conversion (42% and 
37%) but with high enantioselectivity (95:5 e.r. 1.8, and 95:5 e.r. 1.9). Aldehydes containing 
m-methyl and m-trifluoromethyl substituents are also tolerated; diols 1.10 and 1.11 are 
delivered in yields of 76% (92:8: d.r., 98:2 e.r.) and 59% (90:10 d.r., 94:6 e.r.), respectively. 
Sterically hindered aryl aldehydes participate to afford the desired 1,2-hydroxyboronates 
with complete diastereocontrol; for example, both 1.12 (68% yield) and 1.13 (65% yield) are 
formed in >99:1 d.r. and 93:7 e.r. The reaction protocol is not sensitive to N- and O-
containing heteroaryl aldehydes. However, products are formed in diminished 
diastereoselectivity; treatment with 10 mol % Cu and L2 furnish 1.14 in 55% yield (86:14 
d.r., 95:5 e.r.) and 1.15 in 68% yield (83:17 d.r., 90:10 e.r.). 
Table 1.2. Cu(I)-catalyzed 1,2-additions of diboryl ethane to aryl aldehydes. 
 
Ar H
O
+ Me(pin)B
B(pin)
10 mol %
Cu(NCMe4)PF6-(L2)2,
90 mol % LiOt-Am
THF, 22 °C, 48 h
Ar
OH
Me
B(pin)
NaBO3.4H2O
(optional)
Ar
OH
Me
OH
1.3
(NMR conv., d.r.)b
1.4-1.15
(yield of diol; e.r.)c,d
1.1 (2.00 eq.)
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1.5 Cu(I)-catalyzed 1,2-additions of diboryl ethane to alkenyl aldehydes 
α,β-Unsaturated aldehydes react in the presence of 7.5 mol % phosphine–Cu complex 
with 60−80 mol % LiOt-Amv to afford functional organoboron compounds bearing allylic 
alcohols (Scheme 1.8).vi Cu-catalyzed addition to sterically unhindered cinnamaldehyde 
affords diol 1.16 (59% yield) in low diastereoselectivity (54:46 d.r., anti:syn) in slight favor 
of the anti-diastereoisomer; however, both isomers are formed in high enantioselectivity 
                                                
vThe base:boron ratio is important; vinyl aldehydes, especially those lacking an a-substituent, require 
larger loadings of diboryl ethane (2.5-5.0 eq.). 
 
viThe allylic alcohol products demonstrate variable stability to purification, particularly when electron-
donating substituents are present on the aryl ring. 
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F
OH
Me
OH
1.9
37% conv, 35% yield
84:16 d.r. (syn:anti)
95:5 e.r.
NO2
OH
Me
OH
1.10
82% conv, 76% yield
92:8 d.r. (syn:anti)
98:2 e.r.
Me
OH
Me
OH
1.11
65% conv, 59% yield
90:10 d.r. (syn:anti)
94:6 e.r.
CF3
OH
Me
OH
1.12
78% conv, 68% yield
>99:1 d.r. (syn:anti)
93:7 e.r.
Me
aReactions performed under a N2 atmosphere; see Experimental Section (below) for details. bConversion to 1,2-
hydroxyboronate; values determined by analysis of 400 or 600 MHz 1H NMR spectra of unpurified mixtures with HMDS as 
internal standard. cYields of the corresponding purified diol. de.r. determined by HPLC analysis of the diol.
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(97:3 e.r. anti, and 92:8 syn). Electron-withdrawing groups are tolerated: p-Cl and p-NO2 
cinnamaldehyde-derived diols 1.17 and 1.18 are generated in low diastereoselectivity (54:46 
and 45:55 d.r. anti:syn), but the diastereoisomers are formed in high enantioselectivity 
(97:3−95:5 e.r. anti, and 94:6−95:5 e.r. syn). Aryl groups bearing electron-donating ortho-
substituents are compatible as demonstrated by the formation of 1.19 in 75% yield, 45:55 
d.r.vii α-Substituted vinyl aldehydes lead to restoration of syn-diastereoselectivity without 
significant loss in enantioselectivity; 1.20 is delivered in 73% conversion (54% yield) and 
97:3 d.r. and 90:10 e.r. Cyclohexene-derived vinyl aldehydes undergo smooth 
diastereoselective 1,2-addition (96:4 syn:anti) to afford 1.21 in 64% conversion but in 83:17 
enantiomeric ratio. 
 
 
 
 
 
 
 
 
 
 
                                                
viip-OMe cinnamaldehyde is converted to the corresponding 1,2-hydroxyboronate in 75% yield; however, 
the corresponding 1,2-diol product is unstable to purification. 
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Scheme 1.8. Cu(I)-catalyzed 1,2-additions of diboryl ethane to alkenyl aldehydes 
1.6 Mechanism: 
1.6.1 Control of C–B stereogenic center 
To address which stereogenic center is set in high enantioselectivity (allylic versus 
homoallylic) in the cases of low diastereoselectivity observed with vinyl aldehydes, the 
allylic secondary alcohol in diol 1.16 was removed. As shown in Scheme 1.9, diol 1.16 was 
first converted to the allylic carbonate 1.22 with CDI (60% yield), followed by 2 mol % Pd-
catalyzed allylic reduction (Et3N, HCO2H),21 and subsequent hydrogenation to the 
corresponding secondary alcohol 1.23 (50% two steps).viii The enantiomeric purity of 1.23 
was determined to be 92:8 e.r., corresponding to the secondary boronate stereogenic center 
                                                
viiiPd-catalyzed allylic reduction affords mixtures that contained the over-reduced product 1.23 that could 
not be separated. 
G H
O
+ Me(pin)B
B(pin)
7.5 mol %
Cu(NCMe4)PF6-(L2)2,
60-80 mol % LiOt-Am
THF, 48 h, 22 °C;
then NaOH, H2O2
OH
Me
OH
75% conv, 59% yield,
54:46 d.r. (anti:syn),
97:3 e.r., 92:8 e.r.
OH
Me
OHCl
OH
Me
OHO2N
OH
Me
OH
OMe
OH
Me
OHMe
OH
Me
OH
1.21
64% conv, 34% yield
96:4 d.r. (syn:anti)
83:17 e.r.
1.20
73% conv, 54% yield
97:3 d.r. (syn:anti)
90:10 e.r.
1.19
82% conv, 75% yield
45:55 d.r. (anti:syn)
1.18
50% conv, 46% yield
45:55 d.r. (anti:syn)
95:5 e.r., 95:5 e.r.
1.17
57% conv, 38% yield
54:46 d.r. (anti:syn)
97:3 e.r., 94:6 e.r.
1.1
(2.5-5.0 eq.)
1.16
aReactions performed under a N2 atmosphere; see Experimental Section for details. bConversion to 
1,2-hydroxyboronate; values determined by analysis of 400 or 600 MHz 1H NMR spectra of unpurified 
mixtures with HMDS as internal standard. cYields of the corresponding purified diol. de.r. determined 
by HPLC analysis of the diol. e1,2-Diol 1.19 slowly decomposes precluding HPLC analysis.
 15 
being formed in high enantioselectivity in both anti- and syn-diastereoisomers. These data 
suggest a mechanism where the α-boryl nucleophile is formed with high stereopurity through 
catalyst controlled stereodifferentiation of the two B(pin) groups in achiral diboron 1.1. The 
low diastereoselectivity observed for sterically unhindered alkenyl aldehydes is therefore 
likely a result of poor facial discrimination of the C=O by the Cu catalyst. 
 
Scheme 1.9. Control of C–B stereogenic center. 
1.6.2 Catalytic cycle 
Having established that control of absolute stereochemistry resides at the a-boryl 
component, we postulated a catalytic cycle involving transmetallation to form a stereodefined 
a-boryl alkyl Cu(I) complex (Scheme 1.10). The first step towards entering the catalytic 
cycle involves activation of diboryl ethane (1.1) by a lithium alkoxide to generate borate 1.1’, 
a reaction which we have shown to be in an equilibrium that favors 1.1. Borate 1.1’ then 
enters the catalytic cycle by undergoing a transmetalation reaction with an appropriately 
ligated Cu(I) species ([Cu]; potentially L2CuOt-Bu) to form sterodefined a-boryl alkyl Cu(I) 
species I.ix Upon ligation of an aldehyde to form II, a migratory insertion reaction occurs to 
form the Cu(I)-ligated product 1,2-hydroxyboronate III. Release of the product via Cu(I) to 
Li salt metathesis regenerates the catalyst ([Cu]). 
                                                
ixTransmetalation to form stereodefined a-boryl alkyl Cu(I) I could proceed via two possible paths: 1) 
stereoselective transmetalation by dynamic kinetic resolution (or desymmetrization), as is precedented for 
Pd(II);18 or 2) Isomerization of the Cu(I) alkyl. 
Me
OH
OH
1.16
56:44 d.r. (anti:syn)
97:3 e.r., 90:10 e.r.
1) CDI, 
THF, 22 °C
1) 1 mol % Pd2(dba)3, 
2 mol % PPh3,
Et3N, HCO2H, THF
0 to 22 °C, 5 h
Me
OH
1.23
92:8 e.r.
2) H2, Pd/C, MeOH, 
22 °C, 1 h
(50% yield, two steps)
(60% yield)
Me
O
O
O
1.22
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Scheme 1.10. Cu(I) catalytic cycle 
1.7 Functionalizations of 1,2-hydroxyboronates 
The 1,2-hydroxyboronates synthesized through this Cu-catalyzed manifold can be 
elaborated to generate useful functional molecules (Scheme 1.11). In addition to oxidation, 
1,2-hydroxyboronate 1.2 (isolated in 53% yield on 1 mmol scale; 89:11 d.r. and 93:7 e.r.) can 
be converted to the TBS ether (76% yield) followed by homologation to afford alkyl 
organoboron 1.24 in 75% yield and 91:9 d.r. In a similar manner, allylic 1,2-hydroxyboronate 
1.25 (isolated in 54% yield; 98:2 d.r. and 92:8 e.r.) can be protected as the silyl ether (64% 
yield), and then treated with lithiated methoxyamine3 to cause stereospecific C−B to C−N 
conversion to deliver amino alcohol 1.26 (57% yield) after Boc protection. 
chiral
Cu-alkyl
[Cu] Me
B(pin)
R H
O
HR
O
R
OLi
B(pin)
Me
B(pin)(pin)B
Me
LiOR B(pin)(pin)B
Me
*
OR
-pinBOR
Li
Li
[Cu]
[Cu] Me
B(pin)
Li
R
O
B(pin)
Me
[Cu]
Li
transmetalation1.1 1.1’
migratory
insertion
activation
product release /
[Cu] regeneration
I
II
III
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Scheme 1.11. Functionalizations of 1,2-hydroxyboronates. 
In conclusion, Chapter 1 has summarized our studies into the development of the first 
catalytic protocol for the enantio- and diastereoselective synthesis of 1,2-hydroxyboronates. 
The efficiency of the transformation is demonstrated by the concomitant generation of a new 
C−C bond and two vicinal stereogenic centers, while retaining a versatile C−B bond. The 
method is applicable to aryl and alkenyl aldehyde substrates. Mechanistic experiments 
indicate control of absolute stereochemistry at the α-boryl component even in cases of low 
aldehyde facial selectivity. A key aspect of the sp3 B-containing secondary alcohols is the 
stereospecific transformations (e.g., homologation and amination) made available by the 
alkyl B(pin) unit of the corresponding silyl protected hydroxyboronate products. The 
development of a complementary Ag-based catalytic protocol, which enables the 
diastereoselective addition of substituted alkyl 1,1-diboron reagents to aryl, alkenyl, and alkyl 
aldehydes to produce anti-1,2-hydroxyboronates, is discussed in Chapter 2. 
OH
B(pin)
Me
OTBS
Me
B(pin)
1.24
91:9 d.r.
1) TBSCl, imidazole
DMF, 22 °C, 24 h
(76% yield)
2) LiCH2Br (2.2 eq.)
THF, –78 to 22 °C, 2 h
(75% yield)1.2
1 mmol scale: 53% yield
89:11 d.r., 93:7 e.r.
1. Boron homologation
2. Conversion to Boc-protected amine
Me
OH
Me
B(pin)
1.25
54% yield
98:2 d.r., 92:8 e.r.
1) TBSCl, imidazole
DMF, 22 °C, 20 h
(64% yield)
2) H2N-OMe, n-BuLi
THF, –78 to 22 °C, 20 h
3) Boc2O, THF, 22 °C, 2 h
(57% yield 2 steps)
Me
OTBS
Me
NHBoc
1.26
>98:2 d.r.
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1.8 Experimental Section 
1.8.1 General Methods 
All reactions were carried out in oven-dried (150 ˚C) or flame-dried glassware under 
an inert atmosphere of dried N2 unless otherwise noted. Analytical thin-layer 
chromatography was performed on glass plates coated with 0.25 mm of 60 Å mesh silica gel. 
Plates were visualized by exposure to UV light (254 nm) and/or immersion into Seebach’s or 
KMnO4 stain followed by heating. Column chromatography was performed using silica gel 
P60 (mesh 230-400) supplied by Silicycle. All solvents were sparged with argon and then 
purified under a positive pressure of argon through an SG Water, USA Solvent Purification 
System. Tetrahydrofuran (OmniSolv) was passed successively through two columns of 
neutral alumina. 1,4-dioxane was distilled from Na/benzophenone, sparged with N2, and 
stored over 4Å molecular sieves. The ambient temperature in the laboratory was 
approximately 22 ˚C. 
1.8.1.1 Instrumentation 
All 1H NMR spectra were recorded on Bruker Spectrometers (AVANCE-600 and 
AVANCE-400). Chemical shifts are reported in ppm from tetramethylsilane and referenced 
to the residual protio solvent peak (CDCl3: δ 7.26). Data are reported as follows: chemical 
shift, multiplicity (s = singlet, d = doublet, t = triplet, qu = quartet, quint = quinttet, br = 
broad, m = multiplet, app = apparent), integration, and coupling constants are given in Hz. 
13C NMR spectra were recorded on Bruker Spectrometers (AVANCE-600 and AVANCE-
400) with carbon and proton decoupling. Chemical shifts are reported in ppm from 
tetramethylsilane and referenced to the residual protio solvent peak (CDCl3: δ 77.16). All IR 
Spectra were recorded on a Jasco 260 Plus Fourier transform infrared spectrometer. Mass 
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Spectrometry was performed on a Thermo Scientific LTQ-FT-ICR Mass Spectrometer. 
Optical rotations were determined using a Jasco P1010 polarimeter and concentrations are 
reported in g/100mL. Enantiomeric ratios were determined on an Agilent Technologies 1220 
Infinity LC using the following columns: Diacel CHIRALPAK IA (4.6 mm x 250 mmL x 5 
µm), Diacel CHIRALPAK IB (4.6 mm x 250 mmL x 5 µm), and Diacel CHIRALPAK IC 
(4.6 mm x 250 mmL x 5 µm). Enantiomeric ratios for compound 1.18 were determined on a 
Berger Instruments Supercritical Fluid Chromatograph using a Regis RegisPack Column (25 
cm x 4.6 mm x 5 µm). 
1.8.1.2 Reagents 
All liquid aldehydes were distilled from CaH2 under vacuum and then sparged with 
dry N2. Solid aldehydes were purified via recrystallization, followed by azeotropic drying 
with benzene. (R)-Me-Monophos (L2), (R)-Et-Monophos (L3), and (R)-MorphPhos (L4) and 
L5 were synthesized according to published literature procedures.22 (R)-binap, (R)-dtbm 
segphos, and (R,R)-josiphos (L1) were purchased from Strem Chemicals and stored in an N2 
filled glovebox. Copper(II) methoxide, copper(I) chloride, and copper(II) triflate were 
purchased from Strem Chemicals and kept in an N2 filled glove box. Copper(I) 
tetrakisacetonitrile hexafluorophosphate was purchased from Sigma-Aldrich and kept in an 
N2-filled glovebox. Methoxyamine was prepared according to literature procedures as a 
solution in tetrahydrofuran.3a 
 20 
1.8.1.3 Synthesis of diboryl methane 
 
Scheme 1.12. Synthesis of diboryl methane. 
An oven-dried 2-liter, 3-necked flask with a magnetic stir bar was fitted with an 
addition funnel and then allowed to cool under vacuum. After back-filling the apparatus with 
N2 and evacuating it two more times, the entire apparatus was purged out with N2 for 20 
mintues.  Anhydrous THF (552 mL) was added via syringe, followed by diiodomethane (15.6 
mL, 193 mmol). The flask was allowed to cool to –78 ˚C (dry-ice/acetone bath) and the 
addition funnel was charged with iPr-MgCl (93.8 mL, 1.72 M solution in THF). The 
Grignard was then added to the reaction over 20 minutes (care was taken NOT to allow the 
Grignard solution to drip down the side of the flask). After the addition, the addition funnel 
was washed with 5 mL of anhydrous THF and added to the reaction. After allowing the 
reaction to stir at –78 ˚C for 2.5 hours (a white suspension formed), a 0.197 M solution of 
bis(pinacolato)diboron (10.0 g, 39.4 mmol) in THF was transferred via canulla to the reaction 
at –78 ˚C. After an additional 30 minutes of stirring, the flask was transferred to a cryobath 
set to –55 ˚C and the reaction was allowed to stir for 24 h. The reaction was quenched at –55 
˚C with ~200 mL of a saturated aqueous solution of NH4Cl. After allowing the mixture to 
warm to ambient temperature, the biphasic mixture was extracted three times with diethyl 
ether (1.5 L total) and the combined organic extracts were dried over MgSO4, filtered, and 
then concentrated in vacuo. The resulting orange residue was taken up in 50 mL of diethyl 
ether and filtered again and concentrated in vacuo. The crude mixture was purified by silica 
I
I
+
Me Me
MgCl
(4.1 eq.) (4.9 eq.)
THF, –78 °C, 2.5 h
then B2(pin)2 (1 eq.)
–78 °C to –55 °C, 24 h
B
BHH
OO
O
O
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gel chromatography (20:1 hexanes:ethyl acetate) to afford the desired product in 80% yield 
(8.0 g). The spectral data of the diboronate ester matched those previously reported.18a 
1.8.1.4 Synthesis of diboryl ethane (1.1) 
 
Scheme 1.13. Synthesis of diboryl ethane (1.1). 
In an N2-filled glove box, an oven-dried round-bottom flask was charged with diboryl 
methane (3.00 g, 11.2 mmol) and a magnetic stir-bar, capped with a rubber septum, and 
sealed with electrical tape. A separate oven-dried, conical flask was charged with lithium 
2,2,6,6-tetramethylpiperidide (1.73 mg, 11.8 mmol), capped with a rubber septum, and sealed 
with electrical tape. The two flasks were brought out of the glove box, where the diboryl 
methane flask was charged with 47.0 mL of dry THF and the LiTMP-containing flask was 
charged with 93.0 mL of THF (0.17M total). Both flasks were allowed to cool to 0 ˚C 
(ice/water-baths). The LiTMP solution was then cannula transferred to the diboryl methane 
flask with stirring. After the transfer, the reaction was allowed to stir for 10 min at 0 ˚C. 
Iodomethane (1.74 mL, 28.0 mmol) was then added to the reaction via a syringe and allowed 
to warm up to 22 ˚C over 18 hours with stirring. The reaction was quenched with 50 mL of a 
saturated aqueous solution of NH4Cl. The biphasic mixture was extracted 3 times with 
diethyl ether (900 mL total), and the combined organic extracts were dried over MgSO4, 
filtered, and concentrated in vacuo. The crude reaction mixture was purified by silica gel 
column chromatography (20:1 hexanes:EtOAc; Rf = 0.20) to give the desired diboryl reagent 
1) LTMP, THF, 0 °C, 10 min.
2) MeI, 0 °C to 22 °C, 18 h
B
B
OO
O
O
B
B
OO
O
OH Me
1.1
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in 89% yield (2.8 g). The spectral data of the diboronate ester matched those previously 
reported.23 
1.8.1.5 General procedures for the Cu-catalyzed 1,2-addition reaction 
 
Scheme 1.14. General Procedure A (aryl aldehydes). 
Procedure A (aryl aldehydes): In an N2-filled glove box, an 8-mL vial equipped 
with a magnetic stir bar was charged with Cu(MeCN)4PF6 (3.7 mg, 0.010 mmol) and (R)-
Monophos (7.2 mg, 0.020 mmol) and dissolved in 0.50 mL of THF. After allowing the 
reaction to stir for 5 min, LiOtAm (0.90 mg, 0.010 mmol) was added to the reaction as a 
solution in THF (0.10 mL). After an additional 15 min of stirring, diboryl ethane (56 mg, 
0.20 mmol) was added to the vial via syringe, followed by LiOtAm (7.5 mg, 0.080 mmol) as 
a solution in THF (0.20 mL). The resulting solution was allowed to stir at ambient 
temperature for 5 minutes, after which time the aldehyde (0.10 mmol) was added to the 
reaction. The vial was capped, sealed, and then removed from the glove box and allowed to 
stir at ambient temperature for 48 hours. The reaction was quenched with 1.5 mL of a 
saturated aqueous solution of NH4Cl, and the aqueous layer extracted three times with diethyl 
ether. The combined organic extracts were dried over MgSO4, filtered, and concentrated in 
vacuo. Conversion and diastereomeric ratios were determined by 1H NMR using 
hexamethyldisiloxane as an internal standard. 
Oxidation procedure: For the case of aryl hydroxyboronates, the crude reaction 
mixtures were oxidized to the corresponding diols using the following procedure: The crude 
H
O
+
B
B
OO
O
OMe
1.1
10 mol % Cu(MeCN)4PF6,
20 mol % (R)-Monophos,
90 mol % LiOtAm
THF, 22 °C, 48 h
Me
OH
B
O O
1.2
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reaction mixture was dissolved in a 1:1 mixture of THF and H2O and charged with 
NaBO3
.4H2O (5 equivalents). The resulting heterogeneous mixture was allowed to stir 
vigorously at ambient temperature for 2.5 hours and then quenched by the addition of a 
saturated aqueous solution of NH4Cl. The aqueous layer was extracted three times with 
diethyl ether and the combined organic extracts were dried over magnesium sulfate, filtered, 
and concentrated in vacuo. Pinacol was removed by dissolving the crude oxidation mixture in 
1:1 methanol:water, followed by concentration in vacuo on a rotary evaporator with the water 
bath set between 55-60 ˚C. The procedure was repeated until no pinacol was detected by 
TLC (usually 2-3 cycles). Purification by silica gel chromatography yielded the diol. 
 
Scheme 1.15. General Procedure B (α-substituted vinyl aldehydes). 
Procedure B (α-substituted vinyl aldehydes): In an N2-filled glove box, an 8-mL 
vial equipped with a magnetic stir bar was charged with Cu(MeCN)4PF6 (2.8 mg, 7.5 µmol), 
(R)-Monophos (5.4 mg, 0.015 mmol), and LiOtAm (0.7 mg, 7.5 µmol). The reaction was then 
dissolved in 0.56 mL of THF and allowed to stir at ambient temperature for 30 min. Diboryl 
ethane (71 mg, 0.25 mmol) was added to the vial via syringe, and this entire solution was 
added to a solution of LiOtAm (7.5 mg, 0.080 mmol) in THF (0.27 mL). The resulting 
solution was allowed to stir at ambient temperature for 5 minutes, after which time the 
aldehyde (0.10 mmol) was added to the reaction. The vial was capped and then removed 
from the glove box and allowed to stir at 22 °C for 48 h. The reaction was quenched with 1.0 
+
B
B
OO
O
OMe
1.1
7.5 mol % Cu(MeCN)4PF6,
15 mol % (R)-Monophos,
87.5 mol % LiOtAm
THF, 22 °C, 48 h
Me
OH
B
O O
1.26
Me
H
O
Me
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mL of a saturated aqueous solution of NH4Cl and the aqueous layer was extracted three times 
with diethyl ether. The combined organic extracts were dried over MgSO4, filtered, and 
concentrated in vacuo. Conversion and diastereomeric ratios were determined by 1H NMR 
using hexamethyldisiloxane as an internal standard. 
Oxidation procedure: For the case of α-substituted vinyl hydroxyboronates, the crude 
reaction mixtures were oxidized to the corresponding diols using the following procedure: 
The crude reaction mixture was dissolved in 1 mL of THF and then allowed to cool to 0 ˚C 
(ice/water bath). 400 µL of a 3 M NaOH (8 equivalents) solution was then added to the 
reaction, followed by 200 µL of a 30% H2O2 solution (12 equivalents). The reaction was 
allowed to warm up to ambient temperature over 4 hours. The reaction was then quenched at 
0 ˚C with 1 mL of a 1M solution of Na2S2O3. The aqueous layer was extracted three times 
with ethyl acetate and the combined organic extracts were dried over magnesium sulfate, 
filtered, and concentrated in vacuo. Pinacol was removed by dissolving the crude oxidation 
mixture in 1:1 methanol:water, followed by concentration in vacuo on a rotary evaporator 
with the water bath set between 55-60 ˚C. The procedure was repeated until no pinacol was 
detected by TLC (usually 2-3 cycles). Purification by silica gel chromatography yielded the 
diol. 
 
Scheme 1.16. General Procedure C (vinyl aldehydes). 
Procedure C (vinyl aldehydes): In an N2-filled glove box, an 8-mL vial equipped 
with a magnetic stir bar was charged with Cu(MeCN)4PF6 (2.8 mg, 7.5 µmol), (R)-Monophos 
+
B
B
OO
O
OMe
1.1
7.5 mol % Cu(MeCN)4PF6,
15 mol % (R)-Monophos,
67.5 mol % LiOtAm
THF, 22 °C, 48 h
Me
OH
B
O O
H
O
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(5.4 mg, 0.015 mmol), and LiOtAm (0.7 mg, 7.5 µmol). The reaction was then dissolved in 
0.56 mL of THF and allowed to stir at ambient temperature for 30 min. Diboryl ethane (141 
mg, 0.50 mmol) was added to the vial via syringe, and this entire solution was added to a 
solution of LiOtAm (5.6 mg, 0.060 mmol) in THF (0.27 mL). The resulting solution was 
allowed to stir at ambient temperature for 5 minutes, after which time the aldehyde (0.10 
mmol) was added to the reaction. The vial was capped and then removed from the glove box 
and allowed to stir at 22 °C for 48 h. The reaction was quenched with 1.0 mL of a saturated 
aqueous solution of NH4Cl and the aqueous layer was extracted three times with diethyl 
ether. The combined organic extracts were dried over MgSO4, filtered, and concentrated in 
vacuo. Conversion and diastereomeric ratios were determined by 1H NMR using 
hexamethyldisiloxane as an internal standard. 
Oxidation procedure: For the case of unsubstituted vinyl hydroxyboronates, the exact 
procedure above for α-substituted vinyl hydroxyboronates was followed, except 800 µL of 3 
M NaOH and 400 µL H2O2 were used instead. 
1.8.2 Preparation of aryl 1,2-diols 
 
1-phenylpropane-1,2-diol (1.4). Following Procedure A, the crude oxidation mixture 
was purified by silica gel chromatography (1:1 hexanes:ethyl acetate) to yield diol 1.4 as a 
colorless oil in 67% yield (10.2 mg) and 92:8 d.r. (syn:anti). The spectral data of the diol 
matched those previously reported.24 [α]22D = +42.1˚ (c = 0.458, CH2Cl2, l = 100 mm). 
Enantiomeric excess was determined by HPLC analysis compared to the authentic racemic 
material: Diacel CHIRALPAK IA Column; 99:1 hexanes:iPrOH; 1.0 mL/min; 210 nm. Syn-
Me
OH
OH
1.4
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diastereomer: (1S,2S) enantiomer: 32.8 min; (1R,2R) enantiomer 41.2 min: 94:6 e.r. Absolute 
stereochemistry was determined by the [α]D value compared to those previously reported.
24,25 
 
 
Figure 1.1. 1H and 13C{1H} NMR spectra of 1.4. 
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1-(4-fluorophenyl)propane-1,2-diol (1.5). Following Procedure A, the crude 
oxidation mixture was purified by silica gel chromatography (1:1 hexanes:ethyl acetate) to 
yield  diol 1.5 as a colorless oil in 77% yield (13.0 mg) and 92:8 d.r (syn:anti).  Syn 
diastereomer: 1H NMR (CDCl3, 400 MHz): δ 7.36-7.31 (m, 2H), 7.08-7.03 (m, 2H), 4.37 
(d, 1H, J = 7.6 Hz), 3.83 (quintt, 1H, J = 6.6 Hz), 2.73 (br s, 2H), 1.06 (d, 3H, J = 6.4 Hz).  
13C NMR (CDCl3, 101 MHz): δ 136.78, 128.65, 128.57, 115.62, 115.41, 78.96, 72.40, 18.93.  
Anti diastereomer: 1H NMR (CDCl3, 400 MHz) δ 7.36-7.31 (m, 2H), 7.08-7.03 (m, 2H), 
4.68 (d, 1H, J = 4.2 Hz), 4.01 (quintt, 1H, J = 1.9 Hz), 1.93 (br s, 1H), 1.64 (br s, 1H), 1.07 
(d, 3H, J = 6.3 Hz).  13C NMR (CDCl3, 101 MHz): δ 136.75, 128.45, 128.36, 115.45, 115.23, 
78.96, 72.40, 17.37.  HRMS (ESI+) calcd for C9H11O2FNa+ 193.0641, found: 193.0635 
[M+Na].  IR (ν/cm-1): 3399 (br, s), 2980 (s), 1605 (m), 1510 (m), 1455 (m), 1373 (w), 1223 
(m), 1157 (w), 1040 (w), 950 (w), 832 (m), 544 (w).  [α]22D = +22.4 ˚ (c = 0.352, CH2Cl2 ,l = 
100 mm). Enantiomeric excess was determined by HPLC analysis compared to the authentic 
racemic material. Absolute stereochemistry was inferred from the stereochemistry obtained 
for compound 1.4. Diacel CHIRALPAK IC Column; 99:1 hexanes:iPrOH; 1.0 mL/min; 210 
nm. Syn-diastereomer: (1R,2R) enantiomer: 87.3 min; (1S,2S) enantiomer 93.9 min: 94:6 e.r.  
Me
OH
OH
1.5
F
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Figure 1.2. 1H and 13C{1H} NMR spectra of 1.5. 
 
1-(4-bromophenyl)propane-1,2-diol (1.6). Following Procedure A, the crude 
oxidation mixture was purified by silica gel chromatography (1:1 hexanes:ethyl acetate) to 
yield  diol 1.6 as a colorless oil in 91% yield (21.0 mg) and 93:7 d.r (syn:anti).  Syn 
diastereomer: 1H NMR (CDCl3, 400 MHz): δ 7.51 – 7.44 (m, 1H), 7.25 – 7.18 (m, 1H), 
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4.33 (d, 1H, J = 7.3 Hz), 3.79 (quintt, 1H, J = 6.5 Hz), 2.91 (br s, 1H), 2.56 (br s, 1H), 1.05 
(d, 3H, J = 6.2 Hz).  13C NMR (CDCl3, 101 MHz): δ 140.17, 131.71, 128.67, 122.09, 78.89, 
75.20, 18.93.  Anti diastereomer: 1H NMR (CDCl3, 400 MHz): δ 7.51 – 7.44 (m, 2H), 7.25 
– 7.18 (m, 2H), 4.65 (d, 1H, J = 4.1 Hz), 3.98 (dd, 1H, J = 6.6, 4.4 Hz), 2.64 (br s, 1H), 1.71 
(br s, 1H), 1.03 (d, 3H, J = 6.0 Hz).  13C NMR (CDCl3, 101 MHz): δ 140.17, 131.53, 128.66, 
128.45, 122.09, 78.89, 71.21, 17.21.  HRMS (ESI+) calcd for C9H11O2BrNa+ 252.9840, 
found: 252.9835 [M+Na]. IR (ν/cm-1): 3391 (br, s), 2979 (s), 1488 (s), 1373 (m), 1138 (m), 
1071 (w), 1010 9 (w), 951 (w), 820 (m), 526 (w).  [α]22D = +64.3 ˚ (c = 0.457, CH2Cl2, l = 
100 mm). Enantiomeric excess was determined by HPLC analysis compared to the authentic 
racemic material. Absolute stereochemistry was inferred from the stereochemistry obtained 
for compound 1.4. Diacel CHIRALPAK IC Column; 99:1 hexanes:iPrOH; 1.0 mL/min; 210 
nm. Syn-diastereomer: (1R,2R) enantiomer: 45.8 min; (1S,2S) enantiomer 49.0 min: 95:5 e.r. 
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Figure 1.3. 1H and 13C{1H} NMR spectra of 1.6. 
 
1-(4-methoxyphenyl)propane-1,2-diol (1.7). Following Procedure A, the crude 
oxidation mixture was purified by silica gel chromatography (1:1 hexanes:ethyl acetate) to 
yield  diol 1.7 as a colorless oil in 69% yield (12.4 mg) and 97:3 d.r (syn:anti).  Syn 
diastereomer: 1H NMR (CDCl3, 600 MHz): δ 7.32 – 7.23 (m, 2H), 6.95 – 6.84 (m, 2H), 
4.32 (d, 1H, J = 7.6 Hz), 3.84 (m, 1H), 3.81(s, 3H), 2.53 (br s, 2H), 1.04 (d, 3H, J = 6.3 Hz).  
13C NMR (CDCl3, 101 MHz): δ 159.60, 133.27, 128.13, 114.03, 79.28, 72.40, 55.40, 18.85.  
Anti diastereomer: 1H NMR (CDCl3, 600 MHz):  δ 7.32 – 7.23 (m, 2H), 6.95 – 6.84 (m, 
2H), 4.60 (d, 1H, J = 4.6 Hz), 3.98 (m, 1H), 3.81 (s, 3H), 2.53 (br s, 2H), 1.10 (d, 3H, J = 6.3 
Hz).  13C NMR (CDCl3, 101 MHz): δ 159.60, 133.27, 128.04, 113.94, 79.28, 72.40, 55.40, 
17.67.  HRMS (ESI+) calcd for C10H14O3Na+: 205.0841, found: 205.0835 [M+Na]. IR 
(ν/cm-1): 3399 (br, s), 2980 (s), 1613 (s), 1513 (m), 1457 (w), 1372 (m), 1248 (w), 1177 (w), 
1034 (w), 951 (m), 830 (w).  [α]22D = +37.2 ˚ (c = 0.265, CH2Cl2, l = 100 mm). Enantiomeric 
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excess was determined by HPLC analysis compared to the authentic racemic material. 
Absolute stereochemistry was inferred from the stereochemistry obtained for compound 1.4. 
Diacel CHIRALPAK IC Column; 99:1 hexanes:iPrOH; 0.75 mL/min; 210 nm. Syn-
diastereomer: (1R,2R) enantiomer: 143.0 min; (1S,2S) enantiomer 152.0 min: 93:7 e.r. 
 
 
Figure 1.4. 1H and 13C{1H} NMR spectra of 1.7. 
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1-(4-nitrophenyl)propane-1,2-diol (1.8). Following Procedure A, the crude 
oxidation mixture was purified by silica gel chromatography (1:1 hexanes:ethyl acetate) to 
yield  diol 1.8 as an orange oil in 34% yield (6.6 mg) and 96:4 d.r (syn:anti).  Syn 
diastereomer:  1H NMR (CDCl3, 600 MHz): δ 8.28 – 8.21 (m, 2H), 7.61 – 7.55 (m, 2H), 
4.56 (d, 1H, J = 6.7 Hz), 3.88 (quint, 1H, J = 6.4 Hz), 2.94 (s, 2H), 1.16 (d, 1H, J = 6.3 Hz).  
13C NMR (151 MHz, CDCl3): δ 148.33, 147.72, 127.73, 123.66, 78.34, 72.02, 19.09.  Anti 
diastereomer:  1H NMR (CDCl3, 600 MHz): δ 8.28 – 8.21 (m, 2H), 7.61 – 7.55 (m, 2H), 
4.89 (d, 1H, J = 3.9 Hz), 4.12 (qd, 1H, J = 6.4, 3.9 Hz), 2.34 (s, 2H), 1.07 (d, 3H J = 6.4 Hz).  
13C NMR (151 MHz, CDCl3): δ 148.33, 147.60, 127.38, 123.49, 76.35, 71.03, 16.89.  
HRMS (ESI+) calcd for C9H11O4NNa+ 220.0586, found: 220.0581 [M+Na].  IR (ν/cm-1): 
3400 (br, s), 2982 (s), 1528 (s), 1381 (s), 1248 (m), 1217 (m), 1022 (w), 954 (m), 821 (w).  
[α]22D = –32.1 ˚ (c = 0.572, CH2Cl2, l = 100 mm). Enantiomeric excess was determined by 
HPLC analysis compared to the authentic racemic material. Absolute stereochemistry was 
inferred from the stereochemistry obtained for compound 1.4. Diacel CHIRALPAK IA 
Column; 92:8 hexanes:ethyl acetate; 1.0 mL/min; 210 nm. Syn-diastereomer: (1S,2S) 
enantiomer: 162.0 min; (1R,2R) enantiomer 175.7 min: 95:5 e.r. 
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Figure 1.5. 1H and 13C{1H} NMR spectra of 1.8. 
 
1-(3-nitrophenyl)propane-1,2-diol (1.9). Following Procedure A, the crude 
oxidation mixture was purified by silica gel chromatography (1:1 hexanes:ethyl acetate) to 
yield  diol 1.9 as a yellow oil in 35% yield (6.6 mg) and 84:16 d.r (syn:anti).  Syn 
diastereoemer: 1H NMR (CDCl3, 600 MHz): δ 8.25 (t, 1H, J = 2.0 Hz), 8.20 – 8.12 (m, 
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1H), 7.70 (dt, 1H, J = 7.7, 1.4 Hz), 7.54 (td, 1H, J = 7.9, 3.3 Hz), 4.53 (d, 1H, J = 6.8 Hz), 
3.87 (quint, 1H, J = 6.4 Hz), 2.95 (s, 2H), 1.14 (d, 2H, J = 6.3 Hz). 13C NMR (151 MHz, 
CDCl3): δ 148.34, 143.28, 133.00, 129.43, 123.06, 121.89, 78.21, 72.01, 19.09.  Anti 
diastereoemer: 1H NMR (CDCl3, 600 MHz): δ 4.84 (m, 1H), 4.10 (qd, 1H, J = 6.4, 3.9 Hz), 
2.30 (s, 2H), 1.05 (d, 3H, J = 6.4 Hz).  13C NMR (151 MHz, CDCl3): δ 148.34, 142.44, 
132.75, 129.21, 122.72, 121.66, 76.26, 70.97, 17.02.  HRMS (ESI+) calcd for C9H11O4NNa+ 
220.0586, found: 220.0581 [M+Na].  IR (neat): 3402 (br, s), 2987 (s), 1528 (s), 1345 (s), 
1260 (m) 1220 (m), 1025 (w), 954 (m), 821 (w).  [α]22D = ‒45.2 ˚ (c = 0.657, CH2Cl2, l = 100 
mm). Enantiomeric excess was determined by HPLC analysis compared to the authentic 
racemic material.  Absolute stereochemistry was inferred from the stereochemistry obtained 
for compound 1.4. Diacel CHIRALPAK IC Column; 97:3 hexanes:iPrOH; 1.0 mL/min; 210 
nm. Syn-diastereomer: (1S,2S) enantiomer: 35.8 min; (1R,2R) enantiomer 52.3 min: 95:5 e.r. 
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Figure 1.6. 1H and 13C{1H} NMR spectra of 1.9. 
 
1-(3-tolyl)propane-1,2-diol (1.10). Following Procedure A, the crude oxidation 
mixture was purified by silica gel chromatography (1:1 hexanes:ethyl acetate) to yield  diol 
1.10 as a colorless oil in 76% yield (12.6 mg) and 96:4 d.r (syn:anti).  Syn diastereomer: 1H 
NMR (CDCl3, 600 MHz): δ 7.26 – 7.22 (m, 1H), 7.19 – 7.10 (m, 3H), 4.34 (d, 1H J = 7.3 
Hz), 3.90 – 3.83 (m, 1H), 2.63 (s, 1H), 2.53 (s, 1H), 1.06 (d, 3H, J = 6.3 Hz).  13C NMR 
(CDCl3, 151 MHz): δ 141.00, 138.23, 128.91, 128.41, 127.44, 123.94, 79.53, 75.07, 21.46, 
18.79. Anti diastereomer: 1H NMR (CDCl3, 600 MHz):  δ 7.26 – 7.22 (m, 1H), 7.19 – 7.10 
(m, 3H), 4.66 (d, J = 4.5 Hz, 1H), 4.03 (qd, J = 6.4, 4.7 Hz, 1H), 2.63 (s, 1H), 2.53 (s, 1H), 
1.13 (dd, J = 6.4, 0.8 Hz, 3H).  13C NMR (CDCl3, 151 MHz): δ 140.30, 138.09, 128.63, 
128.30, 127.29, 123.73, 77.64, 71.31, 21.50, 17.44.  HRMS (ESI+) calcd for C10H14O2Na+: 
189.0893, found: 189.0888 (M + Na+).  IR (ν/cm-1): 3417 (br, s), 2917 (s), 1646 9 (s), 1456 
(m), 1130 (m), 1038 (w), 544 (m).  [α]22D = +49.2 ˚ (c = 0.675, CH2Cl2, l = 100 mm). 
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Enantiomeric excess was determined by HPLC analysis compared to the authentic racemic 
material. Absolute stereochemistry was inferred from the stereochemistry obtained for 
compound 1.4. Diacel CHIRALPAK IA Column; 99:1 hexanes:iPrOH; 1.0 mL/min; 210 nm. 
Syn-diastereomer: (1S,2S) enantiomer: 23.3 min; (1R,2R) enantiomer 40.2 min: 98:2 e.r. 
 
 
Figure 1.7. 1H and 13C{1H} NMR spectra of 1.10. 
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1-(3-(trifluoromethyl)phenyl)propane-1,2-diol (1.11). Following Procedure A, the 
crude oxidation mixture was purified by silica gel chromatography (1:1 hexanes:ethyl 
acetate) to yield  diol 1.11 as a colorless oil in 59% yield (12.9 mg) and 96:4 d.r (syn:anti).  
Syn diastereomer: 1H NMR (CDCl3, 600 MHz): δ 7.64 (s, 1H), 7.56 (dd, 2H, J = 16.0, 7.7 
Hz), 7.48 (t, 1H, J = 7.7 Hz), 4.45 (d, 1H, J = 7.1 Hz), 3.85 (quint, 1H, J = 6.5 Hz), 3.44 (s, 
1H), 2.89 (s, 1H), 1.10 (d, 3H, J = 6.3 Hz).  13C NMR (CDCl3, 151 MHz):  δ 142.27, 131.11, 
130.90, 130.68, 130.47, 130.33, 128.86, 124.95, 124.83, 124.81, 123.71, 123.68, 123.66, 
123.63, 78.72, 72.04, 18.88.  Anti diastereomer: 1H NMR (CDCl3, 600 MHz):  δ 7.65 (s, 
1H), 7.56 (dd, 2H, J = 16.0, 7.7 Hz), 7.48 (t, 1H, J = 7.7 Hz) 4.79 (d, 1H, J = 3.9 Hz), 4.05 
(dd, 1H, J = 6.4, 4.0 Hz), 3.17 (s, 1H), 2.89 (s, 1H), 1.06 (d, 3H, J = 6.5 Hz). 13C NMR 
(CDCl3, 151 MHz): δ 141.54, 130.71, 130.47, 130.02, 128.65, 124.45, 124.42, 123.42, 
123.39, 123.15, 76.65, 71.10, 16.90.  HRMS (ESI+) calcd for C10H11F3O2Na+: 243.0609, 
found: 243.0604 [M+Na].  IR (ν/cm-1): 3416 (br, s), 2918 (s), 2849 (s), 1647 (m), 1454 (m), 
1329 (w), 1166 (w), 1073 (m), 1127 (w), 802 (m), 705 (w).  [α]22D = +37.5 ˚ (c = 0.225, 
CH2Cl2, l = 100 mm). Enantiomeric excess was determined by HPLC analysis compared to 
the authentic racemic material. Absolute stereochemistry was inferred from the 
stereochemistry obtained for compound 1.4. Diacel CHIRALPAK IC Column; 99:1 
hexanes:iPrOH; 1.0 mL/min; 210 nm. Syn-diastereomer: (1R,2R) enantiomer: 12.7 min; 
(1S,2S) enantiomer 13.4 min: 94:6 e.r. 
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Figure 1.8. 1H and 13C{1H} NMR spectra of 1.11. 
 
1-(2-tolyl)propane-1,2-diol (1.12).  Following Procedure A, the crude oxidation 
mixture was purified by silica gel chromatography (1:1 hexanes:ethyl acetate) to yield diol 
1.12 as a colorless oil in 68% yield (10.8 mg) as a single detectable diastereomer (syn).  1H 
NMR (CDCl3, 600 MHz): δ 7.38 (dd, 1H, J = 7.5, 1.5 Hz), 7.24 – 7.11 (m, 3H), 4.68 (d, 1H, 
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J = 7.3 Hz), 3.91 (quint, 1H, J = 6.6 Hz), 2.91 (br, d, 2H), 2.36 (s, 3H), 1.06 (d, 3H, J = 6.4 
Hz).  13C NMR (CDCl3, 151 MHz): δ 139.42, 135.44, 130.53, 127.67, 126.44, 126.27, 75.01, 
72.10, 19.59, 18.54.  HRMS (ESI+) calcd for C10H14O2Na+: 189.0893, found: 189.0888 (M + 
Na+).  IR (ν/cm-1): 3292 (br, s), 2918 (s), 2360 (s), 1645 (s), 1467 (m), 1035 (w), 545 (m).  
[α]22D = +46.3 ˚ (c = 0.564, CH2Cl2, l = 100 mm). Enantiomeric excess was determined by 
HPLC analysis compared to the authentic racemic material. Absolute stereochemistry was 
inferred from the stereochemistry obtained for compound 1.4. Diacel CHIRALPAK IA 
Column; 99:1 hexanes:iPrOH; 1.0 mL/min; 210 nm. Syn-diastereomer: (1S,2S) enantiomer: 
24.8 min; (1R,2R) enantiomer 27.9 min: 93:7 e.r. 
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Figure 1.9. 1H and 13C{1H} NMR spectra of 1.12. 
 
1-mesitylpropane-1,2-diol (1.13).  Following Procedure A, the crude oxidation 
mixture was purified by silica gel chromatography (1:1 hexanes:ethyl acetate) to yield  diol 
1.13 as a colorless oil in 65% yield (12.7 mg) as a single detectable diastereomer (syn).   1H 
NMR (CDCl3, 600 MHz): δ 6.9 (s, 2H), 4.92 (d, 1H,  J = 9.1 Hz), 4.35 (dq, 1H, J = 9.1, 6.3 
Hz), 2.45 (s, 6H), 2.38 (s, 3H), 1.06 (d, 3H, J = 6.6 Hz).  13C NMR (CDCl3, 151 MHz):  δ 
137.17, 136.88, 133.24, 130.29, 76.36, 69.84, 21.15, 20.77, 18.65.  HRMS (ESI+) calcd for 
C12H18O2Na+ 217.1205, found: 217.1120 [M+Na].  IR (ν/cm-1): 3293 (br, s), 2920 (s), 1644 
(m), 1454 (m), 1121 (w), 1040 (w), 1015 (m), 705 (w).  [α]22D = +64.5 ˚ (c = 0.679, CH2Cl2, l 
= 100 mm). Enantiomeric excess was determined by HPLC analysis compared to the 
authentic racemic material. Absolute stereochemistry was inferred from the stereochemistry 
obtained for compound 1.4. Diacel CHIRALPAK IA Column; 99:1 hexanes:iPrOH; 0.75 
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mL/min; 210 nm. Syn-diastereomer: (1S,2S) enantiomer: 39.7 min; (1R,2R) enantiomer 42.3 
min: 93:7 e.r. 
 
 
Figure 1.10. 1H and 13C{1H} NMR spectra of 1.13. 
 
1-(furan-3-yl)propane-1,2-diol (1.14).  Following Procedure A, the crude oxidation 
mixture was purified by silica gel chromatography (1:1 hexanes:ethyl acetate) to yield diol 
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1.14 as a colorless oil in 56% yield (7.9 mg) and 96:4 d.r. (syn:anti).  Syn diastereomer:  1H 
NMR (CDCl3, 600 MHz): δ 7.42 (d, 1H, J = 1.0 Hz), 6.40-6.38 (m, 2H), 4.41 (m, 1H), 4.45 
(d, 1H, J = 7.0 Hz), 4.12 (m, 1H), 2.71 (s, 2H), 1.18 (d, 3H, J = 6.3 Hz).  13C NMR (CDCl3, 
151 MHz): δ 153.88, 142.40, 110.35, 107.72, 72.60, 69.86, 18.81. Anti diastereomer: 1H 
NMR (CDCl3, 600 MHz): δ 7.44 (d, 1H, J = 3.6 Hz), 6.37-6.35 (m, 2H), 4.67 (d, 1H, J = 4.4 
Hz), 4.15 (m, 1H), 2.61 (br s, 2H), 1.21 (d, 3H, J = 6.0 Hz).  13C NMR (CDCl3, 101 MHz): δ 
153.53, 142.34, 110.35, 107.92, 71.80, 69.97, 18.29.  HRMS (ESI+) calcd for C7H10O3Na+ 
165.0528, found: 165.05221 [M+Na].  IR (ν/cm-1): 3416 (br, s), 2980 (s), 1643 (s), 1454 
(m), 1380 (m), 1148 (w), 1011 (m), 674 (w).  [α]22D = +15.4 ˚ (c = 0.232, CH2Cl2, l = 100 
mm). Enantiomeric excess was determined by HPLC analysis compared to the authentic 
racemic material. Absolute stereochemistry was inferred from the stereochemistry obtained 
for compound 1.4. Diacel CHIRALPAK IA Column; 99:1 hexanes:iPrOH; 1.0 mL/min; 210 
nm. Syn-diastereomer: (1S,2S) enantiomer: 30.4 min; (1R,2R) enantiomer 32.8 min: 95:5 e.r. 
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Figure 1.11. 1H and 13C{1H} NMR spectra of 1.14. 
 
1-(pyridin-3-yl)propane-1,2-diol (1.15).  Following Procedure A, the crude 
oxidation mixture was purified by silica gel chromatography (1:1 hexanes:ethyl acetate) to 
yield diol 1.15 as a colorless oil in 68% yield (10.4 mg) and 84:16 d.r (syn:anti).  Syn 
diastereomer: 1H NMR (CDCl3, 600 MHz): δ 8.60 (br, d, 2H, J = 11.6 Hz), 7.77 (d, 1H, J = 
8.0 Hz), 7.34 (m, 1H), 4.47 (d, 1H, J = 7.0 Hz), 3.90 (m, 1H), 1.13 (d, 3H, J = 4 Hz). 13C 
NMR (CDCl3, 151 MHz) δ 149.09, 148.34, 134.63, 123.44, 77.26, 77.05, 76.84, 75.21, 
70.98, 17.20. Anti Diastereomer: 1H NMR (CDCl3, 600 MHz):  δ 8.60 (br d, 2H, J = 11.6 
Hz), 7.77 (d, 1H, J = 8.0 Hz), 7.34 (m, 1H), 4.78 (d, 1H, J = 4.0 Hz), 4.11 (m, 1H), 1.09 (d, 
3H, J = 6.3 Hz).  13C NMR (CDCl3, 151 MHz) δ 149.09, 148.34, 134.63, 123.44, 77.26, 
77.05, 76.84, 75.21, 70.98, 17.20.  HRMS (ESI+) calcd for C8H12O2N+ 154.168, found: 
154.182 [M+H].  IR (neat): 3322 (br, s), 2963 (s), 1584 (s), 1470 (m), 1370 (m), 1302 (m), 
1290 (m), 1085 (w), 900 (m), 808 (w).  [α]22D = +14.2 ˚ (c = 0.145, CH2Cl2, l = 100 mm). 
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Enantiomeric excess was determined by HPLC analysis compared to the authentic racemic 
material. Absolute stereochemistry was inferred from the stereochemistry obtained for 
compound 1.4. Diacel CHIRALPAK IC Column; 85:15 hexanes:iPrOH; 0.5 mL/min; 210 
nm. Syn-diastereomer: (1R,2R) enantiomer: 37.2 min; (1S,2S) enantiomer 39.8 min: 90:10 e.r. 
 
 
Figure 1.12. 1H and 13C{1H} NMR spectra of 1.15. 
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1.8.3 Preparation of vinyl 1,2-diols 
 
(2R,E)-5-phenylpent-4-ene-2,3-diol (1.16). Following Procedure C, the crude 
oxidation mixture was purified by silica gel chromatography (2:1 to 1:1 hexanes:ethyl 
acetate), the product diol 1.16 was isolated as a colorless oil in 59% yield (10.5 mg) and 
54:46 d.r (anti:syn).  anti-diastereomer: 1H NMR (CDCl3, 600 MHz): δ 7.40 (t, 2H, J = 6.8 
Hz), 7.33 (d, 2H, J = 7.2 Hz), 7.26 (t, 1H, J = 6.6 Hz), 6.67 (d, 1H, J = 12.6 Hz), 6.27 (dd, 
1H, J = 16.2, 7.2 Hz), 4.26 (dd, 1H, J = 7.2, 1.2 Hz), 3.97 (m, 1H), 1.20 (d, 1H, J = 6.6 Hz);  
13C NMR  (CDCl3, 151 MHz): δ 136.51, 133.26, 128.76, 128.12, 127.18, 126.70, 76.70, 
70.45, 17.88;  syn-diastereomer: 1H NMR (CDCl3, 600 MHz): δ 7.40 (t, 2H, J = 6.8 Hz), 
7.33 (d, 2H, J = 7.2 Hz), 7.26 (t, 1H, J = 6.6 Hz), 6.69 (d, 1H, J = 13.2 Hz), 6.19 (dd, 1H, J = 
16.2, 7.2 Hz), 4.04 (td, 1H, J = 8.4, 1.2 Hz), 3.75 (quint, 1H, J = 6.0 Hz), 1.23 (d, 1H, J = 6.0 
Hz);  13C NMR  (CDCl3, 151 MHz): δ 136.47, 133.02, 128.77, 128.45, 128.09, 126.70, 
77.92, 71.08, 19.16;  IR (ν/cm-1): 3385 (OH, br, s), 3027 (w), 2972 (w), 2925 (m), 2870 (w), 
2851 (w), 1457 (m), 1375 (w), 1070 (w), 1027 (w), 968 (m), 748 (m), 693 (m), 505 (w);  
HRMS-(ESI+) [M+Na]+ calcd for C11H14NaO2+ 201.0892, found: 201.0887. Enantiomeric 
purity was determined by HPLC analysis compared to the authentic racemic material. 
Absolute stereochemistry was inferred from the stereochemistry obtained for compound 1.20 
and 1.23 (defunctionalization experiment, see section 1.8.4 below).26 Diacel CHIRALPAK IB 
Column; 98:2 hexanes:iPrOH; 0.75 mL/min; 22 °C, 210 nm. Syn-diastereomers: (2S,3S)-
enantiomer: 87.4 min.; (2R,3R)-enantiomer: 113.1 min.: 92:8 e.r.; anti-diastereomers: 
(2R,3S)-enantiomer: 89.8 min.; (2S,3R)-enantiomer: 142.5 min.: 97:3 e.r. 
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Figure 1.13. 1H and 13C{1H} NMR spectra of 1.16. 
 
(2R,E)-5-(4-chlorophenyl)pent-4-ene-2,3-diol (1.17). Following Procedure C, the 
crude oxidation mixture was purified by silica gel chromatography (2:1 to 1:1 hexanes:ethyl 
acetate), the product diol 1.17 was isolated as a colorless oil in 38% yield (8.1 mg) and 54:46 
d.r (anti:syn).  anti-diastereomer: 1H NMR (600 MHz, CDCl3): δ 7.28-7.32 (m, 4H), 6.60 
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(d, 1H, J = 15.0 Hz), 6.24 (dd, 1H, J = 16.2, 7.2 Hz), 4.25 (dd, 1H, J = 7.2, 1.2 Hz), 3.97 (m, 
1H), 1.19 (d, 1H, J = 6.6 Hz);  syn-diastereomer: 1H NMR (600 MHz, CDCl3): δ 7.28-7.32 
(m, 4H), 6.64 (d, 1H, J = 13.8 Hz), 6.17 (dd, 1H, J = 16.2, 7.2 Hz), 4.03 (t, 1H, J = 6.6 Hz), 
3.75 (quint, 1H, J = 6.0 Hz), 1.23 (d, 1H, J = 7.8 Hz);  mixture of syn- and anti-
diastereomers: 13C NMR (151 MHz, CDCl3): δ 135.04, 134.98, 133.74, 133.69, 131.86, 
131.66, 129.15, 128.93, 128.92, 127.89, 77.67, 76.47, 71.02, 70.42, 19.25, 17.88;  IR (ν/cm-
1): 3384 (OH, br, s), 2973 (m), 2927 (m), 2870 (m), 1491 (m), 1472 (w), 1457 (w), 1405 (w), 
1374 (w), 1135 (w), 1091 (m), 1012 (m), 969 (m), 853 (w), 824 (w);  HRMS-(ESI+) 
[M+Na]+ calcd for C11H13ClNaO2+ 235.0502, found: 235.0496. Enantiomeric purity was 
determined by HPLC analysis compared to the authentic racemic material. Absolute 
stereochemistry was inferred from the stereochemistry obtained for compounds 1.20 and 
1.23. Diacel CHIRALPAK IA Column; 90:10 hexanes:EtOAc; 1.00 mL/min; 22 °C, 254 nm. 
Syn-diastereomers: (2S,3S)-enantiomer: 67.6 min.; (2R,3R)-enantiomer: 71.3 min.: 94:6 e.r.; 
anti-diastereomers: (2R,3S)-enantiomer: 89.8 min.; (2S,3R)-enantiomer: 103.6 min.; 97:3 e.r. 
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Figure 1.14. 1H and 13C{1H} NMR spectra of 1.17. 
 
(2R,E)-5-(4-nitrophenyl)pent-4-ene-2,3-diol (1.18). Following Procedure C, the 
crude oxidation mixture was purified by silica gel chromatography (1:1 pentane:ethyl 
acetate), the product diol 1.18 was isolated as a viscous orange oil in 46% yield (10.2 mg) 
and 55:45 d.r (syn:anti).  syn-diastereomer: 1H NMR (600 MHz, CDCl3): δ 8.19 (d, 2H, J = 
8.4 Hz), 7.52 (d, 2H, J = 8.4 Hz), 6.78 (d, 1H, J = 16.8 Hz), 6.40 (dd, 1H, J = 16.2, 6.0 Hz), 
4.11 (t, 1H, J = 6.6 Hz), 3.79 (quint, 1H, J = 6.6 Hz), 1.27 (d, 1H, J = 6.0 Hz);  anti-
diastereomer: 1H NMR (600 MHz, CDCl3): 8.19 (d, 2H, J = 8.4 Hz), 7.53 (d, 2H, J = 8.4 
Hz), 6.75 (d, 1H, J = 16.2 Hz), 6.46 (dd, 1H, J = 15.6, 6.0 Hz), 4.33 (m, 1H), 4.02 (m, 1H), 
1.21 (d, 1H, J = 6.0 Hz);  mixture of syn- and anti-diastereomers: 13C NMR (151 MHz, 
CDCl3): δ 147.23, 147.20, 143.06, 142.99, 133.52, 132.34, 130.48, 130.36, 127.22, 127.20, 
124.17, 75.99, 70.91, 70.41, 19.39, 17.89;  IR (ν/cm-1): 3392 (OH, br, s), 2976 (w), 2926 (w), 
2855 (w), 1596 (m), 1515 (m), 1345 (m), 1110 (w), 1076 (w), 1027 (w), 975 (w), 913 (w), 
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849 (w), 747 (w);  HRMS-(ESI+) [M+Na]+ calcd for C11H13NNaO4+ 246.0742, found: 
246.0738. Enantiomeric purity was determined by SFC analysis compared to the authentic 
racemic material. Absolute stereochemistry was inferred from the stereochemistry obtained 
for compounds 1.20 and 1.23. Regis RegisPack (RP, cat# 783104) column; 93:7 CO2:MeOH; 
1.00 mL/min; 40 °C, 210 nm (SFC). Syn-diastereomers: (2S,3S)-enantiomer: 66.7 min.; 
(2R,3R)-enantiomer: 81.5 min.: 95:5 e.r.; anti-diastereomers: (2R,3S)-enantiomer: 81.5 min.; 
(2S,3R)-enantiomer: 99.7 min.: 95:5 e.r. 
 
 
Figure 1.15. 1H and 13C{1H} NMR spectra of 1.18. 
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(2R,E)-5-(2-methoxyphenyl)pent-4-ene-2,3-diol (1.19). Following Procedure C, the 
crude oxidation mixture was purified by silica gel chromatography (1:1 pentane:ethyl 
acetate), the product diol 1.19 was isolated as an unstable pale yellow oil inseparable from 
pinacol in maximum 75% yield (15.7 mg) and 55:45 d.r (syn:anti). A 1H NMR spectrum of 
the crude hydroxyboronate product and 1H and 13C NMR spectra of the unstable (impure) 
diol 1.19 are provided, in addition to IR and HRMS data. The product is not sufficiently 
stable to obtain a complete set of clean characterization data, nor was it possible to assay the 
enantiomeric purity of the products via HPLC.  IR (ν/cm-1): 3418 (OH, br, s), 2979 (s), 2939 
(m), 2838 (w), 1598 (w), 1490 (m), 1466 (m), 1439 (m), 1370 (m), 1245 (m), 1156 (m), 1112 
(m), 1030 (m), 975 (w), 951 (m), 884 (w), 829 (w), 751 (w), 671 (w);  HRMS-(ESI+) 
[M+Na]+ calcd for C12H16NaO3+ 231.0997, found: 231.0991. 
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Figure 1.16. 1H of crude hydroxyboronate and 1H and 13C{1H} NMR spectra of diol 1.19. 
 
(2R,3R,E)-4-methyl-5-phenylpent-4-ene-2,3-diol (1.20). Following Procedure B, 
the crude oxidation mixture was purified by silica gel chromatography (2:1 to 1:1 
hexanes:ethyl acetate), the product diol 1.20 was isolated as a colorless oil in 54% yield (10.4 
mg) and 97:3 d.r (syn:anti).  syn-diastereomer: 1H NMR (CDCl3, 600 MHz): δ 7.34 (t, 2H, 
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J = 7.2), 7.28 (d, 2H, J = 7.8), 7.23 (t, 1H, J = 7.2), 6.54 (s, 1H), 3.87-3.91 (m, 2H), 1.88 (d, 
3H, J = 1.2), 1.20 (d, 3H, J = 6.0);  13C NMR  (CDCl3, 151 MHz): δ 137.35, 137.21, 129.12, 
128.57, 128.31, 126.87, 83.20, 69.22, 19.23, 13.82;  IR (ν/cm-1): 3385 (OH, br, s), 3024 (w), 
2970 (m), 2925 (m), 2862 (m), 1457 (m), 1374 (w), 1273 (w), 1127 (m), 1072 (w), 1040 (m), 
1012 (m), 918 (w), 885 (w), 865 (w), 751 (m), 699 (m), 592 (w), 506 (m);  HRMS-(ESI+) 
[M+Na]+ calcd for C12H16NaO2+ 215.1048, found: 215.1043; [α]D19 = +50.2° (c = 0.485, 
CH2Cl2, l = 100 mm), Lit.: [α]D25 = +69.8° (c = 1.2, EtOH),26 Lit.: [α]D20 = +76° (c = 1.0, 
EtOH).27 Enantiomeric purity was determined by HPLC analysis compared to the authentic 
racemic material. Absolute stereochemistry was determined by comparison of the [α]D value 
to those previously reported. Diacel CHIRALPAK IC Column; 90:10 hexanes:EtOAc; 1.00 
mL/min; 22 °C, 254 nm. Syn-diastereomers: (2S,3S)-enantiomer: 20.4 min.; (2R,3R)-
enantiomer: 22.6 min.: 90:10 e.r. 
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Figure 1.17. 1H and 13C{1H} NMR spectra of 1.20. 
 
(1R,2R)-1-(cyclohex-1-en-1-yl)propane-1,2-diol (1.21). Following Procedure B, the 
crude oxidation mixture was purified by silica gel chromatography (2:1 to 1:1 hexanes:ethyl 
acetate), the product diol 1.21 was isolated as a colorless oil in 34% yield (5.3 mg) and 96:4 
d.r (syn:anti).  syn-diastereomer: 1H NMR (600 MHz, CDCl3): δ 5.72 (m, 1H), 3.77 (quint, 
1H, J = 6.6 Hz), 3.67 (d, 1H, J = 7.2 Hz), 2.10-2.14 (m, 2H), 2.03 (m, 2H), 1.49-1.69 (m, 
4H), 1.12 (d, 3H, J = 6.6 Hz);  13C NMR (151 MHz, CDCl3): δ 137.33, 126.09, 81.78, 69.08, 
25.19, 24.26, 22.71, 22.65, 19.07;  IR (ν/cm-1): 3384 (OH, br, s), 2964 (w), 2927 (m), 2857 
(w), 2836 (w), 1507 (w), 1489 (w), 1457 (w), 1437 (w), 1372 (w), 1240 (w), 1126 (w), 1064 
(w), 1020 (m), 918 (w), 838 (w), 816 (w), 777 (w), 696 (w), 506 (w);  HRMS-(ESI+) 
[M+Na]+ calcd for C9H16NaO2+ 179.1048, found: 179.1044; [α]D20 = +2.7° (c = 0.245, 
CH2Cl2, l = 100 mm). Enantiomeric purity was determined by HPLC analysis compared to 
the authentic racemic material. Absolute stereochemistry was inferred from the 
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stereochemistry obtained for compound 1.20 and 1.23. Diacel CHIRALPAK IC Column; 99:1 
hexanes:iPrOH; 0.75 mL/min; 22 °C, 190 nm. Syn-diastereomers: (1R,2R)-enantiomer: 75.5 
min.; (1S,2S)-enantiomer: 81.1 min.: 83:17 e.r. 
 
 
Figure 1.18. 1H and 13C{1H} NMR spectra of 1.21. 
1.8.4 Control of C–B stereogenic center 
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(4R)-4-methyl-5-((E)-styryl)-1,3-dioxolan-2-one (1.22).  Diol 1.16 ((2R,E)-5-
phenylpent-4-ene-2,3-diol) was transformed to the title cyclic carbonate 1.22 according to a 
modified literature procedure.21 A flame-dried 20-mL scintillation vial equipped with a 
magnetic stir bar was flushed with N2 and charged with diol 1.16 (44.7 mg, 0.251 mmol) and 
1.9 mL of anhydrous THF. Carbonyldiimidazole (61.0 mg, 0.376 mmol) was added to the 
stirring solution and the headspace was purged with N2. The solution was allowed to stir for 
5 h, during which time it was monitored by TLC (2:1 hexanes:ethyl acetate, UV 
visualization). Water was added to quench the reaction when the diol was observed to be 
consumed. The crude reaction mixture was purified by silica gel column chromatography 
(2:1 hexanes:ethyl acetate) and the 52:48 d.r. mixture of carbonate diastereomers 1.22 was 
isolated as a viscous oil in 60% yield (30.7 mg).  1H NMR (600 MHz, CDCl3): δ 7.40-7.43 
(m, 4H), 7.35-7.38 (m, 4H), 7.32-7.34 (m, 2H), 6.78 (d, 2H, J = 16.2 Hz), 6.16 (m, 2H), 5.28 
(t, 1H, J = 5.3 Hz), 4.95 (quintt, 1H, J = 7.2 Hz), 4.77 (t, 1H, J = 7.8 Hz), 4.53 (m, 1H), 1.53 
(d, 3H, J = 6 Hz), 1.40 (d, 3H, J = 6.6 Hz);  13C NMR (151 MHz, CDCl3): δ 154.53, 154.39, 
137.11, 136.86, 135.15, 134.93, 129.29, 129.15, 128.98, 128.98, 127.12, 127.06, 121.84, 
119.79, 84.73, 80.67, 78.76, 76.58, 18.19, 15.90;  IR (ν/cm-1): 2979 (w), 2953 (w), 2919 (m), 
2851 (w), 1798 (CO, s), 1450 (w), 1351 (w), 1186 (m), 1070 (m), 1020 (m), 971 (w), 776 
(w), 753 (w), 693 (w), 536 (w);  HRMS-(ESI+) [M+Na]+ calcd for C12H12NaO3+ 227.0684, 
found: 227.0679. The enantiomeric purity of the diol starting material (1.16) for the 
carbonate protection/defunctionalization sequence was independently determined by HPLC 
analysis: Diacel CHIRALPAK IB Column; 98:2 hexanes:iPrOH; 0.75 mL/min; 22 °C, 210 
nm. Syn-diastereomers: (2S,3S)-enantiomer: 90.4 min.; (2R,3R)-enantiomer: 118.9 min.: 
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90:10 e.r.; anti-diastereomers: (2R,3S)-enantiomer: 94.9 min.; (2S,3R)-enantiomer: 147.5 
min.: 97:3 e.r. 
 
 
Figure 1.19. 1H and 13C{1H} NMR spectra of 1.22. 
 
(R)-5-phenylpentan-2-ol (1.23).  Compound 1.22 was defunctionalized and then 
hydrogenated to the title alcohol 1.23 according to a modified literature procedure.21 In an 
N2-filled glove box, an 8-mL vial equipped with a magnetic stir bar and septum cap was 
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charged with carbonate (14.8 mg, 0.0725 mmol) and a 560 µL THF solution containing 
Pd2(dba)3 (0.67 mg, 0.000725 mmol) and PPh3 (0.38 mg, 0.00145). The vial was removed 
from the glove box, cooled to 0 °C, and charged with Et3N (50 µL, 0.363 mmol) and 
HCOOH (27 µL, 0.725 mmol). The reaction was monitored by TLC (2:1 hexanes/diethyl 
ether, UV visualization), and after 5 hours the solvent was removed by purging with a stream 
of H2 gas. Pd/C (15 mg (5 wt %), 0.00725 mmol) was added to the vial, in addition to 1.0 mL 
of wet methanol. The septum cap was replaced and the headspace was purged with H2 gas. 
The solution was allowed to vigorously stir at 22 °C for 1 h before being filtered through a 
plug of silica gel with ethyl acetate. The crude reaction mixture was purified by silica gel 
column chromatography (2:1 hexanes:diethyl ether) to yield the title compound as a clear, 
colorless oil in 50% yield (6.0 mg). The title compound was found to be identical to literature 
spectra.28 HPLC analysis of compound 1.23 in comparison to a previously prepared racemic 
sample provided an enantiomeric ratio of 92:8 e.r., which can be compared to the average e.r. 
of the two diol diastereomers (52:48 (syn:anti); syn: 90:10 e.r.; anti: 97:3 e.r.) from which it 
was derived. The measured optical rotation [α]D20 = –7.4° (c = 0.455, CH2Cl2, l = 100 mm) 
matches the sign and approximate magnitude of the opposite enantiomer of that reported in 
the literature (lit.28 [α]D20 = +8.0° (c = 1.0, CHCl3, 97% ee, (S)-isomer) and lit.29 [α]D27 = 
+8.47° (c = 3.0, CHCl3, (S)-isomer)). Enantiomeric purity was determined by HPLC analysis 
compared to the authentic racemic material. Absolute stereochemistry was determined by 
comparison with the signs of the previously reported [α]D values (above).
 Diacel 
CHIRALPAK IC Column; 99:1 hexanes:iPrOH; 0.20 mL/min; 22 °C, 210 nm. (R)-
enantiomer: 118.3 min., (S)-enantiomer: 126.6 min.: 92:8 e.r. 
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Figure 1.20. 1H and 13C{1H} NMR spectra of 1.23. 
1.8.5 Functionalizations of 1,2-hydroxyboronates 
1.8.5.1 Boron homologation 
 
(1S,2R)-1-phenyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-ol 
(1.2). Following Procedure A, the product was obtained in 75% yield and 85:15 syn:anti d.r 
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(based on hexamethyldisiloxane as an internal standard). The crude residue was purified by 
silica gel column chromatography (20:1 hexanes:ethyl acetate to 2:1 hexanes:diethyl ether) 
and the title compound was isolated as a clear, colorless oil in 53% yield (140 mg) and 89:11 
d.r. (syn:anti).  syn-diastereomer: 1H NMR (CDCl3, 400 MHz): δ 7.30-7.36 (m, 5H), 4.60 
(dd, 1H, J = 8.0, 4.8 Hz), 2.78 (d, 1H, J = 4.8 Hz), 1.54 (quint, 1H, J = 7.6 Hz), 1.24 (s, 
12H), 0.88 (d, 3H, J = 7.2 Hz);  13C NMR (CDCl3, 100 MHz): δ 144.46, 128.24, 127.34, 
126.44, 83.53, 77.54, 24.84, 24.72, 12.47;  IR (ν/cm-1): 3481 (OH, br, s), 3085 (w), 3062 (w), 
3030 (w), 2978 (s), 2932 (m), 2876 (m), 1494 (w), 1458 (m), 1381 (m), 1320 (m), 1275 (w), 
1247 (w), 1215 (w), 1167 (w), 1145 (m), 1111 (w), 1073 (w), 1059 (w), 1009 (w), 966 (w), 
910 (w), 863 (w), 844 (w), 764 (w), 701 (w), 675 (w);  HRMS-(ESI+) [M+Na]+ calcd for 
C15H23BNaO3+ 285.1638, found: 285.1634;  [α]D21 = –10.6° (c = 7.00, CH2Cl2, l = 100 mm). 
The enantiomeric purity of the hydroxyboronate starting material (1.2) for the TBS-
protection/homologation sequence was independently determined by HPLC analysis via 
oxidation of a small portion of hydroxyboronate 1.2 to diol 1.4 according to the general 
oxidation procedure. Diacel CHIRALPAK IA Column; 99:1 hexanes:iPrOH; 1.00 mL/min; 
22 °C, 210 nm. Syn-diastereomers: (S,S)-enantiomer: 29.5 min.; (R,R)-enantiomer: 37.0 min.: 
93:7 e.r. 
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Figure 1.21. 1H and 13C{1H} NMR spectra of 1.2. 
 
tert-butyldimethyl((1S,2R)-1-phenyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)propoxy)silane (1.27).  The title benzylic tert-butyldimethylsilyl ether 1.27 was prepared 
from hydroxyboronate 1.2 according to a standard literature procedure.30 A flame-dried 8-mL 
vial equipped with a magnetic stir bar was charged with hydroxyboronate 1.2 (65.5 mg, 
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0.250 mmol) and 2.0 mL of anhydrous DMF. Imidazole (34.0 mg, 0.500 mmol) was added, 
followed by tert-butyldimethylsilyl chloride (56.5 mg, 0.375 mmol). The vial was capped 
with a screw-cap septum and purged with N2 for 5 minutes before being allowed to stir at 22 
°C for 24 h (TLC monitoring; 2:1 hexanes:diethyl ether, Rf = 0.7, UV and Seebach stain). 
The reaction was quenched with 1.0 mL of a saturated aqueous solution of NH4Cl, and the 
aqueous layer was extracted three times with ethyl acetate. The combined organic layers 
were then washed twice with saturated aqueous NaHCO3, followed by two washes with 
saturated aqueous NaCl. The resulting organic layer was dried over MgSO4, filtered, and 
concentrated in vacuo. The crude residue was purified by silica gel column chromatography 
(25:1 pentane:diethyl ether) and 1.27 was isolated as a colorless oil in 76% yield (71.8 mg) 
and 89:11 d.r. (syn:anti).  syn-diastereomer: 1H NMR (CDCl3, 600 MHz): δ 7.30 (dd, 2H, J 
= 7.8, 1.2 Hz), 7.26 (t, 2H, J = 7.2 Hz), 7.19 (tt, 1H, J = 7.2, 1.8 Hz), 4.71 (d, 1H, J = 7.8 
Hz), 1.49 (quint, 1H, J = 7.8 Hz), 1.24 (d, 12H, J = 5.4 Hz), 0.86 (s, 9H), 0.75 (d, 3H, J = 7.2 
Hz), 0.02 (s, 3H), –0.29 (s, 3H);  13C NMR (CDCl3, 151 MHz): δ 145.21, 127.74, 127.01, 
126.91, 83.06, 77.78, 26.07, 25.35, 24.81, 18.26, 11.68, –4.34, –4.64;  IR (ν/cm-1): 3086 (w), 
3063 (w), 3030 (w), 2978 (m), 2957 (m), 2929 (m), 2886 (m), 2857 (m), 1493 (w), 1471 (w), 
1462 (m), 1402 (w), 1380 (m), 1371 (m), 1319 (m), 1255 (m), 1211 (w), 1184 (w), 1166 (w), 
1146 (m), 1110 (w), 1078 (w), 1060 (m), 1029 (w), 1006 (w), 967 (w), 861 (m), 836 (m), 816 
(w), 775 (m), 754 (w), 701 (m), 670 (w), 588 (w), 533 (w), 510 (w).  HRMS-(ESI+) 
[M+Na]+ calcd for C21H37BNaO3Si+ 399.2503, found: 399.2498;  [α]D17 = –23.8° (c = 3.59, 
CH2Cl2, l = 100 mm). 
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Figure 1.22. 1H and 13C{1H} NMR spectra of 1.27. 
 
tert-butyldimethyl((1S,2S)-2-methyl-1-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)propoxy)silane (1.24).  Homologated pinacol boronic ester 1.24 was 
prepared from TBS-protected 1.27 according to a modified literature procedure.31 To a stirred 
solution of TBS-protected 1.27 (35.0 mg, 0.0930 mmol) and dibromomethane (16 µL, 0.233 
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mmol) in anhydrous THF (0.93 mL) at –78 °C in a flame-dried 8-mL vial equipped with a 
magnetic stir bar, was added n-BuLi (1.6 M in hexanes, 0.205 mmol) dropwise. The resulting 
mixture was stirred for 10 min. at –78 °C and then warmed to 22 °C and allowed to stir for 2 
h. The reaction was quenched with 1.0 mL of a saturated aqueous solution of NH4Cl, and the 
aqueous layer was diluted with 1.0 mL of deionized water and extracted three times with 
diethyl ether. The resulting organic layer was dried over MgSO4, filtered, and concentrated in 
vacuo. The crude residue was purified by silica gel column chromatography (25:1 
pentane:diethyl ether; TLC in 4:1 hexanes:diethyl ether, Rf = 0.65, Seebach stain) and the 
title compound 1.24 was isolated as a colorless oil in 75% yield (27.3 mg) and 91:9 d.r. 
(syn:anti).  syn-diastereomer: 1H NMR (CDCl3, 600 MHz): δ 7.24-7.27 (m, 4H), 7.18-7.21 
(m, 1H), 4.39 (d, 1H, J = 6.0 Hz), 1.97 (m, 1H), 1.23 (d, 12H, J = 3.0 Hz), 1.03 (dd, 1H, J = 
15.6, 4.2 Hz), 0.87 (s, 9H), 0.80 (d, 3H, J = 7.2 Hz), 0.62 (dd, 1H, J = 15.6, 10.2 Hz), 0.01 (s, 
3H), –0.24 (s, 3H);  13C NMR (CDCl3, 151 MHz): δ 144.15, 127.63, 127.24, 126.78, 82.98, 
80.32, 37.99, 26.05, 25.14, 24.83, 18.41, 18.36, –4.48, –4.87;  IR (ν/cm-1): 3087 (w), 3063 
(w), 3028 (w), 2977 (m), 2957 (m), 2929 (m), 2888 (m), 2857 (m), 1493 (w), 1471 (w), 1463 
(w), 1370 (m), 1318 (m), 1255 (m), 1214 (w), 1165 (w), 1146 (m), 1087 (m), 1063 (m), 1027 
(w), 1006 (w), 970 (w), 941 (w), 913 (w), 860 (m), 837 (m), 775 (m), 746 (w), 702 (m), 671 
(w), 629 (w), 577 (w), 548 (w), 502 (w).  HRMS-(ESI+) [M+Na]+ calcd for C22H39BNaO3Si+ 
413.2660, found: 413.2654;  [α]D22 = –24.2° (c = 1.37, CH2Cl2, l = 100 mm). 
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Figure 1.23. 1H and 13C{1H} NMR spectra of 1.24. 
1.8.5.2 Conversion to amine 
 
(3S,4R,E)-2-methyl-1-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)pent-1-en-3-ol (1.25). Following Procedure B, the title hydroxyboronate 1.25 was 
produced in 66% yield and 96:4 d.r. (syn:anti). The crude residue was purified by silica gel 
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column chromatography (20:1 hexanes:ethyl acetate to 2:1 hexanes:diethyl ether) and the 
title compound was isolated as a viscous, clear, yellow oil in 54% yield (115 mg) and 98:2 
d.r. (syn:anti).  syn-diastereomer: 1H NMR (CDCl3, 600 MHz): δ 7.35 (t, 2H, J = 7.2 Hz), 
7.30 (d, 2H, J = 6.6 Hz), 7.23 (t, 1H, J = 7.2 Hz), 6.50 (s, 1H), 4.12 (dd, 1H, J = 9.0 Hz, 4.2 
Hz), 2.61 (d, 1H, J = 4.2 Hz), 1.87 (d, 3H, J = 1.2 Hz), 1.51 (m, 1H, J = 7.8 Hz), 1.29 (d, 
12H, J = 2.4 Hz), 0.98 (d, 3H, J = 7.8 Hz).  13C NMR (CDCl3, 151 MHz): δ 139.72, 137.90, 
129.16, 128.17, 126.68, 126.42, 83.60, 81.33, 24.96, 24.83, 12.88, 12.63;  IR (ν/cm-1): 3494 
(OH, br, m), 2978 (m), 2930 (w), 2874 (w), 1491 (w), 1458 (m), 1381 (m), 1321 (m), 1274 
(w), 1245 (w), 1215 (w), 1167 (w), 1145 (m), 1110 (w), 1056 (w), 998 (m), 966 (w), 917 (w), 
845 (m), 751 (m), 700 (m), 669 (w), 516 (w), 504 (w);  HRMS-(ESI+) [M+Na]+ calcd for 
C18H27BNaO3+ 325.1951, found: 325.1950;  [α]D19 = +20.9° (c = 4.23, CH2Cl2, l = 100 mm). 
The enantiomeric purity of the hydroxyboronate starting material (1.25) for the TBS-
protection/amination sequence was independently determined by HPLC analysis via 
oxidation of a small portion of hydroxyboronate 1.25 to diol 1.20 according to the general 
oxidation procedure. Diacel CHIRALPAK IC Column; 90:10 hexanes:EtOAc; 1.00 mL/min; 
22 °C, 254 nm. Syn-diastereomers: (S,S)-enantiomer: 20.3 min.; (R,R)-enantiomer: 22.4 min.: 
92:8 e.r. 
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Figure 1.24. 1H and 13C{1H} NMR spectra of 1.25. 
 
tert-butyldimethyl(((3S,4R,E)-2-methyl-1-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)pent-1-en-3-yl)oxy)silane (1.28).  The title allylic tert-butyldimethylsilyl 
ether 1.28 was prepared from hydroxyboronate 1.25 according to a literature procedure.30 A 
flame-dried 8-mL vial equipped with a magnetic stir bar was charged with hydroxyboronate 
	
Me
OTBS
B
1.28
Me
O O
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1.25 (57.5 mg, 0.190 mmol) and 1.54 mL of anhydrous DMF. Imidazole (25.9 mg, 0.380 
mmol) was added, followed by tert-butyldimethylsilyl chloride (43.0 mg, 0.285 mmol). The 
vial was capped with a screw-cap septum and purged with N2 for 5 minutes before being 
allowed to stir at 22 °C for 20 h. The progress of the reaction was followed by TLC (2:1 
hexanes:diethyl ether, Rf = 0.75, UV visualization). The reaction was quenched with 1.0 mL 
of a saturated aqueous solution of NH4Cl, and the aqueous layer was extracted three times 
with ethyl acetate. The combined organic layers were then washed twice with saturated 
aqueous NaHCO3, followed by two washes with saturated aqueous NaCl. The resulting 
organic layer was dried over MgSO4, filtered, and concentrated in vacuo. The crude residue 
was purified by silica gel column chromatography (25:1 pentane:diethyl ether) and the title 
compound 1.28 was isolated as a colorless oil in 64% yield (50.6 mg) and as a single 
detectable diastereomer.  syn-diastereomer: 1H NMR (CDCl3, 400 MHz): δ 7.33 (t, 2H, J = 
7.6 Hz), 7.27 (d, 2H, J = 8.4 Hz), 7.21 (t, 1H, J = 7.2 Hz), 6.40 (s, 1H), 4.19 (d, 1H, J = 9.2 
Hz), 1.80 (d, 3H, J = 1.2 Hz), 1.44 (quint, 1H, J = 8.4 Hz), 1.26 (d, 12H, J = 6.4 Hz), 0.91 (s, 
9H), 0.85 (d, 3H, J = 7.6 Hz), 0.12 (s, 3H), 0.03 (s, 3H);  13C NMR (CDCl3, 100 MHz): δ 
140.36, 138.20, 129.02, 128.18, 126.74, 126.27, 83.01, 81.99, 26.17, 25.41, 24.80, 18.36, 
12.64, 12.52, –4.05, –4.65;  IR (ν/cm-1): 3082 (w), 3059 (w), 3025 (w), 2976 (m), 2955 (m), 
2930 (m), 2889 (m), 2857 (m), 1462 (m), 1380 (m), 1320 (m), 1252 (m), 1146 (m), 1109 (w), 
1058 (m), 1005 (m), 967 (w), 876 (m), 836 (m), 775 (m), 749 (w), 699 (m), 666 (w);  
HRMS-(ESI+) [M+Na]+ calcd for C24H41BNaO3Si+ 439.2816, found: 439.2811;  [α]D19 = 
+16.2° (c = 2.53, CH2Cl2, l = 100 mm). 
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Figure 1.25. 1H and 13C{1H} NMR spectra of 1.28. 
 
tert-butyl((2R,3R,E)-3-((tert-butyldimethylsilyl)oxy)-4-methyl-5-phenylpent-4-en-
2-yl)carbamate (1.26).  Carbamate 1.26 was prepared from compound 1.28 according to 
literature procedure.3 A flame-dried 8-mL vial equipped with a magnetic stir bar was flushed 
with N2 and charged with 1.28 (25.2 mg, 0.0605 mmol) and 500 µL of anhydrous THF. A 
Me
OTBS
NHBoc
1.26
Me
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0.928 M solution of O-methylhydroxylamine (196 µL, 0.182 mmol) was added to a separate 
N2-flushed, flame-dried 8-mL vial and then diluted with 418 µL of anhydrous THF. Both 
vials were cooled to –78 °C in a dry ice/acetone bath. A 1.59 M solution of n-butyllithium in 
hexanes (114 µL, 0.182 mmol) was added dropwise to the O-methylhydroxylamine solution 
and this was allowed to stir at –78 °C for 30 minutes. After this time, the in situ generated 
solution of lithium O-methylhydroxylamide was cannula transferred to the cooled solution of 
1.28. The resulting solution was allowed to warm to room temperature and was then heated 
to 60 °C with stirring for 20 h. After this time, the solution was allowed to cool to 22 °C and 
di-tert-butyl dicarbonate (44.5 µL, 0.194 mmol) was added via syringe. The solution was 
allowed to stir for 2 hours at 22 °C. The reaction was quenched with 3 mL of deionized 
water, and the aqueous layer was extracted four times with ethyl acetate. The combined 
organic layers were then dried over Na2SO4, filtered, and concentrated in vacuo. The crude 
residue was purified by silica gel column chromatography (10:1 pentane:diethyl ether), 
yielding both returned starting material (5.6 mg, 22%) and title carbamate 1.26. The title 
compound was isolated as a colorless oil in 57% yield (14.0 mg).  syn-diastereomer: 1H 
NMR (CDCl3, 600 MHz): δ 7.31 (t, 2H, J = 7.2 Hz), 7.24 (d, 2H, J = 7.8 Hz), 7.20 (t, 1H, J 
= 7.2 Hz), 6.49 (s, 1H), 4.65 (s, br, 1H), 3.97 (d, 1H, J = 3.0 Hz), 3.90 (s, br, 1H), 1.85 (d, 
3H, J = 1.2 Hz), 1.37 (s, 9H), 1.19 (d, 3H, J = 6.6 Hz), 0.96 (s, 9H), 0.10 (s, 3H), 0.06 (s, 
3H);  13C NMR (CDCl3, 151 MHz): δ 155.81, 138.07, 137.90, 129.12, 128.13, 126.39, 
126.13, 80.30, 79.01, 49.10, 28.56, 26.08, 19.54, 18.43, 15.32, –4.31, –4.96;  IR (ν/cm-1): 
3449 (w), 3365 (br, w), 2972 (m), 2956 (m), 2930 (m), 2892 (w), 2885 (w), 2857 (m), 1716 
(CO, s), 1496 (s), 1455 (m), 1390 (m), 1365 (m), 1253 (m), 1170 (s), 1106 (m), 1057 (m), 
1007 (w), 942 (w), 865 (m), 837 (m), 776 (m), 751 (w), 699 (m), 512 (w).  HRMS-(ESI+) 
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[M+Na]+ calcd for C23H39NNaO3Si+ 428.2597, found: 428.2594;  [α]D19 = –25.7° (c = 0.650, 
CH2Cl2, l = 100 mm). 
 
 
Figure 1.26. 1H and 13C{1H} NMR spectra of 1.26. 
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2 Chapter 2: Silver(I)-Catalyzed Diastereoselective Synthesis of anti-1,2-
Hydroxyboronates 
This chapter is adapted and reprinted with permission from Joannou, M. V.; Moyer, 
B. S.; Goldfogel, M. J.; Meek, S. J. Angew. Chem. Int. Ed. 2015, 54, 14141-14145. Copyright 
© 2015 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany. This chapter resulted 
from a collaboration with Dr. Matthew V. Joannou and Dr. Matthew J. Goldfogel.
2.1 Introduction 
2.1.1 C–C bond-forming reactions of a-boryl anions / boron-stabilized alkyl nucleophiles 
Functionalized secondary alkyl boronate esters are enabling reagents for chemical 
synthesis; thus, catalytic stereoselective methods for their preparation are a compelling 
objective (see section 1.1.1).1 Carbon–carbon bond-forming reactions of boron-stabilized 
alkyl nucleophiles provide direct approaches to functionalized molecules containing C(sp3)–
B bonds. Specifically, alkylation of aldehydes with a-boryl nucleophiles serves to generate 
secondary alcohols bearing a vicinal alkyl boron unit.32 Such processes form two contiguous 
stereogenic centers with a versatile C(sp3)–B bond.33,34 Despite progress in this area, several 
shortcomings preclude their synthetic utility, the most apparent of which are the lack of 
catalytic processes to afford products in high yield and stereoselectivity. Existing protocols 
for the stereoselective synthesis of 1,2-hydroxyboronates are achieved through 
organocuprates and deprotonations of bis(mesityl)-substituted alkyl boranes. Miyaura and co-
workers reported one example of the stereoselective addition of Knochel’s a-B(pin) 
cyanocuprate [B(pin) = (pinacolato)boron] to benzaldehyde to afford a 1,2-hydroxyboronate 
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in 6:1 d.r. (anti/syn), which can be stereospecifically converted to the boron-Wittig product 
upon heating (6:1 trans/cis) or the diol upon oxidation (6:1 anti/syn); the authors provide a 
steroechemical model to explain the selectivity (Scheme 2.1a).32b The drawback of this 
methodology resides in the necessity to employ both stoichiometric copper and 
superstoichiometric boron trifluoride diethyl etherate. Pelter et al. reported excellent levels of 
anti-selectivity for the addition of dimesityl-boron-stabilized carbanions to aldehydes 
(Scheme 2.1b). However, strong lithium bases and cryogenic conditions (–116 °C) are 
required for carbanion generation and reaction, thus limiting functional-group 
compatibility.32c 
 
Scheme 2.1. Addition of a-boryl reagents to aldehydes. 
a) Diastereoselective cuprate 1,2-addition. b) Deprotonation/1,2-addition of alkyl borons. 
Bench-stable alkyl geminal diborons have emerged as useful difunctional reagents 
which provide effective methods to access a-boryl anion synthons. In the presence of an 
alkoxide or hydroxide activator, 1,1-diborons participate in alkylation and cross-coupling 
reactions. Morken and coworkers demonstrated that the corresponding borates decompose to 
a-boryl-stabilized carbanions, which undergo efficient and diastereoselective alkylation with 
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alkyl halides to generate substituted quaternary carbon atoms.16,35 Catalytic reactions 
developed with difunctional alkyl organoboron reagents have focused on Suzuki cross-
couplings.17,36 Shibata and coworkers demonstrated that palladium-catalyzed cross-couplings 
of alkyl 1,1-diborons effectively proceed under ambient conditions to afford secondary alkyl 
boronates (see Scheme 1.4).17a More recently, the groups of Morken and Hall independently 
reported catalytic enantioselective variants for the stereoselective synthesis of secondary 
benzylic (see Scheme 1.5) and allylboronates.18 Advances notwithstanding, catalytic 
diastereoselective protocols for the addition of 1,1-diborons to carbonyls remain limited. In 
Chapter 1, we discussed our report on the enantio- and diastereoselective copper(I)-catalyzed 
additions of substituted alkyl 1,1-diborons to aldehydes to afford 1,2-hydroxyboronates in 
high syn-selectivity. The reaction most likely proceeds via a chiral a-boron copper(I)–alkyl 
intermediate adding to the aldehyde, and simultaneously forming a new C–C bond and two 
vicinal stereogenic centers, one of which comprises a secondary alkyl boron unit for further 
synthetic elaboration. 
2.1.2 Research objectives 
As a continuation of our laboratory’s stated research objectives described in section 
1.1.2, we sought to find a complementary protocol to our previously described Cu(I) 
manifold that is also broader in terms of reagent and substrate scope. We found that moving 
down the periodic table from Cu(I) to Ag(I) gave us a substantial increase in reactivity, as 
well as a reversal in diastereoselectivity that allowed us to produce complementary anti-1,2-
hydroxyboronates with a variety of sterically voluminous, substituted 1,1-diboryl reagents. 
With further methodological tweaks, we were also able to adapt the Ag(I) system to work 
with enolizable alkyl aldehydes. Unfortunately, despite substantial efforts, no 
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enantioselective variant could be developed. Chapter 2 discusses our success in developing 
this complementary catalytic, diastereoselective protocol based on Ag(I). 
2.2 Strategy for the synthesis of anti-1,2-hydroxyboronates 
In Chapter 2, we outline the first catalytic protocol for the diastereoselective synthesis 
of anti-1,2-hydroxyboronates through the silver-catalyzed addition of 1,1-diboronates to aryl 
and alkyl aldehydes (Scheme 2.2). Reactions are promoted by 10 mol % of a readily 
available silver(I) salt catalyst in conjunction with an alkoxide or alkyl lithium activator. The 
products are delivered in up to 77% yield and 99:1 d.r. The reaction is also tolerant of several 
functional groups, including silyl-ether-protected alcohols, N-Boc-protected nitrogen atoms, 
esters, and acetal-protected aldehydes. 
 
Scheme 2.2. Catalytic, anti-selective 1,2-addition of 1,1-diboronates to aldehydes. 
2.3 Optimization of the catalytic reaction 
Initial studies of catalytic reaction conditions identified silver(I) salts as effective 
promoters for the anti-selective addition of 1,1-diboryl reagents to aldehydes. The data 
illustrated in Table 2.1 summarize the optimization of the reaction conditions. As entry 1 
shows, there is a significant nonselective background reaction with 130 mol % NaOtBu at  
22 °C and it affords 2.2 and 2.3 in 50:50 d.r. (63% conversion), and <2% conversion is 
observed at 0 °C (entry 2).x Catalytic AgOAc (10 mol%) was found to promote the addition 
                                                
xCatalytic NaOtBu does not promote the addition of 2.1 to benzaldehyde. 
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at 0 °C, but with no diastereoselectivity (entry 3). Monodentate (PPh3; entry 4), and bidentate 
(rac-binap; entry 5) phosphines were evaluated for their ability to deliver 2.2 in high 
diastereoselectivity and yield, and rac-binap affords 2.2 in 42% conversion and 84:16 d.r. 
(anti/syn; entry 5). Decreasing the temperature to –25 °C results in lower conversions to 2.2, 
but increases the anti-selectivity (92:8 d.r.; entry 6). Application of KOtBu in place of 
NaOtBu leads to an improved yield at –25 °C with no significant loss in d.r. value.xi 
Monodentate aryl (entry 8) and alkyl (entry 9) phosphines in the presence of KOtBu were 
found to deliver 2.2 with a conversion and selectivity that are similar to those obtained with 
rac-binap. Optimal reaction conditions for the catalytic diastereoselective addition of 2.1 to 
benzaldehyde are those run in the absence of a phosphine ligand; this silver catalyzed 
reaction provides the same anti selectivity as that observed by the groups of Miyaura32b and 
Pelter32c in the 1,2-addition reactions of cyanocuprates, and therefore most likely proceeds 
via their proposed (non-ligated/phosphine-free) synclinal stereochemical model (Scheme 2.1) 
involving an a-boryl alkyl silver species.xii Treatment of benzaldehyde and 2.1 with  
10 mol % AgOAc with KOtBu in THF (–25 °C) delivers 2.2 in 84% yield (NMR analysis) 
and 97:3 d.r. (entry 10). No reaction is observed in the absence of a silver(I) salt (entry 11).xiii 
                                                
xiPreliminary enantioselective results have been obtained with chiral phosphine/Ag(I) complexes 
employing the optimal reaction conditions in Table 1: (a) 10 mol % AgOAc, 10 mol % (R)-Monophos,  
–25 °C; 61% conv., 90:10 d.r., 61:39 e.r.; (b) 10 mol % AgOAc, 10 mol % (R)-(+)-1-[(R)-2-(2’-
dicyclohexylphosphinophenyl)ferrocenyl]ethyldi(bis-3,5-trifluoromethylphenyl)phosphine, –40 °C; 11% 
conv., 95:5 d.r., 77.5:22.5 e.r. 
xiiThe role of silver(I) as a Lewis acid activator for the aldehyde cannot be completely ruled out. 
Monitoring a mixture of AgOAc (or the more soluble [(binap)AgOAc]) and benzaldehyde at 22 °C by 1H 
and 13C NMR spectroscopy shows no change in the chemical shift for the aldehyde signals. This indicates 
that there is unlikely to be a significant interaction between the silver(I) salt and the aldehyde at –25 °C. 
xiiiUse of silver(I) salts with more dissociating counter ions [e.g., AgOTf, AgBF4, AgSbF6, AgClO4, 
Ag(TFA)] afford <10% conversion. 
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Increasing the catalyst loading or reaction times result in only slight increases (<5%) in 
yield.xiv 
Table 2.1. Optimization of reaction conditions for the synthesis of the anti-1,2-hydroxyboronate 2.2.a 
 
 
2.4 Ag(I)-catalyzed anti-1,2-additions of diboryl ethane to aryl and vinyl aldehydes 
We next evaluated the scope of the silver(I)-catalyzed protocol for the addition of 2.1 
to aryl- and alkenyl-substituted aldehydes (Scheme 2.3), and several points are noteworthy: 
1) para-substituted aryl aldehydes bearing either halogens (2.4 and 2.5) or electron-donating 
methoxy (2.6) groups undergo diastereoselective additions to yield hydroxyboronates in good 
yield (64-73%) and high selectivity (up to 97:3 anti/syn). 2) Substitution at the meta and 
                                                
xivFurther optimization demonstrates that increasing the number of equivalents of KOtBu or the boron 
reagent results in lower conversion and decreased anti/syn selectivity. For example, 200 mol % KOtBu or 
2.0 equivalents 2.1 affords 2.2/2.3 in 13% conv. in 86:14 d.r., and 48% conv. in 85:15 d.r., respectively. 
Me(pin)B
B(pin)
OH
Me
B(pin)
O
H +
10 mol % AgOAc
10 mol % ligand
130 mol % MOtBu
THF, T, 24 h
OH
Me
B(pin)
+
2.2 (anti) 2.3 (syn)(1.00 eq.)
Entry
1
2
3
4c
5
6
7d
8c
9
10
11
Silver salt Ligand
—
—
AgOAc
AgOAc
AgOAc
AgOAc
AgOAc
AgOAc
AgOAc
AgOAc
—
—
—
—
rac-binap
rac-binap
rac-binap
—
—
T (°C)
22
0
0
0
0
–25
–25
–25
–25
–25
–25
NMR conv. (%)b d.r. (2.2/2.3)b
63
<2
18
47
42
33
50
47
64
84
<2
50:50
—
50:50
54:46
92:8
93:7
95:5
93:7
97:3
84:16
PPh3
PPh3
PCy3
MOtBu
NaOtBu
NaOtBu
NaOtBu
NaOtBu
NaOtBu
NaOtBu
KOtBu
KOtBu
KOtBu
KOtBu
KOtBu —
aReactions performed under N2 atm. bConversion and diastereomeric ratio (d.r.) determined by analysis of either 400 MHz or 600 
MHz 1H NMR spectra of unpurified reaction mixtures using an internal standard. c20 mol % PPh3. dUse of (R)-binap delivers 2.2 
in 0% ee. The reaction conditions of entry 10 represent the optimized reaction conditions. binap = 2,2’-bis(diphenylphosphino)-
1,1’-binaphthyl.
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ortho positions of the aryl aldehyde are tolerated, as demonstrated by the formation of 2.7-
2.10 in 52-75% yield and 97:3 d.r. (anti/syn). 3) Synthesis of furyl-, pyridyl-, and Boc-
indole-substituted products (2.11-2.13) demonstrate that heteroaryl aldehydes are effective 
substrates with no apparent inhibition. The expected 1,2-hydroxyboronates were isolated in 
45-77% yield and 91:9-99:1 d.r.xv 4) Transformations with sterically unhindered alkenyl 
aldehydes proceed with diminished selectivity, thus producing the allylic alcohols 2.14 and 
2.15 in 88:12 and 86:14 d.r., respectively. However, a-methylcinnamaldehyde-derived 2.16 
was obtained in 64% yield and 92:8 d.r. With respect to the diastereoselectivity that 
accompanies diboryl ethane additions to cinnamyl aldehydes, these findings are generally 
congruent with (but still much higher than) the lower levels of diastereoselectivity obtained 
by emplying the Cu(I)-phosphoramidite protocol (see section 1.5). 
 
                                                
xvThe lower yield of the pyridyl alcohol is attributed to slight decomposition during purification. 
Ar H
O
+ Me(pin)B
B(pin)
10 mol % AgOAc,
130 mol % KOt-Bu
THF, –25 °C, 24 h
OH
Me
B(pin)
2.1 (1.00 eq.)
70% yield
97:3 (anti:syn)
2.2
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Scheme 2.3. Anti-selective Ag(I)-catalyzed 1,2-addition of diboryl ethane to aryl and vinyl aldehydes. 
2.5 Beyond diboryl ethane: Employing substituted 1,1-diboronates in the anti-selective 
1,2-hydroxyboronate synthesis 
Catalytic anti-selective 1,2-additions were extended to include substituted alkyl 1,1-
diboron compounds (see 2.17-2.22; Scheme 2.4). The transformations proceed effectively 
with 10 mol% AgOAc in up to 77% yield at –25 °C in 24 hours. The expected 1,2-
hydroxyboronates, including those that contain functional groups such as a phenyl ring 
(2.17), an alkene (2.18), a silyl ether (2.19), an n-alkyl chain (2.20), or an ester (2.21), were 
obtained in up to 77% yield and greater than 98:2 d.r. (anti/syn) selectivity. Only in the case 
of a tert-butyl-ester-containing reagent was low diastereoselectivity observed; 2.21 was 
isolated in 66% yield and 47:53 d.r. (anti/syn). One shortcoming of the method relates to the 
use of b-branched 1,1-diboryl alkanes, and as an example, the cyclohexyl 2.22 is formed in 
less than 5% yield. 
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MHz or 600 MHz 1H NMR spectra of the unpurified reaction mixtures using hexamethyldisiloxane as an internal standard. 
aYield determined by 1H NMR spectroscopy.
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Scheme 2.4. Scope with respect to substituted 1,1-diboronates in the anti-selective 1,2-
hydroxyboronate synthesis. 
2.6 Ag(I)-catalyzed anti-1,2-additions of 1,1-diboronates to alkyl aldehydes 
Addition of a-boryl nucleophiles was next extended to alkyl aldehydes (Scheme 2.5), 
which is a significant advancement over the Cu(I)-protocol discussed in Chapter 1. With 
cyclohexane carboxaldehyde, under otherwise identical reaction conditions (see Scheme 2.3), 
there was 6% conversion to 2.23 in 79:21 d.r. (Method A, Scheme 2.5a). We reasoned that 
deprotonation of the aldehyde by KOtBu (or borate I) was responsible for low conversion to 
product.xvi To discourage enolization caused by unreacted alkoxide in solution, we 
substituted n-BuLi for KOtBu (Method B, Scheme 2.5a), as an irreversible activation of the 
1,1-diboryl alkane (II) should minimize undesired side reactions. Treatment of 2.1 with 1 
equivalent of n-BuLi in the presence of AgOAc followed by cyclohexane carboxaldehyde at 
                                                
xviThe presence of significant unreacted aldehyde upon aqueous workup supports this hypothesis. 
H
O
+ G(pin)B
B(pin)
10 mol % AgOAc,
130 mol % KOt-Bu
THF, –25 °C, 24 h
OH
G
B(pin)
2.18
74% yield
98:2 d.r. (anti:syn)
OH
B(pin)
2.17
76% yield
92:8 d.r. (anti:syn)
OH
B(pin)
2.19
77% yield
94:6 d.r. (anti:syn)
OH
B(pin)
OH
B(pin)
2.21
66% yield, 
47:53 d.r. (anti:syn)
OH
B(pin)
2.22
<5% yield, 
20:80 d.r. (anti:syn)
Ph
OtBu
O
OTBS
(1.00 eq.) 2.17-2.22
OH
B(pin)
2.20
61% yield, 
91:9 d.r. (anti:syn)
Me
Yields of the purified products are an average of two runs. Diastereomeric ratio (d.r.) 
determined by analysis of either 400 MHz or 600 MHz 1H NMR spectra of the unpurified 
reaction mixtures using hexamethyldisiloxane as an internal standard. G = attached group.
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–25 °C afforded 2.23 in 51% yield and 88:12 d.r. (anti/syn). A less than 5% conversion to 
2.23 is observed in the absence of the silver(I) salt. The n-BuLi protocol proved effective for 
alkyl and aryl aldehydes in combination with substituted 1,1-diboron reagents which contain 
an alkene (2.24), phenyl ring (2.25), acetal (2.26), or silyl ether (2.27; Scheme 2.5b). In 
general, the yields and anti-selectivity of the 1,2-hydroxyboronate products are slightly lower 
than in the case of aryl aldehydes. Alkyl aldehydes lacking a-protons do not require n-BuLi 
as an activator.xvii For example, pivaldehyde undergoes diastereoselective (98:2 d.r., anti/syn) 
addition promoted by KOtBu, but 2.28 is isolated in only 34% yield. The acetal-containing 
product 2.29, while derived from an aryl aldehyde, requires Method B for formation (Method 
A furnishes the product in <5% yield). In general, aryl aldehydes work with Method B, but 
the resulting products are produced in lower yields and diastereoselectivities. 
                                                
xviiOn the other hand, a limitation to this methodology is that primary aldehydes (e.g. 
dihydrocinnamaldehyde) and a-acidic aldehydes (e.g. 2-phenylpropionaldehyde) do not work with either 
method. 
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Scheme 2.5. Ag(I)-catalyzed additions of 1,1-diboronates to alkyl aldehydes. 
2.7 Functionalization of anti-1,2-hydroxyboronates: Stereospecific heteroarylation 
To showcase the synthetic utility of anti-1,2-hydroxyboronates, the TBS-protected 
hydroxyboronate 2.30 (isolated in 77% yield from the parent hydroxyboronate) was 
subjected to stereospecific aryl coupling (Scheme 2.6). The boronate 2.30 was treated with 
1.2 equivalents of a-lithiated furan at –78 °C, followed by N-bromosuccinimide, and finally 
a saturated solution of Na2S2O3 to furnish 1,2-diarylated product 2.31 in 67% yield and 99:1 
d.r.6,37 As was discussed in Chapter 1, these compounds are amenable to numerous 
stereospecific transformations, including oxidation, amination, and carbon homologation.3-7 
H
O
+ Me(pin)B
B(pin)
10 mol % AgOAc,
x mol % Activator
THF, –25 °C, 24 h
OH
Me
B(pin)
Method A: 
6% yield
79:21 (anti:syn)
Method B:
51% yield
88:12 (anti:syn)
(pin)B
B(pin)
G (pin)B
B(pin)
G*
Li
(in situ) (pre-stir)
(pin)B
B(pin)
G*
KOt-Bu n-Bu
(irreversible formation
of ate-complex)
100 mol %
n-BuLi
(Method B)
130 mol %
KOt-Bu
(Method A)
(1.00 eq)
2.1 (1.00 eq.)(2.00 eq.) 2.23
a) Alkoxide versus n-BuLi activator for additions to alkyl aldehydes
I II
2.24 (Method B)
61% yield
78:22 d.r. (anti:syn)
OH
B(pin)
2.25 (Method B)
51% yield
95:5 d.r. (anti:syn)
OH
B(pin)
2.27 (Method B)
49% yield
83:17 d.r. (anti:syn)
OH
B(pin)
OH
B(pin)
2.26 (Method B)
62% yield, 
>98:2 d.r. (anti:syn)
Me
Me
Ph OTBS
O
O
OH
Me
B(pin)
2.28 (Method A)
34% yield, 
98:2 d.r. (anti:syn)
Me
MeMe
b) Alkyl aldehyde scope
OH
B(pin)
2.29 (Method B)
54% yield, 
>98:2 d.r. (anti:syn)
O
O
Yields of the purified products are an average of two runs. Diastereomeric ratio (d.r.) determined by analysis of 
either 400 MHz or 600 MHz 1H NMR spectra of unpurified reaction mixtures using hexamethyldisiloxane as an 
internal standard. TBS = tert-butyldimethylsilyl.
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Scheme 2.6. Stereospecific heteroarylation of 1,2-hydroxyboronate products. 
In conclusion, Chapter 2 has summarized our studies into the development of the first 
catalytic anti-selective addition of various substituted 1,1-diboryl alkanes to a range of aryl-, 
alkenyl-, and particularly alkyl-substituted aldehydes. This methodology is both 
complementary to the Cu(I)-protocol in that opposite diastereoselectivity is observed, in 
addition to being a major advancement over the previous methodology in terms of reagent 
(substituted 1,1-diboronates) and substrate (alkyl aldehydes) scope. Furthermore, 
functionalization of the anti-hydroxyboronates has been demonstrated by a stereospecific 
aryl coupling with furan. One direction for future investigations involves the development of 
enantioselective variants of this protocol. 
2.8 Experimental Section 
2.8.1 General Methods 
All reactions were carried out in oven-dried (150 ˚C) or flame-dried glassware under 
an inert atmosphere of dried N2 unless otherwise noted. Analytical thin-layer 
chromatography was performed on glass plates coated with 0.25 mm of 60 Å mesh silica gel.  
Plates were visualized by exposure to UV light (254 nm) and/or immersion into Seebach’s or 
KMnO4 stain followed by heating. Column chromatography was performed using silica gel 
P60 (mesh 230-400) supplied by Silicycle. Deactivated silica gel was prepared by stirring a 
slurry of the aforementioned silica gel in a 3% NaOAc aqueous solution for 15 minutes. The 
deactivated silica gel was collected by filtration and then dried in a 150 ˚C oven for 3 days. 
OTBS
Me
B(pin)BocN
OTBS
Me
BocN O
2.30
77% yield from
hydroxyboronate,
99:1 d.r.
O Li
THF, –78 °C, 1 h
NBS, –78 °C, 1 h;
Na2S2O3
2.31
67% yield, 99:1 d.r.
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All solvents were sparged with argon and then purified under a positive pressure of argon 
through an SG Water, USA Solvent Purification System. Tetrahydrofuran (OmniSolv) was 
passed successively through two columns of neutral alumina. The ambient temperature in the 
laboratory was approximately 22 ˚C. 
2.8.1.1 Instrumentation 
All 1H NMR spectra were recorded on Bruker Spectrometers (AVANCE-600, 
AVANCE-500 and AVANCE-400). Chemical shifts are reported in ppm from 
tetramethylsilane and referenced to the residual protio solvent peak (CDCl3: δ 7.26, THF-d8: 
δ 1.72). Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = 
triplet, qu = quartet, quint = quintet, br = broad, m = multiplet, app = apparent), integration, 
and coupling constants are given in Hz. 13C NMR spectra were recorded on Bruker 
Spectrometers (AVANCE-600 and AVANCE-400) with carbon and proton decoupling. 
Chemical shifts are reported in ppm from tetramethylsilane and referenced to the residual 
protio solvent peak (CDCl3: δ 77.16). All IR spectra were recorded on a Jasco 260 Plus 
Fourier transform infrared spectrometer. Mass Spectrometry samples were analyzed with a 
hybrid LTQ FT (ICR 7T) (ThermoFisher, Bremen, Germany) mass spectrometer. Samples 
were introduced via a micro-electrospray source at a flow rate of 10 µL/min (solvent 
composition 10:1 MeOH:H2O). Xcalibur (ThermoFisher, Breman, Germany) was used to 
analyze the data. Molecular formula assignments were determined with Molecular Formula 
Calculator (v. 1.2.3). 
2.8.1.2 Reagents 
All liquid aldehydes were distilled from CaH2 or CaSO4 under vacuum and then 
sparged with dry N2. Solid aldehydes were purified via recrystallization, followed by 
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azeotropic drying with benzene. Silver acetate was purchased from Strem Chemicals and 
kept in an N2 filled glove box. Diboryl methane was synthesized according to Scheme 1.12 
(see section 1.8.1.3 above). 
2.8.1.3 Representative synthesis of substituted diboryl reagents 
 
Scheme 2.7. Representative synthesis of substituted diboryl reagents. 
In an N2-filled glove box, an oven-dried round-bottom flask was charged with diboryl 
methane (3.00 g, 11.2 mmol) and a magnetic stir-bar, capped with a rubber septum, and 
sealed with electrical tape. A separate oven-dried, conical shaped flask was charged with 
lithium 2,2,6,6-tetramethylpiperidine (1.73 mg, 11.8 mmol), capped with a rubber septum, 
and sealed with electrical tape. The two flasks were brought out of the glove box, where the 
diboryl methane flask was charged with 47.0 mL of dry THF and the LiTMP-containing 
flask was charged with 93.0 mL of THF (0.17M total). Both flasks were allowed to cool to 0 
˚C (ice/water-baths). The LiTMP solution was then cannula transferred to the diboryl 
methane flask with stirring. After the transfer, the reaction was allowed to stir for 10 min at 0 
˚C. Iodomethane (1.74 mL, 28.0 mmol) was then added to the reaction via a syringe and the 
reaction was allowed to warm up to 22 ˚C over 18 hours with stirring. The reaction was 
quenched with 50 mL of a saturated aqueous solution of NH4Cl. The biphasic mixture was 
extracted 3 times with diethyl ether (900 mL total), and the combined organic extracts were 
dried over MgSO4, filtered, and concentrated in vacuo. The crude reaction mixture was 
purified by silica gel column chromatography (20:1 hexanes:EtOAc; Rf=0.20) to give the 
1) LTMP, THF, 0 °C, 10 min.
2) MeI, 0 °C to 22 °C, 18 h
B
B
OO
O
O
B
B
OO
O
OH Me
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desired diboryl reagent (in this case, diboryl ethane; 1.1/2.1, see section 1.8.1.4 for synthesis) 
in 89% yield (2.8 g). 
 
2,2'-(2-phenylethane-1,1-diyl)bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolane) (R1). 
Following the representative procedure, diboryl methane was alkylated with benzyl bromide 
and the crude reaction mixture was purified via silica gel chromatography in 20:1 
hexanes:EtOAc to yield the product in 90% yield (1.2 g).  1H NMR (600 MHz, CDCl3) δ 
7.28 – 7.21 (m, 4H), 7.17 – 7.11 (m, 1H), 2.90 (d, J = 8.4 Hz, 2H), 1.21 (s, 7H), 1.20 (s, 6H). 
13C NMR (151 MHz, CDCl3) δ 144.6, 128.5, 128.1, 125.5, 83.2, 31.4, 24.9, 24.7. IR (ν/cm-
1): 2978 (m), 2930 (w), 2866 (w), 1453 (w), 1381 (w), 1360 (m), 1320 (s), 1268 (w), 1241 
(w), 1215 (w), 1140 (s).  HRMS (ESI+) [M+Na]+ calcd for C20H32B2NaO4+ 381.2385, found: 
381.2380. 
 
B
B
OO
O
OPh
R1
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Figure 2.1. 1H and 13C{1H} NMR spectra of R1. 
 
2,2'-(4-methylpent-3-ene-1,1-diyl)bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolane) 
(R2).  Following the representative procedure, diboryl methane was alkylated with prenyl 
bromide.  The crude reaction mixture was purified via silica gel chromatography in 20:1 
hexanes:EtOAc to yield the product in 90% yield (1.1 g).  1H NMR (CDCl3, 600 MHz): δ 
5.09 (t, 1H, J = 7.02 Hz), 2.21 (t, 2H, J = 7.8 Hz), 1.63 (s, 3H), 1.60 (s, 3H), 1.22 (s, 12H), 
1.21 (s, 12H), 0.75 (t, 1H, J = 8.4 Hz).  13C NMR  (CDCl3, 151 MHz): δ 130.3, 127.1, 83.1, 
25.9, 25.0, 24.6, 24.2, 18.0.  IR (ν/cm-1): 2978 (s), 2928 (m), 2862 (w), 1446 (w), 1370 (m), 
1357 (m), 1319 (m), 1270 (w), 1246 (w), 1215 (w), 1141 (s).  HRMS (ESI+) [M+Na]+ calcd 
for C18H34B2NaO4+ 359.2541, found: 359.2539. 
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Figure 2.2. 1H and 13C{1H} NMR spectra of R2. 
 
(3,3-bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propoxy)(tert-
butyl)dimethylsilane (R3).  Following the representative procedure, diboryl methane was 
alkylated with (2-bromoethoxy)(tert-butyl)dimethylsilane.  The crude reaction mixture was 
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purified via silica gel chromatography in 20:1 hexanes:EtOAc to yield the product in 92% 
yield (1.4 g).  1H NMR (CDCl3, 400 MHz): δ 3.54 (t, 2H, J = 7.2 Hz), 1.76 (qu, 2H, J = 7.6 
Hz), 1.22 (s, 12H), 1.21 (s, 12H), 0.87 (s, 9H), 0.77 (t, 1H J = 7.6 Hz), 0.03 (s, 6H).  13C 
NMR  (CDCl3, 100 MHz): δ 83.1, 65.2, 28.9, 26.2, 25.1, 24.6, 18.6, –5.1.  IR (ν/cm-1): 2978 
(m), 2956 (m), 2930 (m), 2886 (w), 2857 (m), 1471 (w), 1379 (m), 1362 (m), 1318 (m), 1270 
(w), 1255 (w), 1215 (w), 1165 (w), 1141 (m), 1099 (m), 1037 (w), 1006 (w).  HRMS (ESI+) 
[M+Na]+ calcd for C21H44B2NaO5Si+ 449.3042, found: 449.3040. 
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Figure 2.3. 1H and 13C{1H} NMR spectra of R3. 
 
tert-butyl 3,3-bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propanoate (R4).   
Following the representative procedure, diboryl methane was alkylated with tert-butyl-2-
bromoacetate.  The crude reaction mixture was purified via silica gel chromatography in 20:1 
hexanes:EtOAc to yield the product in 68% yield (485 mg).  1H NMR (500 MHz, CDCl3) δ 
2.52 (d, J = 8.5 Hz, 2H), 1.43 (s, 9H), 1.25 (s, 12H), 1.23 (s, 12H), 1.07 (t, J = 8.5 Hz, 1H).  
13C NMR (126 MHz, CDCl3) δ 174.2, 83.1, 79.6, 31.7, 28.1, 24.9, 24.5.  IR (ν/cm-1): 2977 
(s), 2894 (m), 2094 (w), 1729 (s), 1643 (s), 1468 (m), 1314 (w), 1268 (m), 1213 (m), 1140 
(w).  HRMS (ESI+) [2M+Na]+ calcd for C38H72B4NaO12+ 787.5294, found: 787.5314.  
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Figure 2.4. 1H and 13C{1H} NMR spectra of R4. 
 
2,2'-(2-(1,3-dioxolan-2-yl)ethane-1,1-diyl)bis(4,4,5,5-tetramethyl-1,3,2-
dioxaborolane) (R5).  Following the representative procedure, diboryl methane was 
alkylated with 2-bromomethyl-1,3-dioxolane.  The crude reaction mixture was purified via 
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silica gel chromatography in 20:1 hexanes:EtOAc to yield the product in 44% yield (440 
mg).  1H NMR (CDCl3, 600 MHz): δ 4.94 (t, 1H, J = 3.9 Hz), 3.91-3.96 (m, 2H), 3.79-3.84 
(m, 2H), 1.93 (dd, 2H, J = 7.6, 4.0 Hz), 1.22 (s, 12H), 1.22 (s, 12H), 0.84 (t, 1H, J = 7.6 Hz).  
13C NMR  (CDCl3, 151 MHz): δ 128.5, 105.1, 83.1, 65.1, 30.1, 24.9, 24.7.  IR (ν/cm-1): 2978 
(s), 2930 (m), 2886 (m), 1469 (w), 1440 (w), 1369 (m), 1321 (s), 1270 (w), 1245 (w), 1215 
(w), 1140 (s), 1085 (w), 1034 (w).  HRMS (ESI+) [2M+NH4]+ calcd for C34H68B4NaO12+ 
726.5113, found: 726.5150. 
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Figure 2.5. 1H and 13C{1H} NMR spectra of R5. 
 
2,2'-(cyclohexylmethylene)bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolane) (R6).  
Following the representative procedure, diboryl methane was alkylated with 
bromocyclohexane.  The crude reaction mixture was purified via silica gel chromatography 
in 20:1 hexanes:EtOAc to yield the product in 20% yield (190 mg).  1H NMR (400 MHz, 
CDCl3) δ 1.85 – 1.55 (m, 8H), 1.26 (s, 12H), 1.24 (s, 12H), 1.17 – 1.04 (m, 1H), 1.03 – 0.85 
(m, 2H), 0.66 (d, J = 10.4 Hz, 1H).  13C NMR (101 MHz, CDCl3) δ 82.9, 36.1, 36.1, 26.9, 
26.4, 25.0, 24.7.  IR (v/cm-1): 2978 (s), 2922 (m), 2851 (m), 2082 (m), 1639 (s), 1447 (m), 
1315 (w), 1266 (m), 1140 (w).  HRMS (ESI+) [2M+Na]+ calcd for C38H72B4NaO8+ 
723.5630, found: 723.5603. 
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Figure 2.6. 1H and 13C{1H} NMR spectra of R6. 
 
2,2'-(butane-1,1-diyl)bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolane) (R7).  
Following the representative procedure, diboryl methane was alkylated with 1-iodopropane.  
The crude reaction mixture was purified via silica gel chromatography in 20:1 
B
B
OO
O
O
R7
Me
 94 
hexanes:EtOAc to yield the product in 78% yield (442 mg).  1H NMR (600 MHz, CDCl3) δ 
1.59 – 1.51 (m, 2H), 1.37 – 1.28 (m, 2H), 1.26 (s, 12H), 1.24 (s, 12H), 0.89 (t, J = 7.3 Hz, 
3H), 0.76 (t, J = 7.9 Hz, 1H).  13C NMR (151 MHz, CDCl3) δ 82.9, 27.9, 25.6, 24.9, 24.5, 
14.2.  IR (ν/cm-1): 2976 (s), 2840 (m), 1646 (m), 1314 (m), 1141 (m). HRMS (ESI+) 
[2M+Na]+ calcd for C32H64B4NaO8+ 643.4883, found: 643.4870. 
 
 
Figure 2.7. 1H and 13C{1H} NMR spectra of R7. 
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2.8.1.4 Synthesis of n-BuLi-activated diboryl ethane (2.32) 
 
Scheme 2.8. Synthesis of n-BuLi-activated diboryl ethane (2.32). 
In an N2-filled glove box, an 8-mL vial was equipped with a magnetic stir bar and 
charged with diboryl ethane (2.1; 100 mg, 0.355 mmol) and dissolved in 930 µL of 
anhydrous THF (0.33 M). The vial was sealed with a septa-lined cap and removed from the 
glove box. The reaction was allowed to cool to –78 ˚C (dry ice/acetone) and n-butyllithium 
was added to the solution under nitrogen (530 µL, 0.355 mmol, 0.67 M solution in hexanes).  
The reaction solidified instantaneously and the cooling bath was removed to allow the 
reaction to stir at ambient temperature for 30 minutes. The reaction was then brought back 
into the glove box where it was concentrated in vacuo, taken up in hexanes, and filtered 
through a plug of Celite. After concentrating the filtrate in vacuo, 1 mL of diethyl ether was 
added to the residue and removed in vacuo to yield a glassy solid. This solid was then 
scraped from the sides of the vial to yield a crystalline off-white powder in 98% yield (113 
mg).  1H NMR (500 MHz, THF-d8): δ 1.34 – 1.13 (m, 13H), 1.07 – 0.94 (m, 12H), 0.94 – 
0.75 (m, 9H), 0.22 – 0.04 (m, 2H), -0.16 (qu, J = 7.2 Hz, 1H).  11B NMR (500 MHz, THF-
d8): 35.9 (s), 6.1 (s). 
THF, –78 °C to 22 °C, 
30 min.
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Figure 2.8. 1H and 11B NMR spectra of 2.21. 
2.8.1.5 General procedures for the Ag-catalyzed 1,2-addition reaction 
 
Scheme 2.9. General procedure A (aryl and vinyl aldehydes with diboryl ethane). 
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Procedure A (aryl and vinyl aldehydes with diboryl ethane, 2.1): In an N2-filled 
glove box, an 8-mL vial equipped with a magnetic stir bar was charged with AgOAc (1.7 mg, 
0.010 mmol) and KOtBu (14.6 mg, 0.13 mmol) and then shaken to evenly mix the solids. 
Diboryl ethane (2.1) was then added as a solution in THF down the side of the vial (29.7µL, 
0.1 mmol in 0.8 mL of THF). The vial was sealed with a septa-lined cap and removed from 
the glove box and allowed to stir at 22 ˚C for 5 min. The reaction was then placed in a freezer 
set to –25 ˚C and allowed to stir for 30 more minutes. The aldehyde (0.1 mmol) was then 
added to the reaction via syringe under argon and allowed to stir for 24 hours. The reaction 
was quenched at –25 ˚C with 1.0 mL of a saturated aqueous solution of NH4Cl, and the 
aqueous layer extracted three times with diethyl ether. The combined organic extracts were 
dried over MgSO4, filtered, and concentrated in vacuo. Conversion and diastereomeric ratios 
were determined by 1H NMR using hexamethyldisiloxane as an internal standard. 
 
Scheme 2.10. General procedure B (aryl aldehydes with R1-R7). 
Procedure B (aryl aldehydes with R1-R7): In an N2-filled glove box, an 8-mL vial 
equipped with a magnetic stir bar was charged with AgOAc (1.7 mg, 0.010 mmol) and 
KOtBu (14.6 mg, 0.13 mmol) and then shaken to evenly mix the solids. The diboryl reagent 
was then added as a solution in THF down the side of the vial (0.1 mmol in 0.8 mL of THF). 
The vial was sealed with a septa-lined cap and removed from the glove box and allowed to 
stir at 22 ˚C for 30 min. The reaction was then placed in a freezer set to –25 ˚C and allowed 
to stir for 10 minutes. The aldehyde (0.1 mmol) was then added to the reaction via syringe 
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under argon and allowed to stir for 24 hours. The reaction was quenched at –25 ˚C with 1.0 
mL of a saturated aqueous solution of NH4Cl, and the aqueous layer extracted three times 
with diethyl ether. The combined organic extracts were dried over MgSO4, filtered, and 
concentrated in vacuo. Conversion and diastereomeric ratios were determined by 1H NMR 
using hexamethyldisiloxane as an internal standard. 
 
Scheme 2.11. General procedure C (alkyl aldehydes with all diboryl reagents). 
Procedure C (alkyl aldehydes with all diboryl reagents): In an N2-filled glove box, 
an 8-mL vial equipped with a magnetic stir bar was charged with AgOAc (1.7 mg, 0.010 
mmol) and diboryl ethane (29.7 µL, 0.1 mmol), followed by 0.80 mL of anhydrous THF. The 
vial was sealed with a septa-lined cap and removed from the glove box and allowed to cool 
to –78 ˚C (dry-ice/acetone). n-butyllithium was then added at this temperature (69 µL, 0.10 
mmol, 1.42 M solution in hexanes) and allowed to stir for 20 minutes. The reaction was 
transferred to a freezer set to –25 ˚C and allowed to stir for 10 minutes. The aldehyde (0.2 
mmol) was then added to the reaction via syringe under argon and allowed to stir at –25 ˚C 
for 24 hours. The reaction was quenched at –25 ˚C with 1.0 mL of a saturated aqueous 
solution of NH4Cl, and the aqueous layer extracted three times with diethyl ether. The 
combined organic extracts were dried over MgSO4, filtered, and concentrated in vacuo. 
Conversion and diastereomeric ratios were determined by 1H NMR using 
hexamethyldisiloxane as an internal standard. 
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2.8.2 Preparation of aryl and vinyl anti-1,2-hydroxyboronates 
 
1-phenyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-ol (2.2).  
Following general procedure A, the crude reaction mixture was purified by silica gel 
chromatography (NaOAc deactivated silica gel, 10:1 to 2:1 pentane:diethyl ether, Seebach 
Stain) to yield the hydroxyboronate as a colorless oil in 70% yield (18.3 mg) in 99:1 anti:syn 
diastereomeric ratio.  1H NMR (600 MHz, CDCl3) δ 7.35 (d, J = 7.3 Hz, 2H), 7.31 (t, J = 7.6 
Hz, 2H), 7.23 (m, 1H), 4.84 (dd, J = 6.5, 4.1 Hz, 1H), 2.35 (d, J = 4.1 Hz, 1H), 1.58 (m, 1H), 
1.16 (s, 6H), 1.15 (s, 6H), 0.99 (d, J = 7.4 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 144.1, 
128.2, 127.2, 126.4, 83.4, 75.9, 24.7, 10.8.  IR (ν/cm-1): 3481 (s, br), 3085 (w), 3062 (w), 
3030 (w), 2978 (s), 2932 (m), 2876 (m), 1494 (w), 1458 (m), 1381 (m), 1320 (m), 1275 (w), 
1247 (w), 1215 (w), 1167 (w), 1145 (m), 1111 (w), 1073 (w), 1059 (w), 1009 (w).  HRMS 
(ESI+) [M+Na]+ calcd for C15H23BNaO3+ 285.1638, found: 285.1634. 
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Figure 2.9. 1H and 13C{1H} NMR spectra of 2.2. 
 
1-(4-fluorophenyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-ol 
(2.4).  Following general procedure A, the crude reaction mixture was purified by silica gel 
chromatography (NaOAc deactivated silica gel, 10:1 to 2:1 pentane:diethyl ether, Seebach 
Stain) to yield the hydroxyboronate as a colorless oil in 65% yield (18.2 mg) in 99:1 anti:syn 
diastereomeric ratio.  1H NMR (600 MHz, CDCl3) δ 7.40 – 7.28 (m, 2H), 7.08 – 6.92 (m, 
2H), 4.81 (d, J = 6.7 Hz, 1H), 2.41 (s, 1H), 1.53 (qu, J = 7.3 Hz, 1H), 1.15 (s, 6H), 1.14 (s, 
6H), 0.98 (d, J = 7.4 Hz, 3H).  13C NMR (151 MHz, CDCl3) δ 162.9, 161.2, 139.9, 139.9, 
128.0, 128.0, 115.0, 114.8, 83.5, 75.2, 24.7, 24.7, 10.7.  IR (ν/cm-1): 3496 (s, br), 2979 (m), 
2930 (w), 2877 (w), 1508 (s), 1457 (w), 1381 (s), 1320 (m), 1223 (m), 1144 (m), 1011 (m).   
HRMS (ESI+) [M+Na]+ calcd for C15H22BFO3Na+ 303.1544, found: 303.1537. 
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Figure 2.10. 1H and 13C{1H} NMR spectra of 2.4. 
 
1-(4-bromophenyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-ol 
(2.5).  Following general procedure A, the crude reaction mixture was purified by silica gel 
(NaOAc deactivated silica gel, 10:1 to 2:1 pentane:diethyl ether, Seebach Stain) to yield the 
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hydroxyboronate as a white crystalline solid in 65% yield (22.2 mg) in >99:1 anti:syn 
diastereomeric ratio.  1H NMR (600 MHz, CDCl3) δ 7.47 – 7.38 (m, 2H), 7.25 – 7.18 (m, 
2H), 4.82 (d, J = 6.1 Hz, 1H), 2.48 (s, 1H), 1.56 – 1.46 (m, 1H), 1.18 (s, 6H), 1.17 (s, 6H), 
0.94 (d, J = 7.4 Hz, 3H).  13C NMR (151 MHz, CDCl3) δ 143.1, 131.2, 128.1, 120.9, 83.6, 
75.0, 24.8, 24.7, 10.3.   IR (ν/cm-1): 3467 (s, br), 2978 (s), 2931 (w), 2876 (w), 1653 (w), 
1457 (w), 1374 (s), 1320 (s), 1144 (s), 1010 (m).   HRMS (ESI+) [M+Na]+ calcd for 
C15H22BBrO3Na+ 365.0743, found: 365.0716. 
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Figure 2.11. 1H and 13C{1H} NMR spectra of 2.5. 
 
1-(4-methoxyphenyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-ol 
(2.6).  Following general procedure A, the crude reaction mixture was purified by silica gel 
chromatography (NaOAc deactivated silica gel, 10:1 to 2:1 pentane:diethyl ether, Seebach 
Stain) to yield the hydroxyboronate as a colorless oil in 73% yield (21.3 mg) in 99:1 anti:syn 
diastereomeric ratio.  1H NMR (600 MHz, CDCl3) δ 7.29 – 7.26 (m, 2H), 6.86 – 6.82 (m, 
2H), 4.76 (d, J = 7.1 Hz, 1H), 3.79 (s, 1H), 2.29 (s, 1H), 1.55 (qu, J = 7.3 Hz, 1H), 1.14 (s, 
6H), 1.13 (s, 6H), 1.01 (d, J = 7.2 Hz, 3H).  13C NMR (151 MHz, CDCl3) δ 158.8, 136.5, 
127.6, 113.5, 83.3, 75.7, 55.4, 24.7, 24.7, 11.1.  IR (ν/cm-1): 3495 (s, br), 2978 (s), 2932 (w), 
2873 (w), 1615 (m), 1514 (s), 1457 (m), 1374 (s), 1319 (m), 1248 (s), 1173 (m), 1144 (m).  
HRMS (ESI+) [M+Na]+ calcd for C16H25BO4Na+ 315.1744, found: 315.1737. 
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Figure 2.12. 1H and 13C{1H} NMR spectra of 2.6. 
 
2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(m-tolyl)propan-1-ol (2.7).  
Following general procedure A, the crude reaction mixture was purified by silica gel (NaOAc 
deactivated silica gel, 10:1 to 2:1 pentane:diethyl ether, Seebach Stain) to yield the 
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hydroxyboronate as a colorless oil in 75% yield (20.7 mg) in 97:3 anti:syn diastereomeric 
ratio.  1H NMR (600 MHz, CDCl3) δ 7.20 (t, J = 7.5 Hz, 1H), 7.17 (s, 1H), 7.15 – 7.12 (m, 
1H), 7.04 (d, J = 7.3 Hz, 1H), 4.79 (d, J = 6.7 Hz, 1H), 2.35 (s, 1H), 2.33 (s, 3H), 1.56 (quint, 
J = 7.3 Hz, 1H), 1.16 (s, 6H), 1.14 (s, 6H), 1.00 (d, J = 7.4 Hz, 3H).  13C NMR (151 MHz, 
CDCl3) δ 144.1, 137.6, 128.1, 127.9, 127.1, 123.5, 83.4, 76.0, 24.7, 21.6, 10.9.  IR (ν/cm-1): 
3487 (s, br), 2978(s), 2929 (m), 2874 (w), 1457 (m), 1380 (s), 1319 (m), 1145 (s), 1006 (m).  
HRMS (ESI+) [M+Na]+ calcd for C16H25BO3Na+ 299.1795, found: 299.1788.   
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Figure 2.13. 1H and 13C{1H} NMR spectra of 2.7. 
 
1-(3-nitrophenyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-ol 
(2.8).  Following general procedure A, the crude reaction mixture was purified by silica gel 
chromatography (NaOAc deactivated silica gel, 10:1 to 2:1 pentane:diethyl ether, Seebach 
Stain) to yield the hydroxyboronate as a colorless oil in 36% yield (11.1 mg) in 99:1 anti:syn 
diastereomeric ratio.  1H NMR (600 MHz, CDCl3) δ 8.28 (t, J = 2.0 Hz, 1H), 8.13 (ddd, J = 
8.2, 2.3, 1.0 Hz, 1H), 7.75 – 7.68 (m, 1H), 7.51 (t, J = 7.9 Hz, 1H), 5.02 (d, J = 5.6 Hz, 1H), 
2.77 (s, 1H), 1.60 (qd, J = 7.5, 5.6 Hz, 1H), 1.23 (s, 12H), 0.95 (d, J = 7.5 Hz, 3H).  13C 
NMR (151 MHz, CDCl3) δ 148.2, 146.3, 132.6, 129.0, 122.1, 121.4, 83.8, 74.6, 24.8, 24.8, 
10.0.  IR (ν/cm-1): 3567 (br, s), 2979 (s), 2930 (m), 2877 (w), 1698 (m), 1558 (m), 1540 (s), 
1457 (m), 1351 (s), 1318 (m), 1142 (m), 1018 (w).  HRMS (ESI+) [M+H]+ calcd for 
C15H22BNO5+ 306.1513, found: 306.1519. 
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Figure 2.14. 1H and 13C{1H} NMR spectra of 2.8. 
 
2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(3-(trifluoromethyl)phenyl) 
propan-1-ol (2.9).  Following general procedure A, the crude reaction mixture was purified 
by silica gel chromatography (NaOAc deactivated silica gel, 10:1 to 2:1 pentane:diethyl 
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ether, Seebach Stain) to yield the hydroxyboronate as a colorless oil in 52% yield (17.2 mg) 
in 98:2 anti:syn diastereomeric ratio.  1H NMR (400 MHz, CDCl3) δ 7.66 (s, 1H), 7.56 (d, J 
= 7.6 Hz, 1H), 7.52 (d, J = 7.7 Hz, 1H), 7.45 (t, J = 7.7 Hz, 1H), 4.93 (d, J = 6.3 Hz, 1H), 
2.61 (s, 1H), 1.59 (quint, J = 7.1 Hz, 1H), 1.20 (s, 6H), 1.19 (s, 6H), 0.99 (d, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 145.0, 130.5, 130.1, 129.7, 128.5, 125.6, 123.9, 123.9, 123.2, 
123.2, 122.9, 83.5, 75.1, 24.6, 10.4.  IR (ν/cm-1): 3459 (br, s), 2980 (s), 2934 (w),  2879 (w), 
1451 (m), 1382 (m), 1329 (s), 1165 (s), 1144 (m), 1126 (s), 1073 (m), 1019 (m).   HRMS 
(ESI+) [M+Na]+ calcd for C16H22BF3O3Na+ 353.1512, found: 353.1509. 
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Figure 2.15. 1H and 13C{1H} NMR spectra of 2.9. 
 
2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(o-tolyl)propan-1-ol (2.10).  
Following general procedure A, the crude reaction mixture was purified by silica gel 
chromatography (NaOAc deactivated silica gel, 10:1 to 2:1 pentane:diethyl ether, Seebach 
Stain) to yield the hydroxyboronate as a colorless oil in 69% yield (19.0 mg) in >99:1 
anti:syn diastereomeric ratio.  1H NMR (600 MHz, CDCl3) δ 7.47 (dd, J = 7.7, 1.4 Hz, 1H), 
7.21 (td, J = 7.4, 1.6 Hz, 1H), 7.16 (td, J = 7.3, 1.4 Hz, 1H), 7.14 – 7.11 (m, 1H), 5.08 (d, J = 
6.8 Hz, 1H), 2.40 (s, 3H), 1.67 – 1.60 (m, 1H), 1.15 (s, 6H), 1.13 (s, 6H), 1.06 (d, J = 7.3 Hz, 
3H).  13C NMR (151 MHz, CDCl3) δ 142.0, 134.9, 130.4, 127.1, 126.4, 125.9, 83.3, 72.0, 
24.7, 24.6, 19.4, 10.9.  IR (ν/cm-1): 3482 (br, s), 2978 (s), 2931 (m), 2874 (w), 1459 (m), 
1380 (s), 1319 (s), 1145 (s), 1008 (m).  HRMS (ESI+) [M+Na]+ calcd for C16H25BO3Na+ 
299.1795, found: 299.1788. 
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Figure 2.16. 1H and 13C{1H} NMR spectra of 2.10. 
 
1-(furan-2-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-ol (2.11).  
Following general procedure A, the crude reaction mixture was purified by silica gel (NaOAc 
deactivated silica gel, 10:1 to 2:1 pentane:diethyl ether, Seebach Stain) to yield the 
Me
OH
B
O O
2.11
O
 111 
hydroxyboronate as a yellow oil in 71% yield (17.8 mg) in 94:6 anti:syn diastereomeric ratio.  
1H NMR (600 MHz, CDCl3) δ 7.35 (dd, J = 1.9, 0.8 Hz, 1H), 6.32 (dd, J = 3.3, 1.8 Hz, 1H), 
6.25 (dt, J = 3.2, 0.7 Hz, 1H), 4.73 (d, J = 7.1 Hz, 1H), 2.82 (s, 1H), 1.70 (quint, J = 7.4 Hz, 
1H), 1.25 (s, 6H), 1.24 (s, 6H), 1.01 (d, J = 7.5 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 
156.6, 141.4, 110.0, 106.4, 83.5, 70.1, 24.7, 24.6, 11.3.  IR (ν/cm-1): 3469 (s, br), 2979 (s), 
2932 (m), 2878 (w), 1458 (m), 1381 (s), 1322 (m), 1145 (s), 1009 (m).  HRMS (ESI+) 
[M+Na]+ calcd for C13H21BO4Na+ 275.1431, found: 275.1427. 
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Figure 2.17. 1H and 13C{1H} NMR spectra of 2.11. 
 
1-(pyridin-3-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-ol 
(2.12).  Following general procedure A, the crude reaction mixture was purified by silica gel 
chromatography (NaOAc deactivated silica gel, 10:1 to 2:1 pentane:diethyl ether, Seebach 
Stain) to yield the hydroxyboronate as a colorless oil in 45% yield (11.8 mg) in 99:1 anti:syn 
diastereomeric ratio.  1H NMR (600 MHz, CDCl3) δ 8.59 (d, J = 2.2 Hz, 1H), 8.50 (dd, J = 
4.8, 1.7 Hz, 1H), 7.73 (dt, J = 7.9, 2.0 Hz, 1H), 7.27 (dd, J = 4.8, 0.8 Hz, 1H), 4.93 (d, J = 6.3 
Hz, 1H), 2.74 (s, 1H), 1.67 – 1.53 (m, 1H), 1.20 (s, 6H), 1.19 (s, 6H), 1.00 (d, J = 7.4 Hz, 
3H).  13C NMR (151 MHz, CDCl3) δ 148.5, 148.2, 139.3, 134.1, 123.2, 83.7, 73.5, 24.8, 
24.7, 10.4.  IR (v/cm-1): 3433 (s), 2359 (s), 2085 (w), 1643 (m), 1378 (w), 1320 (w), 1142 
(m).  HRMS (ESI)+ [M+H]+ calcd for C14H23BNO3+ 264.1772, found: 264.1761.   
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Figure 2.18. 1H and 13C{1H} NMR spectra of 2.12. 
 
tert-butyl 3-(anti-1-hydroxy-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)propyl)-1H-indole-1-carboxylate (2.13).  Following general procedure A, the crude 
reaction mixture was purified by silica gel chromatography (NaOAc deactivated silica gel, 
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10:1 to 2:1 pentane:diethyl ether, Seebach Stain) to yield the hydroxyboronate as a colorless 
oil in 77% yield (30.9 mg) in >99:1 anti:syn diastereomeric ratio.  1H NMR (600 MHz, 
CDCl3) δ 8.25 – 8.09 (m, 1H), 7.68 (dt, J = 7.8, 0.9 Hz, 1H), 7.58 (s, 1H), 7.33 (ddd, J = 8.4, 
7.2, 1.2 Hz, 1H), 7.24 (ddd, J = 8.0, 7.3, 1.0 Hz, 1H), 5.17 (dd, J = 6.4, 2.3 Hz, 1H), 2.46 (d, 
J = 4.5 Hz, 1H), 1.85 – 1.75 (m, 1H), 1.68 (s, 9H), 1.21 (s, 6H), 1.21 (s, 6H), 1.08 (d, J = 7.5 
Hz, 3H).  13C NMR (151 MHz, CDCl3) δ 149.8, 135.8, 129.1, 125.6, 124.4, 123.7, 122.8, 
122.5, 120.0, 115.3, 83.5, 69.4, 28.3, 24.8, 24.7, 10.8.   IR (ν/cm-1): 3502 (s, br), 2978 (s), 
2932 (m), 2877 (w), 1733 (s), 1455 (s), 1372 (s), 1321 (m), 1255 (m), 1159 (s), 1081 (m), 
1011 (m).  HRMS (ESI+) [M+Na]+ calcd for C22H32BNO5Na+ 424.2271, found: 424.2272. 
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Figure 2.19. 1H and 13C{1H} NMR spectra of 2.13. 
 
(E)-1-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pent-1-en-3-ol (2.14). 
Following general procedure A, the crude reaction mixture was purified by silica gel 
chromatography (NaOAc deactivated silica gel, 10:1 to 2:1 pentane:diethyl ether, Seebach 
Stain) to yield the hydroxyboronate as a yellow oil in 65% yield (18.7 mg) in 88:12 anti:syn 
diastereomeric ratio.  anti-diastereomer:  1H NMR (600 MHz, CDCl3) δ 7.42 – 7.37 (m, 
2H), 7.35 – 7.31 (m, 2H), 7.27 – 7.22 (m, 1H), 6.61 (dd, J = 15.9, 1.2 Hz, 1H), 6.28 (dd, J = 
15.9, 6.5 Hz, 1H), 4.41 – 4.33 (m, 1H), 2.39 (s, 1H), 1.53 – 1.46 (m, 1H), 1.25 (s, 12H), 1.07 
(d, J = 7.5 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 137.0, 131.7, 130.3, 128.5 127.4, 126.4, 
83.4, 75.0, 24.8, 24.7, 11.0.  syn-diastereomer:  1H NMR (600 MHz, CDCl3) δ 7.43 – 7.36 
(m, 2H), 7.36 – 7.30 (m, 2H), 7.27 – 7.22 (m, 1H), 6.59 (dd, J = 15.0, 1.2 Hz, 1H), 6.25 (dd, 
J = 17.2, 6.5 Hz, 1H), 4.27 (m, 1H), 2.55 (s, 1H), 1.41 (quint, J = 7.4 Hz, 1H), 1.28 (s, 6H), 
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1.27 (s, 6H), 1.07 (d, J = 8.0 Hz, 3H).  13C NMR (151 MHz, CDCl3) δ 137.0, 132.5, 131.7, 
130.2, 127.4, 126.4, 83.5, 75.8, 24.9, 24.7, 12.1.  IR (ν/cm-1): 3446 (s, br), 3026 (w), 2978 
(s), 2931 (m), 2875 (w), 1457 (m), 1380 (s), 1320 (m), 1144 (s), 1006 (m).  HRMS (ESI+) 
[M+Na]+ calcd for C17H25BO3Na+ 311.1795, found: 311.1788. 
 
 
Figure 2.20. 1H and 13C{1H} NMR spectra of 2.14. 
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(E)-1-(4-chlorophenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pent-1-en-
3-ol (2.15).  Following general procedure A, the crude reaction mixture was purified by silica 
gel chromatography (NaOAc deactivated silica gel, 10:1 to 2:1 pentane:diethyl ether, 
Seebach Stain) to yield the hydroxyboronate as a colorless oil in 40% yield (12.9 mg) in 
88:12 anti:syn diastereomeric ratio.  anti diastereomer: 1H NMR (600 MHz, CDCl3) δ 7.31 
– 7.25 (m, 5H), 6.54 (dd, J = 15.9, 1.3 Hz, 1H), 6.23 (dd, J = 15.8, 6.4 Hz, 1H), 4.39 – 4.28 
(m, 1H), 2.36 (s, 1H), 1.48 – 1.43 (m, 1H), 1.22 (s, 6H), 1.22 (s, 6H), 1.04 (d, J = 7.5 Hz, 
3H).  13C NMR (151 MHz, CDCl3) δ 135.5, 133.0, 132.4, 129.0, 128.7, 127.6, 83.5, 74.8, 
24.8, 24.7, 11.0.  syn-diastereomer:  1H NMR (600 MHz, CDCl3) δ 7.34 – 7.27 (m, 5H), 
6.56 – 6.51 (m, 1H), 6.25 – 6.20 (m, 1H), 4.25 (t, J = 6.5 Hz, 1H), 2.57 (s, 1H), 1.43 – 1.36 
(m, 1H), 1.27 (s, 6H), 1.26 (s, 6H), 1.06 (d, J = 7.5 Hz, 3H).  13C NMR (151 MHz, CDCl3) δ 
133.2, 129.2, 128.8, 128.8, 127.6, 125.5, 83.5, 75.7, 24.8, 24.7, 12.1.  IR (v/cm-1): 3433 (s), 
2385 (m), 2083 (s), 1642 (m), 1490 (w), 1378 (m), 1320 (m), 1140 (w).  HRMS (ESI+) 
[M+Na]+ calcd for C17H24BClO3Na 345.1405, found: 345.1394. 
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Figure 2.21. 1H and 13C{1H} NMR spectra of 2.15. 
 
(E)-1-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pent-1-en-3-ol (2.16).  
Following general procedure A, the crude reaction mixture was purified by silica gel 
chromatography (NaOAc deactivated silica gel, 10:1 to 2:1 pentane:diethyl ether, Seebach 
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Stain) to yield the hydroxyboronate as a colorless oil in 64% yield (18.5 mg) in 93:7 anti:syn 
diastereomeric ratio.   1H NMR (600 MHz, CDCl3) δ 7.38 – 7.32 (m, 2H), 7.29 (d, J = 8.8 
Hz, 2H), 7.23 (td, J = 7.2, 1.5 Hz, 1H), 6.55 (s, 1H), 4.32 (d, J = 7.0 Hz, 1H), 2.14 (s, 1H), 
1.88 (s, 3H), 1.55 (m, 1H), 1.24 (s, 12H), 1.05 (d, J = 7.4 Hz, 3H).  13C NMR (151 MHz, 
CDCl3) δ 139.8, 137.9, 129.1, 128.1, 126.3, 125.6, 83.4, 79.1, 24.9, 24.8, 14.2, 10.5.   IR 
(ν/cm-1): 3429 (s), 2568 (m), 2082 (m), 1643 (s), 1143 (m). HRMS (ESI+) [M+Na]+ calcd for 
C18H27BO3Na+ 325.1943, found: 325.1940. 
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Figure 2.22. 1H and 13C{1H} NMR spectra of 2.16. 
2.8.3 Preparation of anti-1,2-hydroxyboronates from substituted 1,1-diboronates 
 
1,3-diphenyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-ol (2.17). 
Following general procedure B, the crude reaction mixture was purified by silica gel 
chromatography (NaOAc deactivated silica gel, 10:1 to 5:1 pentane:diethyl ether, Seebach 
Stain) to yield the hydroxyboronate as a colorless oil in 76% yield (25.7 mg) in 92:8 anti:syn 
diastereomeric ratio.  anti diastereomer: 1H NMR (600 MHz, CDCl3) δ 7.43 – 7.38 (m, 1H), 
7.35 (m, 1H), 7.34 – 7.29 (m, 2H), 7.27 – 7.17 (m, 5H), 7.17 – 7.10 (m, 1H), 4.83 (dd, J = 
8.1, 3.6 Hz, 1H), 3.06 (dd, J = 13.6, 5.6 Hz, 1H), 2.81 – 2.68 (m, 1H), 2.24 (d, J = 3.7 Hz, 
1H), 2.02 (ddd, J = 11.1, 8.0, 5.7 Hz, 1H), 0.90 (s, 6H), 0.89 (s, 6H). 13C NMR (151 MHz, 
CDCl3) δ 143.9, 141.7, 129.1, 128.4, 128.3, 126.8, 126.0, 125.9, 83.4, 76.0, 34.5, 24.7, 24.7.  
syn-diastereomer: 1H NMR (600 MHz, CDCl3) δ 7.43 – 7.38 (m, 1H), 7.35 (m, 1H), 7.34 – 
OH
B
O O
2.17
Ph
 121 
7.29 (m, 2H), 7.27 – 7.17 (m, 5H), 7.17 – 7.10 (m, 1H), 4.70 (t, J = 6.7 Hz, 1H), 2.81 – 2.68 
(m, 2H), 2.62 (d, J = 7.2 Hz, 1H), 1.99 – 1.91 (m, 1H), 1.08 (s, 6H), 1.07 (s, 6H). 13C NMR 
(151 MHz, CDCl3) δ 144.9, 141.3, 129.0, 128.4, 128.3, 127.8, 127.3, 126.0, 83.6, 75.1, 34.5, 
24.9. 24.7. IR (ν/cm-1): 3467 (s, br), 3061 (w), 3028 (m), 2979 (s), 2927 (m), 2865 (w), 1455 
(m), 1380 (s), 1325 (m), 1247 (m), 1143 (s).  HRMS (ES+) [M+Na]+ calcd for 
C21H27BO3Na+ 361.1951, found: 361.1949. 
 
 
Figure 2.23. 1H and 13C{1H} NMR spectra of 2.17. 
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5-methyl-1-phenyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hex-4-en-1-ol 
(2.18).  Following general procedure B, the crude reaction mixture was purified by silica gel 
chromatography (NaOAc deactivated silica gel, 10:1 to 5:1 pentane:diethyl ether, Seebach 
Stain) to yield the hydroxyboronate as a colorless oil in 74% yield (23.4 mg) in 98:2 anti:syn 
diastereomeric ratio. anti-diastereomer: 1H NMR (CDCl3, 600 MHz): δ 7.37 (d, J = 6.6 Hz, 
2H), 7.30 (t, J = 7.8 Hz, 2H), 7.22 (tt, J = 7.2, 1.8 Hz, 1H), 5.17 (t, J = 7.5 Hz, 1H), 4.77 (d, J 
= 9.0 Hz, 1H), 2.33 (d, J = 4.2 Hz, 1H), 2.28-2.31 (m, 1H), 2.23-2.26 (m, 1H), 1.66 (s, 3H), 
1.63-1.64 (m, 1H), 1.60 (s, 3H), 1.05 (s, 6H), 1.02 (s, 6H).  13C NMR  (CDCl3, 151 MHz): δ 
144.1, 132.2, 128.3, 127.6, 126.8, 124.0, 83.3, 75.8, 26.5, 26.0, 24.7, 24.6, 18.0.  syn-
diastereomer: 1H NMR (CDCl3, 600 MHz): δ 7.34 (d, J = 7.2 Hz, 2H), 7.30 (t, J = 7.8 Hz, 
2H), 7.22 (tt, J = 7.2, 1.8 Hz, 1H), 5.11 (t, J = 7.2 Hz, 1H), 4.70 (t, J = 6.6 Hz, 1H), 2.65 (d, J 
= 6.0 Hz, 1H), 2.11-2.16 (m, 1H), 2.00-2.04 (m, 1H), 1.65 (s, 3H), 1.58-1.59 (m, 1H), 1.55 
(s, 3H), 1.19 (s, 12H).  13C NMR  (CDCl3, 151 MHz): δ 144.9, 132.3, 127.3, 126.2, 123.5, 
83.5, 75.7, 27.1, 25.9, 25.0, 24.6, 18.0.  IR (ν/cm-1): 3478 (s, br, OH), 3061 (w), 3030 (w), 
2978 (m), 2925 (m), 2857 (m), 1453 (w), 1410 (w), 1379 (s), 1323 (m), 1245 (m), 1213 (w), 
1166 (w), 1144 (s), 1108 (w), 1052 (w), 1008 (w).  HRMS (ESI+) [2M+Na]+ calcd for 
C38H58B2NaO6+ 655.4318, found: 655.4309. 
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Figure 2.24. 1H and 13C{1H} NMR spectra of 2.18. 
 
4-((tert-butyldimethylsilyl)oxy)-1-phenyl-2-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)butan-1-ol (2.19).  Following general procedure B, the crude reaction 
mixture was purified by silica gel chromatography (NaOAc deactivated silica gel, 10:1 to 5:1 
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pentane:diethyl ether, Seebach Stain) to yield the hydroxyboronate as a colorless oil in 77% 
yield (31.3 mg) in 94:6 anti:syn diastereomeric ratio.  anti-diastereomer: 1H NMR (CDCl3, 
600 MHz): δ 3.77 (dt, J = 10.2, 6.0 Hz, 1H), 3.57-3.61 (m, 1H), 3.48 (qu, J = 5.4 Hz, 1H), 
2.77 (d, J = 6.6 Hz, 1H), 1.90 (m, 1H), 1.68-1.78 (m, 4H), 1.56-1.64 (m, 2H), 1.32-1.43 (m, 
2H), 1.24 (s, 9H), 1.08-1.22 (m, 3H), 0.94-1.06 (m, 2H), 0.89 (s, 6H), 0.88 (s, 6H), 0.06 (s, 
6H).  13C NMR  (CDCl3, 151 MHz): δ 83.3, 76.8, 63.5, 42.2, 33.2, 30.1, 29.3, 27.9, 26.6, 
26.4, 26.3, 26.1, 24.9, 24.9, 18.5, –5.2.  syn-diastereomer: 1H NMR (CDCl3, 600 MHz): δ 
3.67 (ddd, J = 10.0, 7.5, 6.1 Hz, 1H), 3.56-3.61 (m, 1H), 3.34 (qu, J = 7.2 Hz, 1H), 2.25 (d, J 
= 8.4 Hz, 1H), 1.95 (m, 1H), 1.68-1.78 (m, 4H), 1.56-1.64 (m, 2H), 1.32- 1.43 (m, 2H), 1.24 
(s, 9H), 1.08-1.22 (m, 3H), 0.94-1.06 (m, 2H), 0.89 (s, 6H), 0.88 (s, 6H), 0.04 (s, 6H).  13C 
NMR  (CDCl3, 151 MHz): δ 83.4, 77.9, 62.9, 43.7, 36.5, 31.8, 30.0, 28.6, 26.7, 26.6, 26.3, 
26.1, 25.0, 24.9, 18.5, –5.1, –5.1.  IR (ν/cm-1): 3474 (s, br, OH), 2978 (m), 2954 (m), 2929 
(m), 2885 (m), 2857 (m), 1471 (w), 1372 (m), 1321 (m), 1254 (m), 1214 (w), 1167 (w), 1144 
(m), 1096 (m), 1025 (w).  HRMS (ESI+) [M+Na]+ calcd for C22H39BNaO4Si+ 429.2609, 
found: 429.2607. 
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Figure 2.25. 1H and 13C{1H} NMR spectra of 2.19. 
 
1-phenyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentan-1-ol (2.20).  
Following general procedure B, the crude reaction mixture was purified by silica gel 
chromatography (NaOAc, deactivated silica gel, 5:1 pentane:diethyl ether to 2:1 pentane 
diethyl ether, Seebach Stain) to yield the hydroxyboronate as a colorless oil in 60% yield 
(17.4 mg) in 94:6 anti:syn diastereomeric ratio.  1H NMR (600 MHz, CDCl3) δ 7.41 – 7.37 
(m, 2H), 7.33 (dd, J = 8.4, 6.8 Hz, 2H), 7.28 – 7.23 (m, 1H), 4.78 (d, J = 7.6 Hz, 1H), 2.26 (s, 
1H), 1.62 (ddt, J = 12.5, 10.1, 4.5 Hz, 2H), 1.58 – 1.50 (m, 2H), 1.43 – 1.36 (m, 2H), 1.35 – 
1.22 (m, 2H), 1.12 (s, 6H), 1.07 (s, 6H), 0.92 (t, J = 7.3 Hz, 3H).  13C NMR (151 MHz, 
CDCl3) δ 144.3, 128.3, 127.5, 126.7, 83.3, 75.8, 30.0, 24.8, 24.7, 22.7, 14.6.  IR (v/cm-1): 
3432 (s), 2090 (s), 1642 (m), 1454 (m), 1379 (m), 1320 (w), 1247 (m), 1143 (w).  HRMS 
(ESI)+ [2M+Na]+ calcd for C34H54B2O6Na+ 603.4004, found: 603.3987. 
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Figure 2.26. 1H and 13C{1H} NMR spectra of 2.20. 
 
tert-butyl-4-hydroxy-4-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)butanoate (2.21).  Following general procedure B, the crude reaction mixture was 
purified by silica gel chromatography (NaOAc deactivated silica gel, 10:1 to 5:1 
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pentane:diethyl ether, Seebach Stain) to yield the hydroxyboronate as a colorless oil in 66% 
yield (23.9 mg) in a 47:53 anti:syn diastereomeric ratio.  anti-diastereomer:  1H NMR (600 
MHz, CDCl3) δ 7.46 – 7.29 (m, 4H), 7.28 – 7.23 (m, 1H), 4.95 (d, J = 6.1 Hz, 1H), 3.11 (s, 
1H), 2.54 – 2.17 (m, 2H), 1.87 (dt, J = 8.3, 6.1 Hz, 1H), 1.46 (s, 9H), 1.26 (s, 12H).  13C 
NMR (151 MHz, CDCl3) δ 174.1, 143.7, 128.2, 127.2, 126.2, 83.1, 79.8, 74.3, 33.9, 32.7, 
30.0, 28.1, 24.9, 24.8, 24.8.  syn-diastereomer: 1H NMR (600 MHz, CDCl3) δ 7.46 – 7.29 
(m, 4H), 7.28 – 7.23 (m, 1H), 4.81 (d, J = 8.2 Hz, 1H), 2.92 (s, 1H), 2.54 – 2.17 (m, 9H), 
1.80 – 1.73 (m, 1H), 1.44 (s, 9H), 1.28 (s, 6H), 1.27 (s, 6H).  13C NMR (151 MHz, CDCl3) δ 
173.1, 143.7, 128.3, 127.4, 126.3, 83.7, 83.5, 80.5, 80.4, 75.0, 32.7, 30.3, 28.1, 28.1, 24.8, 
24.7, 24.5, 24.5.  IR (v/cm-1): 3429 (s), 2359 (s), 2341 (s), 2094 (w), 1643 (m), 1139 (m).  
HRMS (ESI)+ [2M+Na]+ calcd for C40H62B2O10Na+ 747.4428, found: 747.4407. 
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Figure 2.27. 1H and 13C{1H} NMR spectra of 2.21. 
2.8.4 Preparation of anti-1,2-hydroxyboronates from alkyl aldehydes and substituted 1,1-
diboronates 
 
1-cyclohexyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-ol (2.23). 
Following general procedure C, the crude reaction mixture was purified by silica gel 
chromatography (NaOAc deactivated silica gel, 20:1 pentane:ethyl acetate to 5:1 
pentane:diethyl ether, Seebach Stain) to yield the hydroxyboronate as a crystalline white 
solid in 38% yield (10.3 mg) and 88:12 anti:syn diastereomeric ratio. anti-diastereomer: 1H 
NMR (CDCl3, 600 MHz): δ 3.46 (m, 1H), 1.92-1.95 (m, 2H), 1.71-1.77 (m, 2H), 1.62-1.65 
(m, 2H), 1.56-1.59 (m, 1H), 1.32-1.40 (m, 2H), 1.09-1.24 (m, 3H), 0.98-1.02 (m, 1H), 1.24 
(s, 12H), 0.96 (d, J = 7.8 Hz, 3H).  13C NMR (CDCl3, 151 MHz): δ 83.4, 77.4, 41.1, 29.7, 
28.6, 26.6, 26.5, 26.3, 24.9, 24.8, 9.2.  IR (ν/cm-1): 3522 (s, br, OH), 2977 (m), 2925 (s), 
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2851 (m), 1450 (m), 1379 (s), 1317 (m), 1273 (w), 1214 (w), 1166 (w), 1145 (m), 1008 (w).  
HRMS (ESI+) [2M+Na]+ calcd for C30H58B2NaO6+ 559.4318, found: 559.4314. 
 
 
Figure 2.28. 1H and 13C{1H} NMR spectra of 2.23. 
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1-cyclohexyl-5-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hex-4-en-1-
ol (2.24).  Following general procedure C, the crude reaction mixture was purified by silica 
gel chromatography (NaOAc deactivated silica gel, 20:1 pentane:ethyl acetate to 5:1 
pentane:diethyl ether, Seebach Stain) to yield the hydroxyboronate  as a colorless, crystalline 
white solid in 61% yield (19.5 mg) and 78:22 anti:syn diastereomeric ratio.  anti-
diastereomer: 1H NMR (CDCl3, 600 MHz): δ 5.15 (t, J = 7.2 Hz, 1H), 3.48 (t, J = 6.6 Hz, 
1H), 2.17-2.26 (m, 2H), 1.86-1.92 (m, 2H), 1.72-1.77 (m 2H), 1.66 (s, 3H), 1.62 (s, 3H), 
1.57-1.60 (m, 1H), 1.32-1.39 (m, 2H), 1.22 (s, 6H), 1.22 (s, 6H), 1.08-1.21 (m, 4H), 0.95-
1.06 (m, 1H).  13C NMR  (CDCl3, 151 MHz): δ 131.9, 124.5, 83.3, 42.4, 30.3, 27.4, 26.7, 
26.6, 26.4, 26.0, 25.3, 24.9, 24.8, 18.0.  syn-diastereomer: 1H NMR (CDCl3, 600 MHz): δ 
5.11 (t, J = 7.2 Hz, 1H), 3.32 (qu, J = 7.2 Hz, 1H), 2.10-2.16 (m, 2H), 2.04 (d, 1H, J = 9.0 
Hz), 1.86-1.92 (m, 2H), 1.72-1.77 (m 2H), 1.66 (s, 3H), 1.62 (s, 3H), 1.57-1.60 (m, 1H), 
1.32-1.39 (m, 2H), 1.23 (s, 12H), 1.08-1.21 (m, 4H), 0.95-1.06 (m, 1H).  13C NMR  (CDCl3, 
151 MHz): δ 132.0, 124.1, 83.4, 78.2, 44.1, 30.0, 28.5, 27.7, 26.7, 26.6, 25.9, 25.0, 24.7, 
18.0.  IR (ν/cm-1): 3517 (s, br, OH), 2928 (m), 2925 (s), 2852 (m), 1449 (m), 1378 (s), 1320 
(m), 1245 (w), 1213 (w), 1165 (w), 1144 (s), 1110 (w), 1044 (w).  HRMS (ESI+) [2M+Na]+ 
calcd for C38H70B2NaO6+ 667.5257, found: 667.5249. 
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Figure 2.29. 1H and 13C{1H} NMR spectra of 2.24. 
 
1-cyclohexyl-3-phenyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-
ol (2.25).  Following general procedure C, the crude reaction mixture was purified by silica 
gel chromatography (NaOAc deactivated silica gel, 20:1 pentane:ethyl acetate to 5:1 
OH
B
O O
2.25
Ph
 132 
pentane:diethyl ether, Seebach Stain) to yield the hydroxyboronate as a colorless, crystalline 
white solid in 49% yield (17.0 mg) and 95:5 anti:syn diastereomeric ratio.  anti-
diastereomer: 1H NMR (CDCl3, 600 MHz): δ 7.23 (m, 2H), 7.23 (m, 2H), 7.13 (m, 1H), 
3.53 (t, J = 6.0 Hz, 1H), 2.98 (dd, J = 13.8 Hz, 6.0 Hz, 1H), 2.70 (dd, J = 13.2, 11.4 Hz, 1H), 
1.93-1.96 (m, 1H), 1.87 (s, 1H), 1.73-1.80 (m, 3H), 1.63-1.67 (m, 2H), 1.39-1.46 (m, 1H), 
1.12-1.27 (m, 5H), 1.11 (s, 6H), 1.05 (s, 6H).  13C NMR  (CDCl3, 151 MHz): δ 142.2, 129.1, 
128.2, 125.8, 83.4, 77.3, 42.4, 32.7, 30.3, 27.4, 26.7, 26.6, 26.3, 24.9, 24.8.  IR (ν/cm-1): 
3511 (s, br, OH), 3061 (w), 3027 (w), 2978 (m), 2925 (s), 2852 (w), 1496 (w), 1450 (m), 
1372 (s), 1323 (m), 1249 (w), 1211 (w), 1166 (w), 1143 (m), 1100 (w), 1084 (w), 1072 (w), 
1040 (w).  HRMS (ESI+) [2M+Na]+ calcd for C42H66B2NaO6+ 711.4943, found: 711.4936. 
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Figure 2.30. 1H and 13C{1H} NMR spectra of 2.25. 
 
1-(1,3-dioxolan-2-yl)-4-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)pentan-3-ol (2.26). Following general procedure C, the crude reaction mixture was 
purified by silica gel chromatography (NaOAc deactivated silica gel, 20:1 pentane:ethyl 
acetate to 5:1 pentane:diethyl ether, Seebach Stain) to yield the hydroxyboronate as a 
colorless oil in 62% yield (18.6 mg) and >98:2 anti:syn diastereomeric ratio.  anti-
diastereomer: 1H NMR (CDCl3, 600 MHz): 4.99 (t, 1H, J = 4.2 Hz), 3.94-3.98 (m, 2H), 
3.80-3.85 (m, 2H), 3.43 (t, 1H, J = 6.1 Hz), 2.32 (s, 1H), 1.88-1.95 (m, 2H), 1.67-1.73 (m, 
1H), 1.40-1.44 (m, 1H), 1.24 (s, 12H), 0.92 (dd, J = 13.8, 6.7 Hz, 6H).  13C NMR  (CDCl3, 
151 MHz): δ 104.4, 83.4, 77.1, 65.0, 65.0, 32.2, 30.5, 24.9, 24.9, 20.1, 17.1.  IR (ν/cm-1): 
3495 (s, br), 2976 (m), 2931 (m), 2875 (m), 1470 (w), 1373 (s), 1318 (m), 1249 (w), 1213 
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(w), 1144 (s), 1095 (w).  HRMS (ESI+) [2M+H]+ calcd for C30H59B2O10+ 601.4294, found: 
601.4317. 
 
 
Figure 2.31. 1H and 13C{1H} NMR spectra of 2.26. 
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4-((tert-butyldimethylsilyl)oxy)-1-cyclohexyl-2-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)butan-1-ol (2.27).  Following general procedure C, the crude reaction 
mixture was purified by silica gel chromatography (NaOAc deactivated silica gel, 20:1 
pentane:ethyl acetate to 5:1 pentane:diethyl ether, Seebach Stain) to yield the 
hydroxyboronate as a colorless, crystalline white solid in 49% yield (20.3 mg) and 90:10 
anti:syn diastereomeric ratio.  anti-diastereomer: 1H NMR (CDCl3, 600 MHz): δ 3.77 (dt, J 
= 10.2, 6.0 Hz, 1H), 3.57-3.61 (m, 1H), 3.48 (qu, J = 5.4 Hz, 1H,), 2.77 (d, J = 6.6 Hz, 1H), 
1.90 (m, 1H), 1.68-1.78 (m, 4H), 1.56-1.64 (m, 2H), 1.32- 1.43 (m, 2H), 1.24 (s, 9H), 1.08-
1.22 (m, 3H), 0.94-1.06 (m, 2H), 0.89 (s, 6H), 0.88 (s, 6H), 0.06 (s, 6H).  13C NMR  (CDCl3, 
151 MHz): δ 83.3, 76.8, 63.5, 42.2, 33.2, 30.1, 29.3, 27.9, 26.6, 26.4, 26.3, 26.1, 24.9, 24.9, 
18.5, –5.2.  syn-diastereomer: 1H NMR (CDCl3, 600 MHz): δ 3.67 (ddd, J = 10.0, 7.5, 6.1 
Hz, 1H), 3.56-3.61 (m, 1H), 3.34 (qu, J = 7.2 Hz, 1H), 2.25 (d, J = 8.4 Hz, 1H), 1.95 (m, 
1H), 1.68-1.78 (m, 4H), 1.56-1.64 (m, 2H), 1.32- 1.43 (m, 2H), 1.24 (s, 9H), 1.08-1.22 (m, 
3H), 0.94-1.06 (m, 2H), 0.89 (s, 6H), 0.88 (s, 6H), 0.04 (s, 6H).  13C NMR  (CDCl3, 151 
MHz): δ 83.4, 77.9, 62.9, 43.7, 36.5, 31.8, 30.0, 28.6, 26.7, 26.6, 26.3, 26.1, 25.0, 24.9, 18.5, 
–5.1, –5.1.  IR (ν/cm-1): 3464 (s, br, OH), 2977 (m), 2927 (s), 2854 (m), 1471 (m), 1449 (m), 
1372 (m), 1317 (m), 1254 (m), 1214 (w), 1166 (w), 1145 (m), 1094 (m), 1007 (w).  HRMS 
(ESI+) [M+Na]+ calcd for C22H45BNaO4Si+ 435.3078, found: 435.3077. 
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Figure 2.32. 1H and 13C{1H} NMR spectra of 2.27. 
 
2,2-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentan-3-ol (2.28). 
Following general procedure B, the crude reaction mixture was purified by silica gel 
chromatography (NaOAc deactivated silica gel, 20:1 pentane:ethyl acetate to 5:1 
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pentane:diethyl ether, Seebach Stain) to yield the hydroxyboronate as a colorless, crystalline 
white solid in 33% yield (7.9 mg) and >98:2 anti:syn diastereomeric ratio.  1H NMR (CDCl3, 
600 MHz): δ 3.44 (d, 1H, J = 7.8 Hz), 1.60 (s, 1H), 1.29 (quint, 1H, J = 7.8 Hz), 1.23 (s, 
12H), 1.04 (d, 3H, J = 7.2 Hz), 0.92 (s, 9H).  13C NMR  (CDCl3, 151 MHz): δ 83.2, 79.9, 
36.1, 26.7, 24.8, 24.8, 12.0.  IR (ν/cm-1): 3539 (s, br, OH), 2978 (m), 2953 (m), 2871 (w), 
1481 (w), 1458 (w), 1379 (m), 1334 (w), 1314 (m), 1166 (w), 1145 (m), 1106 (w), 1039 (w).  
HRMS (ESI+) [2M+Na]+ calcd for C26H54B2NaO6+ 507.4004, found: 507.3998. 
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Figure 2.33. 1H and 13C{1H} NMR spectra of 2.28. 
 
3-(1,3-dioxolan-2-yl)-1-phenyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)propan-1-ol (2.29).  Following general procedure C, the crude reaction mixture was 
purified by silica gel chromatography (NaOAc-deactivated silica gel; 2:1 pentane:diethyl 
ether to 1:1 pentane:diethyl ether, Seebach stain) to yield the hydroxyboronate as a colorless, 
crystalline white solid in 54% yield (18.0 mg) and >98:2 anti:syn diastereomeric ratio.  1H 
NMR (CDCl3, 600 MHz): δ 7.38 (d, J = 7.2 Hz, 2H), 7.30 (t, J = 7.8 Hz, 2H), 7.22 (t, J = 7.2 
Hz, 1H), 4.99 (t, J = 4.1 Hz, 1H), 4.75 (d, 1H, J = 8.0 Hz), 3.94-3.99 (m, 2H), 3.81-3.86 (m, 
2H), 2.72 (s, 1H), 2.03 (dt, J = 14.2, 4.2 Hz, 1H), 1.95 (ddd, J = 14.1, 9.7, 4.3 Hz, 1H), 1.73 
(ddd, J = 9.7, 8.1, 4.6 Hz, 1H), 1.10 (s, 6H), 1.01 (s, 6H).  13C NMR  (CDCl3, 151 MHz): δ 
143.9, 128.3, 127.6, 126.9, 104.2, 83.3, 75.2, 65.1, 65.0, 31.8, 24.9, 24.7.  IR (ν/cm-1): 3468 
(s, br), 2977 (m), 2926 (m), 2887 (m), 1455 (w), 1378 (s), 1321 (m), 1249 (w), 1212 (w), 
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1144 (s), 1032 (m).  HRMS (ESI+) [2M+Na]+ calcd for C36H54B2NaO10+ 691.3801, found: 
691.3827. 
 
 
Figure 2.34. 1H and 13C{1H} NMR spectra of 2.29. 
2.8.5 Functionalization of anti-1,2-hydroxyboronates 
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Synthesis of TBS-protected hydroxyboronate 2.30: An 8-mL vial containing 
hydroxyboronate 2.13 (21.6 mg, 0.0538 mmol) was charged with imidazole (9.9 mg, 0.145 
mmol) and tert-butyldimethylchlorosilane (16.3 mg, 0.108 mmol) and then sealed with a 
septa-lined cap. Anhydrous DMF (0.360 mL) was added under N2 and the reaction was 
purged for 10 minutes and allowed to stir at ambient temperature for 48 hours. The reaction 
was quenched by the addition of 1.5 mL of a saturated aqueous solution of NH4Cl and the 
aqueous layer extracted three times with ethyl acetate. The combined organic extracts were 
washed twice with a saturated aqueous solution of NaHCO3 and once with brine. The organic 
extract was dried over MgSO4 and concentrated in vacuo. The crude reaction mixture was 
purified by silica gel chromatography (NaOAc deactivated silica gel; 25:1 pentane:diethyl 
ether, Seebach Stain) to yield the TBS-protected hydroxyboronate in 77% yield (21.3 mg) as 
a colorless oil in 99:1 anti:syn diastereoselectivity. 1H NMR (600 MHz, CDCl3) δ 8.09 (s, 
1H), 7.76 (dt, J = 7.9, 1.0 Hz, 1H), 7.42 (s, 1H), 7.31 – 7.23 (m, 1H), 7.18 (ddd, J = 8.0, 7.2, 
1.1 Hz, 1H), 4.91 (d, J = 9.3 Hz, 1H), 1.73 (dq, J = 9.3, 7.2 Hz, 1H), 4.94 (d, J = 9.3 Hz, 1H), 
1.65 (s, 9H), 1.11 (d, J = 7.3 Hz, 3H), 1.08 (s, 6H), 1.01 (s, 6H), 0.86 (s, 9H), 0.05 (s, 3H), -
0.24 (s, 3H).  13C NMR (151 MHz, CDCl3) δ 149.9, 135.8, 129.0, 125.4, 124.1, 122.4, 122.2, 
121.6, 114.9, 83.23, 82.9, 71.1, 28.3, 26.0, 24.7, 24.5, 18.4, 12.6, -4.4, -4.9.  IR (v/cm-1): 
2990 (s), 2922 (m), 2879 (w), 1734 (s), 1446 (s), 1318 (m), 1255 (m), 1159 (s), 1145 (m), 
1081 (m), 1011 (m).  HRMS (ESI+): [M+Na]+ calcd for C28H46BNO5SiNa+ 538.3137, found: 
538.3139. 
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Figure 2.35. 1H and 13C{1H} NMR spectra of 2.30. 
 
Arylation of 2.30 with lithiated furan: 2.31 was prepared according to a literature 
procedure.6 A flame-dried 8-mL vial was charged with furan (2.60 µL, 0.0363 mmol) and 
anhydrous THF (0.120 mL). The reaction was allowed to cool to –78 ˚C (dry-ice/acetone) 
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and then charged with n-butyllithium (21.7 µL, 0.0363 mmol, 1.67 M solution in hexanes). 
The cooling bath was removed and the reaction was allowed to stir at ambient temperature 
for 1 hour. The mixture was allowed to cool back down to –78 ˚C (dry-ice/acetone) and then 
charged with 2.30 as a 0.4 M solution in THF (15.6 mg, 0.0303 mmol) and allowed to stir at 
that temperature for 1.5 hour. NBS (6.50 mg, 0.0363 mmol) was then added to the reaction as 
a 0.3 M solution in THF. After allowing the reaction to stir for 1.5 hours, 1 mL of a saturated 
aqueous solution of Na2S2O3 was added to the reaction and allowed to stir at ambient 
temperature for 30 minutes. The layers were separated and extracted three times with diethyl 
ether. The combined organic extracts were dried over MgSO4, filtered, and concentrated in 
vacuo. The crude reaction mixture was purified by silica gel chromatography (40:1 
pentane:diethyl ether, Seebach stain) to give the product 2.31 as a colorless oil in 67% yield 
(9.0 mg) and >99:1 anti:syn diastereoselectivity as a mixture rotamers (85:15). 25% of the 
starting material 2.30 was recovered from the reaction. (13C NMR shows signals for only one 
diastereomer, indicating that the 1H NMR contains rotamers). Rotamer 1: 1H NMR (600 
MHz, CDCl3) δ 8.15 (s, 1H), 7.64 (dt, J = 7.8, 1.0 Hz, 1H), 7.47 (s, 1H), 7.36 (dd, J = 1.9, 
0.8 Hz, 1H), 7.33 (ddd, J = 8.4, 7.2, 1.2 Hz, 1H), 7.25 (ddd, J = 8.1, 7.2, 1.1 Hz, 1H), 6.29 
(dd, J = 3.2, 1.8 Hz, 1H), 6.03 (dt, J = 3.2, 0.9 Hz, 1H), 5.33 (dd, J = 3.7, 1.1 Hz, 1H), 3.28 
(td, J = 7.1, 3.8 Hz, 1H), 1.69 (s, 9H), 1.24 (d, J = 7.0 Hz, 3H), 0.88 (s, 9H), -0.20 (s, 3H), -
0.20 (s, 3H). Rotamer 2: 1H NMR (600 MHz, CDCl3) δ 8.15 (s, 1H), 7.64 – 7.61 (m, 1H), 
7.46 (d, J = 5.1 Hz, 1H), 7.36 (dd, J = 1.9, 0.8 Hz, 1H), 7.33 (ddd, J = 8.4, 7.2, 1.2 Hz, 1H), 
7.27 – 7.22 (m, 1H), 6.19 (d, J = 3.2 Hz, 1H), 5.99 (dd, J = 3.3, 1.0 Hz, 1H), 5.31 (dd, J = 
3.8, 1.2 Hz, 1H), 3.25 (m, 1H), 1.69 (s, 9H), 1.21 (d, J = 7.0 Hz, 3H), 0.89 (s, 9H), -0.15 (s, 
3H), -0.17 (s, 3H).  13C NMR (151 MHz, CDCl3) δ 157.8, 140.6, 124.1, 123.6, 123.3, 122.3, 
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119.9, 115.2, 110.2, 105.9, 100.0, 70.9, 65.9, 40.1, 34.1, 28.2, 25.8, 22.4, 18.2, 15.3, 14.1, 
11.5, -5.0, -5.8.  IR (v/cm-1): 2990 (s), 2901 (m), 2864 (w), 2525 (s), 2050 (m), 1736 (s), 
1439 (s), 1324 (m), 1260 (m), 1148 (s), 1141 (m), 1082 (m), 1011 (m).  HRMS (ESI+): 
[M+Na]+ cald for C26H37NO4SiNa+ 478.2384, found: 478.2389. 
 
 
Figure 2.36. 1H and 13C{1H} NMR spectra of 2.31. 
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3 Chapter 3: Taming Silylium Ions for Synthesis: N-Heterocycle Synthesis via 
Stereoselective C–C Bond Formation 
This chapter is adapted from a submission of Moyer, B. S.; Gagné, M. R. Synlett 
(manuscript accepted).
3.1 Applying highly reactive silylium ion catalysts to organic synthesis 
3.1.1 Background 
The development of catalytic, synthetic applications of silylium ions has been 
frustrated by the technicality that, except for in the most extreme cases,38 they do not exist.39 
Despite their apparent structural similarity to carbenium ions and their reduced Pauling 
electronegativity (1.8 vs. 2.5), silylium ions are highly Lewis acidic.40 Their increased size 
and longer bond lengths reduce the efficiency of stabilizing π-conjugative and 
hyperconjugative effects, endowing them with a high affinity for both σ- and π-Lewis bases, 
including solvent molecules and counteranions. Therefore, as silylium ionicity falls on a 
continuum, the most “free” examples so far reported are paired with either [B(C6F5)4]- (i.e. 
BArF20) or [HCB11R5X6]- (halogenated carboranes) as weakly coordinating anions (WCAs) 
in aromatic or halocarbon solvents.41 In particular, the reactive [R3Si]+ equivalent is readily 
accessible as the solvent-stabilized Lewis pair [R3Si(solvent)][B(C6F5)4] via simple Bartlett-
Condon-Schneider hydride abstraction from R3Si–H by the commercially available salt 
[Ph3C][B(C6F5)4] (abbreviated herein trityl BArF20; Scheme 3.1).42 
 
Scheme 3.1. Bartlett-Condon-Schneider hydride abstraction. 
[Ph3C][B(C6F5)4]     +     R3Si—H Ph3C—H     +     [R3Si(solvent)][B(C6F5)4]
(trityl BArF20)
solvent
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To date, catalytic applications of silylium ions in synthesis include alkene 
hydrosilylation,43 carbonyl reduction,44 imine reduction,45 C–F bond activation 
(hydrodefluorination),46 and C–C bond formation (namely Diels-Alder reactions; Scheme 
3.2).47 The C–C bond-forming reactions are arguably the most relevant to organic synthesis, 
as they are useful in building more complex organic scaffolds. The silylium ion-catalyzed 
variant of a classic Diels-Alder reaction (Scheme 3.2, below) is a state of the art example 
(note: there are now enantioselective derivatives, see ref. 47) that illustrates the continuum 
encompassing the classical silicon Lewis acid catalysts that have been used in numerous 
synthetic applications (e.g. Mukaiyama aldol, Hosomi-Sakurai allylation, etc.)48 and more 
reactive silylium ion catalysts such as Lambert’s salt and Oestreich’s ferrocene-based salt. 
The differences are apparent in the conversions and temperatures of operation: low 
conversionsxviii at 0 °C to RT for the former and quantitative conversions at –78 °C to 0 °C 
for the latter. Other (non-Diels-Alder) synthetic examples of note, albeit not technically 
catalytic or self-regenerative in silylium, include applications in C–C49 and Si–C50 bond 
formation ((sila)-Friedel-Crafts reactions). 
                                                
xviiiHigher conversions using Me3Si–NTf2 are attainable with higher catalyst loadings (~10 mol %) and/or 
with certain other Diels-Alder systems; this example was chosen to illustrate the reactivity differences. 
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Scheme 3.2. Comparison between various reported "silylium ion" catalysts. 
3.1.2 Research objectives 
Few examples exist in which silylium ions are employed to catalyze the construction 
of C–C bonds. Our group has long been interested in the synthetic applications of silylium 
ion chemistry in the context of catalytic hydrosilylation with B(C6F5)3 (BCF) and its 
derivatives,51 and has published numerous manuscripts ranging from the deoxygenation/ 
defunctionalization of sugars (cellulosics) and other simple sugar-derivatives to the late-stage 
diversification of natural products.52 Chapter 3 discusses our lab’s progress in applying easily 
accessible silylium ions as catalysts in the stereoselective synthesis of various N-heterocyclic 
pyrrolidine and piperidine scaffolds via a Prins cyclization (Scheme 3.3). The substrates for 
this protocol are acyclic amino aldehydes that are obtained from the corresponding amino 
alcohols in three synthetic steps. Chapter 3 is followed by an appendix (A), which 
summarizes some of our most recent and unpublished work resulting from screening 
alternative Lewis acids (most notably BCF) as catalysts for the Prins cyclization. 
+
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Scheme 3.3. Silylium ion-catalyzed Prins cyclization. 
3.2 Substrate synthesis 
Aldehyde substrates can be obtained in three high-yielding linear steps starting from 
the corresponding amino alcohols; for experimental details and analytical data, see section 
3.7.2. Representative syntheses of (S)-phenylalaninol-derivatives 3.3 and 3.4 are illustrated in 
Scheme 3.4. First, (S)-phenylalaninol 3.1 was sulfonylated with 4-bromobenzenesulfonyl 
chloride (Bs, brosyl) in the presence of triethylamine to afford the Bs-amino alcohol 3.2 in 
92% yield.xix 3.3 was then alkylated with either cinnamyl bromide or 2-phenylallyl bromide 
in the presence of potassium carbonate to yield the corresponding N-alkylated Bs-amino 
alcohols (not shown). These were then oxidized with Dess-Martin periodinane (DMP) to 
yield, respectively, the cinnamyl-amino aldehyde 3.3 in 75% yield (2 steps) and the 2-
phenylallyl-amino aldehyde 3.4 in 77% yield (2 steps).  
                                                
xixThe choice of arylsulfonyl protecting group was based on yield and general ease of substrate synthesis. 
Other N-protecting groups (e.g. Boc, Ac, Bz, TFA, and p-Ns) were found to be difficult to install in 
satisfactory yields and so were not investigated for compatibility in the Prins cyclization. 
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Scheme 3.4. Representative substrate syntheses. 
3.3 N-heterocycle synthesis via stereoselective C–C bond formation 
Representative conditions for the silylium ion-catalyzed Prins-cyclization are given 
below in Scheme 3.5; attempts to further optimize the reaction with respect to 
trialkylhydrosilane, solvent, concentration, and catalyst loading were unfruitful. Using  
10 mol % of the in situ-generated silylium ion equivalent [Et3Si][B(C6F5)4] in CH2Cl2 at  
–78 °C, an appropriately substituted aldehyde rapidly cyclizes and the resulting carbocation 
is trapped by a silyl-protected nucleophile (R3Si–Nu) to form a substituted piperidine 
derivative, following subsequent acid-catalyzed removal of the silyl residue. 
 
Scheme 3.5. Representative reaction conditions. 
3.4 Silylium ion-catalyzed Prins cyclization employing various R3Si–Nu (Et3Si–H, 
Me3Si–allyl, and Me3Si–N3) as trapping nucleophiles 
The trapping nucleophile (R3Si–Nu) scope of the silylium-catalyzed Prins-cyclization 
was investigated; the best examples are listed in Table 3.1.xx Reaction of cinnamyl-amino 
aldehyde 3.3 with Et3Si–H resulted in the formation of pyrrolidine 3.5 in 77% yield as a 
                                                
xxOther R3Si–Nu sources, including TMS–I, TMS–CN, and TMS–OAc, provided complex mixtures of 
products by 1H and 13C NMR. 
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mixture of three diastereomers in 76:13:11 d.r. (entry 1). The reaction of 2-phenylallyl-amino 
aldehyde 3.4 with Et3Si–H resulted in piperidine 3.6 in 92% yield and 60:21:19 d.r. (entry 2). 
Reaction of 3.4 with allyltrimethylsilane led to an 84% yield of piperidine 3.7, which 
contains an all-carbon quaternary center (66:34 d.r., entry 3); from a mechanistic perspective, 
this transformation could be considered a vinylogous analog of the named Hosomi-Sakurai 
allylation.48b,53 When trimethylsilyl azide (Me3Si–N3) was employed as the trapping 
nucleophile, alkyl azide 3.8 was obtained in 78% yield and 79:21 d.r. (entry 4). When 
chlorotrimethylsilane (Me3Si–Cl) was employed as the trapping nucleophile, no chloride-
trapped product was observed (<5%; 3.9, entry 5); Me3Si–Cl is apparently insufficiently 
nucleophilic under these conditions, even upon warming to RT.xxi Fortuitously, the TiCl4-
promoted classic Prins cyclization (see 3.7.5.1) is complementary in that it produces the 
chloride-trapped piperidine 3.9 in 99% isolated yield and 85:9:6 d.r. favoring the vicinal cis-
diastereomer (3JCH-CH = 5.9 Hz). 
                                                
xxiThe substrate is consumed; in the absence of a suitable trapping nucleophile, catalytic [Et3Si][B(C6F5)4] 
leads to a 54% NMR yield of eliminated products 3.22 and 3.23 in 78:22 cis:trans d.r. (see section 3.6). 
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Table 3.1. Scope of trapping nucleophiles. 
 
3.5 Silylium ion-catalyzed Prins cyclization employing silyl enol ethers 
With silyl enol ether trapping nucleophiles, various novel hetero(poly)cyclic 
piperidines (3.13-3.19) are accessible in fair to good yields and as single diastereomers 
(Table 3.2).  These novel bridged tricyclic piperidine scaffolds contain two stereocenters, 
one of which is an all-carbon quaternary center. The initial intramolecular Prins 
cyclization and intermolecular carbocation trapping create the two new C–C bonds (red) in 
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intermediate I; subsequent treatment of I with Brønsted acid (e.g. Dowex resin 50W-X8) 
catalyzes annulation (blue bond) and elimination to diastereomerically pure (>98:2 d.r.) 
tricyclic product. It is noteworthy that the annulation selects for a single diastereomer of 
trapped product; the yields likely reflect this.xxii  
Entry 1 documents the effects of changing the ring size of the silyl enol ether; 
cyclopentanone-derived 3.13 is obtained in only trace amounts (13C NMR and HR-MS, see 
3.7.4.2 and Figure 3.8 therein), presumably due to ring strain, while cyclohexanone- and 
cycloheptanone-derivatives 3.14 and 3.15 are obtained in 64% and 22% yields, 
respectively. Alaninol-derivative 3.16 was obtained in 38% yield (entry 2) and the more 
hindered valinol-derivative was not obtainable under any conditions (not shown; see 
compound 3.40 in section 3.7.4.2). The presence of a conjugated aryl group on the silyl 
enol ether is also not well tolerated; see a-tetralone-derivative 3.17 (11% yield, entry 
3).xxiii Aryl iodide 11, showcasing aryl substitution on the 2-phenylpropene fragment, 
undergoes cyclization and annulation to 3.18 in 24% yield (entry 4); such products could 
potentially be employed in cross-coupling reactions for further synthetic elaboration. 
Methyl-substituted 3.19, derived from the corresponding 2-methylpropenyl-substituted 
starting material 3.12, was obtained in 22% yield (entry 5). 
                                                
xxiiAnalysis of crude pre- and post-annulation 13C NMR suggests the reason for exclusively high d.r. but 
low yield is most likely due to double diastereo-differentiation during annulation of intermediate I; 
diastereomers with a trans-configuration of the C–O and C–Nu bonds decompose and/or are easily 
separated away from the cis-bridged products. We have not attempted to isolate or characterize the 
intermediate ketone diastereomers (I). 
xxiiiReaction with the corresponding acyclic acetophenone-derived silyl enol ether yielded only trace 
cyclized product (see section 3.7.4.2 and Figure 3.13 therein). 
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Table 3.2. Silyl enol ethers as trapping nucleophiles. 
 
3.5.1 Removal of aryl sulfonamide protecting groups and X-ray structure for 3.20 
In light of the knowledge that deprotection of simple aryl sulfonamides (e.g. tosyl 
(Ts), brosyl (Bs)) often requires aggressive reagents,54 we endeavored to demonstrate 
removal under mild conditions. The 2-naphthalene sulfonamide-protected 3.20 was 
synthesized for this purpose (55%, see preparation of 3.20 in section 3.7.4.2 and Figure 
3.16 therein for analytical data), and employing a modification of a previously reported 
reductive protocol,55 provided free amine 3.21 (91% yield, Scheme 3.6a; for 
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experimental details and analytical data, see section 3.7.4.4). It is also notable that the 
more potent Na-naphthalenide reductant was able to effect the Bs-deprotection of 3.14 
(93% yield, see section 3.7.4.4). X-ray analysis of 3.20 (CSD-1548662; Scheme 3.6b, 
see also section 3.7.4.3) confirmed the relative stereochemistry of the C–O bond and 
amino R-group to be cis-(axial-equatorial), respectively, consistent with 3JCH-CH =  
3 Hz.56 
 
Scheme 3.6. Deprotection (a) and X-ray structure (b) of piperidine 3.20. 
3.6 Mechanism: Prins cyclization diastereoselectivity; cyclization in the absence of 
trapping nucleophiles / cyclizations using other Lewis Acids 
Based on the similarity in reactivity and observed vicinal cis-diastereoselectivity 
in the products resulting from both our putative silylium ion manifold and classical 
TiCl4-promoted Prins cyclization conditions (see section 3.7.5.1), we suggest the 
mechanism in Scheme 3.7a: The strongly Lewis acidic silylium ion catalyst 
[R3Si][B(C6F5)4] activates the aldehyde to nucleophilic attack by the appended alkene 
N
S
Ph
O
Ph
3.20
Mg0 (10 eq.)
MeOH, 22 °C, 1 h
with sonication
N
Ph
O
Ph
3.21
91% yield
H
O
O
N
S
Ph
O
Ph
O
O
3.20
H
H
3J = ~3 Hz
(55% yield,
>98:2 d.r.)
a) Removal of 2-naphthalenesulfonyl protecting group
b) Single crystal X-ray structure
    (ORTEP)
 154 
via chair-like transition states TS and TS’;xxiv experimentation has shown TS’ to be 
favored to arrive at the cis-diastereomer (II’). The ensuing trap of II and II’ by R3Si–Nu 
regenerates the [R3Si][B(C6F5)4] catalyst.xxv The multiple observed diastereomers can be 
explained by invoking high facial discrimination in II via a 1,3-diaxial interaction, 
whereas II’ contains almost no inherent facial bias. 
 
Scheme 3.7. Proposed mechanism of the silylium-catalyzed Prins cyclization 
Corroboration of our proposed mechanism was obtained by running the Prins 
cyclization in the absence of suitable trapping nucleophiles; upon warming to room 
temperature, elimination (an effective carbonyl-ene reaction) occurs to yield cis- and trans-
                                                
xxivDFT calculations (wB97X-D//6-311+G**//CPCM:CH2Cl2) on 2-methyl-1-(phenylsulfonyl)piperidine 
show the lowest energy axial conformer to be 3.3 kcal/mol more stable than the lowest energy equatorial 
conformer. We speculate that this is paralleled in TS and TS’. 
xxvInterestingly, 10 mol % HBArF24 ([H(OEt2)2][B(C6H3(CF3)2)4], Brookhart’s acid) as catalyst provided 
hydride-trapped 3.6 (Table 3.1) in an inferior 47% NMR yield but 45:36:19 d.r. favoring the same 
diastereomers as those resulting from the putative silylium ion catalysis (cf. Table 3.1, Entry 2; see section 
3.7.5.2 for experimental details). This suggests that the reaction can be catalyzed by Brønsted acid and that 
co-catalysis could be operative via adventitious water. See: Schmidt, R. K.; Muether, K.; Mueck-
Lichtenfeld, C.; Grimme, S.; Oestreich, M. J. Am. Chem. Soc. 2012, 134, 4421. 
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tetrahydropyridine diastereomers 3.22 and 3.23, respectively (58% yield, 83:17 d.r., 
Scheme 3.7b; see 3.7.5.3 for details).xxvi Intriguingly, application of the neutral Lewis acid 
B(C6F5)3 at RT provides trans-3.23 in 99% yield (see 3.7.5.4 for details).xxvii We attribute 
this reversal of diastereoselectivity to the larger steric environment (and lower reactivity) 
of B(C6F5)3 only allowing for activation of the aldehyde in an exclusively trans-diaxial 
conformation. 
In summary, we have developed a straightforward synthetic protocol that utilizes 
readily accessible, in situ-generated silylium ions to stereoselectively catalyze the 
conversion of acyclic amino alcohol-derived substrates into stereodefined N-heterocyclic 
pyrrolidine and piperidine derivatives. This represents an early and nascent example of 
how silylium ions can be harnessed in complexity-generating organic transformations. We 
hope that their high reactivity can be further modulated to better control and increase their 
selectivity. 
3.7 Experimental Section 
3.7.1 General Methods 
All catalytic reactions were set up in a nitrogen-filled glovebox and run outside the 
glovebox under nitrogen atmosphere in oven-dried (130 °C) 1 dram (4 mL) vials with 
magnetic stirring unless otherwise specified. All catalytic reactions were run in duplicate 
                                                
xxviThe relative stereochemistry of cis- and trans-tetrahydropyridine products was determined via X-ray 
crystallography and comparison of 1H and 13C NMR data (see 3.42, section 3.7.5.4; for X-ray data, see 
section 3.7.5.5). 
xxviia) Attempts to intercept the carbocation with R3Si–Nu in the presence of BCF have been unsuccessful; 
Et3Si–H hydrosilylates the aldehyde in 32% NMR yield (see section A.5.4.1 for details), along with 
producing 44% of trans-tetrahydropyridine 3.23 and 7% and 12%, respectively, of minor diastereomers B 
and C of piperidine 3.6. Unfortunately, variation of addition order and temperature did not allow for the 
clean, high-yielding production of any single product, especially piperidine 3.6. b) Aldehyde 
hydrosilylation has been well documented; see Ref. 51. 
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on 0.05-0.1 mmol scale unless otherwise specified. Catalytic reactions that were performed 
at –78 °C were pre-cooled in vacuum dewars containing an acetone/CO2(s) mixture that 
was maintained throughout the course of the reaction. All other reactions were performed 
at ambient temperature (22 ºC, RT) unless otherwise specified. All solvents were subjected 
to three freeze-pump-thaw cycles and stored over activated molecular sieves in the 
glovebox prior to use. Organic solutions were concentrated under reduced pressure on a 
Büchi rotary evaporator. Column chromatography was performed using SilaFlash P60 40-
63 µm (230-400 mesh). Catalytic reaction products were purified via silica gel column 
chromatography on a 1.5 cm x 22 cm column using mixtures of n-pentane and ethyl 
acetate as eluents and gravity as pressure. Thin layer chromatography (TLC) was 
performed on SiliCycle Silica Gel 60 F254 plates and was visualized with UV light, 
cerium ammonium molybdate (CAM) stain, or potassium permanganate (KMnO4) stain.  
General deprotection procedure: Where indicated, catalytic reactions were treated with an 
acidic resin before attempted isolation to remove labile silyl protecting groups. The 
catalytic reactions were quenched by addition of an excess of Et3N (50 µL) or i-PrNH2  
(50 µL) at –78 °C (unless otherwise stated) and allowed to warm to room temperature 
before concentration in vacuo and placement under high vacuum for at least 1 h to remove 
excess amine. Note: Complete removal of excess amine is necessary for the reproducibility 
of subsequent acid-catalyzed deprotections; repeated azeotroping with CH2Cl2 and drying 
under high vacuum facilitates removal of excess base. The resulting residue was taken up 
in 2 mL of 1:1 CH2Cl2/MeOH, approximately 10-20 beads of Dowex resin (50W-X8) were 
added, and the reaction was stirred at 22 °C for 1 h (or the time indicated). Note: Other, 
less aggressive acidic resins can also afford deprotected product, including pyridinium p-
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toluene sulfonate polymer-bound resin (PPTS) with extent of labeling 3.5 mmol/g toluene 
sulfonate loading purchased through Aldrich. The solution was then filtered by gravity 
through a plug of sand and cotton, rinsed through with excess CH2Cl2 (x2), concentrated in 
vacuo, and placed under high vacuum for at least 1 h before NMR analysis. 
3.7.1.1 Instrumentation 
All NMR spectra were recorded on a Bruker Avance 600 MHz spectrometer at 
standard temperature and pressure. All deuterated solvents were used as received from 
Cambridge Isotope Laboratories, Inc. The residual solvent protons (1H) or the solvent 
carbons (13C) were used as internal references. The following abbreviations are used in 
reporting NMR data: s, singlet; d, doublet; t, triplet; q, quartet; quint, quintet; sept, septet; 
dd, doublet of doublets; dt, doublet of triplets; dq, doublet of quartets; td, triplet of 
doublets; dt, doublet of triplets; tt, triplet of triplets; quint d, quintet of doublets; ddd, 
doublet of doublet of doublets; and m, multiplet. Where necessary, 2D COSY, 2D HSQC, 
and 13C DEPT-135 data were used for peak assignment. All IR spectra were recorded on a 
Jasco 260 Plus Fourier transform infrared spectrometer with reporting from 4000- 
1000 cm-1 using the following abbreviations: s, strong; m, medium; w, weak; br, broad. 
High resolution mass spectra were obtained on a hybrid LTQ FT (ICR 7T) (ThermoFisher, 
Bremen, Germany) mass spectrometer where samples were introduced via a micro-
electrospray source at a flow rate of 3 µL/min. The data were analyzed using Xcalibur 
(ThermoFisher, Breman, Germany) and theoretical masses were calculated using IsoPro 
3.1. Specific rotations were obtained on a Jasco DIP-1000 digital polarimeter equipped 
with a sodium lamp at STP utilizing a 3.5 x 100 mm cell. X-ray crystallographic data were 
recorded on a Bruker APEX-II CCD diffractometer. A NesLab cryobath CB-80 was 
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utilized for reduced temperature reactions where temperature was verified by low-
temperature thermometer. Sonication was performed in a Fisher Scientific FS60 Ultrasonic 
Cleaner with a frequency of 42 kHz. 
3.7.1.2 Chemicals 
Me2EtSiH, Et3SiH, t-BuMe2SiH, and i-Pr3SiH were purchased from Gelest and 
stored over pre-activated molecular sieves in a dry, N2-filled glovebox. Dichloromethane 
(CH2Cl2) and tetrahydrofuran (THF) were purchased from Sigma-Aldrich and used as 
received. Methanol was purchased from Fisher and used as received. Dichloromethane (for 
air/water free reactions) and toluene were passed through an alumina column in a solvent 
purification system prior to use. Trityl tetra(pentafluorophenyl)borate ([Ph3C][B(C6F5)4], 
trityl BArF20) was purchased from Strem and used as received. All aldehyde substrates 
were azeotropically dried three times with either dry toluene (solvent purification system) 
or benzene (freshly distilled over calcium hydride), followed by placement under high 
vacuum (~100 mtorr) overnight, before being stored at room temperature in a dry, N2-filled 
glovebox. Note: Based on periodic checks via 1H NMR, the aldehydes appear to be stable 
for at least 6-12 months when stored at room temperature and under nitrogen in a glove 
box. The aldehydes often start to turn yellowàorangeàbrown over weeks to months of 
time, but no decomposition can be detected from periodic (homogenous) NMR aliquots. 
Silyl enol ethers were prepared from their corresponding freshly distilled (over CaH2) 
parent ketones using modified literature procedures,57 purified via aluminum oxide 
chromatography (Aldrich; activated, neutral, Brockmann activity I slurried with 10% 
H2O), and stored in a dry, N2-filled glovebox. All obtained silyl enol ethers matched 
previously reported 1H and 13C{1H} NMR data. Trityl tetra(pentafluorophenyl)borate 
 159 
(97%, trityl BArF20) was purchased from Strem Chemicals (catalog # 05-5000) and stored 
at room temperature in a dry, N2-filled glove box. Tetrakis[3,5-bis(trifluoromethyl)phenyl] 
borate (HBArF24) was prepared according to literature procedure and stored at –35 °C in a 
dry, N2-filled glove box.58 
 
3.7.2 Substrate synthesis and characterization 
3.7.2.1 Synthesis of N-arylsulfonyl-protected amino alcohols 
Preparation of aryl sulfonamide 3.2: 
 
To a flame-dried 250 mL round-bottom flask equipped with a magnetic stir bar was 
added (S)-phenylalaninol (3.1, 26.5 mmol, 4.00 g, 1.00 eq.) and tetrabutylammonium 
iodide (0.530 mmol, 196 mg, 0.02 eq.). The flask was capped with a septum, an N2 needle 
was inserted, and the headspace of the flask was purged with anhydrous N2. CH2Cl2  
(133 mL) and Et3N (33.1 mmol, 4.62 mL, 1.25 eq.) were added. The flask was placed in an 
ice-water bath and cooled to 0 °C. The septum was quickly removed and 4-bromobenzene 
sulfonyl chloride (brosyl chloride, Bs–Cl; 27.8 mmol, 7.10 g, 1.05 eq.) was added quickly 
and the flask resealed. The homogeneous solution was warmed to 22 °C and stirred for  
24 h. After 24 h, the solution was decanted into a separatory funnel and diluted with excess 
CH2Cl2 and washed with deionized water. The organic phase was separated and the 
aqueous phase was extracted with CH2Cl2 (x4). The combined organics were dried over 
NH2
OH
Ph
CH2Cl2, 0 °C to 22 °C, 24 h
+
Br
SO2Cl
1.00 eq.
NH
OH
Ph
S
O
O
Br
3.21.05 eq.
TBAI (2 mol %),
Et3N (1.25 eq.)
3.1
(S)-phenylalaninol
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Na2SO4, filtered, and concentrated in vacuo. The crude residue was purified by silica gel 
chromatography (9:1 dichloromethane:methanol; Rf = 0.35 in 1:1 hexanes:ethyl acetate) to 
yield the desired N-Bs amino alcohol 3.2 as an off-white, crystalline solid in 92% yield 
(9.05 g). 
(S)-4-bromo-N-(1-hydroxy-3-phenylpropan-2-yl)benzenesulfonamide (3.2). 1H NMR 
(CDCl3, 600 MHz): δ 7.52-7.44 (m, 4H), 7.21-7.15 (m, 3H), 6.96 (d, 2H, J = 6.5 Hz), 4.76 
(d, 1H, J = 7.2 Hz), 3.69 (ddd, 1H, J = 11.3, 6.1, 4.0 Hz), 3.60 (dt, 1H, J = 11.1, 4.8 Hz), 
3.45 (dddd, 1H, J = 11.4, 8.4, 6.2, 4.3 Hz), 2.83 (dd, 1H, J = 14.0, 6.2 Hz), 2.67 (dd, 1H, J 
= 13.9, 8.3 Hz), 2.01 (t, 1H, J = 5.6 Hz); 13C{1H} NMR (CDCl3, 151 MHz): δ 138.8, 
136.6, 132.4, 129.2, 128.9, 128.5, 127.7, 127.0, 64.7, 57.0, 38.0. 
 
Preparation of aryl sulfonamide 3.25: 
 
To a flame-dried 100 mL round-bottom flask equipped with a magnetic stir bar was 
added (S)-alaninol (3.24, 20.0 mmol, 1.56 mL, 1.00 eq.). The flask was capped with a 
septum, an N2 needle was inserted, and the headspace of the flask was purged with 
anhydrous N2. CH2Cl2 (40 mL) and Et3N (22.0 mmol, 3.07 mL, 1.10 eq.) were added. The 
flask was placed in an ice-water bath and cooled to 0 °C. The septum was quickly removed 
and 4-bromobenzenesulfonyl chloride (brosyl chloride, Bs–Cl; 20.0 mmol, 5.11 g, 1.00 
eq.) was added quickly and the flask resealed. The solution was warmed to 22 °C and 
NH2
Me
OH
Et3N (1.10 eq.)
CH2Cl2, 0 °C to 22 °C, 24 h
+
Br
SO2Cl
1.00 eq.
NH
Me
OH
S
O
O
Br
3.251.00 eq.
3.24
(S)-alaninol
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stirred for 24 h. After 24 h, the solution was decanted into a separatory funnel and diluted 
with excess CH2Cl2 and washed with deionized water. The organic phase was separated 
and the aqueous phase was extracted with CH2Cl2 (x4). The combined organics were dried 
over Na2SO4, filtered, and concentrated in vacuo. The crude residue was purified by silica 
gel chromatography (9:1 dichloromethane:methanol; Rf = 0.5 in 2:1 ethylacetate:hexanes) 
to yield the desired N-Bs amino alcohol 3.25 as a white, crystalline solid in 91% yield 
(5.32 g). 
(S)-4-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide (3.25). 1H NMR (CDCl3, 
600 MHz): δ 7.76 (d, 2H, J = 8.6 Hz), 7.66 (d, 2H, J = 8.6 Hz), 4.82 (d, 1H, J = 7.2 Hz), 
3.58 (d, 1H, J = 10.2 Hz), 3.49-3.39 (m, 2H), 1.88 (br s, 1H), 1.07 (d, 3H, J = 6.5 Hz); 
13C{1H} NMR (CDCl3, 151 MHz): δ 139.7, 132.6, 128.8, 127.9, 66.3, 51.6, 18.0. 
 
Preparation of aryl sulfonamide 3.27: 
 
To a flame-dried 100 mL round-bottom flask equipped with a magnetic stir bar was 
added (S)-valinol (3.26, 19.4 mmol, 2.16 mL, 1.00 eq.). The flask was capped with a 
septum, an N2 needle was inserted, and the headspace of the flask was purged with 
anhydrous N2. CH2Cl2 (39 mL) and Et3N (21.3 mmol, 2.97 mL, 1.10 eq.) were added. The 
septum was quickly removed and 4-bromobenzenesulfonyl chloride (brosyl chloride, Bs–
Cl; 19.4 mmol, 4.96 g, 1.00 eq.) was added quickly and the flask resealed. The solution 
NH2
OH
Et3N (1.10 eq.)
CH2Cl2, 22 °C, 75 h
+
Br
SO2Cl
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O
Br
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Me
Me Me
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was stirred for 75 h. After this time, the solution was decanted into a separatory funnel and 
diluted with excess CH2Cl2 and washed with deionized water. The organic phase was 
separated and the aqueous phase was extracted with CH2Cl2 (x4). The combined organics 
were dried over Na2SO4, filtered, and concentrated in vacuo. The crude residue was 
purified by silica gel chromatography (9:1 dichloromethane:methanol) to yield the desired 
N-Bs amino alcohol 3.27 as an off-white, crystalline solid in 84% yield (5.24 g). 
(S)-4-bromo-N-(1-hydroxy-3-methylbutan-2-yl)benzenesulfonamide (3.27). 1H NMR 
(CDCl3, 600 MHz): δ 7.76 (d, 2H, J = 8.6 Hz), 7.65 (d, 2H, J = 8.5 Hz), 4.83 (d, 1H, J = 
8.6 Hz), 3.63-3.54 (m, 2H), 3.09-3.04 (m, 1H), 1.84-1.78 (m, 2H), 0.81 (d, 6H, J = 6.2 Hz); 
13C{1H} NMR (CDCl3, 151 MHz): δ 139.9, 132.5, 128.8, 127.8, 63.1, 61.2, 29.7, 19.3, 
18.6. 
 
Preparation of aryl sulfonamide 3.28: 
 
To a flame-dried 100 mL round-bottom flask equipped with a magnetic stir bar was 
added (S)-phenylalaninol (3.1, 6.61 mmol, 1.00 g, 1.00 eq.) and tetrabutylammonium 
iodide (0.13 mmol, 49 mg, 0.02 eq.). The flask was capped with a septum, an N2 needle 
was inserted, and the headspace of the flask was purged with anhydrous N2. CH2Cl2 (33 
mL) and Et3N (8.27 mmol, 1.15 mL, 1.25 eq.) were added. The flask was placed in an ice-
water bath and cooled to 0 °C. The septum was quickly removed and 2-
NH2
OH
Ph
TBAI (2 mol %),
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+
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naphthalenesulfonyl chloride (Naph–Cl; 6.94 mmol, 1.57 g, 1.05 eq.) was added quickly 
and the flask resealed. The solution was warmed to 22 °C and stirred for 17 h. After 17 h, 
the solution was decanted into a separatory funnel and diluted with excess CH2Cl2 and 
washed with deionized water. The organic phase was separated and the aqueous phase was 
extracted with CH2Cl2 (x4). The combined organics were dried over Na2SO4, filtered, and 
concentrated in vacuo. The crude residue was purified by silica gel chromatography (1:1 
hexanes:ethyl acetate; Rf = 0.3) to yield the desired N-arylsulfonyl amino alcohol 3.28 as a 
white, crystalline solid in 87% yield (1.97 g). 
(S)-N-(1-hydroxy-3-phenylpropan-2-yl)naphthalene-2-sulfonamide (3.28). 1H NMR 
(CDCl3, 600 MHz): δ 8.29 (d, 1H, J = 1.8 Hz), 7.90 (t, 2H, J = 8.3 Hz), 7.83 (d, 1H, J = 
8.6 Hz), 7.66 (td, 1H, J = 6.9, 1.3 Hz), 7.62 (td, 1H, J = 6.8, 1.4 Hz), 7.59 (dd, 1H, J = 8.6, 
1.9 Hz), 7.06-7.01 (m, 3H), 6.90 (dd, 2H, J = 8.0, 1.9), 4.83 (d, 1H, J = 7.0 Hz), 3.67 (ddd, 
1H, J = 10.6, 6.3, 3.9 Hz), 3.57 (dt, 1H, J = 11.1, 5.0 Hz), 3.51 (qd, 1H, J = 7.1, 3.4 Hz), 
2.79 (dd, 1H, J = 13.9, 6.6 Hz), 2.68 (dd, 1H, J = 13.9, 7.7 Hz), 1.06 (t, 1H, J = 6.6 Hz); 
13C{1H} NMR (CDCl3, 151 MHz): δ 136.5, 134.9, 132.2, 129.7, 129.4, 129.1, 129.0, 
128.8, 128.6, 128.0, 127.7, 126.9, 122.2, 64.4, 56.8, 38.0. 
 
3.7.2.2 Preparation of allyl bromides 
Preparation of 2-phenylallyl bromide: 
 
Me
1.00 eq.
+ NO O
Br
TsOH (1 mol %)
1.05 eq.
THF, reflux, 20 h
Br
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2-Phenylallyl bromide was synthesized according to modified literature 
procedure.59 A flame-dried round-bottom flask equipped with a magnetic stir bar was 
charged with α-methylstyrene (100 mmol, 13.0 mL, 1.00 eq.), N-bromosuccinimide (105 
mmol, 18.7 g, 1.05 eq.), tosic acid monohydrate (TsOH.H2O; 1.00 mmol, 190 mg, 0.0100 
eq.) and anhydrous THF (300 mL). The homogeneous solution was brought to reflux and 
vigorously stirred for 20 h. The reaction was allowed to cool to room temperature. The 
solution was decanted into a separatory funnel, diluted with hexanes and deionized water, 
and the organic layer was separated. The aqueous layer was then washed with three 
portions of hexanes. The combined organic layers were dried over Na2SO4, filtered, and 
concentrated in vacuo to afford a yellow oil. The crude residue was purified by silica gel 
column chromatography (hexanes; Rf = 0.5) to provide the desired 2-phenylallyl bromide 
as a clear, light yellow oil in 58% yield (11.4 g). The spectral data of the bromide matched 
those previously reported. 
(3-bromoprop-1-en-2-yl)benzene 1H NMR (CDCl3, 600 MHz): δ 7.52-7.49 (m, 2H), 
7.41-7.32 (m, 3H), 5.57 (s, 1H), 5.50 (s, 1H), 4.40 (s, 2H). 13C{1H} NMR (CDCl3, 151 
MHz): δ 144.3, 137.7, 128.6, 128.4, 126.2, 117.4, 34.4. 
 
Preparation of 1-iodo-2-(prop-1-en-2-yl)benzene (3.29): 
 
The title compound (3.29) was synthesized via modification to a general literature 
procedure.59 A flame-dried Schlenk flask equipped with a magnetic stir bar was charged 
Me
3.29
I
Ph3PMeBr (1.20 eq.),
KOt-Bu (1.20 eq.)
THF, 0 °C to 22 °C, 16 h
Me
O
1.00 eq.
I
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with anhydrous potassium tert-butoxide (14.6 mmol, 1.64 g, 1.20 eq.) and 
methyltriphenylphosphonium bromide (14.6 mmol, 5.23 g, 1.20 eq.). The flask was placed 
under vacuum, backfilled with nitrogen, and then placed in a 0°C ice-water bath. 
Anhydrous THF (16 mL) was added down the side of the flask and the bright yellow 
mixture was stirred at 0°C for 45 minutes. Then a solution of 2’-iodoacetophenone (12.2 
mmol, 1.74 mL, 1.00 eq.) in anhydrous THF (8 mL) was added drop-wise. The solution 
was gradually warmed to room temperature with stirring for 16 h. The solution was 
filtered, the filtrand washed with diethyl ether, and the resulting filtrate concentrated in 
vacuo. The crude residue was purified by silica gel column chromatography (hexanes; Rf = 
0.65) to provide the desired 1-iodo-2-(prop-1-en-2-yl)benzene (3.29) as a clear, colorless 
oil in 89% yield (2.64 g). 
1-iodo-2-(prop-1-en-2-yl)benzene (3.29) 1H NMR (CDCl3, 600 MHz): δ 7.83 (d, 1H, J = 
7.9 Hz), 7.30 (t, 1H, J = 7.5 Hz), 7.18 (d, 1H, J = 7.6 Hz), 6.94 (t, 1H, J = 7.7 Hz), 5.22 (s, 
1H), 4.89 (s, 1H), 2.07 (s, 1H); 13C{1H} NMR (CDCl3, 151 MHz): δ 148.9, 148.6, 139.3, 
128.6, 128.5, 128.2, 116.2, 97.1, 24.1. 
 
Preparation of 2-(o-iodophenyl)allyl bromide 3.30: 
 
The title compound (3.30) was synthesized according to modified literature 
procedure.59 A flame-dried round-bottom flask equipped with a magnetic stir bar was 
charged with 1-iodo-2-(prop-1-en-2-yl)benzene (3.29) (10.6 mmol, 2.57 g, 1.00 eq.), N-
Me
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I
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I
+
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bromosuccinimide (11.1 mmol, 1.97 g, 1.05 eq.), tosic acid monohydrate (TsOH.H2O; 0.11 
mmol, 20 mg, 0.010 eq.) and anhydrous THF (32 mL). The homogeneous solution was 
brought to reflux and vigorously stirred for 4 h. The reaction was then cooled to room 
temperature. The solution was decanted into a separatory funnel, diluted with hexanes and 
deionized water, and the organic layer was separated. The aqueous layer was then washed 
with three portions of hexanes. The combined organic layers were dried over Na2SO4, 
filtered, and concentrated in vacuo to afford a yellow oil. The crude residue was purified 
by silica gel column chromatography (hexanes; Rf = 0.5) to provide the desired 1-(3-
bromoprop-1-en-2-yl)-2-iodobenzene (3.30) as a clear, colorless oil in 10% yield  
(347 mg). Note: 63% (1.62 g) of the starting material was able to be cleanly recovered 
(27% yield BORSM). 
1-(3-bromoprop-1-en-2-yl)-2-iodobenzene (3.30) 1H NMR (CDCl3, 600 MHz): δ 7.86 
(dd, 1H, J = 7.9, 1.2 Hz), 7.36 (td, 1H, J = 7.5, 1.2 Hz), 7.27 (dd, 1H, J = 7.6, 1.8 Hz), 7.02 
(td, 1H, J = 7.7, 1.8 Hz), 5.65 (s, 1H), 5.19 (s, 1H), 4.31 (s, 2H); 13C{1H} NMR (CDCl3, 
151 MHz): δ 148.0, 144.3, 139.3, 130.7, 129.6, 128.1, 121.1, 97.5, 35.9. 
 
3.7.2.3 N-alkylation of N-arylsulfonyl-protected amino alcohols 
Preparation of N-alkylated amino alcohol 3.31: 
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To a flame-dried 50 mL round-bottom flask equipped with a magnetic stir bar was 
added aryl sulfonamide 3.2 (2.97 mmol, 1.10 g, 1.00 eq.) and powdered, anhydrous 
potassium carbonate (8.91 mmol, 1.23 g, 3.00 eq.). The flask was capped with a septum, an 
N2 needle was inserted, and the headspace of the flask was purged with anhydrous N2. 
Anhydrous acetone (22 mL) was added to dissolve the substrate, followed by cinnamyl 
bromide (2.97 mmol, 440 µL, 1.00 eq.). The flask was equipped with a reflux condenser, 
placed in an oil bath, and heated to reflux (approximately 60-65 °C oil bath temperature). 
The heterogeneous mixture was vigorously stirred for 5 h and then cooled to room 
temperature. The mixture was filtered through a cotton plug to remove potassium salts and 
then concentrated in vacuo. The crude residue was purified by silica gel chromatography 
(3:1 hexanes:ethyl acetate; Rf = 0.3) to yield the N-alkylated amino alcohol product 3.31 as 
a clear, colorless, glassy solid in 89% yield (1.29 g). 
(S)-4-bromo-N-cinnamyl-N-(1-hydroxy-3-phenylpropan-2-yl)benzenesulfonamide 
(3.31). 1H NMR (CDCl3, 600 MHz): δ 7.50-7.44 (m, 4H), 7.35-7.31 (m, 2H), 7.31-7.27 
(m, 3H), 7.24-7.21 (m, 3H), 7.08-7.04 (m, 2H), 6.56 (d, 1H, J = 16.0 Hz), 6.10 (ddd, 1H, J 
= 16.0, 7.4, 6.0 Hz), 4.21 (qd, 1H, J = 7.8, 4.6 Hz), 4.13 (ddd, 1H, J = 16.0, 6.0, 1.6 Hz), 
4.06 (ddd, 1H, J = 16.0, 7.4, 1.3 Hz), 3.75 (ddt, 1H, J = 11.6, 8.3, 4.8 Hz), 3.68 (dt, 1H, J = 
11.3, 5.1 Hz), 2.85 (dd, 1H, J = 13.9, 7.6 Hz), 2.78 (dd, 1H, J = 13.9, 7.4 Hz), 1.85 (br s, 
1H, J = 4.8 Hz); 13C{1H} NMR (CDCl3, 151 MHz): δ 139.9, 137.6, 136.1, 133.5, 132.3, 
129.1, 128.9, 128.9, 128.8, 128.4, 127.5, 126.9, 126.6, 126.2, 63.1, 62.2, 46.9, 36.5. 
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Preparation of N-alkylated amino alcohol 3.32: 
 
To a flame-dried 250 mL round-bottom flask equipped with a magnetic stir bar was 
added aryl sulfonamide 3.2 (10.0 mmol, 3.70 g, 1.00 eq.), tetrabutylammonium iodide 
(0.20 mmol, 75 mg, 0.02 eq.), and powdered, anhydrous potassium carbonate (40.0 mmol, 
5.53 g, 4.00 eq.). The flask was capped with a septum, an N2 needle was inserted, and the 
headspace of the flask was purged with anhydrous N2. Anhydrous acetone (75 mL) was 
added to dissolve the substrate, followed by 2-phenylallyl bromide (10.5 mmol, 1.51 mL, 
1.05 eq.). The flask was equipped with a reflux condenser, placed in an oil bath, and heated 
to reflux (approximately 60-65 °C oil bath temperature). The heterogeneous mixture was 
vigorously stirred for 26 h and then cooled to room temperature. The mixture was filtered 
through a cotton plug to remove potassium salts and then concentrated in vacuo. The crude 
residue was purified by silica gel chromatography (3:1 hexanes:ethyl acetate; Rf = 0.3) to 
yield the N-alkylated amino alcohol product 3.32 as a crystalline white solid in 91% yield 
(4.41 g). 
(S)-4-bromo-N-(1-hydroxy-3-phenylpropan-2-yl)-N-(2-phenylallyl)benzene 
sulfonamide (3.32). 1H NMR (CDCl3, 600 MHz): δ 7.62 (d, 2H, J = 8.6 Hz), 7.58 (d, 2H, 
J = 8.6 Hz), 7.42-7.39 (m, 2H), 7.38-7.33 (m, 3H), 7.24-7.18 (m, 3H), 6.95 (dd, 2H, J = 
7.7, 1.7 Hz), 5.49 (s, 1H), 5.44 (s, 1H), 4.54 (d, 1H, J = 16.3 Hz), 4.35 (d, 1H, J = 15.8 
Hz), 3.95 (tdd, 1H, J = 9.1, 5.0, 4.1 Hz), 3.61 (ddd, 1H, J = 12.1, 8.5, 5.5 Hz), 3.49 (ddd, 
acetone, 22 °C to reflux, 26 h
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1H, J = 12.1, 7.2, 4.0 Hz), 2.77 (dd, 1H, J = 13.5, 9.8 Hz), 2.62 (dd, 1H, J = 13.5, 5.0 Hz), 
1.51 (dd, 1H, J = 7.2, 5.6 Hz); 13C{1H} NMR (CDCl3, 151 MHz): δ 145.1, 139.4, 138.4, 
137.7, 132.5, 129.1, 129.1, 129.0, 128.8, 128.5, 127.9, 126.9, 126.8, 116.8, 62.5, 62.3, 
49.4, 36.1. 
 
Preparation of N-alkylated amino alcohol 3.33: 
 
To a flame-dried 100 mL round-bottom flask equipped with a magnetic stir bar was 
added aryl sulfonamide 3.25 (5.10 mmol, 1.50 g, 1.00 eq.), tetrabutylammonium iodide 
(0.10 mmol, 38 mg, 0.02 eq.), and powdered, anhydrous potassium carbonate (20.4 mmol, 
2.82 g, 4.00 eq.). The flask was capped with a septum, an N2 needle was inserted, and the 
headspace of the flask was purged with anhydrous N2. Anhydrous acetone (38 mL) was 
added to dissolve the substrate, followed by 2-phenylallyl bromide (5.35 mmol, 770 µL, 
1.05 eq.). The flask was equipped with a reflux condenser, placed in an oil bath, and heated 
to reflux (approximately 60-65 °C oil bath temperature). The heterogeneous mixture was 
vigorously stirred for 24 h and then cooled to room temperature. The mixture was filtered 
through a cotton plug to remove potassium salts and then concentrated in vacuo. The crude 
residue was purified by silica gel chromatography (25:1 dichloromethane:methanol; Rf = 
0.25 in 2:1 hexanes:ethyl acetate) to yield the N-alkylated amino alcohol product 3.33 as a 
white, crystalline solid in 97% yield (2.03 g). 
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(S)-4-bromo-N-(1-hydroxypropan-2-yl)-N-(2-phenylallyl)benzenesulfonamide (3.33). 
1H NMR (CDCl3, 600 MHz): δ 7.66-7.62 (m, 4H), 7.44 (d, 2H, J = 6.9 Hz), 7.36 (t, 2H, J 
= 7.7 Hz), 7.34 (t, 1H, J = 7.1 Hz), 5.45 (s, 1H), 5.38 (s, 1H), 4.60 (d, 1H, J = 16.1 Hz), 
4.08 (d, 1H, J = 16.1 Hz), 3.94 (dqd, 1H, J = 8.8, 7.0, 4.6 Hz), 3.49 (ddd, 1H, J = 11.7, 8.8, 
4.6 Hz), 3.38 (ddd, 1H, J = 11.7, 8.2, 4.8 Hz), 1.51 (dd, 1H, J = 8.3, 4.7 Hz), 0.91 (d, 3H, J 
= 7.0 Hz); 13C{1H} NMR (CDCl3, 151 MHz): δ 145.0, 139.3, 138.3, 132.5, 129.0, 128.8, 
128.5, 127.8, 126.8, 116.2, 64.7, 56.3, 48.3, 13.7. 
 
Preparation of N-alkylated amino alcohol 3.34: 
 
To a flame-dried 100 mL round-bottom flask equipped with a magnetic stir bar was 
added aryl sulfonamide 3.27 (4.66 mmol, 1.50 g, 1.00 eq.), tetrabutylammonium iodide 
(0.093 mmol, 34 mg, 0.02 eq.), and powdered, anhydrous potassium carbonate (18.6 
mmol, 2.57 g, 4.00 eq.). The flask was capped with a septum, an N2 needle was inserted, 
and the headspace of the flask was purged with anhydrous N2. Anhydrous acetone (35 mL) 
was added to dissolve the substrate, followed by 2-phenylallyl bromide (4.89 mmol, 703 
µL, 1.05 eq.). The flask was equipped with a reflux condenser, placed in an oil bath, and 
heated to reflux (approximately 60-65 °C oil bath temperature). The heterogeneous 
mixture was vigorously stirred for 24 h and then cooled to room temperature. The mixture 
was filtered through a cotton plug to remove potassium salts and then concentrated in 
acetone, 22 °C to reflux, 24 h
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vacuo. The crude residue was purified by silica gel chromatography (3:1 hexanes:ethyl 
acetate; Rf = 0.5 in 2:1 hexanes:ethyl acetate) to yield the N-alkylated amino alcohol 
product 3.34 as a clear, colorless, viscous oil in 86% yield (1.76 g). 
(S)-4-bromo-N-(1-hydroxy-3-methylbutan-2-yl)-N-(2-phenylallyl)benzenesulfonamide 
(3.34). 1H NMR (CDCl3, 600 MHz): δ 7.66 (d, 2H, J = 8.6 Hz), 7.59 (d, 2H, J = 8.6 Hz), 
7.32-7.29 (m, 3H), 7.26-7.24 (m, 2H), 5.42 (s, 1H), 5.39 (s, 1H), 4.40 (d, 1H, J = 16.0 Hz), 
4.28 (d, 1H, J = 16.2 Hz), 3.70 (dt, 1H, J = 12.6, 3.9 Hz), 3.59 (ddd, 1H, J = 12.3, 6.1, 2.8 
Hz), 3.47 (ddd, 1H, J = 10.3, 8.5, 3.6 Hz), 1.89 (dsept, 1H, J = 10.3, 6.6 Hz), 1.62 (br, m, 
1H), 0.88 (d, 3H, J = 6.5 Hz), 0.58 (d, 3H, J = 6.6 Hz); 13C{1H} NMR (CDCl3, 151 MHz): 
δ 145.0, 140.0, 139.0, 132.2, 129.4, 128.7, 128.4, 127.6, 126.7, 117.5, 67.3, 62.4, 49.4, 
28.2, 20.9, 20.4. 
 
Preparation of N-alkylated amino alcohol 3.35: 
 
To a flame-dried 20 mL scintillation vial equipped with a magnetic stir bar was 
added aryl sulfonamide 3.2 (1.07 mmol, 398 mg, 1.00 eq.), tetrabutylammonium iodide 
(0.054 mmol, 20 mg, 0.05 eq.), and powdered, anhydrous potassium carbonate (4.30 
mmol, 594 mg, 4.00 eq.). The vial was capped with a septum, an N2 needle was inserted, 
and the headspace of the vial was purged with anhydrous N2. Anhydrous acetone (8.1 mL) 
was added to dissolve the substrate, followed by 1-(3-bromoprop-1-en-2-yl)-2-
acetone, 22 °C to 65 °C, 13 h
+
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S
O
O
Br
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iodobenzene (3.30, 1.07 mmol, 347 mg, 1.00 eq.). The vial was capped, placed in an oil 
bath, and heated to 65 °C. The heterogeneous mixture was vigorously stirred for 13 h and 
then cooled to room temperature. The mixture was filtered through a cotton plug to remove 
potassium salts and then concentrated in vacuo. The crude residue was purified by silica 
gel chromatography (3:1 hexanes:ethyl acetate; Rf = 0.3) to yield the N-alkylated amino 
alcohol product 3.35 as a white, sticky solid in 77% yield (507 mg). 
(S)-4-bromo-N-(1-hydroxy-3-phenylpropan-2-yl)-N-(2-(2-iodophenyl)allyl)benzene 
sulfonamide (3.35). 1H NMR (CDCl3, 600 MHz): δ 7.85 (d, 1H, J = 7.9 Hz), 7.63 (d, 2H, 
J = 8.7 Hz), 7.55 (d, 2H, J = 8.5 Hz), 7.33 (t, 1H, J = 7.4 Hz), 7.28-7.21 (m, 3H), 7.12 (d, 
1H, J = 7.6 Hz), 7.08 (d, 2H, J = 8.1 Hz), 7.04 (t, 1H, J = 7.7 Hz), 5.62 (s, 1H), 5.20 (s, 
1H), 4.22 (d, 1H, J = 17.3 Hz, 1H), 4.17 (d, 1H, J = 17.2 Hz, 1H), 4.09-4.03 (m, 1H), 3.73 
(ddd, 1H, J = 13.3, 7.9, 5.8 Hz), 3.67 (ddd, 1H, J = 11.6, 6.3, 4.1 Hz), 2.90 (dd, 1H, J = 
13.7, 9.2 Hz), 2.78 (dd, 1H, J = 13.7, 5.6 Hz), 1.89 (t, 1H, J = 6.1 Hz); 13C{1H} NMR 
(CDCl3, 151 MHz): δ 148.0, 144.8, 139.5, 139.2, 137.7, 132.4, 130.1, 129.5, 129.1, 129.0, 
128.8, 128.4, 127.8, 126.9, 118.7, 97.7, 63.2, 63.0, 50.3, 36.5. 
 
Preparation of N-alkylated amino alcohol 3.36: 
 
To a flame-dried 20 mL scintillation vial equipped with a magnetic stir bar was 
added aryl sulfonamide 3.2 (2.03 mmol, 750 mg, 1.00 eq.), tetrabutylammonium iodide 
acetone, 22 °C to 65 °C, 4 h
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(0.041 mmol, 15 mg, 0.02 eq.), and powdered, anhydrous potassium carbonate (8.10 
mmol, 1.12 g, 4.00 eq.). The vial was capped with a septum, an N2 needle was inserted, 
and the headspace of the vial was purged with anhydrous N2. Anhydrous acetone (15 mL) 
was added to dissolve the substrate, followed by 3-bromo-2-methylpropene (2.13 mmol, 
221 µL, 1.05 eq.). The vial was capped, placed in an oil bath, and heated to 65 °C. The 
heterogeneous mixture was vigorously stirred for 4 h and then cooled to room temperature. 
The mixture was filtered through a cotton plug to remove potassium salts and then 
concentrated in vacuo. The crude residue was purified by silica gel chromatography (3:1 
hexanes:ethyl acetate; Rf = 0.3) to yield the N-alkylated amino alcohol product 3.36 as a 
light yellow, viscous oil in 93% yield (800 mg). 
(S)-4-bromo-N-(1-hydroxy-3-phenylpropan-2-yl)-N-(2-methylallyl)benzene 
sulfonamide (3.36). 1H NMR (CDCl3, 600 MHz): δ 7.62 (d, 2H, J = 8.6 Hz), 7.57 (d, 2H, 
J = 8.6 Hz), 7.24-7.16 (m, 3H), 7.00 (dd, 2H, J = 7.2, 2.2 Hz), 5.06 (s, 1H), 5.00 (s, 1H), 
4.01-3.93 (m, 2H), 3.86 (d, 1H, J = 15.8 Hz), 3.70 (ddd, 1H, J = 11.8, 8.1, 6.2 Hz), 3.60 
(ddd, 1H, J = 11.8, 5.9, 4.2 Hz), 2.80 (dd, 1H, J = 13.6, 9.0 Hz), 2.71 (dd, 1H, J = 13.7, 5.8 
Hz), 1.93 (t, 1H, J = 6.1 Hz), 1.80 (s, 3H); 13C{1H} NMR (CDCl3, 151 MHz): δ 142.7, 
139.7, 137.7, 132.4, 129.0, 128.8, 128.8, 127.7, 126.8, 114.5, 62.7, 62.4, 51.6, 36.0, 20.2. 
 
Preparation of N-alkylated amino alcohol 3.37: 
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To a flame-dried 20 mL scintillation vial equipped with a magnetic stir bar was 
added aryl sulfonamide 3.28 (2.20 mmol, 750 mg, 1.00 eq.), tetrabutylammonium iodide 
(0.044 mmol, 16 mg, 0.02 eq.), and powdered, anhydrous potassium carbonate (8.79 
mmol, 1.22 g, 4.00 eq.). The vial was capped with a septum, an N2 needle was inserted, 
and the headspace of the vial was purged with anhydrous N2. Anhydrous acetone (8.8 mL) 
was added to dissolve the substrate, followed by 2-phenylallyl bromide (2.31 mmol, 332 
µL, 1.05 eq.). The vial was capped, placed in an oil bath, and heated to 65 °C. The 
heterogeneous mixture was vigorously stirred for 18 h and then cooled to room 
temperature. The mixture was filtered through a cotton plug to remove potassium salts and 
then concentrated in vacuo. The crude residue was purified by silica gel chromatography 
(3:1 hexanes:ethyl acetate; Rf = 0.25) to yield the N-alkylated amino alcohol product 3.37 
as a white, crystalline solid in 93% yield (937 mg). 
(S)-N-(1-hydroxy-3-phenylpropan-2-yl)-N-(2-phenylallyl)naphthalene-2-sulfonamide 
(3.37). 1H NMR (CDCl3, 600 MHz): δ 8.43 (br s, 1H), 7.96 (d, 1H, J = 8.0 Hz), 7.92 (dd, 
2H, J = 8.4, 5.0 Hz), 7.75 (dd, 1H, J = 8.8, 1.3 Hz), 7.67 (t, 1H, J = 7.0 Hz), 7.64 (t, 1H, J 
= 7.1 Hz), 7.43 (dd, 2H, J = 6.6, 2.9 Hz), 7.34-7.31 (m, 3H), 7.09 (t, 3H, J = 3.2 Hz), 6.83 
(dd, 2H, J = 6.3, 3.1 Hz), 5.50 (s, 1H), 5.47 (s, 1H), 4.68 (d, 1H, J = 16.1 Hz), 4.38 (d, 1H, 
J = 16.1 Hz), 3.99 (tt, 1H, J = 8.7, 4.1 Hz), 3.61 (ddd, 1H, J = 12.2, 8.6, 5.4 Hz), 3.48 (ddd, 
1H, J = 11.8, 7.6, 3.8 Hz), 2.74 (dd, 1H, J = 13.3, 10.4 Hz), 2.53 (dd, 1H, J = 13.3, 4.4 
Hz), 1.60 (dd, 1H, J = 7.6, 5.4 Hz); 13C{1H} NMR (CDCl3, 151 MHz): δ 145.4, 138.4, 
137.7, 137.0, 135.0, 132.3, 129.7, 129.4, 129.2, 129.1, 129.0, 128.8, 128.7, 128.5, 128.1, 
127.8, 126.8, 126.7, 122.7, 116.5, 62.4, 62.2, 49.4, 36.0. 
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3.7.2.4 Synthesis of amino aldehydes 
General procedure 3.1 
To a flame-dried scintillation vial or round-bottom flask equipped with a magnetic 
stir bar was added N-alkylated amino alcohol (1.00 eq.) and Dess-Martin periodinane 
(DMP; 2.00 eq.). The flask was capped with a septum, an N2 needle was inserted, the 
headspace of the flask was purged with anhydrous N2, and the flask was placed in a 0 °C 
ice-water bath. Anhydrous CH2Cl2 (0.1 M in substrate) was added down the side of the 
flask with vigorous stirring, resulting in a colorless, homogeneous solution. Deionized 
water (1.10 eq.) was injected via microliter syringe and the ice-water bath was removed, 
allowing the solution to warm to RT. The solution rapidly became heterogeneous and 
milky white upon addition of the water. The heterogeneous mixture was vigorously stirred 
for approximately 1.0 h, at which time thin layer chromatography on SiO2 showed 
complete conversion. The mixture was again cooled to 0 °C in an ice-water bath and 
quenched by the drop-wise addition of an equal volume of 1:1 sat. NaHCO3 (aq.) : sat. 
Na2S2O3 (aq.) (sodium thiosulfate). After evolution of CO2 (g) was complete, the solution was 
warmed to RT and stirred for an additional 30 minutes. The resulting homogeneous 
solution was then decanted into a separatory funnel, diluted with excess CH2Cl2, and 
washed with deionized water. The organic phase was separated and the aqueous phase was 
extracted with CH2Cl2 (x4). The combined organics were dried over Na2SO4, filtered, and 
concentrated in vacuo. The crude residue was purified first by filtration with CH2Cl2 
through a short plug of neutral aluminum oxide (Brockmann activity I slurried with 10% 
H2O), followed by silica gel chromatography (mixtures of hexanes:ethyl acetate) to yield 
the pure amino aldehyde products. 
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Preparation of amino aldehyde 3.3: 
 
Following general procedure 3.1, N-alkylated amino alcohol 3.31 (0.905 mmol, 440 
mg, 1.00 eq.) was oxidized with DMP (2.00 eq.) over 1.0 h. The crude residue was purified 
by silica gel chromatography (4:1 hexanes:ethyl acetate; Rf = 0.4) to yield the amino 
aldehyde product 3.3 as an off-white crystalline solid in 84% yield (370 mg). 
(S)-4-bromo-N-cinnamyl-N-(1-oxo-3-phenylpropan-2-yl)benzenesulfonamide (3.3).  
1H NMR (CDCl3, 600 MHz): δ 9.72 (s, 1H), 7.47 (d, 2H, J = 8.6 Hz), 7.40 (d, 2H, J = 8.6 
Hz), 7.35-7.30 (m, 2H), 7.30-7.26 (m, 3H), 7.26-7.20 (m, 3H), 7.06 (d, 2H, J = 6.6 Hz), 
6.42 (d, 1H, J = 15.8 Hz), 5.98 (dt, 1H, J = 15.9, 7.0 Hz), 4.59 (dd, 1H, J = 9.5, 5.2 Hz), 
4.03-3.92 (m, 2H), 3.45 (dd, 1H, J = 14.7, 5.2 Hz), 2.83 (dd, 1H, J = 14.7, 9.5 Hz); 
13C{1H} NMR (CDCl3, 151 MHz): δ 198.9, 139.2, 136.9, 135.8, 135.6, 132.4, 129.1, 
128.9, 128.9, 128.8, 128.6, 127.9, 127.0, 126.7, 123.7, 67.7, 48.6, 33.3; [α]D26 = –129.0° (c 
= 1.070, CH2Cl2, l = 100 mm). 
 
Preparation of amino aldehyde 3.4: 
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Following general procedure 3.1, N-alkylated amino alcohol 3.32 (4.79 mmol, 2.33 
g, 1.00 eq.) was oxidized with DMP (2.00 eq.) over 0.75 h. Note: In our hands, 1.75-2.00 
eq. of DMP are necessary to attain full conversion. The crude residue was purified by 
silica gel chromatography (4:1 hexanes:ethyl acetate; Rf = 0.5) to yield the amino aldehyde 
product 3.4 as a beige solid in 85% yield (1.98 g). 
(S)-4-bromo-N-(1-oxo-3-phenylpropan-2-yl)-N-(2-phenylallyl)benzenesulfonamide 
(3.4). 1H NMR (CDCl3, 600 MHz): δ 9.15 (s, 1H), 7.61-7.55 (m, 4H), 7.32-7.27 (m, 3H), 
7.23-7.20 (m, 3H), 7.20-7.18 (m, 2H), 7.00-6.96 (m, 2H), 5.41 (s, 1H), 5.04 (s, 1H), 4.37 
(d, 1H, J = 14.8 Hz), 4.10 (dd, 1H, J = 8.3, 5.5 Hz), 3.94 (d, 1H, J = 14.8 Hz), 3.41 (dd, 
1H, J = 14.6, 5.5 Hz), 2.82 (dd, 1H, J = 14.6, 8.3 Hz); 13C{1H} NMR (CDCl3, 151 MHz): 
δ 197.9, 142.9, 138.8, 137.6, 137.5, 132.6, 129.3, 129.2, 128.8, 128.8, 128.6, 128.4, 127.0, 
126.7, 119.3, 67.5, 51.5, 33.6; [α]D25 = –100.7° (c = 1.525, CH2Cl2, l = 100 mm). 
 
Preparation of amino aldehyde 3.10: 
 
Following general procedure 3.1, N-alkylated amino alcohol 3.33 (2.44 mmol, 1.00 
g, 1.00 eq.) was oxidized with DMP (2.50 eq.) over 1.0 h. The crude residue was purified 
by silica gel chromatography (3:1 hexanes:ethyl acetate; Rf = 0.5) to yield the amino 
aldehyde product 3.10 as a white, crystalline solid in 54% yield (524 mg). 
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(S)-4-bromo-N-(1-oxopropan-2-yl)-N-(2-phenylallyl)benzenesulfonamide (3.10).  
1H NMR (CDCl3, 600 MHz): δ 9.17 (s, 1H), 7.66 (s, 4H), 7.36-7.32 (m, 5H), 5.49 (s, 1H), 
5.29 (s, 1H), 4.47 (d, 1H, J = 14.9 Hz), 4.17 (d, 1H, J = 14.9 Hz), 4.07 (q, 1H, J = 7.0 Hz), 
1.18 (d, 3H, J = 7.0 Hz); 13C{1H} NMR (CDCl3, 151 MHz): δ 199.5, 142.5, 138.6, 137.4, 
132.7, 129.1, 128.8, 128.6, 128.4, 126.8, 118.8, 61.5, 50.0, 11.0; [α]D26 = –3.04° (c = 
0.540, CH2Cl2, l = 100 mm). 
 
Preparation of amino aldehyde 3.38: 
 
Following general procedure 3.1, N-alkylated amino alcohol 3.34 (1.71 mmol, 750 
mg, 1.00 eq.) was oxidized with DMP (2.50 eq.) over 1.0 h. The crude residue was purified 
by silica gel chromatography (4:1 hexanes:ethyl acetate) to yield the amino aldehyde 
product 3.38 as a clear, colorless, viscous oil in 94% yield (701 mg). 
(S)-4-bromo-N-(3-methyl-1-oxobutan-2-yl)-N-(2-phenylallyl)benzenesulfonamide 
(3.38). 1H NMR (CDCl3, 600 MHz): δ 9.36 (s, 1H), 7.61-7.58 (m, 4 H), 7.31-7.26 (m, 3H), 
7.25-7.21 (m, 2H), 5.43 (s, 1H), 5.30 (s, 1H), 4.40 (d, 1H, J = 15.7 Hz), 4.28 (d, 1H, J = 
15.8), 3.70 (d, 1H, J = 10.1), 2.32 (dsept, 1H, J = 10.1, 6.6 Hz), 1.03 (d, 3H, J = 6.5 Hz), 
0.79 (d, 3H, J = 6.7 Hz); 13C{1H} NMR (CDCl3, 151 MHz): δ 198.4, 143.3, 139.1, 138.3, 
132.4, 129.3, 128.7, 128.4, 128.4, 126.7, 118.8, 71.5, 51.3, 27.9, 20.5, 20.3; [α]D26 = –
3.13° (c = 0.565, CH2Cl2, l = 100 mm). 
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Preparation of amino aldehyde 3.11: 
 
Following general procedure 3.1, N-alkylated amino alcohol 3.35 (0.804 mmol, 492 
mg, 1.00 eq.) was oxidized with DMP (2.00 eq.) over 1.0 h. The crude residue was purified 
by silica gel chromatography (4:1 hexanes:ethyl acetate; Rf = 0.4) to yield the amino 
aldehyde product 3.11 as a light yellow, waxy solid in 79% yield (386 mg). 
(S)-4-bromo-N-(2-(2-iodophenyl)allyl)-N-(1-oxo-3-phenylpropan-2-yl)benzene 
sulfonamide (3.11). 1H NMR (CDCl3, 600 MHz): δ 9.62 (s, 1H), 7.68 (dd, 1H, J = 8.0, 
1.2 Hz), 7.47 (d, 2H, J = 8.7 Hz), 7.44 (d, 2H, J = 8.7 Hz), 7.34-7.30 (m, 2H), 7.28-7.24 
(m, 3H), 7.20 (td, 1H, J = 7.5, 1.2 Hz), 6.96 (td, 1H, J = 7.7, 1.7 Hz), 6.82 (dd, 1H, J = 7.6, 
1.7 Hz), 5.14 (s, 1H), 5.09 (s, 1H), 4.21 (dd, 1H, J = 8.7, 5.2 Hz), 4.15 (d, 1H, J = 15.7 
Hz), 3.59 (dd, 1H, J = 14.5, 5.2 Hz), 3.41 (d, 1H, J = 15.7 Hz), 3.08 (dd, 1H, J = 14.5, 8.7 
Hz); 13C{1H} NMR (CDCl3, 151 MHz): δ 197.6, 145.9, 143.4, 139.7, 137.8, 137.7, 132.4, 
129.5, 129.5, 129.4, 129.4, 129.0, 128.5, 128.2, 127.2, 121.9, 97.5, 67.9, 52.4, 35.0; [α]D26 
= –58.2° (c = 0.645, CH2Cl2, l = 100 mm). 
 
Preparation of amino aldehyde 3.12: 
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Following general procedure 3.1, N-alkylated amino alcohol 3.36 (1.91 mmol, 812 
mg, 1.00 eq.) was oxidized with DMP (2.00 eq.) over 1.0 h. The crude residue was purified 
by silica gel chromatography (4:1 hexanes:ethyl acetate; Rf = 0.4) to yield the amino 
aldehyde product 3.12 as an off-white, crystalline solid in 75% yield (603 mg). 
(S)-4-bromo-N-(2-methylallyl)-N-(1-oxo-3-phenylpropan-2-yl)benzenesulfonamide 
(3.12). 1H NMR (CDCl3, 600 MHz): δ 9.70 (s, 1H), 7.57 (s, 4H), 7.22-7.17 (m, 3H), 7.01-
6.97 (m, 2H), 4.96 (s, 1H), 4.81 (s, 1H), 4.20 (dd, 1H, J = 8.5, 5.7 Hz), 3.78 (d, 1H, J = 
14.7 Hz), 3.52 (d, 1H, J = 14.7 Hz), 3.43 (dd, 1H, J = 14.6, 5.7 Hz), 2.83 (dd, 1H, J = 14.6, 
8.5 Hz), 1.66 (s, 3H); 13C{1H} NMR (CDCl3, 151 MHz): δ 198.2, 139.6, 139.1, 137.2, 
132.5, 129.1, 129.1, 128.9, 128.1, 127.0, 117.7, 67.4, 53.3, 33.3, 19.9. [α]D25 = –52.3° (c = 
0.650, CH2Cl2, l = 100 mm). 
 
Preparation of amino aldehyde 3.39: 
 
Following general procedure 3.1, N-alkylated amino alcohol 3.37 (1.37 mmol, 625 
mg, 1.00 eq.) was oxidized with DMP (2.00 eq.) over 1.0 h. The crude residue was purified 
by silica gel chromatography (4:1 hexanes:ethyl acetate; Rf = 0.4) to yield the amino 
aldehyde product 3.39 as an off-white to light yellow crystalline solid in 95% yield  
(591 mg). 
N
OH
Ph
S
O
O
3.37
DMP (2.00 eq.),
H2O (1.10 eq.)
CH2Cl2, 0 °C to 22 °C, 1.0 h
N
O
Ph
S
O
O
3.39
PhPh
 181 
(S)-N-(1-oxo-3-phenylpropan-2-yl)-N-(2-phenylallyl)naphthalene-2-sulfonamide 
(3.39). 1H NMR (CDCl3, 600 MHz): δ 9.19 (s, 1H), 8.39 (d, 1H, J = 1.9 Hz), 7.95 (d, 2H, 
J = 9.3 Hz), 7.92 (d, 1H, J = 8.7 Hz), 7.75-7.60 (m, 3H), 7.26-7.22 (m, 1H), 7.19-7.13 (m, 
4H), 7.15-7.12 (m, 3H), 6.91 (d, 2H, J = 6.4 Hz), 5.39 (s, 1H), 4.99 (s, 1H), 4.46 (d, 1H, J 
= 14.7 Hz), 4.11 (dd, 1H, J = 8.0, 5.5 Hz), 3.97 (d, 1H, J = 14.7 Hz), 3.42 (dd, 1H, J = 
14.5, 5.4 Hz), 2.84 (dd, 1H, J = 14.5, 8.1 Hz); 13C{1H} NMR (CDCl3, 151 MHz): δ 198.1, 
142.9, 137.8, 137.4, 136.4, 135.1, 132.2, 129.7, 129.5, 129.5, 129.3, 129.2, 128.6, 128.6, 
128.5, 128.0, 127.9, 126.7, 126.7, 122.8, 119.1, 67.3, 51.5, 33.5; [α]D26 = –110.5° (c = 
0.515, CH2Cl2, l = 100 mm). 
 
3.7.3 Prins cyclization products obtained by employing Et3Si–H, Me3Si–allyl, and 
Me3Si–N3 as trapping nucleophiles 
3.7.3.1 General procedures 
 
Prins cyclization and trapping with R3Si–Nu (non-silyl enol ether): 
In a dry, N2-filled glove box, aldehyde 3.4 (1.00 eq.) and [Ph3C][B(C6F5)4] (trityl 
BArF20; 0.10 eq.) were weighed into a screw cap 1 dram vial equipped with a stir bar and 
sealed with a septum cap. In a separate screw cap 1 dram vial, Et3SiH (0.12 eq.) and R3Si–
Nu (2.50 eq.) were dissolved in CH2Cl2 (0.05 M in substrate) and the vial sealed with a 
septum cap. Both vials were removed from the glove box and placed under a positive N2 
atmosphere via piercing of the septa with N2 needles, and the vial containing the aldehyde 
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and trityl BArF20 was cooled to –78 °C in an acetone/CO2(s) bath. Using careful inert 
atmosphere technique, the room temperature solution in CH2Cl2 was syringed drop-wise 
and slowly down the side of the vial into the vigorously stirring solution over 
approximately 5 minutes. During the addition, the solution turned clear bright yellow in 
color, which persisted throughout the course of the reaction. The solution was stirred for an 
additional 1 h at –78 °C, quenched at the cryogenic temperature with 50 µL i-PrNH2 
(resulting in rapid loss of color), and warmed to room temperature. The residue was 
repeatedly washed with CH2Cl2 and concentrated in vacuo (x3; to remove excess base), 
and then placed under high vacuum for ≥1 h to remove excess i-PrNH2 (residual base must 
be removed before the acid-catalyzed deprotection step; this can be facilitated by repetitive 
azeotroping with CH2Cl2).  
Acid-catalyzed silyl ether cleavage (deprotection):  
The crude residue was taken up in 2 mL of 1:1 CH2Cl2/MeOH, approximately 10-
20 beads of Dowex resin (50W-X8) were added and the reaction was stirred at 22 °C for 1-
24 h (–OSiMe3 requires significantly less time (~1 h) compared to –OSiEt3 or larger 
(~overnight)). Note: for potentially sensitive products, less aggressive acidic resins can 
also afford deprotected product, including pyridinium p-toluene sulfonate polymer-bound 
resin (PPTS). The solution was then filtered by gravity through a plug of sand and cotton 
to remove the Dowex beads, rinsed with 2x1mL CH2Cl2, and concentrated in vacuo. 
Dimethylformamide (0.050 mmol, 3.9 µL) was added as an internal standard and the 
residue taken up in CDCl3 for 1H and 13C NMR analyses to determine conversion, product 
identity, NMR yield, and crude diastereomeric ratios (d.r.). After re-concentration in 
vacuo, the crude residue was purified by silica gel chromatography (mixtures of n-
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pentane:ethyl acetate), providing analytically pure heterocycles 3.6-3.9 for which isolated 
yields and post-purification diastereomeric ratios are reported. 
 
3.7.3.2 Preparation and characterization 
Preparation of pyrrolidine 3.5: 
 
In a dry, N2-filled glove box, aldehyde 3.3 (0.100 mmol, 48.4 mg, 1.00 eq.) and 
[Ph3C][B(C6F5)4] (trityl BArF20, 0.010 mmol, 9.2 mg, 0.10 eq.) were weighed into a screw 
cap 1 dram vial equipped with a stir bar and sealed with a septum cap. In a separate screw 
cap 1 dram vial, Et3SiH (0.250 mmol, 40 µL, 2.50 eq.) was dissolved in 2.00 mL of 
CH2Cl2 and the vial sealed with a septum cap. Both vials were removed from the glove box 
and placed under a positive N2 atmosphere via piercing of the septa with N2 needles, and 
the vial containing the aldehyde and trityl BArF20 was cooled to –78 °C in an 
acetone/CO2(s) bath. The room temperature solution in CH2Cl2 was syringed drop-wise and 
slowly down the side of the vial into the vigorously stirring solution over approximately 10 
minutes. The solution was stirred for an additional 1 h at –78 °C, quenched at the 
cryogenic temperature with 50 µL i-PrNH2, and warmed to room temperature. The residue 
was repeatedly washed with CH2Cl2 and concentrated in vacuo (x3), and was then placed 
under high vacuum for ≥1 h to remove excess i-PrNH2. The resulting residue was taken up 
in 2 mL of 1:1 CH2Cl2/MeOH, approximately 10-20 beads of Dowex resin (50W-X8) were 
added, and the reaction was stirred at 22 °C for 18 h. The solution was then filtered by 
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gravity through a plug of sand and cotton, rinsed with 2x1mL CH2Cl2, and concentrated in 
vacuo. The crude residue was purified by silica gel chromatography (3:1 n-pentane:ethyl 
acetate; Rf = 0.3-0.4) to yield pyrrolidine 3.5 as a white, crystalline solid in 77% yield 
(37.5 mg average on a 0.1 mmol scale) and as a mixture of three partially separable 
diastereomers in 76:13:11 d.r. (major diastereomer A separates from co-eluting minor 
diastereomers B and C). 
(2S)-2,4-dibenzyl-1-((4-bromophenyl)sulfonyl)pyrrolidin-3-ol (3.5). Major 
diastereomer (A): 1H NMR (CDCl3, 600 MHz): δ 7.70-7.64 (m, 4H), 7.32-7.16 (m, 8H), 
6.99 (d, 2H, J = 6.8 Hz), 3.78 (q, 1H, J = 3.9 Hz), 3.74 (dt, 1H, J = 11.5, 4.1 Hz), 3.55-3.50 
(m, 2H), 3.36 (t, 1H, J = 11.8 Hz), 3.09 (dd, 1H, J = 13.5, 11.4 Hz), 2.69 (dd, 1H, J = 13.8, 
7.3 Hz), 2.56 (dd, 1H, J = 13.9, 7.9 Hz), 1.69-1.60 (m, 2H); 13C{1H} NMR (CDCl3, 151 
MHz): δ 139.3, 138.4, 137.0, 132.6, 129.0, 128.9, 128.9, 128.8, 128.5, 127.9, 126.8, 126.6, 
72.2, 67.8, 52.3, 45.3, 36.0, 32.4; 13C NMR DEPT-135 (CDCl3, 151 MHz): δ 132.6 (CH), 
129.0 (CH), 128.9 (CH), 128.9 (CH), 128.8 (CH), 128.5 (CH), 126.8 (CH), 126.6 (CH), 
72.2 (CH), 67.8 (CH), 52.3 (CH2), 45.3 (CH), 36.0 (CH2), 32.4 (CH2); IR (ν/cm-1): 3529 
(s, br, OH), 3085 (w), 3061 (w), 3027 (w), 3002 (w), 2925 (m), 2856 (w), 1603 (w), 1574 
(m), 1495 (m), 1470 (w), 1454 (m), 1389 (m), 1347 (s), 1295 (w), 1275 (w), 1162 (s), 1126 
(w), 1088 (m), 1068 (m), 1032 (w), 1009 (m); HRMS-(ESI+) [M+H]+ calcd for 
C24H25NO3SBr+ 486.0739, found: 486.0738; [α]D25 = +40.1° (c = 1.13, CH2Cl2, l = 100 
mm). Minor diastereomers (B, C): 1H NMR (CDCl3, 600 MHz; aliphatic resonances only, 
distinguished by 1D TOCSY): δ 4.02 (ddd, 1H, J = 8.5, 6.8, 3.8 Hz, C), 3.79-3.75 (m, 1H, 
B), 3.63 (td, 1H, J = 6.8, 4.4 Hz, C), 3.51-3.47 (m, 1H, B), 3.46-3.42 (m, 1H, B), 3.44 (dd, 
1H, J = 10.3, 7.0 Hz, C), 3.38 (dd, 1H, J = 11.8, 7.3 Hz, B), 3.18 (dd, 1H, J = 13.8, 4.4 Hz, 
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C), 3.07 (dd, 1H, J = 13.8, 9.0 Hz, C), 2.99-2.91 (m, 2H, B), 2.94 (dd, 1H, J = 10.1, 7.1 Hz, 
C), 2.78 (dd, 1H, J = 13.8, 5.3 Hz, B), 2.62 (dd, 1H, J = 13.6, 5.2 Hz, C), 2.38 (dd, 1H, J = 
13.9, 9.7 Hz, B), 2.34 (dd, 1H, J = 13.9, 8.6 Hz, C), 2.30-2.22 (m, 1H, C), 1.70 (ttd, 1H, J 
= 9.6, 7.4, 5.3 Hz, B), 1.53 (d, 1H, J = 4.3 Hz, C), 1.07 (d, 1H, J = 3.8 Hz, B); 13C{1H} 
NMR (CDCl3, 151 MHz): δ 138.9, 138.6, 138.5, 137.2, 137.0, 136.2, 132.6, 132.5, 129.8, 
129.7, 129.1, 129.1, 129.0, 128.9, 128.9, 128.8, 128.8, 128.7, 128.5, 128.1, 127.8, 127.1, 
126.7, 126.7, 79.4 (B), 75.8 (C), 68.2 (B), 63.8 (C), 51.6 (B), 50.3 (C), 46.6 (B), 44.9 (C), 
40.5 (B), 36.6 (C), 36.5 (C), 36.4 (B); IR (ν/cm-1): 3516 (s, br, OH), 3086 (w), 3061 (w), 
3027 (w), 2924 (m), 2855 (w), 1603 (w), 1574 (m), 1496 (m), 1471 (w), 1454 (m), 1389 
(m), 1346 (s), 1275 (w), 1164 (s), 1088 (m), 1069 (m), 1031 (w), 1008 (m); HRMS-(ESI+) 
[M+H]+ calcd for C24H25NO3SBr+ 486.0739, found: 486.0741. 
 
N
Ph
S
O
O
Br
*
*
3.5
OH
Ph
(major diastereomer A)
 186 
 
 
Figure 3.1. 1H, 13C{1H}, and 13C DEPT-135 NMR spectra for pyrrolidine 3.5  
(major diastereomer A). 
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Figure 3.2. 1H and 13C{1H} NMR spectra for pyrrolidine 3.5 (minor diastereomers B/C) 
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[Ph3C][B(C6F5)4] (trityl BArF20, 0.0050 mmol, 4.6 mg, 0.10 eq.) were weighed into a 
screw cap 1 dram vial equipped with a stir bar and sealed with a septum cap. In a separate 
screw cap 1 dram vial, Et3SiH (0.060 mmol, 9.6 µL, 1.20 eq.) was dissolved in 1.00 mL of 
CH2Cl2 and the vial sealed with a septum cap. Both vials were removed from the glove box 
and placed under a positive N2 atmosphere via piercing of the septa with N2 needles, and 
the vial containing the aldehyde and trityl BArF20 was cooled to –78 °C in an 
acetone/CO2(s) bath. The room temperature solution in CH2Cl2 was syringed drop-wise and 
slowly down the side of the vial into the vigorously stirring solution over approximately 5 
minutes. The solution was stirred for an additional 1 h at –78 °C, quenched at the 
cryogenic temperature with 50 µL Et3N, and warmed to room temperature. The residue 
was repeatedly washed with CH2Cl2 and concentrated in vacuo (x3), and was then placed 
under high vacuum for ≥1 h to remove excess Et3N. The resulting residue was taken up in 
2 mL of 1:1 CH2Cl2/MeOH, approximately 10-20 beads of Dowex resin (50W-X8) were 
added, and the reaction was stirred at 22 °C for 16 h. The solution was then filtered by 
gravity through a plug of sand and cotton, rinsed with 2x1mL CH2Cl2, and concentrated in 
vacuo. Dimethylformamide (0.050 mmol, 3.9 µL) was added as an internal standard and 
the residue taken up in CDCl3 for 1H and 13C NMR analyses to determine crude NMR 
yield and diastereomeric ratios; the desired piperidine 3.6 was produced in 69% yield and 
in 51:29:20 d.r. 
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Preparation of piperidine 3.6 with 2.50 eq. Et3Si–H: 
 
In a dry, N2-filled glove box, aldehyde 3.4 (0.0500 mmol, 24.2 mg, 1.00 eq.) and 
[Ph3C][B(C6F5)4] (trityl BArF20, 0.0050 mmol, 4.6 mg, 0.10 eq.) were weighed into a 
screw cap 1 dram vial equipped with a stir bar and sealed with a septum cap. In a separate 
screw cap 1 dram vial, Et3SiH (0.125 mmol, 20.0 µL, 2.50 eq.) was dissolved in 1.00 mL 
of CH2Cl2 and the vial sealed with a septum cap. Both vials were removed from the glove 
box and placed under a positive N2 atmosphere via piercing of the septa with N2 needles, 
and the vial containing the aldehyde and trityl BArF20 was cooled to –78 °C in an 
acetone/CO2(s) bath. The room temperature solution in CH2Cl2 was syringed drop-wise and 
slowly down the side of the vial into the vigorously stirring solution over approximately 5 
minutes. The solution was stirred for an additional 1 h at –78 °C, quenched at the 
cryogenic temperature with 50 µL Et3N, and warmed to room temperature. The residue 
was repeatedly washed with CH2Cl2 and concentrated in vacuo (x3), and was then placed 
under high vacuum for ≥1 h to remove excess Et3N. The resulting residue was taken up in 
2 mL of 1:1 CH2Cl2/MeOH, approximately 10-20 beads of Dowex resin (50W-X8) were 
added, and the reaction was stirred at 22 °C for 16 h. The solution was then filtered by 
gravity through a plug of sand and cotton, rinsed with 2x1mL CH2Cl2, and concentrated in 
vacuo. The crude residue was purified by silica gel chromatography (3:1 n-pentane:ethyl 
acetate; Rf = 0.2-0.3) to yield piperidine 3.6 as a white, crystalline solid in 92% yield (22.3 
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mg average per reaction over two 0.05 mmol scale trials) and as a mixture of three 
inseparable diastereomers in 60:21:19 d.r. (partial separation of minor diastereomer C and 
application of 1D TOCSY experiments allowed for full characterization of diastereomers). 
(2S)-2-benzyl-1-((4-bromophenyl)sulfonyl)-5-phenylpiperidin-3-ol (3.6). Major 
diastereomer A: 1H NMR (CDCl3, 600 MHz): δ 7.38-7.32 (m, 4H), 7.30-7.25 (m, 4H), 
7.17 (t, 2H, J = 8.3 Hz), 7.07 (d, 2H, J = 7.1 Hz), 6.99 (d, 2H, J = 8.6 Hz), 4.54 (dq, 1H, J 
= 11.6, 4.0 Hz), 4.26 (dt, 1H, J = 11.8, 4.9 Hz), 3.63 (dd, 1H, J = 14.1, 4.4 Hz), 3.19 (dd, 
1H, J = 14.3, 3.7 Hz), 3.11 (ddt, 1H, J = 12.6, 8.9, 4.6 Hz), 3.00 (dd, 1H, J = 14.1, 12.0 
Hz), 2.82 (dd, 1H, J = 14.4, 11.6 Hz), 2.25 (s, br, 1H), 2.13 (dt, 1H, J = 12.9, 4.2 Hz), 2.06 
(dd, 1H, J = 12.2, 12.2 Hz); 13C{1H} NMR (CDCl3, 151 MHz): δ 141.0, 139.2, 138.5, 
132.0, 129.3, 128.9, 128.8, 128.6, 127.4, 127.2, 127.1, 126.5, 69.4, 59.1, 45.6, 42.1, 34.4, 
29.4; Minor diastereomer B: 1H NMR (CDCl3, 600 MHz): δ 7.44 (d, 2H, J = 8.6 Hz), 
7.34 (d, 2H, J = 9.1 Hz), 7.30-7.21 (m, 8H), 7.13 (dd, 2H, J = 6.6, 2.9 Hz), 4.42 (t, 1H, J = 
8.0 Hz), 4.02-3.97 (m, 1H), 3.74 (dd, 1H, J = 13.9, 4.4 Hz), 3.35-3.24 (m, 1H), 3.11 (t, 1H, 
J = 13.1 Hz), 2.89 (d, 2H, J = 7.9 Hz), 2.48 (s, br, 1H), 2.13 (dt, 1H, J = 14.6, 5.8 Hz), 
2.09-2.02 (m, 1H); 13C{1H} NMR (CDCl3, 151 MHz): δ 141.8, 139.3, 137.4, 132.2, 129.1, 
129.0, 128.9, 128.9, 127.3, 127.3, 127.0, 126.8, 66.2, 60.5, 46.3, 35.6, 35.6, 33.0; Minor 
diastereomer C: 1H NMR (CDCl3, 600 MHz): δ 7.53-7.48 (m, 4H), 7.32-7.26 (m, 4H), 
7.26-7.21 (m, 4H), 7.17 (d, 2H, J = 6.7 Hz), 4.02 (dd, 1H, J = 13.4, 4.3 Hz), 3.89 (dt, 1H, J 
= 6.4, 3.3 Hz), 3.76 (ddd, 1H, J = 9.7, 5.0, 2.9 Hz), 3.36 (dd, 1H, J = 12.8, 7.8 Hz), 3.31 (tt, 
1H, J = 8.4, 4.3 Hz), 3.26 (dd, 1H, J = 13.7, 9.7 Hz), 3.01 (dd, 1H, J = 13.7, 5.1 Hz), 2.18-
2.13 (m, 1H), 1.87 (ddd, 1H, J = 13.9, 8.9, 3.4 Hz); 13C{1H} NMR (CDCl3, 151 MHz): δ 
141.7, 139.9, 138.2, 132.4, 129.4, 128.8, 128.8, 128.6, 127.6, 127.4, 127.0, 126.8, 65.1, 
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63.6, 51.8, 37.5, 36.0, 34.0; IR (ν/cm-1): 3512 (s, br, OH), 3087 (w), 3061 (w), 3028 (m), 
3004 (w), 2934 (s), 2871 (m), 1603 (w), 1575 (m), 1496 (m), 1471 (m), 1454 (m), 1389 
(m), 1327 (s), 1267 (m), 1212 (w), 1155 (s), 1115 (w), 1100 (w), 1088 (m), 1068 (m), 1030 
(w), 1011 (m); HRMS-(ESI+) [M+H]+ calcd for C24H25NO3SBr+ 486.0739, found: 
486.0741. 
 
 
Figure 3.3. 1H and 13C{1H} spectra for piperidine 3.6 (diastereomers A-C). 
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Figure 3.4. 1H and 13C{1H} NMR spectra for piperidine 3.6 (minor diastereomer C). 
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screw cap 1 dram vial equipped with a stir bar and sealed with a septum cap. In a separate 
screw cap 1 dram vial, Et3SiH (0.0060 mmol, 1.0 µL, 0.12 eq.) and allyltrimethylsilane 
(0.0550 mmol, 8.7 µL, 1.10 eq.) were dissolved in 1.00 mL of CH2Cl2 and the vial sealed 
with a septum cap. Both vials were removed from the glove box and placed under a 
positive N2 atmosphere via piercing of the septa with N2 needles, and the vial containing 
the aldehyde and trityl BArF20 was cooled to –78 °C in an acetone/CO2(s) bath. The room 
temperature solution in CH2Cl2 was syringed drop-wise and slowly down the side of the 
vial into the vigorously stirring solution over approximately 5 minutes. The solution was 
stirred for an additional 15 minutes at –78 °C, after which time the reaction was transferred 
to a –30 °C cryobath and stirred overnight for 20 h (this was necessary for increased yield 
and reproducibility). The reaction was then quenched at the cryogenic temperature with 50 
µL i-PrNH2 and warmed to room temperature. The residue was repeatedly washed with 
CH2Cl2 and concentrated in vacuo (x3), and was then placed under high vacuum for ≥1 h 
to remove excess i-PrNH2. The resulting residue was taken up in 2 mL of 1:1 
CH2Cl2/MeOH, a spatula tip of PPTS resin was added, and the reaction was stirred at 22 
°C for 24 h. The solution was then filtered by gravity through a plug of sand and cotton, 
rinsed with 2x1mL CH2Cl2, and concentrated in vacuo. Dimethylformamide (0.050 mmol, 
3.9 µL) was added as an internal standard and the residue taken up in CDCl3 for 1H and 13C 
NMR analyses to determine crude NMR yield and diastereomeric ratios (d.r.); the desired 
allyl-piperidine 3.7 was produced in 57% yield and in 58:42 d.r. 
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Preparation of piperidine 3.7 with 2.50 eq. allyltrimethylsilane (Me3Si–allyl): 
 
In a dry, N2-filled glove box, aldehyde 3.4 (0.0500 mmol, 24.2 mg, 1.00 eq.) and 
[Ph3C][B(C6F5)4] (trityl BArF20, 0.0050 mmol, 4.6 mg, 0.10 eq.) were weighed into a 
screw cap 1 dram vial equipped with a stir bar and sealed with a septum cap. In a separate 
screw cap 1 dram vial, Et3SiH (0.0060 mmol, 1.0 µL, 0.12 eq.) and allyltrimethylsilane 
(0.125 mmol, 19.9 µL, 2.50 eq.) were dissolved in 1.00 mL of CH2Cl2 and the vial sealed 
with a septum cap. Both vials were removed from the glove box and placed under a 
positive N2 atmosphere via piercing of the septa with N2 needles, and the vial containing 
the aldehyde and trityl BArF20 was cooled to –78 °C in an acetone/CO2(s) bath. The room 
temperature solution in CH2Cl2 was syringed drop-wise and slowly down the side of the 
vial into the vigorously stirring solution over approximately 5 minutes. The solution was 
stirred for an additional 15 minutes at –78 °C, after which time the reaction was transferred 
to a –30 °C cryobath and stirred overnight for 20 h (this was necessary for increased yield 
and reproducibility). The reaction was then quenched at the cryogenic temperature with 50 
µL i-PrNH2 and warmed to room temperature. The residue was repeatedly washed with 
CH2Cl2 and concentrated in vacuo (x3), and was then placed under high vacuum for ≥1 h 
to remove excess i-PrNH2. The resulting residue was taken up in 2 mL of 1:1 
CH2Cl2/MeOH, a spatula tip of PPTS resin was added, and the reaction was stirred at 22 
°C for 24 h. The solution was then filtered by gravity through a plug of sand and cotton, 
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rinsed with 2x1mL CH2Cl2, and concentrated in vacuo. The crude residue was purified by 
silica gel chromatography (4:1 n-pentane:ethyl acetate; Rf = 0.3) to yield allyl-piperidine 
3.7 as a clear, colorless oil in 84% yield (22.1 mg average per reaction over two 0.05 mmol 
scale trials) and as a mixture of two inseparable diastereomers in 66:34 d.r.. 
(2S)-5-allyl-2-benzyl-1-((4-bromophenyl)sulfonyl)-5-phenylpiperidin-3-ol (3.7). 1H 
NMR (CDCl3, 600 MHz; non-aromatic resonances delineated as major diastereomer A and 
minor diastereomer B): δ 7.41 (t, 1H, J = 7.7 Hz), 7.35 (d, 1H, J = 7.2 Hz), 7.33-7.20 (m, 
20H), 7.22-7.16 (m, 1H), 7.15-7.12 (m, 1H), 7.10 (d, 2H, J = 8.6 Hz), 7.01 (t, 1H, J = 7.6 
Hz), 6.85 (d, 1H, J = 7.2 Hz), 5.37-5.27 (m, 2H, A,B), 5.03-4.91 (m, 4H, 2A,2B), 4.43-4.34 
(m, 3H, A,2B), 4.17 (d, 1H, J = 13.9 Hz, B), 4.08 (q, 1H, J = 5.9 Hz, A), 3.94 (ddd, 1H, J = 
12.2, 5.7, 3.9 Hz, A), 3.21-3.15 (m, 2H, A,B), 3.14 (d, 1H, J = 14.0 Hz, A), 2.98 (dd, 1H, J 
= 14.5, 3.8 Hz, B), 2.85 (dd, 1H, J = 14.2, 5.1 Hz, A), 2.81 (dd, 1H, J = 14.5, 9.2 Hz, B), 
2.58-2.52 (m, 2H, 2B), 2.46 (dt, 1H, J = 13.9, 2.9 Hz, A), 2.35 (dd, 1H, J = 13.6, 6.8 Hz, 
A), 2.30-2.25 (m, 2H, A,B), 1.94 (t, 1H, J = 12.2 Hz, B), 1.80 (dd, 1H, J = 14.0, 12.1 Hz, 
A), 1.46 (s, br, 2H, A,B); 13C{1H} NMR (CDCl3, 151 MHz; aliphatic resonances delineated 
as major diastereomer A and minor diastereomer B): δ 144.5, 141.8, 139.7, 139.3, 138.9, 
138.4, 133.6, 132.6, 132.1, 132.0, 129.4, 129.1, 128.8, 128.7, 128.6, 128.6, 128.6, 128.1, 
127.3, 127.1, 127.0, 127.0, 126.6, 126.5, 126.3, 125.8, 118.8, 118.4, 66.7 (A), 66.1 (B), 
59.6 (B), 59.2 (A), 48.7 (B), 48.6 (A), 48.3 (A), 43.5 (A), 42.7 (B), 41.5 (B), 36.2 (A), 34.2 
(B), 31.8 (A), 29.2 (B); 13C NMR DEPT-135 (CDCl3, 151 MHz): δ 133.6 (CH), 132.6 
(CH), 132.1 (CH), 132.0 (CH), 129.4 (CH), 129.1 (CH), 128.8 (CH), 128.7 (CH), 128.6 
(CH), 128.6 (CH), 128.6 (CH), 128.1 (CH), 127.1 (CH), 127.0 (CH), 126.6 (CH), 126.5 
(CH), 126.3 (CH), 125.8 (CH), 118.8 (CH2), 118.4 (CH2), 66.7 (CH), 66.1 (CH), 59.6 
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(CH), 59.2 (CH), 48.7 (CH2), 48.6 (CH2), 48.3 (CH2), 41.5 (CH2), 36.2 (CH2), 34.2 (CH2), 
31.8 (CH2), 29.2 (CH2); IR (ν/cm-1): 3519 (s, br, OH), 3086 (w), 3061 (w), 3027 (w), 3005 
(w), 2926 (s), 2870 (w), 1638 (w), 1602 (w), 1576 (m), 1497 (m), 1470 (m), 1454 (m), 
1446 (m), 1416 (w), 1389 (m), 1334 (s), 1276 (w), 1266 (w), 1158 (s), 1089 (m), 1069 (m), 
1029 (w); HRMS-(ESI+) [M+H]+ calcd for C27H29NO3SBr+ 526.1052, found: 526.1055. 
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Figure 3.5. 1H, 13C{1H}, and 13C DEPT-135 NMR spectra for allyl-piperidine 3.7  
(diastereomers A/B). 
 
Preparation of piperidine 3.8 with 1.10 eq. Me3Si–N3: 
 
In a dry, N2-filled glove box, aldehyde 3.4 (0.0500 mmol, 24.2 mg, 1.00 eq.) and 
[Ph3C][B(C6F5)4] (trityl BArF20, 0.0050 mmol, 4.6 mg, 0.10 eq.) were weighed into a 
screw cap 1 dram vial equipped with a stir bar and sealed with a septum cap. In a separate 
screw cap 1 dram vial, Et3SiH (0.0060 mmol, 1.0 µL, 0.12 eq.) and Me3Si–N3 (0.0550 
mmol, 7.2 µL, 1.10 eq.) were dissolved in 1.00 mL of CH2Cl2 and the vial sealed with a 
septum cap. Both vials were removed from the glove box and placed under a positive N2 
atmosphere via piercing of the septa with N2 needles, and the vial containing the aldehyde 
and trityl BArF20 was cooled to –78 °C in an acetone/CO2(s) bath. The room temperature 
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solution in CH2Cl2 was syringed drop-wise and slowly down the side of the vial into the 
vigorously stirring solution over approximately 5 minutes. The solution was stirred for an 
additional 2 h at –78 °C, after which time the reaction was quenched at the cryogenic 
temperature with 50 µL i-PrNH2 and warmed to room temperature. The residue was 
repeatedly washed with CH2Cl2 and concentrated in vacuo (x3), and was then placed under 
high vacuum for ≥1 h to remove excess i-PrNH2. The resulting residue was taken up in 2 
mL of 1:1 CH2Cl2/MeOH, a spatula tip of PPTS resin was added, and the reaction was 
stirred at 22 °C for 16 h. The solution was then filtered by gravity through a plug of sand 
and cotton, rinsed with 2x1mL CH2Cl2, and concentrated in vacuo. The crude residue was 
purified by silica gel chromatography (3:1 n-pentane:ethyl acetate; Rf = 0.3-0.4) to yield 
azido-piperidine 3.8 as a white, crystalline solid in 78% yield (41.0 mg average per 
reaction over two 0.05 mmol scale trials) and as a mixture of two separable diastereomers 
in 79:21 d.r.. 
Preparation of piperidine 3.8 with 2.50 eq. Me3Si–N3: 
 
In a dry, N2-filled glove box, aldehyde 3.4 (0.0500 mmol, 24.2 mg, 1.00 eq.) and 
[Ph3C][B(C6F5)4] (trityl BArF20, 0.0050 mmol, 4.6 mg, 0.10 eq.) were weighed into a 
screw cap 1 dram vial equipped with a stir bar and sealed with a septum cap. In a separate 
screw cap 1 dram vial, Et3SiH (0.0060 mmol, 1.0 µL, 0.12 eq.) and Me3Si–N3 (0.125 
mmol, 16.4 µL, 2.50 eq.) were dissolved in 1.00 mL of CH2Cl2 and the vial sealed with a 
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septum cap. Both vials were removed from the glove box and placed under a positive N2 
atmosphere via piercing of the septa with N2 needles, and the vial containing the aldehyde 
and trityl BArF20 was cooled to –78 °C in an acetone/CO2(s) bath. The room temperature 
solution in CH2Cl2 was syringed drop-wise and slowly down the side of the vial into the 
vigorously stirring solution over approximately 5 minutes. The solution was stirred for an 
additional 2 h at –78 °C, after which time the reaction was quenched at the cryogenic 
temperature with 50 µL i-PrNH2 and warmed to room temperature. The residue was 
repeatedly washed with CH2Cl2 and concentrated in vacuo (x3), and was then placed under 
high vacuum for ≥1 h to remove excess i-PrNH2. The resulting residue was taken up in 2 
mL of 1:1 CH2Cl2/MeOH, a spatula tip of PPTS resin was added, and the reaction was 
stirred at 22 °C for 16 h. The solution was then filtered by gravity through a plug of sand 
and cotton, rinsed with 2x1mL CH2Cl2, and concentrated in vacuo. The crude residue was 
purified by silica gel chromatography (3:1 n-pentane:ethyl acetate; Rf = 0.3-0.4) to yield 
azido-piperidine 3.8 as a white, crystalline solid in 85% yield (45.0 mg average per 
reaction over two 0.05 mmol scale trials) and as a mixture of two separable diastereomers 
in 62:38 d.r.. 
(2S)-5-azido-2-benzyl-1-((4-bromophenyl)sulfonyl)-5-phenylpiperidin-3-ol (3.8). 
Major diastereomer A: 1H NMR (CDCl3, 600 MHz): δ 7.52 (d, 2H, J = 7.1 Hz), 7.48 (t, 
2H, J = 8.1 Hz), 7.42 (t, 1H, J = 6.3 Hz), 7.29 (s, 4H), 7.14 (t, 1H, J = 7.1 Hz), 7.05 (t, 2H, 
J = 7.6 Hz), 6.91 (d, 2H, J = 7.2 Hz), 4.50 (dt, 1H, J = 11.3, 4.8 Hz), 4.28-4.26 (m, 1H), 
4.24 (dd, 1H, J = 14.0, 2.0 Hz), 3.33 (d, 1H, J = 14.6 Hz), 3.09 (dd, 1H, J = 14.4, 3.9 Hz), 
2.65 (dd, 1H, J = 14.4, 10.3 Hz), 2.39 (ddd, 1H, J = 13.7, 4.3, 2.3 Hz), 2.34 (s, br, 1H), 
2.26 (dd, 1H, J = 13.7, 11.7 Hz); 13C{1H} NMR (CDCl3, 151 MHz): δ
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132.0, 129.4, 129.1, 129.1, 128.6, 128.5, 127.3, 126.4, 125.7, 66.3, 65.6, 59.3, 47.5, 36.2, 
29.4; 13C NMR DEPT-135 (CDCl3, 151 MHz): δ 132.0 (CH), 129.4 (CH), 129.1 (CH), 
129.1 (CH), 128.6 (CH), 128.5 (CH), 126.4 (CH), 125.7 (CH), 65.6 (CH), 59.3 (CH), 47.5 
(CH2), 36.2 (CH2), 29.4 (CH2); IR (ν/cm-1): 3514 (s, br, OH), 3087 (w), 3061 (w), 3028 
(w), 3004 (w), 2931 (s), 2853 (w), 2105 (s, N3), 1602 (w), 1576 (m), 1496 (m), 1471 (m), 
1448 (m), 1389 (m), 1332 (s), 1304 (m), 1264 (m), 1248 (m), 1200 (w), 1154 (s), 1103 
(m), 1088 (m), 1069 (m), 1030 (w), 1011 (m); HRMS-(ESI+) [M+Na]+ calcd for 
C24H23N4O3NaSBr+ 549.0572, found: 549.0579; [α]D24 = –53.9° (c = 1.61, CH2Cl2, l = 100 
mm). Minor diastereomer B: 1H NMR (CDCl3, 600 MHz): δ 7.50-7.48 (m, 2H), 7.42-7.39 
(m, 3H), 7.35 (d, 2H, J = 8.6 Hz), 7.25-7.19 (m, 5H), 7.15-7.12 (m, 2H), 4.26 (d, 1H, J = 
13.8 Hz), 4.01-3.91 (m, 2H), 3.55 (d, 1H, J = 13.5 Hz), 3.20 (dd, 1H, J = 14.0, 7.3 Hz), 
2.87 (dd, 1H, J = 14.0, 5.6 Hz), 2.58 (d, 1H, J = 12.7 Hz), 2.23 (dd, 1H, J = 13.8, 10.1 Hz), 
1.99 (s, br, 1H); 13C{1H} NMR (CDCl3, 151 MHz): δ 139.0, 138.3, 137.2, 132.3, 129.3, 
129.2, 129.1, 128.8, 128.5, 127.7, 127.0, 126.7, 66.3, 64.5, 60.2, 49.5, 37.3, 31.8; 13C 
NMR DEPT-135 (CDCl3, 151 MHz): δ 132.3 (CH), 129.3 (CH), 129.2 (CH), 129.1 (CH), 
128.8 (CH), 128.5 (CH), 127.0 (CH), 126.7 (CH), 66.3 (CH), 60.2 (CH), 49.5 (CH2), 37.3 
(CH2), 31.8 (CH2); IR (ν/cm-1): 3517 (s, br, OH), 3087 (w), 3061 (w), 3029 (w), 2924 (s), 
2851 (m), 2099 (s, N3), 1603 (w), 1575 (m), 1496 (m), 1470 (m), 1454 (m), 1389 (m), 
1335 (s), 1312 (m), 1264 (m), 1244 (m), 1160 (s), 1101 (m), 1087 (m), 1069 (m), 1030 
(w), 1011 (m); HRMS-(ESI+) [M+Na]+ calcd for C24H23N4O3NaSBr+ 549.0572, found: 
549.0578; [α]D25 = –12.1° (c = 0.440, CH2Cl2, l = 100 mm). 
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Figure 3.6. 1H, 13C{1H}, and 13C DEPT-135 NMR spectra for azido-piperidine 3.8  
(major diastereomer A). 
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Figure 3.7. 1H, 13C{1H}, and 13C DEPT-135 NMR spectra for azido-piperidine 3.8  
(minor diastereomer B). 
 
Preparation of piperidine 3.9: 
 
In a dry, N2-filled glove box, aldehyde 3.4 (0.0500 mmol, 24.2 mg, 1.00 eq.) and 
[Ph3C][B(C6F5)4] (trityl BArF20, 0.0050 mmol, 4.6 mg, 0.10 eq.) were weighed into a 
screw cap 1 dram vial equipped with a stir bar and sealed with a septum cap. In a separate 
screw cap 1 dram vial, Et3SiH (0.0060 mmol, 1.0 µL, 0.12 eq.) was dissolved in 1.00 mL 
of CH2Cl2 and the vial sealed with a septum cap. Both vials were removed from the glove 
box and placed under a positive N2 atmosphere via piercing of the septa with N2 needles. 
Freshly distilled Me3Si–Cl (0.125 mmol, 15.9 µL, 2.50 eq.) was syringed from a Schlenk 
flask into the vial containing the solution of Et3SiH in CH2Cl2. The vial containing the 
aldehyde and trityl BArF20 was cooled to –78 °C in an acetone/CO2(s) bath. The room 
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temperature solution in CH2Cl2 was syringed drop-wise and slowly down the side of the 
vial into the vigorously stirring solution over approximately 5 minutes. The stirring 
solution was allowed to gradually warm from –78 °C to 22 °C in the dewar over the course 
of 8 h, after which time the reaction was quenched at room temperature with 50 µL i-
PrNH2 and warmed to room temperature. The residue was repeatedly washed with CH2Cl2 
and concentrated in vacuo (x3), and was then placed under high vacuum for ≥1 h to 
remove excess i-PrNH2. The resulting residue was taken up in 2 mL of 1:1 CH2Cl2/MeOH, 
a spatula tip of PPTS resin was added, and the reaction was stirred at 22 °C for 16 h. The 
solution was then filtered by gravity through a plug of sand and cotton, rinsed with 2x1mL 
CH2Cl2, and concentrated in vacuo. Dimethylformamide (0.050 mmol, 3.9 µL) was added 
as an internal standard and the residue taken up in CDCl3 for 1H and 13C NMR analyses to 
determine conversion, product identity, crude NMR yield, and diastereomeric ratios (d.r.): 
The starting material was completely consumed; <5% of the desired chloride-trapped 
piperidine 3.9 was formed. Elimination was instead observed and tetrahydropiperidine 
diastereomers 3.22 and 3.23 were obtained in 54% NMR yield and in 78:22 cis:trans d.r. 
(see Scheme 3.7). 
 
3.7.4 Prins cyclization products obtained by employing silyl enol ethers as trapping 
nucleophiles 
3.7.4.1 General procedures 
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Prins cyclization and trapping with silyl enol ether: 
In a dry, N2-filled glove box, aldehyde (1.00 eq.) and [Ph3C][B(C6F5)4] (trityl 
BArF20; 0.10 eq.) were weighed into a screw cap 1 dram vial equipped with a stir bar and 
sealed with a septum cap. In a separate screw cap 1 dram vial, Et3SiH (0.12 eq.) and silyl 
enol ether (2.50 eq.) were dissolved in CH2Cl2 (0.05 M in substrate) and the vial sealed 
with a septum cap. Both vials were removed from the glove box and placed under a 
positive N2 atmosphere via piercing of the septa with N2 needles, and the vial containing 
the aldehyde and trityl BArF20 was cooled to –78 °C in an acetone/CO2(s) bath. Using 
careful inert atmosphere technique, the room temperature solution in CH2Cl2 was syringed 
drop-wise and slowly down the side of the vial into the vigorously stirring solution over 
approximately 5 minutes. During the addition, the reaction turned clear bright yellow in 
color, which persisted throughout the course of the reaction. The solution was stirred for an 
additional 1 h at –78 °C, quenched at the cryogenic temperature with 50 µL i-PrNH2 
(resulting in rapid loss of color), and warmed to room temperature. The residue was 
repeatedly washed with CH2Cl2 and concentrated in vacuo (x3; to remove excess base), 
and was then placed under high vacuum for ≥1 h to remove excess i-PrNH2 (when issues 
of reproducibility arise, they are often the result of incomplete removal of residual base; 
this can be rectified by repetitive washing with CH2Cl2).  
Acid-catalyzed annulation and elimination:  
The crude residue was taken up in 2 mL of 1:1 CH2Cl2/MeOH, approximately 10-
20 beads of Dowex resin (50W-X8) were added, and the reaction was stirred at 22 °C for 1 
h. The solution was then filtered by gravity through a plug of sand and cotton to remove 
the Dowex beads, rinsed with 2x1mL CH2Cl2, and concentrated in vacuo. 
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Dimethylformamide (0.050 mmol, 3.9 µL) was added as an internal standard and the 
residue taken up in CDCl3 for 1H and 13C NMR analyses to determine conversion, product 
identity, NMR yield, and crude diastereomeric ratios (d.r.). After re-concentration in 
vacuo, the crude residue was purified by silica gel chromatography (mixtures of n-
pentane:ethyl acetate), providing analytically pure heterocycle for which isolated yields 
and post-purification diastereomeric ratios are reported. 
 
3.7.4.2 Preparation and Characterization 
Preparation of piperidine 3.13: 
 
In a dry, N2-filled glove box, aldehyde 3.4 (0.0500 mmol, 24.2 mg, 1.00 eq.) and 
[Ph3C][B(C6F5)4] (trityl BArF20, 0.0050 mmol, 4.6 mg, 0.10 eq.) were weighed into a 
screw cap 1 dram vial equipped with a stir bar and sealed with a septum cap. In a separate 
screw cap 1 dram vial, Et3SiH (0.0060 mmol, 1.0 µL, 0.12 eq.) and cyclopentanone-
derived silyl enol ether (0.0550 mmol, 9.8 µL, 1.10 eq.) were dissolved in 1.00 mL of 
CH2Cl2 and the vial sealed with a septum cap. Both vials were removed from the glove box 
and placed under a positive N2 atmosphere via piercing of the septa with N2 needles, and 
the vial containing the aldehyde and trityl BArF20 was cooled to –78 °C in an 
acetone/CO2(s) bath. The room temperature solution in CH2Cl2 was syringed drop-wise and 
slowly down the side of the vial into the vigorously stirring solution over approximately 5 
minutes. The solution was stirred and allowed to slowly warm to room temperature in the 
N
S
O
O
Ph
O
Ph
N
S
O
O
Br
Ph
Ph
O
OSiMe3
Trityl BArF20 (10 mol %),
Et3Si–H (12 mol %)+
3.4 1.10 eq.
CH2Cl2, –78 °C to 22 °C, 16 h;
Dowex resin, 22 °C, 16 h
3.13
Br
 207 
dewar overnight for 16 h. The reaction was then quenched with 50 µL Et3N. The solution 
was diluted with CH2Cl2, concentrated in vacuo (x2), and then placed under high vacuum 
for ≥1 h to remove excess Et3N. The resulting residue was taken up in 2 mL of 1:1 
CH2Cl2/MeOH, approximately 10-20 beads of Dowex resin (50W-X8) were added, and the 
mixture was stirred at 22 °C for 16 h. The mixture was then filtered by gravity through a 
plug of sand and cotton, rinsed with 2x1mL CH2Cl2, and concentrated in vacuo. 
Dimethylformamide (0.050 mmol, 3.9 µL) was added as an internal standard and the 
residue taken up in CDCl3 for 1H and 13C NMR analyses to determine conversion, product 
identity, NMR yield, and crude diastereomeric ratios (d.r.). Despite full consumption of 
starting materials, only trace 3.13 is visible by 13C. 
(2S,3S,6R)-3-benzyl-4-((4-bromophenyl)sulfonyl)-6-phenyl-2,3,4,5,6,7,8,9-octahydro-
2,6-methanocyclopenta[g][1,4]oxazocine (3.13). 13C{1H} NMR (CDCl3, 151 MHz): δ 
109.6 (diagnostic vinyl ether peak); HRMS-(ESI+) [M+H]+ calcd for C29H29NO3SBr+ 
550.1052, found: 550.1054. 
 
Figure 3.8. 13C{1H} spectrum for piperidine 3.13. 
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Preparation of piperidine 3.14 with 1.10 eq. silyl enol ether: 
 
In a dry, N2-filled glove box, aldehyde 3.4 (0.0500 mmol, 24.2 mg, 1.00 eq.) and 
[Ph3C][B(C6F5)4] (trityl BArF20, 0.0050 mmol, 4.6 mg, 0.10 eq.) were weighed into a 
screw cap 1 dram vial equipped with a stir bar and sealed with a septum cap. In a separate 
screw cap 1 dram vial, Et3SiH (0.0060 mmol, 1.0 µL, 0.12 eq.) and cyclohexanone-derived 
silyl enol ether (0.0550 mmol, 10.6 µL, 1.10 eq.) were dissolved in 1.00 mL of CH2Cl2 and 
the vial sealed with a septum cap. Both vials were removed from the glove box and placed 
under a positive N2 atmosphere via piercing of the septa with N2 needles, and the vial 
containing the aldehyde and trityl BArF20 was cooled to –78 °C in an acetone/CO2(s) bath. 
The room temperature solution in CH2Cl2 was syringed drop-wise and slowly down the 
side of the vial into the vigorously stirring solution over approximately 5 minutes. The 
solution was stirred for an additional 1 h at –78 °C, quenched at the cryogenic temperature 
with 50 µL Et3N, and warmed to room temperature. The solution was diluted with CH2Cl2, 
concentrated in vacuo, and then placed under high vacuum for ≥1 h to remove excess Et3N. 
The resulting residue was taken up in 2 mL of 1:1 CH2Cl2/MeOH, approximately 10-20 
beads of Dowex resin (50W-X8) were added, and the mixture was stirred at 22 °C for 1 h. 
The mixture was then filtered by gravity through a plug of sand and cotton, rinsed with 
2x1mL CH2Cl2, and concentrated in vacuo. The crude residue was purified by silica gel 
chromatography (5:1 n-pentane:ethyl acetate; Rf = 0.6) to yield the tricyclic piperidine 
product 3.14 as a white, crystalline solid in 52% yield (14.7 mg). 
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Preparation of piperidine 3.14 with 2.50 eq. silyl enol ether: 
 
In a dry, N2-filled glove box, aldehyde 3.4 (0.100 mmol, 48.4 mg, 1.00 eq.) and 
[Ph3C][B(C6F5)4] (trityl BArF20, 0.010 mmol, 9.2 mg, 0.10 eq.) were weighed into a screw 
cap 1 dram vial equipped with a stir bar and sealed with a septum cap. In a separate screw 
cap 1 dram vial, Et3SiH (0.012 mmol, 1.9 µL, 0.12 eq.) and cyclohexanone-derived silyl 
enol ether (0.250 mmol, 48 µL, 2.50 eq.) were dissolved in 2.00 mL of CH2Cl2 and the vial 
sealed with a septum cap. Both vials were removed from the glove box and placed under a 
positive N2 atmosphere via piercing of the septa with N2 needles, and the vial containing 
the aldehyde and trityl BArF20 was cooled to –78 °C in an acetone/CO2(s) bath. The room 
temperature solution in CH2Cl2 was syringed drop-wise and slowly down the side of the 
vial into the vigorously stirring solution over approximately 10 minutes. The solution was 
stirred for an additional 2 h at –78 °C, quenched at the cryogenic temperature with 50 µL 
Et3N, and warmed to room temperature. The residue was repeatedly washed with CH2Cl2 
and concentrated in vacuo (x3), and was then placed under high vacuum for ≥1 h to 
remove excess Et3N. The resulting residue was taken up in 2 mL of 1:1 CH2Cl2/MeOH, 
approximately 10-20 beads of Dowex resin (50W-X8) were added, and the mixture was 
stirred at 22 °C for 3 h. The mixture was then filtered by gravity through a plug of sand 
and cotton, rinsed with 2x1mL CH2Cl2, and concentrated in vacuo. The crude residue was 
purified by silica gel chromatography (5:1 n-pentane:ethyl acetate; Rf = 0.6) to yield the 
tricyclic piperidine product 3.14 as a white, crystalline solid in 64% yield (36.4 mg average 
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per reaction over two 0.1 mmol scale trials). 
(2R,3S,6S)-3-benzyl-4-((4-bromophenyl)sulfonyl)-6-phenyl-3,4,5,6,7,8,9,10-octahydro-
2H-2,6-methanobenzo[g][1,4]oxazocine (3.14). 1H NMR (CDCl3, 600 MHz): δ 7.77 (d, 
2H, J = 8.6 Hz), 7.67 (d, 2H, J = 8.6 Hz), 7.35 (t, 2H, J = 7.9 Hz), 7.30-7.27 (m, 3H), 7.25-
7.24 (m, 2H), 7.21 (t, 1H, J = 7.4 Hz), 7.18 (d, 2H, J = 6.6 Hz), 4.57 (dd, 1H, J = 11.6, 2.7 
Hz), 3.89 (dt, 1H, J = 4.0, 1.9 Hz), 3.41 (dd, 1H, J = 12.7, 3.6 Hz), 3.32 (d, 1H, J = 11.5 
Hz), 3.27 (ddd, 1H, J = 11.6, 3.6, 1.8 Hz), 2.83 (t, 1H, J = 11.6 Hz), 2.36 (dt, 1H, J = 13.2, 
4.2 Hz), 2.32-2.25 (m, 1H), 2.23-2.18 (m, 1H), 1.87-1.82 (m, 1H), 1.67-1.56 (m, 4H), 1.55-
1.45 (m, 2H); 13C{1H} NMR (CDCl3, 151 MHz): δ 150.1, 143.3, 141.9, 138.0, 132.4, 
129.8, 128.7, 128.6, 128.4, 127.5, 126.8, 126.7, 126.4, 106.3, 67.3, 65.4, 54.1, 39.1, 39.0, 
35.8, 27.8, 24.7, 23.3, 23.1; 13C NMR DEPT-135 (CDCl3, 151 MHz): δ 132.4 (CH), 129.8 
(CH), 128.7 (CH), 128.6 (CH), 128.4 (CH), 126.8 (CH), 126.7 (CH), 126.4 (CH), 67.3 
(CH), 65.4 (CH), 54.1 (CH2), 39.0 (CH2), 35.8 (CH2), 27.8 (CH2), 24.7 (CH2), 23.3 (CH2), 
23.1 (CH2); IR (ν/cm-1): 3086 (w), 3060 (w), 3027 (w), 2931 (s), 2885 (m), 2857 (m), 2840 
(m), 1679 (m), 1602 (w), 1575 (m), 1496 (m), 1471 (w), 1452 (w), 1446 (m), 1389 (w), 
1373 (m), 1331 (s), 1266 (w), 1236 (m), 1215 (w), 1166 (s), 1153 (s), 1138 (m), 1126 (m), 
1089 (m), 1067 (m), 1023 (w), 1009 (m); HRMS-(ESI+) [M+H]+ calcd for C30H31NO3SBr+ 
564.1208, found: 564.1207; [α]D26 = +28.9° (c = 3.640, CH2Cl2, l = 100 mm). 
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Figure 3.9. 1H, 13C{1H}, and 13C DEPT-135 spectra for piperidine 3.14. 
 
Preparation of piperidine 3.15: 
 
In a dry, N2-filled glove box, aldehyde 3.4 (0.100 mmol, 48.4 mg, 1.00 eq.) and 
[Ph3C][B(C6F5)4] (trityl BArF20, 0.010 mmol, 9.2 mg, 0.10 eq.) were weighed into a screw 
cap 1 dram vial equipped with a stir bar and sealed with a septum cap. In a separate screw 
cap 1 dram vial, Et3SiH (0.012 mmol, 1.9 µL, 0.12 eq.) and cycloheptanone-derived silyl 
enol ether (0.250 mmol, 53 µL, 2.50 eq.) were dissolved in 2.00 mL of CH2Cl2 and the vial 
sealed with a septum cap. Both vials were removed from the glove box and placed under a 
positive N2 atmosphere via piercing of the septa with N2 needles, and the vial containing 
the aldehyde and trityl BArF20 was cooled to –78 °C in an acetone/CO2(s) bath. The room 
temperature solution in CH2Cl2 was syringed drop-wise and slowly down the side of the 
vial into the vigorously stirring solution over approximately 10 minutes. The solution was 
stirred for an additional 2 h at –78 °C, quenched at the cryogenic temperature with 50 µL 
Et3N, and warmed to room temperature. The residue was repeatedly washed with CH2Cl2 
and concentrated in vacuo (x3), and was then placed under high vacuum for ≥1 h to 
remove excess Et3N. The resulting residue was taken up in 2 mL of 1:1 CH2Cl2/MeOH, 
approximately 10-20 beads of Dowex resin (50W-X8) were added, and the mixture was 
stirred at 22 °C for 3 h. The mixture was then filtered by gravity through a plug of sand 
and cotton, rinsed with 2x1mL CH2Cl2, and concentrated in vacuo. The crude residue was 
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purified by silica gel chromatography (5:1 n-pentane:ethyl acetate; Rf = 0.65) to yield the 
tricyclic piperidine product 3.15 as a white, crystalline solid in 22% yield (12.9 mg average 
per reaction over two 0.1 mmol scale trials). 
(2R,3S,6S)-3-benzyl-4-((4-bromophenyl)sulfonyl)-6-phenyl-2,3,4,5,6,7,8,9,10,11-
decahydro-2,6-methanocyclohepta[g][1,4]oxazocine (3.15). 1H NMR (CDCl3, 600 
MHz): δ 7.80 (d, 2H, J = 8.6 Hz), 7.73 (d, 2H, J = 8.6 Hz), 7.34 (t, 2H, J = 8.7 Hz), 7.29-
7.19 (m, 6H), 7.15 (d, 2H, J = 6.9 Hz), 4.44 (dd, 1H, J = 11.2, 2.7 Hz), 3.80 (dt, 1H, J = 
4.1, 2.0 Hz), 3.54 (dd, 1H, J = 12.8, 3.6 Hz), 3.28 (d, 1H, J = 11.1 Hz), 3.06 (ddd, 1H, J = 
11.6, 3.6, 1.9 Hz), 2.94 (t, 1H, J = 12.2 Hz), 2.44 (t, 2H, J = 5.4 Hz), 2.21 (dt, 1H, J = 13.4, 
4.0 Hz), 1.79-1.62 (m, 6H), 1.48 (dd, 1H, J = 13.3, 2.2 Hz), 1.48-1.43 (m, 1H), 1.38-1.30 
(m, 1H); 13C{1H} NMR (CDCl3, 151 MHz): 155.5, 144.2, 140.0, 138.0, 132.6, 129.7, 
128.7, 128.7, 128.6, 127.7, 126.8, 126.7, 126.2, 110.1, 67.3, 64.8, 55.0, 40.8, 39.1, 36.2, 
33.9, 32.2, 28.8, 27.2, 25.8; 13C NMR DEPT-135 (CDCl3, 151 MHz): δ 132.6, 129.7, 
128.7, 128.7, 128.6, 126.8, 126.7, 126.2, 67.3 (CH), 64.8 (CH), 55.0 (CH2), 39.1 (CH2), 
36.2 (CH2), 33.9 (CH2), 32.2 (CH2), 28.8 (CH2), 27.2 (CH2), 25.8 (CH2); IR (ν/cm-1): 3086 
(w), 3060 (w), 3027 (w), 2924 (s), 2849 (m), 1669 (m), 1602 (w), 1575 (m), 1496 (m), 
1471 (w), 1445 (m), 1389 (w), 1373 (w), 1337 (s), 1265 (w), 1237 (m), 1168 (s), 1125 (m), 
1090 (m), 1068 (m), 1030 (w), 1008 (m); HRMS-(ESI+) [M+H]+ calcd for C31H33NO3SBr+ 
578.1365, found: 578.1382; [α]D25 = +32.9° (c = 0.405, CH2Cl2, l = 100 mm). 
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Figure 3.10. 1H, 13C{1H}, and 13C DEPT-135 spectra for piperidine 3.15. 
 
Preparation of piperidine 3.16: 
 
In a dry, N2-filled glove box, aldehyde 3.10 (0.100 mmol, 40.8 mg, 1.00 eq.) and 
[Ph3C][B(C6F5)4] (trityl BArF20, 0.010 mmol, 9.2 mg, 0.10 eq.) were weighed into a screw 
cap 1 dram vial equipped with a stir bar and sealed with a septum cap. In a separate screw 
cap 1 dram vial, Et3SiH (0.012 mmol, 1.9 µL, 0.12 eq.) and cyclohexanone-derived silyl 
enol ether (0.250 mmol, 48 µL, 2.50 eq.) were dissolved in 2.00 mL of CH2Cl2 and the vial 
sealed with a septum cap. Both vials were removed from the glove box and placed under a 
positive N2 atmosphere via piercing of the septa with N2 needles, and the vial containing 
the aldehyde and trityl BArF20 was cooled to –78 °C in an acetone/CO2(s) bath. The room 
temperature solution in CH2Cl2 was syringed drop-wise and slowly down the side of the 
vial into the vigorously stirring solution over approximately 10 minutes. The solution was 
stirred for an additional 2 h at –78 °C, quenched at the cryogenic temperature with 50 µL 
Et3N, and warmed to room temperature. The residue was repeatedly washed with CH2Cl2 
and concentrated in vacuo (x3), and was then placed under high vacuum for ≥1 h to 
remove excess Et3N. The resulting residue was taken up in 2 mL of 1:1 CH2Cl2/MeOH, 
approximately 10-20 beads of Dowex resin (50W-X8) were added, and the mixture was 
stirred at 22 °C for 3 h. The mixture was then filtered by gravity through a plug of sand 
and cotton, rinsed with 2x1mL CH2Cl2, and concentrated in vacuo. The crude residue was 
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purified by silica gel chromatography (5:1 n-pentane:ethyl acetate; Rf = 0.5) to yield the 
tricyclic piperidine product 3.16 as a white, crystalline solid in 38% yield (18.7 mg average 
per reaction over two 0.1 mmol scale trials). 
(2R,3S,6S)-4-((4-bromophenyl)sulfonyl)-3-methyl-6-phenyl-3,4,5,6,7,8,9,10-
octahydro-2H-2,6-methanobenzo[g][1,4]oxazocine (3.16). 1H NMR (CDCl3, 600 MHz): 
δ 7.71 (d, 2H, J = 8.5 Hz), 7.65 (d, 2H, J = 8.5 Hz), 7.35 (t, 2H, J = 7.7 Hz), 7.26-7.24 (m, 
3H), 4.49 (dd, 1H, J = 11.3, 2.6 Hz), 3.97 (dt, 1H, J = 3.8, 1.9 Hz), 3.17 (d, 1H, J = 11.3 
Hz), 3.12 (qd, 1H, J = 6.7, 1.8 Hz), 2.46 (dt, 1H, J = 13.1, 3.3 Hz), 2.21-2.12 (m, 1H), 2.10 
(dt, 1H, J = 17.4, 4.9 Hz), 1.83-1.79 (m, 1H), 1.78 (dd, 1H, J = 13.0, 2.1 Hz), 1.65-1.43 (m, 
5H), 1.42 (d, 3H, J = 6.6 Hz); 13C{1H} NMR (CDCl3, 151 MHz): δ 150.0, 143.3, 140.7, 
132.3, 128.7, 128.6, 127.4, 126.7, 126.4, 106.5, 73.7, 59.1, 53.9, 39.4, 39.1, 27.6, 24.7, 
23.2, 23.0, 18.4; 13C NMR DEPT-135 (CDCl3, 151 MHz): δ 132.3, 128.7, 128.6, 126.7, 
126.4, 73.7 (CH), 59.1 (CH), 53.9 (CH2), 39.1 (CH2), 27.6 (CH2), 24.7 (CH2), 23.2 (CH2), 
23.0 (CH2), 18.4 (CH3); IR (ν/cm-1): 3087 (w), 3059 (w), 3024 (w), 2982 (w), 2931 (s), 
2886 (w), 2855 (m), 2841 (m), 1678 (m), 1603 (w), 1575 (m), 1496 (w), 1471 (m), 1446 
(m), 1389 (m), 1372 (m), 1325 (s), 1286 (w), 1270 (w), 1248 (w), 1235 (w), 1217 (w), 
1174 (s), 1154 (s), 1136 (m), 1089 (m), 1068 (m), 1037 (m), 1010 (m); HRMS-(ESI+) 
[M+H]+ calcd for C24H27NO3SBr+ 488.0895, found: 488.0895; [α]D26 = +2.02° (c = 1.865, 
CH2Cl2, l = 100 mm). 
 217 
 
 
 
 218 
Figure 3.11. 1H, 13C{1H}, and 13C DEPT-135 spectra for piperidine 3.16. 
 
Preparation of piperidine 3.40: 
 
In a dry, N2-filled glove box, aldehyde 3.38 (0.0500 mmol, 21.8 mg, 1.00 eq.) and 
[Ph3C][B(C6F5)4] (trityl BArF20, 0.0050 mmol, 4.6 mg, 0.10 eq.) were weighed into a 
screw cap 1 dram vial equipped with a stir bar and sealed with a septum cap. In a separate 
screw cap 1 dram vial, Et3SiH (0.0060 mmol, 1.0 µL, 0.12 eq.) and cyclohexanone-derived 
silyl enol ether (0.0550 mmol, 10.6 µL, 1.10 eq.) were dissolved in 1.00 mL of CH2Cl2 and 
the vial sealed with a septum cap. Both vials were removed from the glove box and placed 
under a positive N2 atmosphere via piercing of the septa with N2 needles, and the vial 
containing the aldehyde and trityl BArF20 was cooled to –78 °C in an acetone/CO2(s) bath. 
The room temperature solution in CH2Cl2 was syringed drop-wise and slowly down the 
side of the vial into the vigorously stirring solution over approximately 5 minutes. The 
solution was stirred for an additional 5 minutes at –78 °C, after which time the reaction 
was transferred to a –30 °C cryobath and stirred overnight for 24 h. The reaction was then 
quenched at the cryogenic temperature with 50 µL Et3N and warmed to room temperature. 
The solution was diluted with CH2Cl2, concentrated in vacuo (x2), and then placed under 
high vacuum for ≥1 h to remove excess Et3N. The resulting residue was taken up in 2 mL 
of 1:1 CH2Cl2/MeOH, approximately 10-20 beads of Dowex resin (50W-X8) were added, 
and the mixture was stirred at 22 °C for 1 h. The solution was then filtered by gravity 
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through a plug of sand and cotton, rinsed with 2x1mL CH2Cl2, and concentrated in vacuo. 
Dimethylformamide (0.050 mmol, 3.9 µL) was added as an internal standard and the 
residue taken up in CDCl3 for 1H and 13C NMR analyses to determine conversion, product 
identity, NMR yield, and crude diastereomeric ratios (d.r.). Despite full consumption of 
starting materials, no trace of 3.40 is visible by 1H or 13C NMR. 
(2S,3S,6R)-4-((4-bromophenyl)sulfonyl)-3-isopropyl-6-phenyl-3,4,5,6,7,8,9,10-
octahydro-2H-2,6-methanobenzo[g][1,4]oxazocine (3.40). The starting material was 
consumed with no generation of desired product detectable by 1H and 13C{1H} NMR or 
HRMS-(ESI+). 
 
Preparation of piperidine 3.17: 
 
In a dry, N2-filled glove box, aldehyde 3.4 (0.100 mmol, 48.4 mg, 1.00 eq.) and 
[Ph3C][B(C6F5)4] (trityl BArF20, 0.010 mmol, 9.2 mg, 0.10 eq.) were weighed into a screw 
cap 1 dram vial equipped with a stir bar and sealed with a septum cap. In a separate screw 
cap 1 dram vial, Et3SiH (0.012 mmol, 1.9 µL, 0.12 eq.) and α-tetralone-derived silyl enol 
ether (0.250 mmol, 54.6 mg, 2.50 eq.) were dissolved in 2.00 mL of CH2Cl2 and the vial 
sealed with a septum cap. Both vials were removed from the glove box and placed under a 
positive N2 atmosphere via piercing of the septa with N2 needles, and the vial containing 
the aldehyde and trityl BArF20 was cooled to –78 °C in an acetone/CO2(s) bath. The room 
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temperature solution in CH2Cl2 was syringed drop-wise and slowly down the side of the 
vial into the vigorously stirring solution over approximately 10 minutes. The solution was 
stirred for an additional 2 h at –78 °C, quenched at the cryogenic temperature with 50 µL 
Et3N, and warmed to room temperature. The residue was repeatedly washed with CH2Cl2 
and concentrated in vacuo (x3), and was then placed under high vacuum for ≥1 h to 
remove excess Et3N. The resulting residue was taken up in 2 mL of 1:1 CH2Cl2/MeOH, 
approximately 10-20 beads of Dowex resin (50W-X8) were added, and the mixture was 
stirred at 22 °C for 3 h. The mixture was then filtered by gravity through a plug of sand 
and cotton, rinsed with 2x1mL CH2Cl2, and concentrated in vacuo. The crude residue was 
purified by silica gel chromatography (10:1 n-pentane:ethyl acetate; Rf = 0.3), followed by 
washing with n-pentane to remove co-eluting α-tetralone, to yield the tetracyclic piperidine 
product 3.17 as a white, crystalline solid in 11% yield (6.8 mg average per reaction over 
two 0.1 mmol scale trials). 
(2R,3S,6S)-3-benzyl-4-((4-bromophenyl)sulfonyl)-6-phenyl-3,4,5,6,7,8-hexahydro-2H-
2,6-methanonaphtho[2,1-g][1,4]oxazocine (3.17). 1H NMR (CDCl3, 600 MHz): δ 7.57 
(d, 3H, J = 8.6 Hz), 7.39 (t, 2H, J = 7.7 Hz), 7.35-7.31 (m, 5H), 7.31-7.27 (m, 4H), 7.26 (t, 
1H, J = 5.9 Hz), 7.19 (d, 1H, J = 6.3 Hz), 7.15 (d, 2H, J = 8.6 Hz), 4.61 (dd, 1H, J = 11.7, 
2.7 Hz), 4.16 (dt, 1H, J = 3.9, 1.8 Hz), 3.54 (dd, 1H, J = 12.5, 3.5 Hz), 3.46 (d, 1H, J = 
11.7 Hz), 3.39 (ddd, 1H, J = 11.9, 3.6, 1.7 Hz), 2.85-2.70 (m, 2H), 2.66 (t, 1H, J = 12.1 
Hz), 2.48 (dt, 1H, J = 13.5, 4.1 Hz), 2.04 (ddd, 1H, J = 15.8, 11.7, 6.5 Hz), 1.88 (dt, 1H, J 
= 15.9, 6.6 Hz), 1.73 (dd, 1H, J = 13.4, 2.1 Hz); 13C{1H} NMR (CDCl3, 151 MHz): δ 
147.5, 143.7, 141.5, 137.8, 136.2, 132.2, 131.0, 129.9, 128.9, 128.8, 128.6, 127.9, 127.5, 
127.4, 127.1, 127.0, 126.7, 126.2, 121.5, 110.2, 68.0, 65.5, 53.3, 40.3, 38.9, 35.7, 28.2, 
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23.8; 13C NMR DEPT-135 (CDCl3, 151 MHz): δ 132.2, 129.9, 128.9, 128.8, 128.6, 127.9, 
127.5, 127.1, 127.0, 126.7, 126.2, 121.5, 68.0 (CH), 65.5 (CH), 53.3 (CH2), 38.9 (CH2), 
35.7 (CH2), 28.2 (CH2), 23.8 (CH2); IR (ν/cm-1): 3086 (w), 3060 (w), 3027 (w), 3002 (w), 
2952 (m), 2930 (m), 2854 (w), 1645 (m), 1601 (w), 1574 (m), 1496 (m), 1470 (w), 1446 
(w), 1427 (w), 1389 (w), 1371 (w), 1329 (m), 1314 (s), 1266 (w), 1243 (w), 1232 (w), 
1154 (s), 1121 (w), 1088 (m), 1069 (m), 1025 (w), 1011 (w); HRMS-(ESI+) [M+H]+ calcd 
for C34H31NO3SBr+ 612.1208, found: 612.1212; [α]D25 = +2.53° (c = 0.675, CH2Cl2, l = 
100 mm). 
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Figure 3.12. 1H, 13C{1H}, and 13C DEPT-135 spectra for piperidine 3.17. 
 
Preparation of piperidine 3.41: 
 
In a dry, N2-filled glove box, aldehyde 3.4 (0.0500 mmol, 24.2 mg, 1.00 eq.) and 
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[Ph3C][B(C6F5)4] (trityl BArF20, 0.0050 mmol, 4.6 mg, 0.10 eq.) were weighed into a 
screw cap 1 dram vial equipped with a stir bar and sealed with a septum cap. In a separate 
screw cap 1 dram vial, Et3SiH (0.0060 mmol, 1.0 µL, 0.12 eq.) and acetophenone-derived 
silyl enol ether (0.0550 mmol, 11.3 µL, 1.10 eq.) were dissolved in 1.00 mL of CH2Cl2 and 
the vial sealed with a septum cap. Both vials were removed from the glove box and placed 
under a positive N2 atmosphere via piercing of the septa with N2 needles, and the vial 
containing the aldehyde and trityl BArF20 was cooled to –78 °C in an acetone/CO2(s) bath. 
The room temperature solution in CH2Cl2 was syringed drop-wise and slowly down the 
side of the vial into the vigorously stirring solution over approximately 5 minutes. The 
solution was allowed to stir for an additional 15 minutes at –78 °C, after which time the 
reaction was transferred to a –30 °C cryobath and stirred overnight for 21 h. The reaction 
was then quenched at the cryogenic temperature with 50 µL Et3N and warmed to room 
temperature. The solution was diluted with CH2Cl2, concentrated in vacuo (x2), and then 
placed under high vacuum for ≥1 h to remove excess Et3N. The resulting residue was taken 
up in 2 mL of 1:1 CH2Cl2/MeOH, approximately 10-20 beads of Dowex resin (50W-X8) 
were added, and the mixture was stirred at 22 °C for 16 h. The mixture was then filtered by 
gravity through a plug of sand and cotton, rinsed with 2x1mL CH2Cl2, and concentrated in 
vacuo. Dimethylformamide (0.050 mmol, 3.9 µL) was added as an internal standard and 
the residue taken up in CDCl3 for 1H and 13C NMR analyses to determine conversion, 
product identity, NMR yield, and crude diastereomeric ratios (d.r.). Despite full 
consumption of starting materials, only trace 3.41 is visible by 13C. 
(1S,5S,8S)-8-benzyl-7-((4-bromophenyl)sulfonyl)-3,5-diphenyl-2-oxa-7-
azabicyclo[3.3.1]non-3-ene (3.41). 13C{1H} NMR (CDCl3, 151 MHz): δ 101.9 (diagnostic 
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vinyl ether peak); HRMS-(ESI+) [M+H]+ calcd for C32H29NO3SBr+ 586.1052, found: 
586.1054. 
 
Figure 3.13. 13C{1H} spectrum for piperidine 3.41. 
 
Preparation of piperidine 3.18: 
 
In a dry, N2-filled glove box, aldehyde 3.11 (0.0500 mmol, 30.5 mg, 1.00 eq.) and 
[Ph3C][B(C6F5)4] (trityl BArF20, 0.0050 mmol, 4.6 mg, 0.10 eq.) were weighed into a 
screw cap 1 dram vial equipped with a stir bar and sealed with a septum cap. In a separate 
screw cap 1 dram vial, Et3SiH (0.0060 mmol, 1.0 µL, 0.12 eq.) and cyclohexanone-derived 
silyl enol ether (0.125 mmol, 24.1 µL, 2.50 eq.) were dissolved in 1.00 mL of CH2Cl2 and 
the vial sealed with a septum cap. Both vials were removed from the glove box and placed 
under a positive N2 atmosphere via piercing of the septa with N2 needles, and the vial 
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containing the aldehyde and trityl BArF20 was cooled to –78 °C in an acetone/CO2(s) bath. 
The room temperature solution in CH2Cl2 was syringed drop-wise and slowly down the 
side of the vial into the vigorously stirring solution over approximately 5 minutes. The 
solution was allowed to stir for an additional 15 minutes at –78 °C, after which time the 
reaction was transferred to a –30 °C cryobath and stirred overnight for 22 h (this was 
necessary for increased yield and reproducibility). The reaction was then quenched at the 
cryogenic temperature with 50 µL i-PrNH2 and warmed to room temperature. The residue 
was repeatedly washed with CH2Cl2 and concentrated in vacuo (x3), and was then placed 
under high vacuum for ≥1 h to remove excess i-PrNH2. The resulting residue was taken up 
in 2 mL of 1:1 CH2Cl2/MeOH, approximately 10-20 beads of Dowex resin (50W-X8) were 
added, and the mixture was stirred at 22 °C for 22 h. The mixture was then filtered by 
gravity through a plug of sand and cotton, rinsed with 2x1mL CH2Cl2, and concentrated in 
vacuo. The crude residue was purified by silica gel chromatography (5:1 n-pentane:ethyl 
acetate; Rf = 0.5) to yield the tricyclic piperidine product 3.18 as a light yellow oil in 24% 
yield (8.2 mg average per reaction over two 0.05 mmol scale trials). 
(2S,3S,6S)-3-benzyl-4-((4-bromophenyl)sulfonyl)-6-(2-iodophenyl)-3,4,5,6,7,8,9,10-
octahydro-2H-2,6-methanobenzo[g][1,4]oxazocine (3.18). 1H NMR (CDCl3, 600 MHz): 
δ 7.99 (dd, 1H, J = 7.9, 1.4 Hz), 7.79 (d, 2H, J = 8.6 Hz), 7.68 (d, 2H, J = 8.6 Hz), 7.35 (td, 
1H, J = 7.7, 1.4 Hz), 7.26 (t, 2H, J = 3.8 Hz), 7.22-7.15 (m, 4H), 6.92 (td, 1H, J = 7.6, 1.5 
Hz), 4.55 (dd, 1H, J = 11.1, 3.0 Hz), 3.90 (dt, 1H, J = 4.2, 1.8 Hz), 3.40-3.33 (m, 2H), 
3.30-3.23 (m, 2H), 2.83 (t, 1H, J = 12.1 Hz), 2.33-2.25 (m, 1H), 2.21 (dt, 1H, J = 16.8, 5.5 
Hz), 1.86-1.80 (m, 2H), 1.81-1.75 (m, 1H), 1.65-1.50 (m, 3H), 1.31 (dd, 1H, J = 13.3, 1.9 
Hz); 13C{1H} NMR (CDCl3, 151 MHz): δ 151.7, 143.7, 142.8, 141.9, 137.8, 132.5, 129.8, 
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128.7, 128.6, 128.4, 128.4, 127.6, 127.5, 126.9, 103.4, 96.3, 67.1, 65.7, 55.4, 40.9, 35.9, 
34.1, 27.8, 24.8, 23.3, 22.4; 13C NMR DEPT-135 (CDCl3, 151 MHz): δ 143.7 (CH), 132.5 
(CH), 129.8 (CH), 128.7 (CH), 128.6 (CH), 128.4 (CH), 128.4 (CH), 127.5 (CH), 126.9 
(CH), 67.1 (CH), 65.7 (CH), 55.4 (CH2), 35.9 (CH2), 34.1 (CH2), 27.8 (CH2), 24.8 (CH2), 
23.3 (CH2), 22.4 (CH2); IR (ν/cm-1): 3084 (w), 3060 (w), 3027 (w), 3002 (w), 2929 (s), 
2857 (m), 2836 (m), 1684 (m), 1602 (w), 1575 (m), 1496 (w), 1470 (w), 1457 (m), 1388 
(m), 1374 (m), 1352 (m), 1333 (s), 1265 (w), 1232 (m), 1209 (w), 1164 (s), 1154 (s), 1128 
(w), 1112 (w), 1089 (m), 1067 (m), 1053 (w), 1009 (m); HRMS-(ESI+) [M+H]+ calcd for 
C30H30NO3SBrI+ 690.0175, found: 690.0185; [α]D25 = +21.6° (c = 0.820, CH2Cl2, l = 100 
mm). 
 
 227 
 
 
Figure 3.14. 1H, 13C{1H}, and 13C DEPT-135 spectra for piperidine 3.18. 
 
Preparation of piperidine 3.19: 
 
In a dry, N2-filled glove box, aldehyde 3.12 (0.0500 mmol, 21.1 mg, 1.00 eq.) and 
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Dowex resin, 22 °C, 24 h 3.19
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[Ph3C][B(C6F5)4] (trityl BArF20, 0.0050 mmol, 4.6 mg, 0.10 eq.) were weighed into a 
screw cap 1 dram vial equipped with a stir bar and sealed with a septum cap. In a separate 
screw cap 1 dram vial, Et3SiH (0.0060 mmol, 1.0 µL, 0.12 eq.) and cyclohexanone-derived 
silyl enol ether (0.125 mmol, 24.1 µL, 2.50 eq.) were dissolved in 1.00 mL of CH2Cl2 and 
the vial sealed with a septum cap. Both vials were removed from the glove box and placed 
under a positive N2 atmosphere via piercing of the septa with N2 needles, and the vial 
containing the aldehyde and trityl BArF20 was cooled to –78 °C in an acetone/CO2(s) bath. 
The room temperature solution in CH2Cl2 was syringed drop-wise and slowly down the 
side of the vial into the vigorously stirring solution over approximately 5 minutes. The 
solution was allowed to stir for an additional 15 minutes at –78 °C, after which time the 
reaction was transferred to a –30 °C cryobath and stirred overnight for 20 h (this was 
necessary for increased yield and reproducibility). The reaction was then quenched at the 
cryogenic temperature with 50 µL i-PrNH2 and warmed to room temperature. The residue 
was repeatedly washed with CH2Cl2, concentrated in vacuo (x3), and was then placed 
under high vacuum for ≥1 h to remove excess i-PrNH2. The resulting residue was taken up 
in 2 mL of 1:1 CH2Cl2/MeOH, approximately 10-20 beads of Dowex resin (50W-X8) were 
added, and the mixture was stirred at 22 °C for 24 h. The mixture was then filtered by 
gravity through a plug of sand and cotton, rinsed with 2x1mL CH2Cl2, and concentrated in 
vacuo. The crude residue was purified by silica gel chromatography (10:1 n-pentane:ethyl 
acetate; Rf = 0.4) to yield the tricyclic piperidine product 3.19 as a white solid in 22% yield 
(5.5 mg average per reaction over three 0.05 mmol scale trials). 
(2S,3S,6S)-3-benzyl-4-((4-bromophenyl)sulfonyl)-6-methyl-3,4,5,6,7,8,9,10-octahydro-
2H-2,6-methanobenzo[g][1,4]oxazocine (3.19). 1H NMR (CDCl3, 600 MHz): δ 7.69 (d, 
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2H, J = 8.5 Hz), 7.63 (d, 2H, J = 8.5 Hz), 7.25 (t, 2H, J = 7.4 Hz), 7.19 (t, 1H, J = 7.3 Hz), 
7.15 (d, 2H, J = 7.0 Hz), 3.91 (dd, 1H, J = 11.9, 2.4 Hz), 3.84 (dt, 1H, J = 4.0, 2.0 Hz), 
3.36 (dd, 1H, J = 12.6, 3.7 Hz), 3.24 (ddd, 1H, J = 11.5, 3.7, 2.0 Hz), 2.70 (t, 1H, J = 12.0 
Hz), 2.68 (d, 1H, J = 11.9 Hz), 2.23-2.14 (m, 1H), 2.09 (dt, 1H, J = 16.9, 4.9 Hz), 2.05-
2.00 (m, 2H), 1.84 (dt, 2H, J = 12.9, 2.8 Hz), 1.83-1.75 (m, 1H), 1.67-1.47 (m, 2H), 1.33 
(dd, 1H, J = 13.0, 2.0 Hz), 1.02 (s, 3H); 13C{1H} NMR (CDCl3, 151 MHz): δ 148.1, 141.9, 
138.2, 132.3, 129.8, 128.6, 128.4, 127.3, 126.7, 106.7, 67.3, 65.1, 56.7, 37.2, 35.7, 31.1, 
27.5, 23.4, 22.9, 22.9, 22.0; 13C NMR DEPT-135 (CDCl3, 151 MHz): δ 132.3 (CH), 129.8 
(CH), 128.6 (CH), 128.4 (CH), 126.7 (CH), 67.3 (CH), 65.1 (CH), 56.7 (CH2), 37.2 (CH2), 
35.7 (CH2), 27.5 (CH2), 23.4 (CH2), 22.9 (CH2), 22.9 (CH2), 22.0 (CH3); IR (ν/cm-1): 3086 
(w), 3061 (w), 3028 (w), 2929 (s), 2875 (m), 2855 (m), 2840 (m), 1679 (m), 1603 (w), 
1575 (m), 1495 (w), 1471 (w), 1455 (m), 1387 (m), 1357 (m), 1331 (s), 1315 (m), 1267 
(w), 1244 (w), 1189 (m), 1156 (s), 1142 (m), 1130 (m), 1114 (w), 1091 (m), 1068 (m), 
1052 (w), 1036 (w), 1008 (m); HRMS-(ESI+) [M+H]+ calcd for C25H29NO3SBr+ 502.1052, 
found: 502.1054; [α]D25 = +0.699° (c = 0.830, CH2Cl2, l = 100 mm). 
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Figure 3.15. 1H, 13C{1H}, and 13C DEPT-135 spectra for piperidine 3.19. 
 
Preparation of piperidine 3.20: 
 
In a dry, N2-filled glove box, aldehyde 3.39 (0.150 mmol, 68.3 mg, 1.00 eq.) and 
[Ph3C][B(C6F5)4] (trityl BArF20, 0.015 mmol, 13.8 mg, 0.10 eq.) were weighed into a 
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screw cap 1 dram vial equipped with a stir bar and sealed with a septum cap. In a separate 
screw cap 1 dram vial, Et3SiH (0.018 mmol, 2.9 µL, 0.12 eq.) and cyclohexanone-derived 
silyl enol ether (0.375 mmol, 72 µL, 2.50 eq.) were dissolved in 3.00 mL of CH2Cl2 and 
the vial sealed with a septum cap. Both vials were removed from the glove box and placed 
under a positive N2 atmosphere via piercing of the septa with N2 needles, and the vial 
containing the aldehyde and trityl BArF20 was cooled to –78 °C in an acetone/CO2(s) bath. 
The room temperature solution in CH2Cl2 was syringed drop-wise and slowly down the 
side of the vial into the vigorously stirring solution over approximately 10 minutes. The 
solution was stirred for an additional 2 h at –78 °C, quenched at the cryogenic temperature 
with 50 µL Et3N, and warmed to room temperature. The residue was repeatedly washed 
with CH2Cl2 and concentrated in vacuo (x3), and was then placed under high vacuum for 
≥1 h to remove excess Et3N. The resulting residue was taken up in 2 mL of 1:1 
CH2Cl2/MeOH, approximately 10-20 beads of Dowex resin (50W-X8) were added, and the 
mixture was stirred at 22 °C for 3 h. The mixture was then filtered by gravity through a 
plug of sand and cotton, rinsed with 2x1mL CH2Cl2, and concentrated in vacuo. The crude 
residue was purified by silica gel chromatography (5:1 n-pentane:ethyl acetate; Rf = 0.5) to 
yield the tricyclic piperidine product 3.20 as a white, crystalline solid in 55% yield  
(44.3 mg). 
(2R,3S,6S)-3-benzyl-4-(naphthalen-2-ylsulfonyl)-6-phenyl-3,4,5,6,7,8,9,10-octahydro-
2H-2,6-methanobenzo[g][1,4]oxazocine (3.20). 1H NMR (CDCl3, 600 MHz; piperidine 
ring protons assigned in red): δ 8.50 (d, 1H J = 1.9 Hz), 8.01 (d, 1H, J = 8.7 Hz), 7.99 (d, 
1H, J = 8.2 Hz), 7.95 (d, 1H, J = 8.0 Hz), 7.90 (dd, 1H, J = 8.7, 1.9 Hz), 7.67 (ddd, 1H, J = 
8.2, 6.9, 1.4 Hz), 7.63 (ddd, 1H, J = 8.2, 6.8, 1.4 Hz), 7.37 (t, 2H, J = 7.7 Hz), 7.29 (dd, 
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2H, J = 8.2, 1.3 Hz), 7.27-7.22 (m, 3H), 7.18 (d, 1H, J = 7.4 Hz), 7.16 (dd, 2H, J = 7.1, 1.6 
Hz), 4.69 (dd, 1H, J = 11.4, 2.7 Hz, 1), 3.89 (dt, 1H, J = 4.0, 1.9 Hz, 4), 3.57 (dd, 1H, J = 
12.7, 3.5 Hz, 6), 3.40 (d, 1H, J = 11.5 Hz, 1), 3.30 (ddd, 1H, J = 11.6, 3.6, 1.8 Hz, 5), 2.85 
(t, 1H, J = 12.8, 11.6 Hz, 6), 2.39-2.32 (m, 2H, 3), 2.24-2.19 (m, 1H), 1.94-1.90 (m, 1H), 
1.72-1.53 (m, 6H, 3); 13C{1H} NMR (CDCl3, 151 MHz; piperidine ring carbons assigned 
in red): δ 150.1, 143.5, 139.6, 138.2, 134.8, 132.4, 129.8, 129.4, 129.3, 128.9, 128.6, 
128.6, 128.1, 127.8, 127.7, 126.7, 126.6, 126.4, 122.5, 106.3, 67.4 (4), 65.5 (5), 54.1 (1), 
39.1 (2), 39.0 (3), 35.8 (6), 27.8, 24.8, 23.4, 23.1; 13C NMR DEPT-135 (CDCl3, 151 
MHz): δ 129.8 (CH), 129.4 (CH), 129.3 (CH), 128.9 (CH), 128.6 (CH), 128.6 (CH), 128.1 
(CH), 127.8 (CH), 127.7 (CH), 126.7 (CH), 126.6 (CH), 126.4 (CH), 122.5 (CH), 67.4 
(CH), 65.5 (CH), 54.1 (CH2), 39.0 (CH2), 35.8 (CH2), 27.8 (CH2), 24.8 (CH2), 23.4 (CH2), 
23.1 (CH2); IR (ν/cm-1): 3059 (w), 3027 (w), 2928 (s), 2855 (m), 1679 (m), 1602 (w), 1496 
(m), 1445 (m), 1373 (m), 1327 (s), 1267 (w), 1236 (w), 1166 (s), 1151 (s), 1130 (m), 1074 
(m), 1063 (w), 1021 (w); HRMS-(ESI+) [M+H]+ calcd for C34H34NO3S+ 536.2260, found: 
536.2259; [α]D26 = +11.7° (c = 1.70, CH2Cl2, l = 100 mm). A single crystal X-ray structure 
was obtained from this compound via recrystallization (solvent vapor) from a mixture of 
C6H6/n-pentane. The data indicate a surprising cis-(axial-equatorial) configuration of the 
C–O bond and the amino R-group, respectively. 
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Figure 3.16. 1H, 13C{1H}, 13C DEPT-135, 2D COSY, and 2D HSQC spectra for piperidine 3.20. 
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3.7.4.3 X-ray crystallographic data and structure for 3.20 
 
Figure 3.17. ORTEP representation of solid state molecular structure of 3.20. 
 
The ORTEP representation of the solid state molecular structure of 3.20 (CSD-
1548662) is shown in Figure 3.17; ellipsoids are drawn at 50% probability, the majority of 
hydrogen atoms are omitted for clarity.56 There is disorder in the orientation of the 2-
naphthalenesulfonyl group; only one of two adopted conformations of the naphthyl group 
is shown for clarity. The X-ray crystallographic data are shown in Table 3.3. 
 
Table 3.3. Solid state molecular structure data for 3.20. 
Empirical formula C34H33NO3S Dcalcd (Mg m-3) 1.333 
Fw 535.70 Radiation Cu Ka , λ = 
1.54178 Å 
Colour, habit Colourless, Plate Absorption coeff. (µ) 
(mm-1) 
1.37 
Crystal dimensions 
(mm) 
0.23 x 0.10 x 0.06 Absorption correction Numerical 
Crystal system  Monoclinic F(000) 1137 
Space group P21/c qmin to qmax (°) 3.4 to 66.7 
Z 4 Measured reflections 39148 
a (Å) 13.1751(2) Independent reflections 4720 
(Rint=0.047) 
b (Å) 10.6097(2) Data/restraints/parameters 4720/150/454 
c (Å) 19.5344(3) Maximum shift/error <0.001 
a (°) 90.00 Goodness-of-fit on F2 1.19 
b (°) 102.0226(9) Final R indices  
(I > 2s(I)) 
R1 = 0.054 
wR2 = 0.114 
g (°) 90.00 
 
R indices (all data) R1 = 0.067 
wR2 = 0.119 
Collection ranges h = –15→15 Extinction coefficient N/A 
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k = –12→12 
l = –23→22 
Temperature (K) 100 Largest diff. peak and 
hole (e Å-3) 
0.21 and –0.38 
Volume (Å3) 2670.70(8)   
 
 
 
3.7.4.4 Removal of aryl sulfonamide protecting groups 
Deprotection of piperidine 3.20: 
 
2-naphthalenesulfonyl-protected piperidine 3.20 (0.0609 mmol, 32.6 mg, 1.00 eq.) 
and elemental magnesium (50 mesh; 0.609 mmol, 14.8 mg, 10.0 eq.) were weighed into a 
screw cap 1 dram vial equipped with a stir bar and sealed with a septum cap. The vial was 
purged with a stream of dry N2 for 5 minutes, at which time anhydrous methanol (1.82 
mL) was added via syringe. The milky white suspension was sonicated for 1 h, during 
which time the substrate and magnesium dissolved to produce a homogeneous gray 
solution; TLC (25:1 CH2Cl2:MeOH; product Rf = 0.4) showed spot-to-spot conversion. 
The reaction was quenched with saturated aqueous NH4Cl, diluted with excess CH2Cl2 and 
rinsed into a separatory funnel, basified with excess aqueous 1M NaOH (until pH ≥ 10), 
diluted with saturated aqueous NaCl, and then extracted with CH2Cl2 (x5). The combined 
organic washes were dried over Na2SO4, filtered, and concentrated in vacuo. The crude 
residue was purified by silica gel chromatography (25:1 dichloromethane:methanol with 
trace triethylamine; Rf = 0.4) to yield the free piperidine 3.21 as a clear, colorless oil in 
91% yield (19.1 mg). 
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Deprotection of piperidine 3.14: 
 
The reductive deprotection of brosyl-protected piperidine 14 was effected via 
application of a modified literature procedure.6 A stock solution of sodium naphthalenide 
was prepared by dissolving finely chopped sodium metal (4.06 mmol, 93 mg) and 
naphthalene (4.47 mmol, 572 mg) in 5.00 mL of freshly distilled 1,2-dimethoxyethane 
(DME) and stirring at 22 °C for 2 h. Note: the solution rapidly became dark green in color. 
Piperidine 14 (0.0406 mmol, 22.9 mg, 1.00 eq.) was weighed into a screw cap 1 dram vial 
equipped with a stir bar and sealed with a septum cap. The vial was purged with a stream 
of dry N2 for 5 minutes, at which time anhydrous DME (500 µL) was added via syringe 
and the vial was cooled to –78 °C in an acetone/CO2(s) bath. Sodium naphthalenide 
solution (approx. 0.406 mmol, 600 µL, 10-12 eq.) was added dropwise via syringe. The 
dark green solution was vigorously stirred for an additional 5 minutes at –78 °C, at which 
time the solution froze. The reaction was quenched at the cryogenic temperature by the 
addition of 500 µL of saturated aqueous NaHCO3, warmed to room temperature, and 
rinsed into a separatory funnel with excess CH2Cl2. The organic layer was basified with 
aqueous 1M NaOH (10 mL), diluted with saturated aqueous NaCl (10 mL), and then 
extracted with CH2Cl2 (x5). The combined organic washes were dried over Na2SO4, 
filtered, and concentrated in vacuo. The crude residue was purified by silica gel 
chromatography (25:1 dichloromethane:methanol with trace triethylamine; Rf = 0.4) to 
yield the free amine product 21 as a light yellow oil in 93% yield (13.0 mg). 
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(2R,3S,6S)-3-benzyl-6-phenyl-3,4,5,6,7,8,9,10-octahydro-2H-2,6-methanobenzo[g][1,4] 
oxazocine (3.21). 1H NMR (CDCl3, 600 MHz): δ 7.34-7.29 (m, 6H), 7.24-7.19 (m, 4H), 
3.88 (d, 1H, J = 4.1 Hz), 3.19-3.10 (m, 2H), 2.91-2.81 (m, 3H), 2.37-2.29 (m, 2H), 2.27-
2.21 (m, 1H), 1.90 (br s, 1H, NH), 1.82-1.77 (m, 1H), 1.74 (dd, J = 13.1, 1.8 Hz, 1H), 
1.63-1.58 (m, 2H), 1.54-1.47 (m, 1H), 1.37-1.33 (m, 2H); 13C{1H} NMR (CDCl3, 151 
MHz): δ 151.0, 144.9, 139.1, 129.6, 128.5, 128.4, 126.8, 126.3, 126.2, 106.3, 69.1, 63.8, 
51.7, 39.4, 39.1, 39.0, 27.8, 24.9, 23.6, 23.3; 13C NMR DEPT-135 (CDCl3, 151 MHz): δ 
129.6 (CH), 128.5 (CH), 128.4 (CH), 126.8 (CH), 126.3 (CH), 126.2 (CH), 69.1 (CH), 
63.8 (CH), 51.7 (CH2), 39.4 (CH2), 39.1 (CH2), 27.8 (CH2), 24.9 (CH2), 23.6 (CH2), 23.3 
(CH2); IR (ν/cm-1): 3084 (w), 3059 (w), 3026 (w), 2927 (s), 2854 (s), 1669 (m), 1603 (w), 
1556 (w), 1495 (m), 1446 (m), 1372 (w), 1348 (w), 1266 (w), 1232 (m), 1215 (w), 1150 
(m), 1136 (m), 1108 (w), 1058 (w), 1032 (w); HRMS-(ESI+) [M+H]+ calcd for C24H28NO+ 
346.2171, found: 346.2164; [α]D25 = +117° (c = 0.955, CH2Cl2, l = 100 mm). 
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Figure 3.18. 1H, 13C{1H}, and 13C DEPT-135 spectra for free piperidine 3.21. 
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3.7.5 Prins cyclizations in the absence of trapping nucleophiles / cyclizations using other 
Lewis Acids 
3.7.5.1 Prins cyclization promoted by TiCl4 
Preparation of chloro-piperidine 3.9 
 
In a dry, N2-filled glove box, aldehyde 3.4 (0.100 mmol, 48.4 mg) was weighed 
into a screw cap 1 dram vial equipped with a stir bar. CH2Cl2 (1.00 mL, 0.1 M) was added 
and the vial was sealed with a septum cap. Simultaneously, a 1.0 M solution of TiCl4 in 
CH2Cl2 was prepared in a 1 dram vial and the vial was sealed with a septum cap. Both 
vials were removed from the glove box. The vial containing the substrate was equipped 
with a nitrogen line and cooled to –78 °C in an acetone/CO2(s) bath. The 1.0 M TiCl4 
solution in CH2Cl2 (0.110 mmol, 110 µL) was taken up by syringe and added drop-wise to 
the rapidly stirring solution of substrate at –78 °C over 30 seconds. The color was observed 
to change from light yellow to deep reddish-orange. After 5 minutes, the solution was 
quenched (resulting in rapid loss of color) by drop-wise addition of a CH2Cl2 solution (800 
µL) containing NEt3 (80 µL) and MeOH (30 µL). The solution was stirred at –78 °C for 10 
minutes, and was then allowed to warm to room temperature over 10 minutes. The reaction 
was worked up by dilution with CH2Cl2, followed by sequential washes with saturated 
aqueous NH4Cl, NaHCO3, and NaCl, followed by drying over anhydrous MgSO4 and 
concentration in vacuo. The crude residue was purified by silica gel chromatography (3:1 
n-pentane:ethyl acetate; Rf = 0.3-0.4) to yield chloro-piperidine 3.9 as a white, crystalline 
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solid in 99% yield (51.5 mg) and as a mixture of three partially separable diastereomers in 
85:9:6 d.r. (see section 3.4 and Table 3.1 therein). 
(2S)-2-benzyl-1-((4-bromophenyl)sulfonyl)-5-chloro-5-phenylpiperidin-3-ol (3.9). 
Major diastereomer A (co-eluted with minor diastereomer B): 1H NMR (CDCl3, 600 
MHz): δ 7.59-7.55 (m, 2H), 7.36-7.33 (m, 3H), 7.27 (d, 2H, J = 8.4 Hz), 7.24-7.18 (m, 
3H), 7.16-7.13 (m, 2H), 7.09 (d, 2H, J = 8.2 Hz), 4.80 (d, 1H, J = 13.9 Hz), 4.11 (q, 1H, J 
= 6.1 Hz), 3.99 (dt, 1H, J = 10.6, 4.6 Hz), 3.74 (d, 1H, J = 13.9 Hz), 3.20 (dd, 1H, J = 14.3, 
6.4 Hz), 3.06 (dt, 1H, J = 13.9, 3.1 Hz), 2.86 (dd, 1H, J = 14.3, 6.4 Hz), 2.50 (dd, 1H, J = 
13.8, 11.9 Hz), 1.91 (s, br, 1H); 13C{1H} NMR (CDCl3, 151 MHz): δ 139.5, 138.4, 138.4, 
132.2, 129.3, 128.8, 128.8, 128.7, 128.5, 127.6, 127.1, 126.6, 66.9, 66.1, 58.9, 50.8, 41.5, 
31.0; 13C NMR DEPT-135 (CDCl3, 151 MHz): δ 132.2 (CH), 129.3 (CH), 128.8 (CH), 
128.8 (CH), 128.7 (CH), 128.5 (CH), 127.1 (CH), 126.6 (CH), 66.9 (CH), 58.9 (CH), 50.8 
(CH2), 41.5 (CH2), 31.0 (CH2); IR (ν/cm-1): 3520 (s, br, OH), 3087 (w), 3061 (w), 3028 
(w), 2953 (w), 2926 (w), 2853 (w), 1603 (w), 1575 (m), 1496 (m), 1470 (m), 1449 (m), 
1389 (m), 1335 (s), 1311 (m), 1277 (m), 1266 (m), 1231 (w), 1159 (s), 1098 (m), 1086 
(m), 1069 (s), 1031 (w); HRMS-(ESI+) [M–Cl-]+ calcd for C24H23NO3SBr+ 484.0582, 
found: 484.0588; [α]D25 = –22.2° (c = 2.35, CH2Cl2, l = 100 mm). Minor diastereomer B 
(co-eluted with major diastereomer A; aliphatic peaks reported where visible): 1H NMR 
(CDCl3, 600 MHz; aliphatic only): δ 4.62 (dt, 1H, J = 10.6, 4.7 Hz), 4.50 (dd, 1H, J = 14.9, 
2.3 Hz), 4.33 (dt, 1H, J = 9.7, 4.9 Hz), 3.47 (d, 1H, J = 14.9 Hz), 3.10-3.08 (m, 1H), 2.67-
2.60 (m, 1H), 2.57 (dt, 1H, J = 13.7, 3.4 Hz), 2.45 (dd, 1H, J = 14.0, 11.4 Hz); 13C{1H} 
NMR (CDCl3, 151 MHz; aliphatic only): δ 70.6, 66.2, 59.3, 51.1, 40.3, 30.0; 13C NMR 
DEPT-135 (CDCl3, 151 MHz; aliphatic only): δ 66.2 (CH), 59.3 (CH), 51.1 (CH2), 40.3 
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(CH2), 30.0 (CH2). Minor diastereomer C: 1H NMR (CDCl3, 600 MHz): δ 1H NMR 7.81 
(d, 2H, J = 8.6 Hz), 7.62 (d, 2H, J = 8.6 Hz), 7.55 (d, 2H, J = 7.8 Hz), 7.45 (t, 2H, J = 7.7 
Hz), 7.41-7.22 (m, 4H), 7.14 (d, 2H, J = 6.9 Hz), 4.56 (dd, 1H, J = 15.2, 2.5 Hz), 4.34 (dd, 
1H, J = 11.0, 4.7 Hz), 3.86 (ddt, 1H, J = 11.4, 4.1, 2.0 Hz), 3.67 (d, 1H, J = 14.8 Hz), 3.30 
(d, 1H, J = 11.4 Hz), 2.93 (dd, 1H, J = 13.6, 4.6 Hz), 2.74 (dd, 1H, J = 13.6, 10.9 Hz), 2.70 
(d, 1H, J = 14.9 Hz), 2.53 (dd, 1H, J = 15.6, 4.0 Hz); 13C{1H} NMR (CDCl3, 151 MHz): δ 
141.8, 139.5, 136.8, 132.4, 129.2, 129.2, 129.1, 128.8, 128.0, 127.3, 127.2, 125.3, 68.6, 
65.5, 61.5, 51.6, 37.6, 36.3; 13C NMR DEPT-135 (CDCl3, 151 MHz): δ 132.4 (CH), 129.2 
(CH), 129.2 (CH), 129.1 (CH), 128.8 (CH), 127.3 (CH), 127.2 (CH), 125.3 (CH), 65.5 
(CH), 61.5 (CH), 51.6 (CH2), 37.6 (CH2), 36.3 (CH2); IR (ν/cm-1): 3566 (m, br, OH), 3086 
(w), 3061 (w), 3028 (w), 2921 (s), 2850 (m), 1733 (w), 1716 (w), 1698 (w), 1684 (w), 
1647 (w), 1636 (w), 1601 (w), 1575 (m), 1558 (w), 1541 (w), 1521 (w), 1507 (w), 1496 
(m), 1472 (w), 1456 (m), 1448 (w), 1419 (w), 1389 (m), 1340 (s), 1266 (m), 1214 (w), 
1163 (s), 1090 (m), 1068 (m), 1030 (m), 1010 (m); HRMS-(ESI+) [M–Cl-]+ calcd for 
C24H23NO3SBr+ 484.0582, found: 484.0589. 
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Figure 3.19. 1H, 13C{1H}, and 13C DEPT-135 NMR spectra of chloro-piperidine 3.9  
(diastereomers A/B). 
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Figure 3.20. 1H, 13C{1H}, and 13C DEPT-135 NMR spectra of chloro-piperidine 3.9  
(minor diastereomer C). 
 
3.7.5.2 Prins cyclization catalyzed by HBArF24 (Brookhart’s acid) 
Alternate preparation of piperidine 3.6 
 
In a dry, N2-filled glove box, aldehyde 3.4 (0.0500 mmol, 24.2 mg, 1.00 eq.) and 
[H(OEt2)2][B(C6H3(CF3)2)4] (HBArF24 (Brookhart’s acid), 0.0050 mmol, 5.1 mg, 0.10 eq.) 
were weighed into a screw cap 1 dram vial equipped with a stir bar and sealed with a 
septum cap. In a separate screw cap 1 dram vial, Et3SiH (0.0600 mmol, 9.6 µL, 1.20 eq.) 
was dissolved in 1.00 mL of CH2Cl2 and the vial sealed with a septum cap. Both vials were 
removed from the glove box and placed under a positive N2 atmosphere via piercing of the 
septa with N2 needles, and the vial containing the aldehyde and HBArF24 was cooled to –
78 °C in an acetone/CO2(s) bath. The room temperature solution in CH2Cl2 was syringed 
drop-wise and slowly down the side of the vial into the vigorously stirring solution over 
approximately 5 minutes. The solution was stirred for an additional 15 minutes at –78 °C, 
after which time the reaction was transferred to a –30 °C cryobath and stirred overnight for 
18 h. The reaction was then quenched at the cryogenic temperature with 50 µL Et3N and 
warmed to room temperature. The residue was repeatedly washed with CH2Cl2 and 
concentrated in vacuo (x3), and was then placed under high vacuum for ≥1 h to remove 
excess Et3N. The resulting residue was taken up in 2 mL of 1:1 CH2Cl2/MeOH, 
N
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Dowex resin, 22 °C, 18 h
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approximately 10-20 beads of Dowex resin (50W-X8) were added, and the mixture was 
stirred at 22 °C for 18 h. The mixture was then filtered by gravity through a plug of sand 
and cotton, rinsed with 2x1mL CH2Cl2, and concentrated in vacuo. Dimethylformamide 
(0.050 mmol, 3.9 µL) was added as an internal standard and the residue taken up in CDCl3 
for 1H and 13C NMR analyses to determine crude NMR yield and diastereomeric ratios 
(d.r.); the desired piperidine 3.6 was produced in 47% yield and in 45:36:19 d.r. favoring 
the same diastereomers as those resulting from the putative silylium ion catalysis (see 
section 3.4 and Table 3.1 therein). 
 
3.7.5.3 Silylium-ion catalyzed Prins cyclization in the absence of trapping nucleophiles 
Preparation of tetrahydropyridines 3.22 and 3.23 
 
In a dry, N2-filled glove box, aldehyde 3.4 (0.100 mmol, 48.4 mg) and 
[Ph3C][B(C6F5)4] (trityl BArF20, 0.0100 mmol, 9.2 mg) were weighed into a screw cap 1 
dram vial equipped with a magnetic stir bar and sealed with a septum cap. In a separate 
screw cap 1 dram vial, Et3SiH (0.0120 mmol, 1.9 µL) was dissolved in 2.00 mL of CH2Cl2 
and the vial sealed with a septum cap. Both vials were removed from the glove box and 
placed under a positive N2 atmosphere via piercing of the septa with N2 needles, and the 
vial containing the aldehyde and trityl BArF20 was cooled to –78 °C in an acetone/CO2(s) 
bath. The room temperature solution in CH2Cl2 was syringed drop-wise and slowly down 
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the side of the vial over 5 minutes with magnetic stirring. During addition, the reaction 
turned clear bright yellow in color, which persisted throughout the course of the reaction. 
The reaction was allowed to freely and slowly (in the dewar) warm to 22 °C with stirring 
over the course of 8 hours, after which time the reaction was quenched with 100 µL of i-
PrNH2 and concentrated in vacuo. The crude residue was purified by silica gel 
chromatography (gradient of 5:1 to 3:1 n-pentane:ethyl acetate; Rf = 0.2-0.3) to yield cis-
tetrahydropyridine 3.22 and trans-tetrahydropyridine 3.23 as clear, colorless oils in 58% 
yield (28.0 mg on a 0.1 mmol scale) and as a mixture of two chromatographically 
separable diastereomers in 83:17 cis:trans diastereomeric ratio (see section 3.6 and 
Scheme 3.7 therein). 
(2S,3S)-2-benzyl-1-((4-bromophenyl)sulfonyl)-5-phenyl-1,2,3,4-tetrahydropyridin-3-
ol (3.22). Cis-diastereomer: 1H NMR (CDCl3, 600 MHz): δ 7.54 (d, 2H, J = 8.6 Hz), 7.50 
(d, 2H, J = 8.6 Hz), 7.42 (d, 2H, J = 7.3 Hz), 7.38 (t, 2H, J = 7.6 Hz), 7.30 (t, 3H, J = 7.1 
Hz), 7.26 (t, 1H, J = 3.6 Hz), 7.20 (d, 2H, J = 6.7 Hz), 7.04 (s, 1H), 4.27 (dt, 1H, J = 9.2, 
4.3 Hz), 3.62 (dt, 1H, J = 10.5, 5.4 Hz), 3.02 (dd, 1H, J = 13.9, 4.2 Hz), 2.70 (ddd, 1H, J = 
17.1, 6.0, 1.6 Hz), 2.65 (dd, 1H, J = 13.9, 9.5 Hz), 2.40 (ddd, 1H, J = 17.2, 10.4, 1.9 Hz), 
1.78 (s, br, 1H); 13C{1H} NMR (CDCl3, 151 MHz): δ 137.9, 137.8, 137.8, 132.6, 129.7, 
128.8, 128.6, 128.5, 128.1, 127.6, 126.8, 125.0, 120.3, 119.3, 66.6, 59.1, 32.1, 30.2; 13C 
NMR DEPT-135 (CDCl3, 151 MHz): δ 132.6 (CH), 129.7 (CH), 128.8 (CH), 128.6 (CH), 
128.5 (CH), 127.6 (CH), 126.8 (CH), 125.0 (CH), 119.3 (CH), 66.6 (CH), 59.1 (CH), 32.1 
(CH2), 30.2 (CH2); IR (ν/cm-1): 3532 (s, br, OH), 3086 (w), 3061 (w), 3028 (w), 2925 (m), 
2849 (w), 1632 (m), 1601 (w), 1574 (m), 1496 (m), 1471 (w), 1455 (w), 1445 (w), 1389 
(w), 1349 (s), 1265 (w), 1220 (w), 1166 (s), 1093 (m), 1070 (m), 1053 (w), 1018 (w), 1006 
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(m); HRMS-(ESI+) [M+H]+ calcd for C24H23NO3SBr+ 484.0582, found: 484.0590; [α]D25 = 
–41.4° (c = 1.150, CH2Cl2, l = 100 mm).  
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Figure 3.21. 1H, 13C{1H}, and 13C DEPT-135 NMR spectra for cis-tetrahydropyridine 3.22. 
 
(2S,3R)-2-benzyl-1-((4-bromophenyl)sulfonyl)-5-phenyl-1,2,3,4-tetrahydropyridin-3-
ol (3.23). Trans-diastereomer: 1H NMR (CDCl3, 600 MHz): δ 7.70 (d, 2H, J = 8.4 Hz), 
7.59 (d, 2H, J = 8.3 Hz), 7.41-7.35 (m, 4H), 7.33 (t, 2H, J = 7.4 Hz), 7.30-7.26 (m, 2H), 
7.25-7.22 (m, 3H), 4.23 (ddd, 1H, J = 9.5, 5.7, 2.6 Hz), 3.94 (dd, 1H, J = 4.3, 2.3 Hz), 3.11 
(dd, 1H, J = 13.8, 5.6 Hz), 2.70 (ddd, 1H, J = 18.0, 4.4, 2.0 Hz), 2.64 (dd, 1H, J = 13.8, 
10.1 Hz), 2.49 (d, 1H, J = 18.1 Hz), 1.03 (s, br, 1H); 13C{1H} NMR (CDCl3, 151 MHz): δ 
138.7, 138.4, 136.6, 132.5, 129.3, 128.9, 128.8, 128.7, 127.3, 127.1, 124.8, 119.6, 115.1, 
63.3, 60.4, 39.1, 28.5; 13C NMR DEPT-135 (CDCl3, 151 MHz): δ 132.5, 129.3, 128.9, 
128.8, 128.7, 128.1, 127.3, 127.1, 124.8, 119.6, 63.3 (CH), 60.4 (CH), 39.1 (CH2), 28.5 
(CH2); IR (ν/cm-1): 3542 (s, br, OH), 3085 (w), 3060 (w), 3028 (w), 2923 (m), 2850 (w), 
1639 (m), 1599 (w), 1574 (m), 1495 (m), 1471 (w), 1454 (w), 1446 (w), 1389 (m), 1352 
(s), 1266 (w), 1215 (w), 1198 (w), 1164 (s), 1092 (s), 1067 (m), 1058 (m), 1032 (w), 1009 
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(w); HRMS-(ESI+) [M+H]+ calcd for C24H23NO3SBr+ 484.0582, found: 484.0591; [α]D25 = 
–21.4° (c = 1.20, CH2Cl2, l = 100 mm). 
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Figure 3.22. 1H, 13C{1H}, and 13C DEPT-135 NMR spectra for trans-tetrahydropyridine 3.23. 
 
3.7.5.4 Prins cyclization catalyzed by B(C6F5)3 
Independent preparation of trans-tetrahydropyridine 3.23 
 
In a dry, N2-filled glove box, aldehyde 3.4 (0.0500 mmol, 24.2 mg) and B(C6F5)3 
(BCF, 0.0050 mmol, 2.6 mg) were weighed into a screw cap 1 dram vial equipped with a 
magnetic stir bar. CH2Cl2 (1.00 mL, 0.05 M) was added and the vial was sealed with a 
septum cap and removed from the glove box. The solution was stirred at 22 °C for 1 h, 
after which time the catalyst was quenched with 50 µL of Et3N and the solvent was 
removed in vacuo. The crude residue was purified by silica gel chromatography (5:1 n-
pentane:ethyl acetate; Rf = 0.3) to yield the tetrahydropyridine product 3.23 as a clear, 
colorless oil in 99% yield (24.0 mg on a 0.05 mmol scale) and as a single diastereomer 
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(>98:2). Analytical data match that of trans-tetrahydropyridine 3.23 (vide supra) obtained 
as the minor product of silylium-catalyzed Prins-cyclization in the absence of trapping 
nucleophiles (see section 3.6 and Scheme 3.7 therein). Absolute configuration was 
assigned by analogy between the 1H NMR spectra of trans-tetrahydropyridine products 
3.23 and 3.42 (vide infra). 
 
Preparation of trans-tetrahydropyridine 3.42 via B(C6F5)3-catalyzed Prins cyclization: 
 
In a dry, N2-filled glove box, aldehyde 3.39 (0.0500 mmol, 22.8 mg) and B(C6F5)3 
(BCF, 0.0050 mmol, 2.6 mg) were weighed into a screw cap 1 dram vial equipped with a 
stir bar. CH2Cl2 (1.00 mL, 0.05 M) was added and the vial was sealed with a septum cap 
and removed from the glove box. The solution was stirred at 22 °C for 1 h, after which 
time the catalyst was quenched with 50 µL of Et3N and the solvent was removed in vacuo. 
The crude residue was purified by silica gel chromatography (5:1 n-pentane:ethyl acetate; 
Rf = 0.3) to yield the tetrahydropyridine product 3.42 as a white, crystalline solid in 99% 
yield (22.6 mg on a 0.05 mmol scale) and as a single diastereomer (≥98:2).  
(2S,3R)-2-benzyl-1-(naphthalen-2-ylsulfonyl)-5-phenyl-1,2,3,4-tetrahydropyridin-3-ol 
(3.42). 1H NMR (CDCl3, 600 MHz): δ 8.47 (d, 1H, J = 2.0 Hz), 7.96 (dd, 1H, J = 8.0, 1.5 
Hz), 7.92 (d, 1H, J = 8.7 Hz), 7.87 (d, 1H, J = 7.3 Hz), 7.80 (dd, 1H, J = 8.7, 1.9 Hz), 7.64-
7.57 (m, 2H), 7.41 (dd, 2H, J = 8.2, 1.4 Hz), 7.39-7.35 (m, 3H), 7.34-7.30 (m, 2H), 7.29-
7.23 (m, 4H), 4.35-4.29 (m, 1H), 3.92-3.87 (m, 1H), 3.16 (dd, 1H, J = 13.7, 5.4 Hz), 2.72-
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2.62 (m, 2H), 2.47 (dd, 1H, J = 18.1, 1.6 Hz), 0.94 (d, 1H, J = 7.8 Hz); 13C{1H} NMR 
(CDCl3, 151 MHz): δ 138.9, 136.7, 136.2, 135.0, 132.2, 129.7, 129.5, 129.3, 129.1, 128.9, 
128.8, 128.5, 128.1, 127.8, 127.1, 127.1, 124.8, 122.2, 120.0, 114.4, 63.3, 60.3, 39.2, 28.4; 
13C NMR DEPT-135 (CDCl3, 151 MHz): δ 129.7 (CH), 129.5 (CH), 129.3 (CH), 129.1 
(CH), 128.9 (CH), 128.8 (CH), 128.5 (CH), 128.1 (CH), 127.8 (CH), 127.1 (CH), 127.1 
(CH), 124.8 (CH), 122.2 (CH), 120.0 (CH), 63.3 (CH), 60.3 (CH), 39.2 (CH2), 28.4 (CH2); 
IR (ν/cm-1): 3540 (m, br, OH), 3058 (w), 3028 (w), 2925 (m), 2853 (w), 1639 (m), 1596 
(w), 1496 (w), 1454 (w), 1447 (w), 1348 (s), 1267 (w), 1216 (w), 1198 (w), 1161 (s), 1132 
(m), 1076 (m), 1056 (m), 1032 (w); HRMS-(ESI+) [M+H]+ calcd for C28H26NO3S+ 
456.1634, found: 456.1644; [α]D25 = –74.1° (c = 1.06, CH2Cl2, l = 100 mm). A single 
crystal X-ray structure was obtained from this compound via recrystallization (solvent 
vapor) from a mixture of CDCl3/n-pentane. The data indicate a trans-di-pseudoequatorial 
configuration between the amino alcohol R-group and the hydroxyl group. 
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Figure 3.23. 1H, 13C{1H}, and 13C DEPT-135 NMR spectra for trans-tetrahydropyridine 3.42. 
3.7.5.5 X-ray crystallographic data and structure for 3.42 
 
Figure 3.24. ORTEP representation of solid state molecular structure of 3.42. 
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The ORTEP representation of the solid state molecular structure of 3.42 (CSD-
1548661) is shown in Figure 3.24; ellipsoids drawn at 50% probability, the majority of 
hydrogen atoms are omitted for clarity.60 The X-ray crystallographic data are shown in 
Table 3.4. 
 
Table 3.4. Solid state molecular structure data for 3.42. 
Empirical formula C28H25NO3S Dcalcd (Mg m-3) 1.361 
Fw 455.57 Radiation Cu Ka , λ = 
1.54178 Å 
Colour, habit Colourless, block Absorption coeff. (µ) 
(mm-1) 
1.55 
Crystal dimensions 
(mm) 
0.31 x 0.09 x 0.07 Absorption correction Numerical 
Crystal system  Orthorhombic F(000) 960 
Space group P212121 qmin to qmax (°) 2.5 to 68.1 
Z 4 Measured reflections 35988 
a (Å) 5.6499(1) Independent reflections 4067 
(Rint=0.049) 
b (Å) 11.1424(2) Data/restraints/parameters 4067/0/302 
c (Å) 35.3036(7) Maximum shift/error <0.001 
a (°) 90.00  Goodness-of-fit on F2 1.06 
b (°) 90.00 Final R indices  
(I > 2s(I)) 
R1 = 0.030 
wR2 = 0.073 
g (°) 90.00 R indices (all data) R1 = 0.032 
wR2 = 0.074 
Collection ranges h = –6→6 
k = –13→13 
l = –42→42 
absolute structure 
parameter 
0.038(7) 
Temperature (K) 100 Extinction coefficient N/A 
Volume (Å3) 2222.48(7) Largest diff. peak and 
hole (e Å-3) 
0.23 and –0.29 
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APPENDIX A: APPLYING B(C6F5)3 TO N-HETEROCYCLE SYNTHESIS 
The results and data contained within Appendix A are unpublished and represent 
further investigations with respect to substrate scope of the published discovery in section 
3.6 above that B(C6F5)3 catalyzes a stereospecific Prins cyclization followed by an 
elimination (formally a carbonyl-ene reaction) to form trans-tetrahydropyridine products in 
exceptionally high yield and diastereoselectivity. Background, breadth of amino alcohol-
derived substrate scope, and reactivity of various fluoroaryl borane catalysts are discussed. 
A.1  Introduction 
Tris(pentafluorophenyl)borane (BCF) has proven itself to be a robust, selective, and 
versatile catalyst, improving the efficiency of many catalytic processes and opening the 
door to multiple potential reactivity pathways. To that extent, BCF is best known for its 
frustrated Lewis pair (FLP) reactivity and its peculiar affinity for silane activation  
(R3Si–H; h1-binding) in hydrosilylation methodology.51a However, BCF can serve many 
roles, including as a traditional oxophilic Lewis acid catalyst towards a variety of Lewis 
basic functional groups such as carbonyls and C–C p-bonds.52d,61 It is in this latter capacity 
that we decided to apply BCF as a neutral, less reactive, and potentially more selective 
alternative to the silylium ion ([R3Si]+) protocol discussed in Chapter 3. 
A.2  Substrate scope 
The serendipitous discovery (section 3.6, Scheme 3.7) that neutral perfluoroaryl 
borane Lewis acids (e.g. BCF) could catalyze a stereospecific Prins cyclization to the 
complementary trans-diastereomerxxviii, followed by elimination (overall carbonyl-ene 
                                                
xxviiiThe relative configuration of the tetrahydropyridine products was assigned in analogy to the X-ray 
crystal structure of 3.42 (see section 3.7.5.4; for X-ray data, see section 3.7.5.5). 
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reaction) to produce trans-tetrahydropyridine scaffolds in exceptionally high yield and 
diastereoselectivity and under very mild conditions (e.g. room temperature) led us to 
further investigate the potential substrate scope of this N-heterocycle-forming 
transformation.xxix The amino aldehyde substrates for this expanded scope were obtained 
analogously to the syntheses described in Scheme 3.4; for experimental details and 
complete analytical data, see section A.5.1-3. 
Representative, unoptimized conditions for the BCF-catalyzed Prins 
cyclization/elimination are given below in Table A.1. 10 mol % of BCF in CH2Cl2 at 22 °C 
is sufficient to induce rapid cyclization and elimination to yield free tetrahydropyridine 
products from a variety of substituted aldehydes (see section A.5.4 for experimental details 
and analytical data). Products 3.23 and A.1-A.6 showcase steric and functional group 
variation in the amino alcohol-derived sidechain (R). “Glycinol”-derived A.1, which lacks 
an R-group, was obtained in 67% yield (the lower yield is most likely due to enolization 
and subsequent decomposition of the substrate) and as a racemate; this reaction could 
potentially be an interesting model with which to screen chiral perfluoroaryl borane 
derivatives.62 Alaninol-derivative A.2 was obtained in 85% yield and 91:9 d.r. (trans:cis); 
comparison of this result to the previously reported phenylalaninol-derivative 3.23 (99% 
yield and >98:2 d.r.) illuminates the minimum steric demand necessary to achieve high 
                                                
xxixa) Attempts to intercept the carbocation with R3Si–Nu in the presence of BCF have been unsuccessful; 
Et3Si–H hydrosilylates the aldehyde in 32% NMR yield (see section A.5.4.1 for details), along with 
producing 44% of trans-tetrahydropyridine 3.23 and 7% and 12%, respectively, of minor diastereomers B 
and C of piperidine 3.6. Unfortunately, variation of addition order and temperature did not allow for the 
clean, high-yielding production of any single product, especially piperidine 3.6. b) Aldehyde 
hydrosilylation has been well documented; see Ref. 51. 
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diastereoselectivity.xxx Conforming to this apparent trend in sterics, valinol- and tert-
leucinol-derivatives A.3 and A.4 were obtained in 90% and 95% yields, respectively, and 
in >98:2 d.r. Serinol-derivative A.5 and lysinol-derivative A.6 both illustrate the functional 
group/heteroatom tolerance of BCF and the potential for an expanded number of 
subsequent synthetic manipulations on the products. Serinol-derivative A.5 was produced 
in 94% NMR yield and 94:6 d.r. (trans:cis) and was able to be isolated in 87% as a single 
diastereomer (>98:2 d.r.). Lysinol-derivative A.6 was produced and isolated in 88% yield 
and 85:15 d.r. (trans:cis). 
                                                
xxxIn agreement with our observations in section 3.6, 10 mol % HBArF24 ([H(OEt2)2][B(C6H3(CF3)2)4], 
Brookhart’s acid) as catalyst provided the corresponding alaninol-derived cis-tetrahydropyridine (A.2’) in 
81% yield and 72:28 d.r. (cis:trans); see A.5.4.2 for experimental details and analytical data. 
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Table A.1. Trans-tetrahydropyridine substrate scope. 
 
Table A.1 also discloses a preliminary screen of N-protecting groups (ArSO2) and 
allyl group substitution (G). Tosyl(Ts)- and 2-naphthalenesulfonyl(2-Naph)-protected 
products A.7 and 3.42, respectively, were obtained in 97% and 99% yields and both in 
>98:2 d.r., indicating that slightly less electron-withdrawing aryl sulfonamide groups do 
not impede the reaction or harm diastereoselectivity. Methyl-substituted A.8, derived from 
the corresponding 2-methylpropenyl-substituted starting material 3.12, was obtained in 
61% yield. 
B(C6F5)3 (10 mol %)
CH2Cl2, 22 °C, 1 h
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67% yield
A.2
85% yield,
91:9 d.r. (trans:cis)
A.3
90% yield,
>98:2 d.r. (trans:cis)
3.23
99% yield,
>98:2 d.r. (trans:cis)
A.4
95% yield,
>98:2 d.r. (trans:cis)
A.5
87% yield,
>98:2 d.r. (trans:cis)
A.6
88% yield,
85:15 d.r. (trans:cis)
aReactions were run on a 0.05 mmol scale. bBs = 4-bromobenzenesulfonyl; Ts = p-toluenesulfonyl; 2-
Naph = 2-naphthalenesulfonyl; c94% NMR yield in 94:6 d.r. (trans:cis) before purification; DMF as internal 
standard. d3 h reaction time necessary for completion.
A.7
97% yield,
>98:2 d.r. (trans:cis)
3.42
99% yield,
>98:2 d.r. (trans:cis)
A.8
61% yield,
>98:2 d.r. (trans:cis)
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With respect to functionalization, Scheme A.1 demonstrates the ease with which 
these free tetrahydropyridine products can be protected preceding further 
functionalization.xxxi In situ addition of tert-butyldimethylhydrosilane (1.10 eq.) results in 
quantitative dehydrocoupling (with concomitant slow evolution of hydrogen gas) in <1 h 
to the corresponding silyl ether A.9 (see section A.5.4.3). It is also worth noting that this 
one-pot transformation substantiates the catalytic competence of the BCF catalyst and 
lends further evidence against Brønsted acid co-catalysis via [H]+. 
 
Scheme A.1. In situ BCF-catalyzed cyclization and dehydrocoupling / silyl-protection. 
Application of this BCF-catalytic manifold to the corresponding cinnamyl amino 
aldehyde substrates to produce pyrrolidines was unsuccessful (Scheme A.2; see section 
A.5.4.4). Subjection of A.10 to BCF (10 mol %) at the very mild conditions of slowly 
warming from –78 °C to 22 °C overnight resulted in 32% consumption of starting material 
and apparent decomposition; no pyrrolidine A.11 was formed. We hypothesize that the 
driving force of the Prins cyclization / elimination reaction is the generation of a 
conjugated styrenyl enamide; absent a 1,2-hydride migration preceding the elimination (to 
form a 2,3-dihydropyrrole, not shown), a styrenyl enamide cannot form from the cinnamyl 
amino aldehyde substrates (e.g. A.10).  
                                                
xxxiAlthough not discussed herein, other synthetic transformations/deprotections of the 
tetrahydropyridines, such as catalytic hydrogenation of the styrenyl enamide moiety or removal of the 
arylsulfonyl protecting group, were unsuccessful. 
N
A.9
Ph
OSiMe2t-Bu
Ph1) B(C6F5)3 (10 mol %),
CH2Cl2, 22 °C, 1 h
2) t-BuMe2Si–H (1.10 eq.),
CH2Cl2, 22 °C, 1 h
N
3.39
Ph
O
Ph2-Naph 2-Naph
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Scheme A.2. BCF-catalyzed cyclization / elimination to produce pyrrolidines. 
A.3  Reactivity of various perfluoroaryl borane catalysts 
We conducted a brief screen of perfluoroaryl borane Lewis acids as catalysts for the 
Prins cyclization / elimination manifold using substrate 3.38 (Scheme A.3; see section 
A.5.4.5). In comparison to BCF (Table A.1 above; 90% yield, >98:2 d.r.), 3,5-CF3-BCF 
provided the same trans-tetrahydropyridine product A.3 in almost identical 95% yield and 
>98:2 d.r. Anomalously, the similarly Lewis acidic 2,4,6-BCF provided only 7% NMR 
yield of the desired A.3, despite 38% consumption of the starting material.xxxii Finally, the 
more sterically hindered, but highly Lewis acidic PNB catalyst provided desired A.3 in 
91% NMR yield and >98:2 d.r. These results are generally in line with the reactivity and 
diastereoselectivity expected of large, neutral Lewis acid catalysts in this Prins cyclization 
reaction; modification of the perfluoroaryl borane catalyst could potentially be used to 
increase marginal diastereoselectivity in the examples where BCF itself was suboptimal 
(e.g. alaninol-, serinol-, and lysinol-derivatives A.2, A.5, and A.6, respectively, Table A.1 
above). 
                                                
xxxiiA recent computational study quantified the hydride donor abilities of these Lewis acids and validated 
the inverse relationship (proxy) between computed hydride donor ability and experimental Lewis acidity; 
Hydride donor ability for HBR3- DG (kcal/mol): BCF (65), 3,5-CF3-BCF (53), 2,4,6-BCF (52), PNB (69). 
See Heiden, Z. M.; Lathem, A. P. Organometallics 2015, 34, 1818. 
N
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Me
B(C6F5)3 (10 mol %)
CH2Cl2, –78 °C to 22 °C, 17 h
N
A.10
Me
O
Ph
OH
Ph
*
MeMe
BsBs
 262 
 
Scheme A.3. Perfluoroaryl borane catalyst screen. 
A.4  Mechanism 
As discussed in section 3.6 above (Scheme 3.7), the mechanism of the BCF-
catalyzed cyclization is proposed to proceed via TS à II (Scheme A.4 below). The 
neutral, Lewis acidic perfluoroaryl borane catalyst activates the aldehyde to nucleophilic 
attack by the appended alkene exclusively via chair-like transition state TS; the larger 
steric environment (and lower reactivity) of BCF only allows for activation of the aldehyde 
in an enclusively trans-diaxial conformation (TS) to minimize interactions between BCF 
and the amino R-group.xxxiii The cyclization is then followed by rapid (at RT) intra- or 
intermolecular elimination of the resulting carbocation (II) by an alkoxide functionality to 
form the trans-tetrahydropyridine product and concomitantly regenerate the free 
perfluoroaryl borane catalyst. 
 
Scheme A.4. Proposed mechanism of the BCF-catalyzed Prins cyclization / elimination. 
                                                
xxxiiiDFT calculations (wB97X-D//6-311+G**//CPCM:CH2Cl2) on 2-methyl-1-(phenylsulfonyl)piperidine 
show the lowest energy axial conformer to be 3.3 kcal/mol more stable than the lowest energy equatorial 
conformer. We speculate that this is paralleled in TS. 
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A.5  Experimental Section 
A.5.1  Synthesis of N-arylsulfonyl-protected amino alcohols 
Preparation of aryl sulfonamide A.13: 
 
To a flame-dried 50 mL round-bottom flask equipped with a magnetic stir bar was 
added ethanolamine (A.12, 10.0 mmol, 604 µL, 1.00 eq.). The flask was capped with a 
septum, an N2 needle was inserted, and the headspace of the flask was purged with 
anhydrous N2. CH2Cl2 (20 mL) and Et3N (11.0 mmol, 1.53 mL, 1.10 eq.) were added. The 
flask was placed in an ice-water bath and cooled to 0 °C. The septum was quickly removed 
and 4-bromobenzenesulfonyl chloride (brosyl chloride, Bs–Cl; 10.0 mmol, 2.56 g, 1.00 
eq.) was added quickly and the flask resealed. The homogeneous solution was warmed to 
22 °C and stirred for 16 h. After 16 h, the solution was decanted into a separatory funnel 
and diluted with excess CH2Cl2 and washed with deionized water. The organic phase was 
separated and the aqueous phase was extracted with CH2Cl2 (x4). The combined organics 
were dried over Na2SO4, filtered, and concentrated in vacuo. The crude residue was 
purified by silica gel chromatography (9:1 dichloromethane:methanol; Rf = 0.6) to yield 
the desired N-Bs amino alcohol A.13 in 85% yield (2.38 g). 
4-bromo-N-(2-hydroxyethyl)benzenesulfonamide (A.13). 1H NMR (CDCl3, 600 MHz): 
δ 7.74 (d, 2H, J = 8.6 Hz), 7.67 (d, 2H, J = 8.6 Hz), 5.02 (s, 1H), 3.72 (q, 2H, J = 5.0 Hz), 
NH2
OH
CH2Cl2, 0 °C to 22 °C, 16 h
+
Br
SO2Cl
1.00 eq.
NH
OH
S
O
O
Br
A.13
1.00 eq.
Et3N (1.10 eq.)
ethanolamine
A.12
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3.12 (q, 2H, J = 5.8 Hz), 1.88 (s, 1H); 13C{1H} NMR (CDCl3, 151 MHz): δ 138.8, 132.6, 
128.8, 128.0, 61.4, 45.2. 
 
 
Figure A.1. 1H and 13C{1H} NMR spectra of A.13. 
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Preparation of aryl sulfonamide A.15: 
 
To a flame-dried 50 mL round-bottom flask equipped with a magnetic stir bar was 
added (S)-tert-leucinol (A.14, 8.53 mmol, 1.00 g, 1.00 eq.) and tetrabutylammonium iodide 
(0.171 mmol, 63 mg, 0.02 eq.). The flask was capped with a septum, an N2 needle was 
inserted, and the headspace of the flask was purged with anhydrous N2. CH2Cl2 (17 mL) 
and Et3N (10.7 mmol, 1.49 mL, 1.25 eq.) were added. The flask was placed in an ice-water 
bath and cooled to 0 °C. The septum was quickly removed and 4-bromobenzenesulfonyl 
chloride (brosyl chloride, Bs–Cl; 8.96 mmol, 2.29 g, 1.05 eq.) was added quickly and the 
flask resealed. The homogeneous solution was warmed to 22 °C and stirred for 68 h. After 
68 h, the solution was decanted into a separatory funnel and diluted with excess CH2Cl2 
and washed with deionized water. The organic phase was separated and the aqueous phase 
was extracted with CH2Cl2 (x4). The combined organics were dried over Na2SO4, filtered, 
and concentrated in vacuo. The crude residue was purified by silica gel chromatography 
(1:1 hexanes:ethyl acetate; Rf = 0.5) to yield the desired N-Bs amino alcohol A.15 in 94% 
yield (2.70 g). 
(S)-4-bromo-N-(1-hydroxy-3,3-dimethylbutan-2-yl)benzenesulfonamide (A.15).  
1H NMR (CDCl3, 600 MHz): δ 7.77 (d, 2H, J = 8.6 Hz), 7.65 (d, 2H, J = 8.6 Hz), 4.95 (d, 
1H, J = 9.3 Hz), 3.68-3.57 (m, 2H), 3.03 (ddd, 1H, J = 9.6, 6.1, 3.8 Hz), 2.00 (dd, 1H, J = 
NH2
OH
CH2Cl2, 0 °C to 22 °C, 68 h
+
Br
SO2Cl
1.00 eq.
NH
OH
S
O
O
Br
A.151.05 eq.
TBAI (2 mol %),
Et3N (1.25 eq.)
(S)-tert-leucinol
A.14
Me
Me
Me Me
Me
Me
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6.9, 4.2 Hz); 13C{1H} NMR (CDCl3, 151 MHz): δ 139.9, 132.4, 128.9, 127.8, 64.2, 62.2, 
34.3, 27.1. 
 
 
Figure A.2. 1H and 13C{1H} NMR spectra of A.15. 
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Preparation of aryl sulfonamide A.17: 
 
To a flame-dried 25 mL round-bottom flask equipped with a magnetic stir bar was 
added O-benzyl-L-serinol hydrochloride (A.16, CAS Reg. No. 58577-87-0; 2.30 mmol, 
500 mg, 1.00 eq.) and tetrabutylammonium iodide (0.0460 mmol, 17.0 mg, 0.02 eq.). The 
flask was capped with a septum, an N2 needle was inserted, and the headspace of the flask 
was purged with anhydrous N2. CH2Cl2 (10.0 mL) and Et3N (5.75 mmol, 800 µL, 2.50 eq.) 
were added. The flask was placed in an ice-water bath and cooled to 0 °C. The septum was 
quickly removed and 4-bromobenzenesulfonyl chloride (brosyl chloride, Bs–Cl; 2.41 
mmol, 616 mg, 1.05 eq.) was added quickly and the flask resealed. The homogeneous 
solution was warmed to 22 °C and stirred for 93 h. After 93 h, the solution was decanted 
into a separatory funnel and diluted with excess CH2Cl2 and washed with deionized water. 
The organic phase was separated and the aqueous phase was extracted with CH2Cl2 (x4). 
The combined organics were dried over Na2SO4, filtered, and concentrated in vacuo. The 
crude residue was purified by silica gel chromatography (10:1 dichloromethane:methanol; 
Rf = 0.4 in 1:1 hexanes:ethyl acetate) to yield the desired N-Bs amino alcohol A.17 as an 
off-white, crystalline solid in 78% yield (721 mg). 
(R)-N-(1-(benzyloxy)-3-hydroxypropan-2-yl)-4-bromobenzenesulfonamide (A.17).  
1H NMR (CDCl3, 600 MHz): δ 7.69 (d, 2H, J = 8.5 Hz), 7.59 (d, 2H, J = 8.6 Hz), 7.38-
7.31 (m, 3H), 7.23-7.20 (m, 2H), 5.22 (d, 1H, J = 7.3 Hz), 4.40 (q, 2H, J = 13.7 Hz), 3.72 
NH3Cl
OH
CH2Cl2, 0 °C to 22 °C, 93 h
+
Br
SO2Cl
1.00 eq.
NH
OH
S
O
O
Br
A.17
1.05 eq.
TBAI (2 mol %),
Et3N (2.50 eq.)
O-Bn-L-serinol.HCl
A.16
O
OPh
Ph
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(dt, 1H, J = 11.4, 3.9 Hz), 3.58-3.52 (m, 2H), 3.45-3.39 (m, 2H), 2.12 (dd, 1H, J = 8.2, 4.2 
Hz); 13C{1H} NMR (CDCl3, 151 MHz): δ 139.6, 137.2, 132.5, 128.8, 128.7, 128.3, 127.9, 
127.8, 73.7, 70.3, 63.3, 54.4. 
 
 
Figure A.3. 1H and 13C{1H} NMR spectra of A.17. 
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Preparation of aryl sulfonamide A.19: 
 
To a flame-dried 25 mL round-bottom flask equipped with a magnetic stir bar was 
added L-lysinol(Z) (A.18, CAS Reg. No. 101250-90-2; 1.88 mmol, 500 mg, 1.00 eq.) and 
tetrabutylammonium iodide (0.0375 mmol, 14.0 mg, 0.02 eq.). The flask was capped with 
a septum, an N2 needle was inserted, and the headspace of the flask was purged with 
anhydrous N2. CH2Cl2 (9.4 mL) and Et3N (2.06 mmol, 290 µL, 1.10 eq.) were added. The 
flask was placed in an ice-water bath and cooled to 0 °C. The septum was quickly removed 
and 4-bromobenzenesulfonyl chloride (brosyl chloride, Bs–Cl; 1.97 mmol, 503 mg, 1.05 
eq.) was added quickly and the flask resealed. The homogeneous solution was warmed to 
22 °C and stirred for 18 h. After 18 h, the solution was decanted into a separatory funnel 
and diluted with excess CH2Cl2 and washed with deionized water. The organic phase was 
separated and the aqueous phase was extracted with CH2Cl2 (x4). The combined organics 
were dried over Na2SO4, filtered, and concentrated in vacuo. The crude residue was 
purified by silica gel chromatography (1:2 hexanes:ethyl acetate; Rf = 0.3) to yield the 
desired N-Bs amino alcohol A.19 as a white, crystalline powder in 72% yield (660 mg). 
benzyl (S)-(5-((4-bromophenyl)sulfonamido)-6-hydroxyhexyl)carbamate (A.19).  
1H NMR (CDCl3, 600 MHz): δ 7.73 (d, 2H, J = 8.5 Hz), 7.63 (d, 2H, J = 8.5 Hz), 7.37 (d, 
4H, J = 4.3 Hz), 7.35-7.31 (m, 1H), 5.16 (d, 1H, J = 7.9 Hz), 5.12 (d, 2H, J = 2.2 Hz), 4.78 
(t, 1H, J = 6.2 Hz), 3.51-3.41 (m, 2H), 3.24-3.18 (m, 1H), 3.18-3.11 (m, 2H), 2.22 (t, 1H, J 
NH2
OH
CH2Cl2, 0 °C to 22 °C, 18 h
+
Br
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1.00 eq.
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S
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O
Br
A.191.05 eq.
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H
N
H
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3
3
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= 5.9 Hz), 1.57-1.51 (m, 1H), 1.51-1.44 (m, 1H), 1.43-1.36 (m, 2H), 1.23-1.18 (m, 1H), 
1.17-1.09 (m, 1H); 13C{1H} NMR (CDCl3, 151 MHz): δ 157.2, 140.0, 136.5, 132.5, 128.7, 
128.7, 128.4, 128.3, 127.7, 67.1, 64.4, 55.6, 39.7, 30.6, 29.8, 21.7. 
 
 
Figure A.4. 1H and 13C{1H} NMR spectra of A.19. 
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Preparation of aryl sulfonamide A.20: 
 
To a flame-dried 100 mL round-bottom flask equipped with a magnetic stir bar was 
added (S)-phenylalaninol (3.1, 6.61 mmol, 1.00 g, 1.00 eq.) and tetrabutylammonium 
iodide (0.132 mmol, 49 mg, 0.02 eq.). The flask was capped with a septum, an N2 needle 
was inserted, and the headspace of the flask was purged with anhydrous N2. CH2Cl2 (29 
mL) and Et3N (8.26 mmol, 1.15 mL, 1.25 eq.) were added. The flask was placed in an ice-
water bath and cooled to 0 °C. The septum was quickly removed and 4-bromobenzene-
sulfonyl chloride (tosyl chloride, Ts–Cl; 6.94 mmol, 1.32 g, 1.05 eq.) was added quickly 
and the flask resealed. The homogeneous solution was warmed to 22 °C and stirred for 60 
h. After 60 h, the solution was decanted into a separatory funnel and diluted with excess 
CH2Cl2 and washed with deionized water. The organic phase was separated and the 
aqueous phase was extracted with CH2Cl2 (x4). The combined organics were dried over 
Na2SO4, filtered, and concentrated in vacuo. The crude residue was purified by silica gel 
chromatography (1:1 hexanes:ethyl acetate; Rf = 0.3) to yield the desired N-Ts amino 
alcohol A.20 as a yellow oil in 91% yield (1.84 g). 
(S)-N-(1-hydroxy-3-phenylpropan-2-yl)-4-methylbenzenesulfonamide (A.20).  
1H NMR (CDCl3, 600 MHz): δ 7.58 (d, 2H, J = 8.3 Hz), 7.20 (d, 2H, J = 8.1 Hz), 7.19-
7.17 (m, 3H), 6.98-6.95 (m, 2H), 4.88 (d, 1H, J = 7.1 Hz), 3.64 (ddd, 1H, J = 10.6, 6.4, 3.9 
Hz), 3.53 (dt, 1H, J = 10.8, 5.0 Hz), 3.44 (qdd, 1H, J = 7.2, 4.8, 3.9 Hz), 2.78 (dd, 1H, J = 
NH2
OH
CH2Cl2, 0 °C to 22 °C, 60 h
+
Me
SO2Cl
1.00 eq.
NH
OH
S
O
O
Me
A.20
1.05 eq.
TBAI (2 mol %),
Et3N (1.25 eq.)
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3.1
Ph
Ph
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13.8, 7.0 Hz), 2.68 (dd, 1H, J = 13.8, 7.3 Hz), 2.41 (s, 3H), 2.21 (t, 1H, J = 5.9 Hz); 
13C{1H} NMR (CDCl3, 151 MHz): δ 143.6, 136.8, 136.8, 129.8, 129.3, 128.8, 127.1, 
126.9, 64.2, 56.7, 37.9, 21.7.  
 
 
Figure A.5. 1H and 13C{1H} NMR spectra of A.20. 
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A.5.2  N-alkylation of N-arylsulfonyl-protected amino alcohols 
Preparation of N-alkylated amino alcohol A.21: 
 
To a flame-dried 20 mL scintillation vial equipped with a magnetic stir bar was 
added aryl sulfonamide A.13 (2.00 mmol, 560 mg, 1.00 eq.), tetrabutylammonium iodide 
(0.040 mmol, 15 mg, 0.02 eq.), and powdered, anhydrous potassium carbonate (8.00 
mmol, 1.11 g, 4.00 eq.). The vial was capped with a septum, an N2 needle was inserted, 
and the headspace of the vial was purged with anhydrous N2. Anhydrous acetone (15 mL) 
was added to dissolve the substrate, followed by 2-phenylallyl bromide (2.10 mmol, 302 
µL, 1.05 eq.). The vial was sealed, placed in an oil bath, and heated to reflux 
(approximately 60-65 °C oil bath temperature). The heterogeneous mixture was vigorously 
stirred for 18 h and then cooled to room temperature. The mixture was filtered through a 
cotton plug to remove potassium salts and then concentrated in vacuo. The crude residue 
was purified by silica gel chromatography (1:1 hexanes:ethyl acetate; Rf = 0.45) to yield 
the alkylated amino alcohol product A.21 as a viscous yellow oil in 99% yield (793 mg). 
4-bromo-N-(2-hydroxyethyl)-N-(2-phenylallyl)benzenesulfonamide (A.21). 1H NMR 
(CDCl3, 600 MHz): δ 7.64-7.59 (m, 4H), 7.43-7.40 (m, 2H), 7.37-7.31 (m, 3H), 5.49 (s, 
1H), 5.23 (s, 1H), 4.28 (s, 2H), 3.60 (q, 2H, J = 5.6 Hz), 3.19 (t, 2H, J = 5.4 Hz), 1.94 (t, 
1H, J = 6.0 Hz); 13C{1H} NMR (CDCl3, 151 MHz): δ 142.9, 137.8, 137.6, 132.5, 129.1, 
128.8, 128.5, 128.0, 126.6, 117.3, 60.9, 53.5, 50.0. 
acetone, 22 °C to reflux, 18 h
+
A.13 (1.00 eq.) 1.05 eq.
TBAI (2 mol %),
K2CO3 (4.00 eq.)
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Figure A.6. 1H and 13C{1H} NMR spectra of A.21. 
 
Preparation of N-alkylated amino alcohol A.22: 
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To a flame-dried 50 mL round-bottom flask equipped with a magnetic stir bar was 
added aryl sulfonamide A.15 (3.00 mmol, 1.01 g, 1.00 eq.), tetrabutylammonium iodide 
(0.300 mmol, 111 mg, 0.10 eq.), and powdered, anhydrous potassium carbonate (12.0 
mmol, 1.66 g, 4.00 eq.). The flask was capped with a septum, an N2 needle was inserted, 
and the headspace of the flask was purged with anhydrous N2. Anhydrous acetone (23 mL) 
was added to dissolve the substrate, followed by 2-phenylallyl bromide (3.15 mmol, 453 
µL, 1.05 eq.). The flask was sealed, placed in an oil bath, and heated to reflux 
(approximately 60-65 °C oil bath temperature). The heterogeneous mixture was vigorously 
stirred for 45 h, at which time cesium carbonate (3.00 mmol, 977 mg, 1.00 eq.) was added 
and the mixture refluxed for another 25 h. The mixture was cooled to room temperature 
and filtered through a cotton plug to remove potassium and cesium salts and was then 
concentrated in vacuo. The crude residue was purified by silica gel chromatography (4:1 
hexanes:ethyl acetate; Rf = 0.35) to yield the alkylated amino alcohol product A.22 as a 
glassy solid in 61% yield (829 mg). 
(S)-4-bromo-N-(1-hydroxy-3,3-dimethylbutan-2-yl)-N-(2-phenylallyl)benzene 
sulfonamide (A.22). 1H NMR (CDCl3, 600 MHz): δ 7.71 (d, 2H, J = 8.6 Hz), 7.58 (d, 2H, 
J = 8.6 Hz), 7.30-7.24 (m, 3H), 7.12-7.06 (m, 2H), 5.48 (s, 1H), 5.34 (s, 1H), 4.34-4.24 (m, 
2H), 3.88 (s, br, 1H), 3.75-3.70 (m, 1H), 3.58 (s, br, 1H), 1.27 (s, br, 1H), 0.98 (s, 9H); 
13C{1H} NMR (CDCl3, 151 MHz): δ 143.7, 140.4, 139.8, 131.9, 129.9, 128.6, 128.2, 
127.4, 126.4, 117.7, 69.1, 59.7, 49.2, 34.8, 28.4. 
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Figure A.7. 1H and 13C{1H} NMR spectra of A.22. 
 
Preparation of N-alkylated amino alcohol A.23: 
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To a flame-dried 20 mL scintillation vial equipped with a magnetic stir bar was 
added aryl sulfonamide A.17 (1.25 mmol, 500 mg, 1.00 eq.), tetrabutylammonium iodide 
(0.025 mmol, 9.2 mg, 0.02 eq.), and powdered, anhydrous potassium carbonate (5.00 
mmol, 691 mg, 4.00 eq.). The vial was capped with a septum, an N2 needle was inserted, 
and the headspace of the vial was purged with anhydrous N2. Anhydrous acetone (9.4 mL) 
was added to dissolve the substrate, followed by 2-phenylallyl bromide (1.31 mmol, 189 
µL, 1.05 eq.). The vial was sealed, placed in an oil bath, and heated to reflux 
(approximately 60-65 °C oil bath temperature). The heterogeneous mixture was vigorously 
stirred for 7 h and then cooled to room temperature. The mixture was filtered through a 
cotton plug to remove potassium salts and then concentrated in vacuo. The crude residue 
was purified by silica gel chromatography (2:1 hexanes:ethyl acetate; Rf = 0.3) to yield the 
N-alkylated amino alcohol product A.23 as a clear, colorless oil in 92% yield (597 mg). 
(R)-N-(1-(benzyloxy)-3-hydroxypropan-2-yl)-4-bromo-N-(2-phenylallyl)benzene 
sulfonamide (A.23). 1H NMR (CDCl3, 600 MHz): δ 7.64 (d, 2H, J = 8.5 Hz), 7.51 (d, 2H, 
J = 8.5 Hz), 7.39-7.30 (m, 8H), 7.11 (dd, 2H, J = 7.4, 2.0 Hz), 5.41 (s, 1H), 5.28 (s, 1H), 
4.48 (d, 1H, J = 16.3 Hz), 4.30-4.20 (m, 3H), 4.04 (p, 1H, J = 6.5 Hz), 3.65-3.56 (m, 2H), 
3.50-3.44 (m, 2H), 1.75 (t, 1H, J = 6.4 Hz); 13C{1H} NMR (CDCl3, 151 MHz): δ 145.0, 
139.4, 138.5, 137.4, 132.1, 129.2, 128.7, 128.6, 128.4, 128.1, 128.0, 127.6, 126.7, 116.3, 
73.3, 68.1, 62.2, 60.0, 49.7; 13C NMR DEPT135 (CDCl3, 151 MHz): δ 132.1 (CH), 129.2 
(CH), 128.7 (CH), 128.6 (CH), 128.4 (CH), 128.1 (CH), 128.0 (CH), 126.7 (CH), 116.3 
(CH2), 73.3 (CH2), 68.1 (CH2), 62.2 (CH2), 60.0 (CH), 49.7 (CH2). 
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Figure A.8. 1H, 13C{1H}, and 13C DEPT-135 NMR spectra of A.23. 
 
Preparation of N-alkylated amino alcohol A.24: 
 
To a flame-dried 20 mL scintillation vial equipped with a magnetic stir bar was 
added aryl sulfonamide A.19 (0.906 mmol, 440 mg, 1.00 eq.), tetrabutylammonium iodide 
(0.018 mmol, 6.7 mg, 0.02 eq.), and powdered, anhydrous potassium carbonate (3.62 
mmol, 501 mg, 4.00 eq.). The vial was capped with a septum, an N2 needle was inserted, 
and the headspace of the vial was purged with anhydrous N2. Anhydrous acetone (6.8 mL) 
was added to dissolve the substrate, followed by 2-phenylallyl bromide (0.951 mmol, 137 
µL, 1.05 eq.). The vial was sealed, placed in an oil bath, and heated to reflux 
(approximately 60-65 °C oil bath temperature). The heterogeneous mixture was vigorously 
stirred for 6 h and then cooled to room temperature. The mixture was filtered through a 
acetone, 22 °C to reflux, 6 h
+
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TBAI (2 mol %),
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cotton plug to remove potassium salts and then concentrated in vacuo. The crude residue 
was purified by silica gel chromatography (1:1 hexanes:ethyl acetate; Rf = 0.3) to yield the 
N-alkylated amino alcohol product A.24 as a clear, amorphous solid in 98% yield  
(532 mg). 
benzyl (S)-(5-((4-bromo-N-(2-phenylallyl)phenyl)sulfonamido)-6-hydroxyhexyl) 
carbamate (A.24). 1H NMR (CDCl3, 600 MHz): δ 7.63 (d, 2H, J = 8.2 Hz), 7.60 (d, 2H, J 
= 8.3 Hz), 7.39-7.34 (m, 6H), 7.33 (d, 4H, J = 8.0 Hz), 5.42 (s, 1H), 5.37 (s, 1H), 5.10 (s, 
2H), 4.67-4.63 (m, 1H), 4.41 (d, 1H, J = 16.0 Hz), 4.27 (d, 1H, J = 16.0 Hz), 3.75-3.69 (m, 
1H), 3.58-3.43 (m, 2H), 3.08-2.96 (m, 2H), 1.63-1.56 (m, 1H), 1.47-1.37 (m, 1H), 1.34-
1.21 (m, 3H), 1.08-0.89 (m, 2H); 13C{1H} NMR (CDCl3, 151 MHz): δ 156.5, 145.0, 139.6, 
138.5, 136.7, 132.4, 129.2, 128.7, 128.7, 128.4, 128.3, 128.3, 127.7, 126.8, 116.9, 66.8, 
63.2, 60.9, 48.9, 40.7, 29.8, 28.9, 23.9; 13C NMR DEPT135 (CDCl3, 151 MHz): δ 132.4 
(CH), 129.2 (CH), 128.7 (CH), 128.7 (CH), 128.4 (CH), 128.3 (CH), 128.3 (CH), 126.8 
(CH), 116.9 (CH2), 66.8 (CH2), 63.2 (CH2), 60.9 (CH), 48.9 (CH2), 40.7 (CH2), 29.8 
(CH2), 28.9 (CH2), 23.9 (CH2). 
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Figure A.9. 1H, 13C{1H}, and 13C DEPT-135 NMR spectra of A.24. 
 
Preparation of N-alkylated amino alcohol A.25: 
 
acetone, 22 °C to reflux, 16 h
+
A.20 (1.00 eq.) 1.05 eq.
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To a flame-dried 20 mL scintillation vial equipped with a magnetic stir bar was 
added aryl sulfonamide A.20 (2.51 mmol, 765 mg, 1.00 eq.), tetrabutylammonium iodide 
(0.0501 mmol, 18.5 mg, 0.02 eq.), and powdered, anhydrous potassium carbonate (10.0 
mmol, 1.39 g, 4.00 eq.). The vial was capped with a septum, an N2 needle was inserted, 
and the headspace of the vial was purged with anhydrous N2. Anhydrous acetone (10.0 
mL) was added to dissolve the substrate, followed by 2-phenylallyl bromide (2.63 mmol, 
378 µL, 1.05 eq.). The vial was sealed, placed in an oil bath, and heated to reflux 
(approximately 60-65 °C oil bath temperature). The heterogeneous mixture was vigorously 
stirred for 16 h and then cooled to room temperature. The mixture was filtered through a 
cotton plug to remove potassium salts and then concentrated in vacuo. The crude residue 
was purified by silica gel chromatography (3:1 hexanes:ethyl acetate; Rf = 0.3) to yield the 
alkylated amino alcohol product A.25 as a viscous, light yellow oil in 90% yield (953 mg). 
(S)-N-(1-hydroxy-3-phenylpropan-2-yl)-4-methyl-N-(2-phenylallyl)benzene 
sulfonamide (A.25). 1H NMR (CDCl3, 600 MHz): δ 7.72 (d, 2H, J = 8.2 Hz), 7.46-7.43 
(m, 2H), 7.39-7.33 (m, 3H), 7.30 (d, 2H, J = 8.2 Hz), 7.23-7.19 (m, 2H), 7.19-7.15 (m, 
1H), 6.93 (d, 2H, J = 6.7 Hz), 5.50 (s, 1H), 5.45 (s, 1H), 4.60 (d, 1H, J = 16.2 Hz), 4.31 (d, 
1H, J = 16.1 Hz), 3.91 (ddt, 1H, J = 10.7, 8.3, 4.0 Hz), 3.56 (ddd, 1H, J = 12.1, 8.6, 5.3 
Hz), 3.44 (ddd, 1H, J = 11.9, 7.8, 3.8 Hz), 2.72 (dd, 1H, J = 13.3, 10.6 Hz), 2.52 (dd, 1H, J 
= 13.3, 4.2 Hz), 2.44 (s, 3H), 1.60-1.54 (m, 1H); 13C{1H} NMR (CDCl3, 151 MHz): δ 
145.3, 143.9, 138.4, 137.9, 137.3, 129.9, 129.1, 128.8, 128.7, 128.5, 127.7, 126.8, 126.8, 
116.3, 62.3, 62.0, 49.3, 35.8, 21.7. 
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Figure A.10. 1H and 13C{1H} NMR spectra of A.25. 
 
Preparation of N-alkylated amino alcohol A.26: 
 
To a flame-dried 50 mL round-bottom flask equipped with a magnetic stir bar was 
added aryl sulfonamide 3.27 (2.33 mmol, 750 mg, 1.00 eq.), tetrabutylammonium iodide 
acetone, 22 °C to reflux, 16 h
+
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(0.047 mmol, 17 mg, 0.02 eq.), and powdered, anhydrous potassium carbonate (9.31 mmol, 
1.29 g, 4.00 eq.). The flask was capped with a septum, an N2 needle was inserted, and the 
headspace of the flask was purged with anhydrous N2. Anhydrous acetone (17.5 mL) was 
added to dissolve the substrate, followed by cinnamyl bromide (2.44 mmol, 362 µL, 1.05 
eq.). The flask was sealed, placed in an oil bath, and heated to reflux (approximately 55-60 
°C oil bath temperature). The heterogeneous mixture was vigorously stirred for 16 h and then 
cooled to room temperature. The mixture was filtered through a cotton plug to remove 
potassium salts and then concentrated in vacuo. The crude residue was purified by silica gel 
chromatography (3:1 hexanes:ethyl acetate; Rf = 0.3) to yield the alkylated amino alcohol 
product A.26 as a colorless, viscous oil in 91% yield (925 mg). 
(S)-4-bromo-N-cinnamyl-N-(1-hydroxy-3-methylbutan-2-yl)benzenesulfonamide (A.26). 
1H NMR (CDCl3, 600 MHz): δ 7.72 (d, 2H, J = 8.6 Hz), 7.57 (d, 2H, J = 8.6 Hz), 7.34-7.30 
(m, 2H), 7.29-7.24 (m, 3H), 6.52 (d, 1H, J = 15.9 Hz), 6.13 (dt, 1H, J = 15.9, 6.8 Hz), 4.10 
(ddd, 1H, J = 16.1, 6.9, 1.4 Hz), 3.94 (ddd, 1H, J = 16.0, 6.9, 1.4 Hz), 3.80 (ddd, 1H, J = 
11.6, 5.6, 3.5 Hz), 3.65 (ddd, 1H, J = 11.6, 8.8, 5.4 Hz), 3.59 (ddd, 1H, J = 10.1, 8.6, 3.6 Hz), 
1.93-1.82 (m, 1H), 1.76 (t, 1H, J = 5.7 Hz), 0.94 (d, 3H, J = 6.6 Hz), 0.79 (d, 3H, J = 6.7 Hz); 
13C{1H} NMR (CDCl3, 151 MHz): δ 140.5, 136.2, 133.4, 132.2, 129.2, 128.8, 128.1, 127.4, 
126.6, 126.1, 66.8, 62.2, 46.8, 28.2, 20.9, 20.3. 
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Figure A.11. 1H and 13C{1H} NMR spectra of A.26. 
 
A.5.3  Synthesis of amino aldehydes 
Preparation of amino aldehyde A.27: 
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Following general procedure 3.1 (section 3.7.2.4 above), N-alkylated amino alcohol 
A.26 (1.01 mmol, 400 mg, 1.00 eq.) was oxidized with DMP (2.50 eq.) over 1.25 h. The 
crude residue was purified by silica gel chromatography (3:1 hexanes:ethyl acetate; Rf = 0.4) 
to yield the amino aldehyde product A.27 as a white, crystalline solid in 68% yield (270 mg). 
4-bromo-N-(2-oxoethyl)-N-(2-phenylallyl)benzenesulfonamide (A.27). 1H NMR (CDCl3, 
600 MHz): δ 9.16 (s, 1H), 7.67 (d, 2H, J = 8.6 Hz), 7.64 (d, 2H, J = 8.6 Hz), 7.43 (dd, 2H, J 
= 8.0, 1.7 Hz), 7.38-7.32 (m, 3H), 5.54 (s, 1H), 5.20 (s, 1H), 4.30 (s, 2H), 3.71 (s, 2H); 
13C{1H} NMR (CDCl3, 151 MHz): δ 197.8, 141.8, 137.0, 137.0, 132.7, 129.1, 128.9, 128.8, 
128.4, 126.6, 118.5, 55.4, 53.2. 
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Figure A.12. 1H and 13C{1H} NMR spectra of A.27. 
 
Preparation of amino aldehyde A.28: 
 
Following general procedure 3.1 (section 3.7.2.4 above), N-alkylated amino alcohol 
A.22 (1.00 mmol, 452 mg, 1.00 eq.) was oxidized with DMP (2.00 eq.) over 1.25 h. The 
crude residue was purified by silica gel chromatography (5:1 hexanes:ethyl acetate; Rf = 0.4) 
to yield the amino aldehyde product A.28 as a colorless, viscous oil in 92% yield (415 mg). 
(S)-4-bromo-N-(3,3-dimethyl-1-oxobutan-2-yl)-N-(2-phenylallyl)benzenesulfonamide 
(A.28). 1H NMR (CDCl3, 600 MHz): δ 9.50 (s, 1H), 7.66 (d, 2H, J = 8.6 Hz), 7.62 (d, 2H, J 
= 8.6 Hz), 7.31-7.28 (m, 3H), 7.22-7.18 (m, 2H), 5.59 (s, 1H), 5.55 (s, 1H), 4.52 (dt, 1H, J = 
17.9, 1.9 Hz), 4.14 (s, 1H), 4.01 (d, 1H, J = 17.9 Hz), 1.21 (s, 9H); 13C{1H} NMR (CDCl3, 
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151 MHz): δ 198.6, 143.5, 139.4, 138.1, 132.4, 129.5, 128.6, 128.5, 128.2, 126.3, 116.9, 
75.1, 52.6, 36.4, 28.4; [α]D25 = –18.4° (c = 0.675, CH2Cl2, l = 100 mm). 
 
 
Figure A.13. 1H and 13C{1H} NMR spectra of A.28. 
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Preparation of amino aldehyde A.29: 
 
To a flame-dried, N2-filled, 25 mL round-bottom flask equipped with a magnetic stir 
bar and rubber septum were added anhydrous CH2Cl2 (1.0 mL) and oxalyl chloride (2.91 
mmol, 249 µL, 5.00 eq.). The solution was cooled to –78 °C in an acetone/CO2(s) bath. A 
solution of dimethylsulfoxide (DMSO; 5.81 mmol, 416 µL, 10.0 eq.) in CH2Cl2 (1.0 mL) 
was added dropwise and the resulting solution stirred for 15 minutes at –78 ° C. Then a 
solution of the N-alkylated amino alcohol A.23 (0.581 mmol, 300 mg, 1.00 eq.) in CH2Cl2 
(1.0 mL) was slowly added dropwise and the resulting solution stirred for an additional 30 
minutes at –78 °C. Finally, Hünig’s base (i-Pr2EtN; 8.72 mmol, 1.52 mL, 15.0 eq.) was 
slowly added dropwise. The resulting solution was stirred at –78 °C for 1 h and then warmed 
to 0 °C in an ice bath and stirred for an addition 1 h. The solution was poured into ice-cold 1 
M HCl(aq.) and extracted with CH2Cl2 (x4). The combined organic layers were washed with 
pH 7.0 phosphate buffer (x4), dried over Na2SO4, filtered, and concentrated in vacuo. The 
crude residue was purified by silica gel chromatography (3:1 hexanes:ethyl acetate; Rf = 0.4) 
to yield the amino aldehyde product A.29 as a viscous, yellow oil in 93% yield (278 mg). 
(S)-N-(1-(benzyloxy)-3-oxopropan-2-yl)-4-bromo-N-(2-phenylallyl)benzenesulfonamide 
(A.29). 1H NMR (CDCl3, 600 MHz): δ 9.09 (s, 1H), 7.68 (d, 2H, J = 8.0 Hz), 7.56 (d, 2H, J 
= 8.3 Hz), 7.39-7.35 (m, 2H), 7.35-7.30 (m, 6H), 7.10-7.06 (m, 2H), 5.48 (s, 1H), 5.20 (s, 
1H), 4.46-4.36 (m, 2H), 4.32-4.25 (m, 2H), 4.11 (d, 1H, J = 11.4 Hz), 3.90 (dd, 1H, J = 10.5, 
4.9 Hz), 3.72 (dd, 1H, J = 10.4, 8.9 Hz); 13C{1H} NMR (CDCl3, 151 MHz): δ 197.8, 143.0, 
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138.8, 137.4, 137.2, 132.3, 129.3, 128.8, 128.6, 128.5, 128.1, 128.0, 127.8, 126.8, 118.5, 
73.4, 66.5, 65.2, 51.9; [α]D25 = –2.48° (c = 0.730, CH2Cl2, l = 100 mm). 
 
 
Figure A.14. 1H and 13C{1H} NMR spectra of A.29. 
 
Preparation of amino aldehyde A.30: 
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Following general procedure 3.1 (section 3.7.2.4 above), N-alkylated amino alcohol 
A.24 (0.866 mmol, 521 mg, 1.00 eq.) was oxidized with DMP (2.00 eq.) over 1.0 h. The 
crude residue was purified by silica gel chromatography (2:1 hexanes:ethyl acetate; Rf = 0.3) 
to yield the amino aldehyde product A.30 as a light yellow, amorphous solid in 62% yield  
(320 mg). 
benzyl (S)-(5-((4-bromo-N-(2-phenylallyl)phenyl)sulfonamido)-6-oxohexyl)carbamate 
(A.30). 1H NMR (CDCl3, 600 MHz): δ 9.11 (s, 1H), 7.63-7.58 (m, 4H), 7.39-7.35 (m, 4H), 
7.31 (s, 6H), 5.47 (s, 1H), 5.30 (s, 1H), 5.10 (d, 2H, J = 2.3 Hz), 4.74-4.68 (m, 1H), 4.38 (d, 
1H, J = 15.0 Hz), 4.30 (d, 1H, J = 15.0 Hz), 3.88 (dd, 1H, J = 8.0, 6.0 Hz), 3.07 (q, 2H, J = 
6.7 Hz), 1.94 (ddt, 1H, J = 14.2, 11.3, 5.7 Hz), 1.47 (tdd, 1H, J = 13.7, 9.3, 5.2 Hz), 1.39 (dq, 
1H, J = 16.9, 6.6 Hz), 1.29 (ddt, 1H, J = 19.0, 12.5, 6.4 Hz), 1.21 (ddt, 1H, J = 20.4, 10.2, 5.2 
Hz), 1.05 (dtd, 1H, J = 20.9, 10.4, 5.1 Hz); 13C{1H} NMR (CDCl3, 151 MHz): δ 199.0, 
156.5, 142.9, 138.9, 137.5, 136.7, 132.6, 129.1, 128.8, 128.7, 128.6, 128.3, 128.3, 128.2, 
126.8, 119.1, 66.8, 65.8, 51.0, 40.6, 29.8, 26.7, 23.9; 13C NMR DEPT135 (CDCl3, 151 
MHz): δ 132.6 (CH), 129.1 (CH), 128.8 (CH), 128.7 (CH), 128.6 (CH), 128.3 (CH), 128.3 
(CH), 126.8 (CH), 119.1 (CH2), 66.8 (CH2), 65.8 (CH), 51.0 (CH2), 40.6 (CH2), 29.8 (CH2), 
26.7 (CH2), 23.9 (CH2); [α]D25 = –2.12° (c = 1.38, CH2Cl2, l = 100 mm). 
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Figure A.15. 1H, 13C{1H}, and 13C DEPT-135 NMR spectra of A.30. 
 
Preparation of amino aldehyde A.31: 
 
Following general procedure 3.1 (section 3.7.2.4 above), N-alkylated amino alcohol 
A.25 (1.19 mmol, 500 mg, 1.00 eq.) was oxidized with DMP (2.00 eq.) over 0.75 h. The 
crude residue was purified by silica gel chromatography (4:1 hexanes:ethyl acetate; Rf = 0.4) 
to yield the amino aldehyde product A.31 as a clear, colorless, viscous oil in 86% yield  
(427 mg). 
(S)-4-methyl-N-(1-oxo-3-phenylpropan-2-yl)-N-(2-phenylallyl)benzenesulfonamide 
(A.31). 1H NMR (CDCl3, 600 MHz): δ 9.12 (s, 1H), 7.68 (d, 2H, J = 8.3 Hz), 7.31 (d, 2H, J 
= 8.1 Hz), 7.29-7.24 (m, 3H), 7.21-7.17 (m, 5H), 6.97-6.94 (m, 2H), 5.39 (s, 1H), 4.95 (s, 
1H), 4.40 (d, 1H, J = 14.7 Hz), 4.02 (dd, 1H, J = 7.9, 5.5 Hz), 3.83 (d, 1H, J = 14.7), 3.39 
(dd, 1H, J = 14.5, 5.5 Hz), 2.80 (dd, 1H, J = 14.4, 7.9 Hz), 2.48 (s, 3H); 13C{1H} NMR 
(CDCl3, 151 MHz): δ 197.9, 144.2, 142.8, 138.0, 137.4, 136.8, 130.0, 129.3, 128.7, 128.6, 
128.5, 128.0, 126.8, 126.7, 118.8, 67.3, 51.5, 33.4, 21.8; [α]D26 = –118.0° (c = 0.570, CH2Cl2, 
l = 100 mm). 
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Figure A.16. 1H and 13C{1H} NMR spectra of A.31. 
 
Preparation of amino aldehyde A.10: 
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Following general procedure 3.1 (section 3.7.2.4 above), N-alkylated amino alcohol 
A.26 (0.969 mmol, 425 mg, 1.00 eq.) was oxidized with DMP (2.50 eq.) over 1.5 h. The 
crude residue was purified by silica gel chromatography (4:1 hexanes:ethyl acetate; Rf = 0.4) 
to yield the amino aldehyde product A.10 as a colorless, viscous oil in 86% yield (362 mg). 
(S)-4-bromo-N-cinnamyl-N-(3-methyl-1-oxobutan-2-yl)benzenesulfonamide (A.10).  
1H NMR (CDCl3, 600 MHz): δ 9.62 (s, 1H), 7.69 (d, 2H, J = 8.6 Hz), 7.60 (d, 2H, J = 8.6 
Hz), 7.34-7.29 (m, 2H), 7.28-7.24 (m, 3H), 6.44 (d, 1H, J = 15.8 Hz), 6.02 (dt, 1H, J = 15.9, 
7.0 Hz), 4.05 (d, 1H, J = 10.3 Hz), 4.02-3.92 (m, 2H), 2.30-2.21 (m, 1H), 1.11 (d, 3H, J = 6.5 
Hz), 0.96 (d, 3H, J = 6.7 Hz); 13C{1H} NMR (CDCl3, 151 MHz): δ 198.7, 139.8, 135.9, 
134.6, 132.4, 129.1, 128.8, 128.3, 127.9, 126.6, 124.8, 71.7, 48.7, 27.3, 20.4, 20.3; [α]D24 =  
–2.75° (c = 1.11, CH2Cl2, l = 100 mm). 
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Figure A.17. 1H and 13C{1H} NMR spectra of A.10. 
 
A.5.4  BCF-catalyzed Prins cyclizations (carbonyl-ene reactions) 
Preparation of tetrahydropyridine A.1 
 
In a dry, N2-filled glove box, amino aldehyde A.27 (0.0500 mmol, 19.7 mg) and 
B(C6F5)3 (BCF, 0.0050 mmol, 2.6 mg) were weighed into a screw cap 1 dram vial equipped 
with a magnetic stir bar. CH2Cl2 (1.00 mL, 0.05 M) was added and the vial was sealed with a 
septum cap and removed from the glove box. The solution was stirred at 22 °C for 1 h, after 
which time the catalyst was quenched with 50 µL of Et3N and the solvent was removed in 
vacuo. The crude residue was purified by silica gel chromatography (2:1 n-pentane:ethyl 
acetate; Rf = 0.3) to yield the tetrahydropyridine product A.1 as a colorless, viscous oil in 
67% yield (13.2 mg). 
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1-((4-bromophenyl)sulfonyl)-5-phenyl-1,2,3,4-tetrahydropyridin-3-ol (A.1). 1H NMR 
(CDCl3, 600 MHz): δ 7.71-7.64 (m, 4H), 7.36-7.30 (m, 4H), 7.27-7.23 (m, 1H), 4.22-4.18 
(m, 1H), 3.50-3.42 (m, 2H), 2.69-2.63 (m, 1H), 2.42 (dd, 1H, J = 17.1, 5.2 Hz), 1.76 (s, br, 
1H); 13C{1H} NMR (CDCl3, 151 MHz): δ 138.8, 137.0, 132.8, 128.8, 128.7, 128.4, 127.3, 
124.8, 121.2, 116.8, 63.1, 48.8, 32.9; 13C NMR DEPT135 (CDCl3, 151 MHz): δ 132.8 (CH), 
128.8 (CH), 128.7 (CH), 127.3 (CH), 124.8 (CH), 121.2 (CH), 63.1 (CH), 48.8 (CH2), 32.9 
(CH2); IR (ν/cm-1): 3525 (s, br, OH), 3086 (w), 3058 (w), 3031 (w), 2924 (m), 2850 (w), 
1639 (m), 1598 (w), 1574 (m), 1496 (w), 1471 (w), 1446 (w), 1389 (m), 1351 (s), 1265 (w), 
1218 (w), 1168 (s), 1089 (m), 1068 (m), 1049 (w), 1026 (w), 1008 (w); HRMS-(ESI+) 
[M+H]+ calcd for C17H17NO3SBr+ 394.0112, found: 394.0108. 
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Figure A.18. 1H, 13C{1H}, and 13C DEPT-135 NMR spectra of A.1. 
 
Preparation of trans-tetrahydropyridine A.2 
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In a dry, N2-filled glove box, amino aldehyde 3.10 (0.0500 mmol, 20.4 mg) and 
B(C6F5)3 (BCF, 0.0050 mmol, 2.6 mg) were weighed into a screw cap 1 dram vial equipped 
with a magnetic stir bar. CH2Cl2 (1.00 mL, 0.05 M) was added and the vial was sealed with a 
septum cap and removed from the glove box. The solution was stirred at 22 °C for 1 h, after 
which time the catalyst was quenched with 50 µL of Et3N and the solvent was removed in 
vacuo. The crude residue was purified by silica gel chromatography (3:1 n-pentane:ethyl 
acetate; Rf = 0.3) to yield the tetrahydropyridine product A.2 as a white, crystalline solid in 
85% yield (17.3 mg) and 91:9 trans:cis d.r.. 
(2S,3R)-1-((4-bromophenyl)sulfonyl)-2-methyl-5-phenyl-1,2,3,4-tetrahydropyridin-3-ol 
(A.2). 1H NMR (CDCl3, 600 MHz): δ 7.73 (d, 2H, J = 8.6 Hz), 7.62 (d, 2H, J = 8.6 Hz), 
7.38-7.32 (m, 4H), 7.27-7.23 (m, 1H), 7.20 (s, 1H), 4.11-4.05 (m, 1H), 3.99-3.95 (m, 1H), 
2.58 (ddd, 1H, J = 18.0, 4.2, 2.1 Hz), 2.48 (d, 1H, J = 18.3 Hz), 1.19 (d, 3H, J = 6.8 Hz), 1.10 
(s, br, 1H); 13C{1H} NMR (CDCl3, 151 MHz): δ 138.8, 138.6, 132.5, 128.8, 128.6, 128.1, 
127.1, 124.7, 119.5, 114.2, 66.3, 54.8, 28.3, 18.1; 13C NMR DEPT135 (CDCl3, 151 MHz): δ 
132.5 (CH), 128.8 (CH), 128.6 (CH), 127.1 (CH), 124.7 (CH), 119.5 (CH), 66.3 (CH), 54.8 
(CH), 28.3 (CH2), 18.1 (CH3); IR (ν/cm-1): 3545 (s, br, OH), 3086 (w), 3058 (w), 3032 (w), 
2979 (w), 2919 (m), 2849 (w), 1639 (m), 1598 (w), 1574 (m), 1496 (w), 1471 (w), 1446 (w), 
1389 (m), 1350 (s), 1266 (m), 1202 (w), 1166 (s), 1118 (m), 1090 (m), 1067 (m), 1028 (w), 
1003 (s); HRMS-(ESI+) [M+H]+ calcd for C18H19NO3SBr+ 408.0269, found: 408.0263; 
[α]D26 = –11.6° (c = 0.865, CH2Cl2, l = 100 mm). 
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Figure A.19. 1H and 13C{1H} spectra of trans-A.2. 
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In a dry, N2-filled glove box, amino aldehyde 3.38 (0.0500 mmol, 21.8 mg) and 
B(C6F5)3 (BCF, 0.0050 mmol, 2.6 mg) were weighed into a screw cap 1 dram vial equipped 
with a magnetic stir bar. CH2Cl2 (1.00 mL, 0.05 M) was added and the vial was sealed with a 
septum cap. The solution was stirred at 22 °C for 1 h, after which time the catalyst was 
quenched with 50 µL of Et3N and the solvent was removed in vacuo. The crude residue was 
purified by silica gel chromatography (5:1 n-pentane:ethyl acetate; Rf = 0.3) to yield the 
tetrahydropyridine product A.3 as a white, crystalline solid in 90% yield (19.6 mg) and  
>98:2 d.r.. 
(2S,3R)-1-((4-bromophenyl)sulfonyl)-2-isopropyl-5-phenyl-1,2,3,4-tetrahydropyridin-3-
ol (A.3). 1H NMR (CDCl3, 600 MHz): δ 7.72 (d, 2H, J = 8.6 Hz), 7.60 (d, 2H, J = 8.6 Hz), 
7.34 (d, 4H, J = 4.4 Hz), 7.28-7.22 (m, 1H), 7.16 (s, 1H), 4.25 (s, 1H), 3.73 (dd, 1H, J = 10.2, 
3.0 Hz), 2.54 (ddd, 1H, J = 18.6, 4.6, 1.7 Hz), 2.42 (d, 1H, J = 18.5 Hz), 1.62 (ddt, 1H, J = 
13.3, 10.1, 6.7 Hz), 1.13 (d, 3H, J = 6.7 Hz), 1.00 (d, 3H, J = 6.7 Hz), 0.74 (s, br, 1H); 
13C{1H} NMR (CDCl3, 151 MHz): δ 138.7, 138.6, 132.3, 128.9, 128.8, 127.9, 127.3, 124.7, 
119.8, 117.2, 65.3, 63.6, 29.7, 29.1, 20.8, 19.2; IR (ν/cm-1): 3542 (s, br, OH), 3085 (w), 3058 
(w), 3027 (w), 2966 (m), 2928 (m), 2874 (w), 2850 (w), 1638 (m), 1598 (w), 1574 (m), 1496 
(w), 1471 (m), 1446 (w), 1389 (m), 1369 (w), 1348 (s), 1266 (m), 1201 (w), 1164 (s), 1090 
(s), 1067 (m), 1057 (m), 1028 (m), 1009 (m); HRMS-(ESI+) [M+H]+ calcd for 
C20H23NO3SBr+ 436.0582, found: 436.0577; [α]D26 = –85.7° (c = 1.04, CH2Cl2, l = 100 mm). 
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Figure A.20. 1H and 13C{1H} NMR spectra of A.3. 
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In a dry, N2-filled glove box, amino aldehyde A.28 (0.0500 mmol, 22.5 mg) and 
B(C6F5)3 (BCF, 0.0050 mmol, 2.6 mg) were weighed into a screw cap 1 dram vial equipped 
with a magnetic stir bar. CH2Cl2 (1.00 mL, 0.05 M) was added and the vial was sealed with a 
septum cap and removed from the glove box. The solution was stirred at 22 °C for 1 h, after 
which time the catalyst was quenched with 50 µL of Et3N and the solvent was removed in 
vacuo. The crude residue was purified by silica gel chromatography (5:1 n-pentane:ethyl 
acetate; Rf = 0.2) to yield the tetrahydropyridine product A.4 as a white, crystalline solid in 
95% yield (21.4 mg) and >98:2 d.r.. 
(2S,3R)-1-((4-bromophenyl)sulfonyl)-2-(tert-butyl)-5-phenyl-1,2,3,4-tetrahydropyridin-
3-ol (A.4). 1H NMR (CDCl3, 600 MHz): δ 7.73 (d, 2H, J = 8.6 Hz), 7.58 (d, 2H, J = 8.6 Hz), 
7.36-7.32 (m, 2H), 7.31-7.29 (m, 2H), 7.28-7.25 (m, 1H), 7.16 (s, 1H), 4.33-4.30 (m, 1H), 
3.90-3.87 (m, 1H), 2.60 (ddd, 1H, J = 18.7, 4.9, 1.7 Hz), 2.40 (dd, 1H, J = 18.7, 1.6 Hz), 1.05 
(s, 9H), 0.73 (s, br, 1H); 13C{1H} NMR (CDCl3, 151 MHz): δ 138.7, 138.2, 132.1, 129.4, 
128.8, 128.0, 127.4, 124.8, 121.9, 118.7, 67.5, 63.8, 34.8, 31.2, 27.9.; IR (ν/cm-1): 3586 (m), 
3460 (s, br, OH), 3146 (w), 3081 (m), 3056 (m), 3032 (w), 2966 (s), 2917 (m), 2871 (w), 
1637 (m), 1595 (w), 1573 (w), 1495 (w), 1474 (m), 1445 (w), 1392 (m), 1364 (m), 1338 (s), 
1302 (w), 1272 (w), 1238 (w), 1224 (w), 1196 (m), 1170 (s), 1090 (m), 1068 (w), 1050 (w), 
1039 (w), 1028 (w), 1017 (m), 1008 (w); HRMS-(ESI+) [M+H]+ calcd for C21H25NO3SBr+ 
450.0739, found: 450.0733; [α]D26 = –78.1° (c = 1.07, CH2Cl2, l = 100 mm). 
 304 
 
 
Figure A.21. 1H and 13C{1H} NMR spectra of A.4. 
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In a dry, N2-filled glove box, amino aldehyde A.29 (0.0500 mmol, 25.7 mg) and 
B(C6F5)3 (BCF, 0.0050 mmol, 2.6 mg) were weighed into a screw cap 1 dram vial equipped 
with a magnetic stir bar. CH2Cl2 (1.00 mL, 0.05 M) was added and the vial was sealed with a 
septum cap and removed from the glove box. The solution was stirred at 22 °C for 1 h, after 
which time the catalyst was quenched with 50 µL of Et3N and the solvent was removed in 
vacuo. 1H and 13C NMR analysis indicated that the desired tetrahydropyridine product A.5 
was produced in 94% yield and in 94:6 d.r.. The crude residue was purified by silica gel 
chromatography (3:1 n-pentane:ethyl acetate; Rf = 0.3) to yield the tetrahydropyridine 
product A.5 as a crystalline, white solid in 87% yield (22.3 mg) and as a single (enriched) 
diastereomer in >98:2 d.r.. 
(2S,3R)-2-((benzyloxy)methyl)-1-((4-bromophenyl)sulfonyl)-5-phenyl-1,2,3,4-
tetrahydropyridin-3-ol (A.5). 1H NMR (CDCl3, 600 MHz): δ 7.72 (d, 2H, J = 8.7 Hz), 7.60 
(d, 2H, J = 8.6 Hz), 7.37-7.28 (m, 9H), 7.26-7.23 (m, 1H), 7.16 (s, 1H), 4.55 (d, 1H, J = 11.9 
Hz), 4.47 (d, 1H, J = 11.8 Hz), 4.41-4.36 (m, 1H), 4.25-4.20 (m, 1H), 3.71 (dd, 1H, J = 9.8, 
5.4 Hz), 3.42 (t, 1H, J = 9.5 Hz), 2.53 (ddd, 1H, J = 18.0, 4.2, 2.1 Hz), 2.45 (ddt, 1H, J = 
18.0, 2.3, 1.3 Hz), 1.03 (s, br, 1H); 13C{1H} NMR (CDCl3, 151 MHz): δ 138.8, 138.1, 137.7, 
132.5, 128.8, 128.7, 128.6, 128.2, 128.1, 127.8, 127.2, 124.8, 119.9, 115.2, 73.6, 69.8, 62.8, 
57.7, 28.7; 13C NMR DEPT135 (CDCl3, 151 MHz): δ 132.5 (CH), 128.8 (CH), 128.7 (CH), 
128.6 (CH), 128.1 (CH), 127.8 (CH), 127.2 (CH), 124.8 (CH), 119.9 (CH), 115.2, 73.6 
(CH2), 69.8 (CH2), 62.8 (CH), 57.7 (CH), 28.7 (CH2); IR (ν/cm-1): 3540 (s, br, OH), 3086 
(w), 3060 (w), 3030 (w), 2922 (m), 2861 (m), 1640 (m), 1598 (w), 1574 (m), 1496 (w), 1471 
(w), 1453 (w), 1447 (w), 1389 (m), 1353 (s), 1276 (w), 1203 (w), 1166 (s), 1092 (s), 1068 
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(m), 1059 (m), 1028 (w), 1009 (m); HRMS-(ESI+) [M+H]+ calcd for C25H25NO4SBr+ 
514.0687, found: 514.0681; [α]D25 = –18.7° (c = 0.920, CH2Cl2, l = 100 mm). 
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Figure A.22. 1H, 13C{1H}, and 13C DEPT-135 NMR spectra of A.5. 
 
Preparation of tetrahydropyridine A.6 
 
In a dry, N2-filled glove box, amino aldehyde A.30 (0.0500 mmol, 30.0 mg) and 
B(C6F5)3 (BCF, 0.0050 mmol, 2.6 mg) were weighed into a screw cap 1 dram vial equipped 
with a magnetic stir bar. CH2Cl2 (1.00 mL, 0.05 M) was added and the vial was sealed with a 
septum cap and removed from the glove box. The solution was stirred at 22 °C for 3 h, after 
which time the catalyst was quenched with 50 µL of Et3N and the solvent was removed in 
vacuo. Note: incomplete conversion was observed in a separate experiment that was 
quenched after just 1 h. The crude residue was purified by silica gel chromatography (2:1 n-
pentane:ethyl acetate; Rf = 0.2) to yield the tetrahydropyridine product A.6 as an amorphous, 
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white solid in 88% yield (26.5 mg) and as a mixture of two chromatographically inseparable 
diastereomers in 85:15 trans:cis d.r. (no diastereoenrichment occured during purification).  
benzyl (4-((2S,3R)-1-((4-bromophenyl)sulfonyl)-3-hydroxy-5-phenyl-1,2,3,4-tetrahydro- 
pyridin-2-yl)butyl)carbamate (A.6). 1H NMR (CDCl3, 600 MHz): δ 7.72 (d, 2H, J = 8.6 
Hz), 7.59 (d, 2H, J = 8.6 Hz), 7.36-7.35 (m, 5H), 7.34-7.32 (m, 4H), 7.32-7.28 (m, 1H), 7.15 
(s, 1H), 5.09 (s, 2H), 4.88 (t, 1H, J = 6.1 Hz), 4.04-3.96 (m, 2H), 3.25-3.16 (m, 2H), 2.56-
2.50 (m, 1H), 2.41 (d, 1H, J = 18.2 Hz), 1.63-1.46 (m, 6H), 1.00 (s, 1H); 13C{1H} NMR 
(CDCl3, 151 MHz): δ 156.6, 138.7, 138.6, 136.8, 132.8, 132.4, 128.8, 128.8, 128.6, 128.2, 
128.0, 127.3, 124.8, 119.5, 115.9, 66.7, 65.1, 59.1, 40.9, 31.6, 29.8, 28.8, 22.9; 13C NMR 
DEPT135 (CDCl3, 151 MHz): δ 132.8 (CH), 132.4 (CH), 128.8 (CH), 128.8 (CH), 128.6 
(CH), 128.2 (CH), 127.3 (CH), 124.8 (CH), 119.5 (CH), 66.7 (CH2), 65.1 (CH), 59.1 (CH), 
40.9 (CH2), 31.6 (CH2), 29.8 (CH2), 28.8 (CH2), 22.9 (CH2); IR (ν/cm-1): 3410 (s, br, OH), 
3087 (w), 3060 (w), 3033 (w), 2931 (s), 2862 (m), 1700 (s, C=O), 1638 (m), 1597 (w), 1574 
(m), 1525 (s), 1496 (w), 1470 (w), 1454 (w), 1446 (w), 1389 (m), 1349 (s), 1250 (s), 1164 
(s), 1090 (m), 1067 (m), 1028 (w), 1009 (w); HRMS-(ESI+) [M+H]+ calcd for 
C29H32N2O5SBr+ 599.1215, found: 599.1208; [α]D25 = –11.6° (c = 1.19, CH2Cl2,  
l = 100 mm). 
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Figure A.23. 1H, 13C{1H}, and 13C DEPT-135 NMR spectra of A.6. 
 
Preparation of tetrahydropyridine A.7 
 
In a dry, N2-filled glove box, amino aldehyde A.31 (0.0500 mmol, 21.1 mg) and 
B(C6F5)3 (BCF, 0.0050 mmol, 2.6 mg) were weighed into a screw cap 1 dram vial equipped 
with a magnetic stir bar. CH2Cl2 (1.00 mL, 0.05 M) was added and the vial was sealed with a 
septum cap and removed from the glove box. The solution was stirred at 22 °C for 1 h, after 
which time the catalyst was quenched with 50 µL of Et3N and the solvent was removed in 
vacuo. The crude residue was purified by silica gel chromatography (5:1 to 3:1 n-
pentane:ethyl acetate; Rf = 0.3 in 3:1) to yield the tetrahydropyridine product A.7 as a white, 
crystalline solid in 97% yield (20.4 mg) and >98:2 d.r.. 
(2S,3R)-2-benzyl-5-phenyl-1-tosyl-1,2,3,4-tetrahydropyridin-3-ol (A.7). 1H NMR 
(CDCl3, 600 MHz): δ 7.76 (d, 2H, J = 8.4 Hz), 7.42-7.39 (m, 2H), 7.36 (t, 2H, J = 8.0 Hz), 
7.33 (t, 2H, J = 7.6 Hz), 7.29 (d, 2H, J = 6.0 Hz), 7.28-7.26 (m, 3H), 7.24 (d, 2H, J = 7.1 Hz), 
4.27-4.20 (m, 1H), 3.89 (s, br, 1H), 3.14 (dd, 1H, J = 13.8, 5.3 Hz), 2.68 (ddd, 1H, J = 18.0, 
4.4, 2.0 Hz), 2.62 (dd, 1H, J = 13.8, 10.4 Hz), 2.49 (dd, 1H, J = 18.0, 1.6 Hz), 2.39 (s, 3H), 
0.96-0.91 (m, 1H); 13C{1H} NMR (CDCl3, 151 MHz): δ 144.1, 138.9, 136.8, 136.5, 130.0, 
129.3, 128.9, 128.8, 127.1, 127.1, 124.7, 120.0, 114.1, 63.3, 60.2, 39.3, 28.4, 21.7; 13C NMR 
DEPT135 (CDCl3, 151 MHz): δ 130.0 (CH), 129.3 (CH), 128.9 (CH), 128.8 (CH), 127.1 
(CH), 127.1 (CH), 124.7 (CH), 120.0 (CH), 63.3 (CH), 60.2 (CH), 39.3 (CH2), 28.4 (CH2), 
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21.7 (CH3); IR (ν/cm-1): 3541 (s, br, OH), 3084 (w), 3060 (w), 3028 (w), 3003 (w), 2924 
(m), 2854 (w), 1639 (m), 1598 (m), 1495 (m), 1454 (w), 1447 (w), 1349 (s), 1307 (w), 1266 
(w), 1216 (w), 1198 (w), 1185 (w), 1161 (s), 1093 (s), 1056 (m), 1032 (m); HRMS-(ESI+) 
[M+H]+ calcd for C25H26NO3S+ 420.1634, found: 420.1628; [α]D25 = –20.6° (c = 1.02, 
CH2Cl2, l = 100 mm). 
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Figure A.24. 1H, 13C{1H}, and 13C DEPT-135 NMR spectra of A.7. 
 
Preparation of tetrahydropyridine A.8 
 
In a dry, N2-filled glove box, amino aldehyde 3.12 (0.0500 mmol, 21.1 mg) and 
B(C6F5)3 (BCF, 0.0050 mmol, 2.6 mg) were weighed into a screw cap 1 dram vial equipped 
with a magnetic stir bar. CH2Cl2 (1.00 mL, 0.05 M) was added and the vial was sealed with a 
septum cap and removed from the glove box. The solution was stirred at 22 °C for 1 h, after 
which time the catalyst was quenched with 50 µL of Et3N and the solvent was removed in 
vacuo. The crude residue was purified by silica gel chromatography (5:1 n-pentane:ethyl 
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acetate; Rf = 0.3) to yield the tetrahydropyridine product A.8 as a colorless oil in 61% yield 
(12.8 mg) and >98:2 d.r.. 
(2S,3R)-2-benzyl-1-((4-bromophenyl)sulfonyl)-5-methyl-1,2,3,4-tetrahydropyridin-3-ol 
(A.8). 1H NMR (CDCl3, 600 MHz): δ 7.63 (d, 2H, J = 8.5 Hz), 7.58 (d, 2H, J = 8.6 Hz), 7.30 
(t, 2H, J = 7.7 Hz), 7.24 (t, 1H, J = 7.5 Hz), 7.19 (d, 2H, J = 7.9 Hz), 6.46 (s, 1H), 4.18-4.13 
(m, 1H), 3.76 (s, br, 1H), 2.97 (dd, 1H, J = 13.8, 6.0 Hz), 2.56 (dd, 1H, J = 13.7, 9.5 Hz), 
2.35 (d, 1H, J = 18.4 Hz), 1.87 (d, 1H, J = 18.5 Hz), 1.73 (s, 3H), 0.97 (s, br, 1H); 13C{1H} 
NMR (CDCl3, 151 MHz): δ 138.7, 136.9, 132.4, 129.3, 128.8, 128.7, 127.8, 127.0, 116.9, 
113.2, 63.7, 60.1, 38.8, 31.5, 20.9; 13C NMR DEPT135 (CDCl3, 151 MHz): δ 132.4 (CH), 
129.3 (CH), 128.8 (CH), 128.7 (CH), 127.0 (CH), 116.9 (CH), 63.7 (CH), 60.1 (CH), 38.8 
(CH2), 31.5 (CH2), 20.9 (CH3); IR (ν/cm-1): 3533 (s, br, OH), 3086 (w), 3062 (w), 3028 (w), 
2917 (m), 2852 (w), 1677 (w), 1602 (w), 1574 (m), 1495 (w), 1471 (w), 1454 (w), 1389 (m), 
1370 (w), 1346 (m), 1274 (w), 1216 (w), 1182 (m), 1160 (s), 1092 (m), 1067 (m), 1052 (m), 
1011 (m); HRMS-(ESI+) [M+H]+ calcd for C19H21NO3SBr+ 422.0425, found: 422.0420; 
[α]D26 = +77.7° (c = 0.640, CH2Cl2, l = 100 mm). 
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Figure A.25. 1H, 13C{1H}, and 13C DEPT-135 NMR spectra of A.8. 
 
A.5.4.1   BCF-catalyzed aldehyde hydrosilylation 
 
In a dry, N2-filled glove box, amino aldehyde 3.4 (0.0500 mmol, 24.2 mg) was 
weighed into a screw cap 1 dram vial equipped with a magnetic stir bar. In a separate 1 dram 
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vial was added B(C6F5)3 (BCF, 0.0050 mmol, 2.6 mg), followed by CH2Cl2 (1.00 mL, 0.05 
M) and Et3SiH (0.0550 mmol, 8.8 µL). The solution in CH2Cl2 was added all at once to the 
neat substrate; vigorous bubbling was observed. The solution was stirred at 22 °C for 5 
minutes, after which time the catalyst was quenched with 50 µL of Et3N and the solvent was 
removed in vacuo. Note: The residue was treated with PPTS resin to facilitate NMR 
identification and quantification of the products. The residue was repeatedly washed with 
CH2Cl2 and concentrated in vacuo (x3), and was then placed under high vacuum overnight to 
remove excess Et3N. The resulting residue was taken up in 2 mL of 1:1 CH2Cl2/MeOH, a 
spatula tip of PPTS resin was added, and the mixture was stirred at 22 °C for 24 h. The 
mixture was then filtered through a short plug of neutral aluminum oxide (Brockmann 
activity I slurried with 10% H2O) and concentrated in vacuo. Dimethylformamide (0.050 
mmol, 3.9 µL) was added as an internal standard and the residue taken up in CDCl3 for 1H 
and 13C NMR analyses; full conversion of starting material was observed with concomitant 
production of amino alcohol 3.32 (32%; resulting from the deprotection of silyl ether A.32), 
in addition to 44% of trans-tetrahydropyridine 3.23 and 7% and 12%, respectively, of minor 
diastereomers B and C of piperidine 3.6. 
 
A.5.4.2   HBarF24-catalyzed Prins cyclization 
Preparation of cis-tetrahydropyridine A.2’ 
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In a dry, N2-filled glove box, amino aldehyde 3.10 (0.0500 mmol, 20.4 mg) and 
[H(OEt2)2][B(C6H3(CF3)2)4] (HBArF24 (Brookhart’s acid); 0.0050 mmol, 5.1 mg) were 
weighed into a screw cap 1 dram vial equipped with a magnetic stir bar. CH2Cl2 (1.00 mL, 
0.05 M) was added and the vial was sealed with a septum cap and removed from the glove 
box. The solution was stirred at 22 °C for 1 h, after which time the catalyst was quenched 
with 50 µL of Et3N and the solvent was removed in vacuo. The crude residue was purified by 
silica gel chromatography (3:1 n-pentane:ethyl acetate; Rf = 0.3) to yield the 
tetrahydropyridine product A.2’/A.2 as a white, crystalline solid in 81% yield (16.6 mg) and 
72:28 cis:trans d.r.. 
 
(2S,3S)-1-((4-bromophenyl)sulfonyl)-2-methyl-5-phenyl-1,2,3,4-tetrahydropyridin-3-ol 
(A.2’). Cis-diastereomer: 1H NMR (CDCl3, 600 MHz): δ 7.69 (d, 2H, J = 8.7 Hz), 7.65 (d, 
2H, J = 8.7 Hz), 7.38-7.32 (m, 4H), 7.28-7.24 (m, 1H), 7.08 (s, 1H), 4.13-4.07 (m, 1H), 3.57-
3.51 (m, 1H), 2.61 (dd, 1H, J = 16.8, 5.7 Hz), 2.29 (ddd, 1H, J = 16.8, 10.5, 2.1 Hz), 1.71 (s, 
1H), 1.16 (d, 3H, J = 6.7 Hz); 13C{1H} NMR (CDCl3, 151 MHz): δ 138.3, 138.2, 132.8, 
128.8, 128.4, 128.2, 127.3, 124.8, 119.4, 117.4, 66.2, 52.8, 29.2, 11.8; 13C NMR DEPT135 
(CDCl3, 151 MHz): δ 132.8 (CH), 128.8 (CH), 128.4 (CH), 127.3 (CH), 124.8 (CH), 119.4 
(CH), 66.2 (CH), 52.8 (CH), 29.2 (CH2), 11.8 (CH3). 
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Figure A.26. 1H, 13C{1H}, and 13C DEPT-135 NMR spectra of cis-A.2’. 
 
A.5.4.3   In situ BCF-catalyzed cyclization and dehydrocoupling / silyl-protection 
Preparation of silyl-protected tetrahydropyridine A.9 
 
In a dry, N2-filled glove box, amino aldehyde 3.39 (0.250 mmol, 114 mg) and 
B(C6F5)3 (BCF, 0.0250 mmol, 12.8 mg) were weighed into a screw cap 1 dram vial equipped 
with a magnetic stir bar. CH2Cl2 (2.50 mL, 0.10 M) was added and the vial was sealed with a 
septum cap. The solution was stirred at 22 °C for 1 h, after which time t-BuMe2SiH (0.275 
mmol, 46 µL, 1.10 eq.) was added dropwise via syringe with concomitant slow evolution of 
bubbles. The solution was stirred for an additional 1 h, after which time the catalyst was 
quenched with 100 µL of Et3N and the solvent was removed in vacuo. The crude residue was 
purified by silica gel chromatography (9:1 hexanes:ethyl acetate; Rf = 0.5) to yield the silyl-
N
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Ph
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Ph
Si
Me
Me
t-Bu
1) B(C6F5)3 (10 mol %),
CH2Cl2, 22 °C, 1 h
2) t-BuMe2Si–H (1.10 eq.),
CH2Cl2, 22 °C, 1 h
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protected tetrahydropyridine product A.9 as a colorless, viscous oil in 94% yield (134 mg) 
and 91:9 trans:cis d.r.. 
(2S,3R)-2-benzyl-3-((tert-butyldimethylsilyl)oxy)-1-(naphthalen-2-ylsulfonyl)-5-phenyl-
1,2,3,4-tetrahydropyridine (A.9). 1H NMR (CDCl3, 600 MHz): δ 8.46 (s, 1H), 7.95 (dd, 
1H, J = 8.2, 1.5 Hz), 7.88 (d, 1H, J = 8.7 Hz), 7.85 (d, 1H, J = 8.0 Hz), 7.81 (dd, 1H, J = 8.8, 
1.9 Hz), 7.63-7.55 (m, 2H), 7.41 (d, 2H, J = 8.2 Hz), 7.39-7.31 (m, 5H), 7.29-7.23 (m, 4H), 
4.18 (ddd, 1H, J = 11.1, 5.7, 3.3 Hz), 3.94 (dt, 1H, J = 4.3, 2.1 Hz), 3.28 (dd, 1H, J = 13.7, 
4.7 Hz), 2.67-2.60 (m, 2H), 2.38 (d, 1H, J = 17.1 Hz), 0.38 (s, 9H), –0.46 (s, 3H), –0.49 (s, 
3H); 13C{1H} NMR (CDCl3, 151 MHz): δ 139.8, 137.4, 137.2, 135.1, 132.3, 129.6, 129.4, 
129.2, 128.9, 128.8, 128.7, 128.3, 127.9, 127.5, 127.0, 126.6, 124.7, 122.7, 120.4, 113.6, 
63.6, 61.0, 39.9, 28.8, 25.7, 18.2, –5.0, –5.2.; IR (ν/cm-1): 3083 (w), 3059 (w), 3028 (w), 
2952 (m), 2928 (m), 2884 (w), 2855 (m), 1644 (m), 1598 (w), 1495 (w), 1470 (w), 1462 (w), 
1455 (w), 1447 (w), 1387 (w), 1350 (s), 1328 (w), 1254 (m), 1229 (m), 1215 (w), 1198 (w), 
1163 (s), 1132 (m), 1100 (w), 1078 (s), 1057 (w), 1029 (w), 1004 (w); HRMS-(ESI+) 
[M+H]+ calcd for C34H40NO3SiS+ 570.2498, found: 570.2490; [α]D27 = –78.6° (c = 0.750, 
CH2Cl2, l = 100 mm). 
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Figure A.27. 1H and 13C{1H} NMR spectra of A.9. 
 
A.5.4.4   BCF-catalyzed cyclization / elimination to produce pyrrolidines 
Preparation of pyrrolidine A.11 
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In a dry, N2-filled glove box, cinnamyl amino aldehyde A.10 (0.0500 mmol, 21.8 mg) 
and B(C6F5)3 (BCF, 0.0050 mmol, 2.6 mg) were weighed into a screw cap 1 dram vial 
equipped with a magnetic stir bar and sealed with a septum cap. The vial was removed from 
the glove box and cooled to –78 °C in an acetone/CO2(s) bath. CH2Cl2 (1.00 mL, 0.05 M) was 
added slowly dropwise down the side of the vial. The solution was allowed to slowly warm 
to room temperature overnight in the dewar with magnetic stirring. After 17 h, the catalyst 
was quenched with 50 µL of Et3N and the solvent was removed in vacuo. 
Dimethylformamide (0.050 mmol, 3.9 µL) was added as an internal standard and the residue 
taken up in CDCl3 for 1H and 13C NMR analyses to determine conversion, product identity, 
NMR yield, and crude diastereomeric ratios (d.r.). Despite 32% consumption of starting 
material, no trace of A.11 is visible by 1H or 13C NMR. 
(2S)-4-benzylidene-1-((4-bromophenyl)sulfonyl)-2-isopropylpyrrolidin-3-ol (A.11). 32% 
of the starting material was consumed with no generation of desired product detectable by 1H 
and 13C{1H} NMR. The substrate appears to slowly decompose under the reaction conditions. 
 
A.5.4.5   Perfluoroaryl borane catalyst screen 
Preparation of tetrahydropyridine A.3 
 
In a dry, N2-filled glove box, amino aldehyde 3.38 (0.0500 mmol, 21.8 mg) and 
B(C6H3(CF3)2)3 (3,5-CF3-BCF; 0.0050 mmol, 3.3 mg) were weighed into a screw cap 1 dram 
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vial equipped with a magnetic stir bar. CH2Cl2 (1.00 mL, 0.05 M) was added and the vial was 
sealed with a septum cap. The solution was stirred at 22 °C for 1 h, after which time the 
catalyst was quenched with 50 µL of Et3N and the solvent was removed in vacuo. 
Dimethylformamide (0.050 mmol, 3.9 µL) was added as an internal standard and the residue 
taken up in CDCl3 for 1H and 13C NMR analyses; the desired tetrahydropyridine A.3 was 
produced in 95% NMR yield and >98:2 d.r..  The crude residue was purified by silica gel 
chromatography (5:1 n-pentane:ethyl acetate; Rf = 0.3) to yield the tetrahydropyridine 
product A.3 as a white, crystalline solid in 95% yield (20.7 mg) and >98:2 d.r.. 
Preparation of tetrahydropyridine A.3 
 
In a dry, N2-filled glove box, amino aldehyde 3.38 (0.0500 mmol, 21.8 mg) and 
B(C6H2F3)3 (2,4,6-BCF; 0.0050 mmol, 2.0 mg) were weighed into a screw cap 1 dram vial 
equipped with a magnetic stir bar. CH2Cl2 (1.00 mL, 0.05 M) was added and the vial was 
sealed with a septum cap. The solution was stirred at 22 °C for 1 h, after which time the 
catalyst was quenched with 50 µL of Et3N and the solvent was removed in vacuo. 
Dimethylformamide (0.050 mmol, 3.9 µL) was added as an internal standard and the residue 
taken up in CDCl3 for 1H and 13C NMR analyses; the desired tetrahydropyridine A.3 was 
produced in 7% NMR yield (62% returned starting material). 
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Preparation of tetrahydropyridine A.3 
 
In a dry, N2-filled glove box, amino aldehyde 3.38 (0.0500 mmol, 21.8 mg) and B(2-
(C10F7))3 (PNB; 0.0050 mmol, 3.9 mg) were weighed into a screw cap 1 dram vial equipped 
with a magnetic stir bar. CH2Cl2 (1.00 mL, 0.05 M) was added and the vial was sealed with a 
septum cap. The solution was stirred at 22 °C for 1 h, after which time the catalyst was 
quenched with 50 µL of Et3N and the solvent was removed in vacuo. Dimethylformamide 
(0.050 mmol, 3.9 µL) was added as an internal standard and the residue taken up in CDCl3 
for 1H and 13C NMR analyses; the desired tetrahydropyridine A.3 was produced in 91% 
NMR yield and >98:2 d.r.. 
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